



US 20110105586A1

(19) **United States**

(12) **Patent Application Publication**
Dobie et al.

(10) **Pub. No.: US 2011/0105586 A1**
(43) **Pub. Date:** **May 5, 2011**

(54) **COMPOSITIONS AND THEIR USES
DIRECTED TO GEMIN GENES**

(60) Provisional application No. 60/609,711, filed on Sep. 13, 2004.

(75) Inventors: **Kenneth W. Dobie**, Del Mar, CA (US); **Susan M. Freier**, San Diego, CA (US)

Publication Classification

(51) **Int. Cl.**
A61K 31/7088 (2006.01)
C12N 5/071 (2010.01)
A61P 35/00 (2006.01)

(52) **U.S. Cl.** **514/44 A; 435/375**

(73) Assignee: **Isis Pharmaceuticals, Inc.**, Carlsbad, CA (US)

(57) **ABSTRACT**

(21) Appl. No.: **12/787,764**

Disclosed herein are compounds, compositions and methods for modulating the expression of a Gemin Gene. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

(22) Filed: **May 26, 2010**

Related U.S. Application Data

(63) Continuation of application No. 11/226,884, filed on Sep. 13, 2005, now Pat. No. 7,759,479.

COMPOSITIONS AND THEIR USES DIRECTED TO GEMIN GENES

REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 11/226,884, filed Sep. 13, 2005, which claims benefit of U.S. provisional application 60/609,711, filed Sep. 13, 2004, the entire contents of each is being expressly incorporated herein by reference.

SEQUENCE LISTING

[0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled RTS0491USC1SEQ.txt, created on May 26, 2010 which is 261 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0003] Disclosed herein are compounds, compositions and methods for modulating the expression of a Gemin gene in a cell, tissue or animal.

BACKGROUND OF THE INVENTION

[0004] Targeting disease-causing gene sequences was first suggested more than thirty years ago (Belikova et al., *Tet. Lett.*, 1967, 37, 3557-3562), and antisense activity was demonstrated in cell culture more than a decade later (Zamecnik et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1978, 75, 280-284). One advantage of antisense technology in the treatment of a disease or condition that stems from a disease-causing gene is that it is a direct genetic approach that has the ability to modulate (increase or decrease) the expression of specific disease-causing genes. Another advantage is that validation of a therapeutic target using antisense compounds results in direct and immediate discovery of the drug candidate; the antisense compound is the potential therapeutic agent.

[0005] Generally, the principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and modulates gene expression activities or function, such as transcription or translation. The modulation of gene expression can be achieved by, for example, target degradation or occupancy-based inhibition. An example of modulation of RNA target function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound. Another example of modulation of gene expression by target degradation is RNA interference (RNAi). RNAi generally refers to antisense-mediated gene silencing involving the introduction of dsRNA leading to the sequence-specific reduction of targeted endogenous mRNA levels. Regardless of the specific mechanism, this sequence-specificity makes antisense compounds extremely attractive as tools for target validation and gene functionalization, as well as therapeutics to selectively modulate the expression of genes involved in the pathogenesis of malignancies and other diseases.

[0006] Antisense compounds have been employed as therapeutic agents in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs are being safely and effectively administered to humans in numerous clinical trials. In 1998, the antisense compound, Vitravene® (fomivirsen; developed by Isis Pharmaceuticals Inc., Carlsbad, Calif.) was the first antisense drug to achieve marketing

clearance from the U.S. Food and Drug Administration (FDA), and is currently used in the treatment of cytomegalovirus (CMV)-induced retinitis in AIDS patients. A New Drug Application (NDA) for Genasense™ (oblimersen sodium; developed by Genta, Inc., Berkeley Heights, N.J.), an antisense compound which targets the Bcl-2 mRNA overexpressed in many cancers, was accepted by the FDA. Many other antisense compounds are in clinical trials, including those targeting c-myc (NeuGene® AVI-4126, AVI Biopharma, Ridgefield Park, N.J.), TNF-alpha (ISIS 104838, developed by Isis Pharmaceuticals, Inc.), VLA4 (ATL1102, Antisense Therapeutics Ltd., Toorak, Victoria, Australia) and DNA methyltransferase (MG98, developed by MGI Pharma, Bloomington, Minn.), to name a few.

[0007] New chemical modifications have improved the potency and efficacy of antisense compounds, uncovering the potential for oral delivery as well as enhancing subcutaneous administration, decreasing potential for side effects, and leading to improvements in patient convenience. Chemical modifications increasing potency of antisense compounds allow administration of lower doses, which reduces the potential for toxicity, as well as decreasing overall cost of therapy. Modifications increasing the resistance to degradation result in slower clearance from the body, allowing for less frequent dosing. Different types of chemical modifications can be combined in one compound to further optimize the compound's efficacy.

[0008] Much of the information regarding the biogenesis of the small nuclear ribonucleoproteins (snRNPs) came from studies of spinal muscular atrophy (SMA). SMA, a motor neuron degenerative disease that results from deletions or mutations in the Survival of Motor Neurons (SMN) gene, is an autosomal recessive disease that is the leading hereditary cause of infant mortality (Gubitz et al., *Exp. Cell. Res.*, 2004, 296, 51-56). The SMN protein is present in the cytoplasm and nucleus, where it is enriched within discrete bodies called Gems (for "Gemini of Cajal bodies") which are related to and often associated with Cajal bodies (Gubitz et al., *Exp. Cell. Res.*, 2004, 296, 51-56; Liu and Dreyfuss, *Embo J.*, 1996, 15, 3555-3565; Yong et al., *Trends Cell Biol.*, 2004, 14, 226-232). Cajal bodies are known to contain high levels of factors involved in the transcription and processing of many types of nuclear RNAs, including snRNPs, nucleolar ribonucleoproteins (snRNPs), and the three eukaryotic RNA polymerases, and are most likely sites of assembly and modification of the nuclear transcription and RNA machinery (Gubitz et al., *Exp. Cell. Res.*, 2004, 296, 51-56).

[0009] The snRNP particles are components of the spliceosome, the eukaryotic pre-mRNA splicing machinery. Each major snRNP contains a small nuclear RNA (snRNA) as well as a common set of Sm proteins and a set of proteins specific to the particular snRNA. The common Sm proteins are arranged into a core on a uridine-rich sequence in the cytoplasm after nuclear export of the nascent snRNAs. Proper assembly of the core is required for subsequent import of the snRNPs into the nucleus. As compared to other RNP complexes, such as the small nucleolar RNPs which are assembled in the nucleus where they function, the assembly of snRNPs appears to be strictly regulated and complex (Yong et al., *Trends Cell Biol.*, 2004, 14, 226-232).

[0010] The SMN protein oligomerizes with a group of proteins named the Geminis. The Geminis include Gemin2, Gemin3, a DEAD/H box helicase, Gemin4, Gemin5, Gemin6, and Gemin7. The Geminis colocalize with SMN in

gems and are present in the cytoplasm and nucleoplasm (Gubitz et al., *Exp. Cell. Res.*, 2004, 296, 51-56). It appears that individual Gemin5 of the SMN complex interact with distinct sets of Sm proteins indicating that multiple contacts are likely to be important for the function of the SMN complex in snRNP core assembly (Baccon et al., *J. Biol. Chem.*, 2002, 277, 31957-31962). The SMN complex was found to function as a specificity factor for the assembly of spliceosomal snRNP, ensuring that Sm cores are only formed on the correct RNA molecules (Pellizzoni et al., *Science*, 2002, 298, 1775-1779).

[0011] Gemin2 (also known as SIP1, SMP-interacting protein 1, and survival of motor neuron protein interacting protein 1) was isolated in a yeast two-hybrid screen of a HeLa cell library using SMN as bait. These proteins were tightly associated and colocalized to Gems, prompting a search for other protein components of the complex. The SMN/Gemin2 pair was found to interact directly with several of the snRNP Sm core proteins (Liu et al., *Cell*, 1997, 90, 1013-1021). Further implicating the pair in snRNP biogenesis, the SMN/Gemin2 complex associated with spliceosomal snRNAs U1 and U5 in the cytoplasm of *Xenopus oocytes*, and antibodies against Gemin2 inhibited Sm core assembly of the spliceosomal snRNPs U1, U2, U4, and U5 and their transport to the nucleus (Fischer et al., *Cell*, 1997, 90, 1023-1029).

[0012] Together with Gemin2, Gemin3 and Gemin4 (also known as GIP1 or gem-associated protein 4) were also found to complex with SMN and snRNP proteins (Charroux et al., *J. Cell Biol.*, 1999, 147, 1181-1194; Charroux et al., *J. Cell Biol.*, 2000, 148, 1177-1186). Gemin3 was the only protein of the SMN complex that bound specifically to GST-Gemin4, suggesting that the presence of Gemin4 in the complex is a result of its direct interaction with Gemin3, but not with SMN. The direct and avid interaction of Gemin4 with the DEAD/H box-containing helicase protein Gemin3 may indicate that they function together. Gemin4 also interacts with several of the core Sm proteins, and co-localizes with SMN to gems. Gemin4 localizes to the nucleolus, potentially indicating additional functions in ribosome biogenesis (Charroux et al., *J. Cell Biol.*, 2000, 148, 1177-1186).

[0013] Gemin4 proteins are found predominantly in the SMN complex, however, a less abundant Gemin3-Gemin4 complex has also been found (Charroux et al., *J. Cell Biol.*, 2000, 148, 1177-1186; Mourelatos et al., *Genes & Development*, 2002, 16, 720-728). Immunoprecipitation studies showed that Gemin3 and Gemin4 are associated in a complex with eIF2c2, a member of the large Argonaute family of proteins, members of which have been implicated in RNA interference (RNAi) mechanisms and developmental regulation by short temporal RNAs (stRNAs). The complex, a miRNP, also contained RNAs about 22 nucleotides in length, corresponding to microRNAs (miRNAs). 40 miRNAs were captured in these studies (Mourelatos et al., *Genes & Development*, 2002, 16, 720-728). Monoclonal antibodies to either Gemin3 or Gemin4 immunoprecipitated let-7-programmed RNA-induced silencing complex (RISC) activity, leading to the notion that the Gemin4-containing miRNP may be the human RISC which can carry out both target cleavage in the RNAi pathway and translational control in the miRNA pathway (Hutvagner and Zamore, *Science*, 2002, 297, 2056-2060).

[0014] In a yeast-two hybrid assay, Gemin4 was found to interact with galectin-1 and galectin-3, nuclear-localized proteins that were shown to be required factors for splicing in a

cell-free assay. This interaction is thought to be functionally relevant in the splicing pathway (Park et al., *Nucleic Acids Res.*, 2001, 29, 3595-3602).

[0015] Gemin5 (also known as DKFZP586M1824 protein; gem-associated protein 5) was found by coimmunoprecipitation of proteins that associate with SMN in vivo. Like SMN, Gemin5 is localized in the cytoplasm, nucleoplasm, and is highly enriched in the nuclear gems. It binds to SMN by direct protein-protein interaction in vitro and interacts with several of the snRNP core Sm proteins. The Gemin5 protein is predicted to contain up to 13 WD repeats in its amino-terminal half, and a coiled-coil near its carboxyl terminus. Because both WD repeats and coiled-coil motifs are protein-protein interaction domains, Gemin5 may serve as a structural platform for protein assembly (Gubitz et al., *J. Biol. Chem.*, 2002, 277, 5631-5636).

[0016] Extracts from stable cell lines expressing epitope-tagged SMN or Gemin2 proteins were analyzed by immunoprecipitation with an antibody recognizing the epitope. Both tagged-proteins were isolated with the SMN complex which was found to contain additional previously unidentified proteins including Gemin6 (also known as GEM-associated protein 6 or hypothetical protein FLJ23459). Database searches revealed that Gemin6 is not significantly homologous to other proteins and contains no common motifs which may be indicative of function. Like the other members of the SMN complex, Gemin6 was shown to interact with several Sm proteins (Baccon et al., *J. Biol. Chem.*, 2002, 277, 31957-31962). The Gemin6 localization is similar to the other components of the SMN complex, but direct interaction of Gemin6 with SMN, Gemin2, Gemin3, Gemin4 or Gemin5 was not detectable (Pellizzoni et al., *J. Biol. Chem.*, 2002, 277, 7540-7545).

[0017] However, Gemin7 (also known as hypothetical protein FLJ13956), also identified using the epitope-tagged system to purify SMN complexes, was shown to bind directly to Gemin6 and SMN in vitro, therefore it likely mediates the association of Gemin6 with the SMN complex. Like Gemin6, Gemin7 does not contain any known motifs that may suggest possible functions, but it does interact with a subset of the Sm proteins. Like the other complex members, Gemin7 colocalizes with SMN in gems (Baccon et al., *J. Biol. Chem.*, 2002, 277, 31957-31962).

[0018] Beyond interactions with Sm proteins and snRNAs, the SMN complex interacts directly with several protein targets that are components of RNPs which function in various aspects of RNA metabolism. Among these substrates are the Sm-like (Lsm) proteins of the snRNPs, also essential components of the splicing machinery (Friesen and Dreyfuss, *J. Biol. Chem.*, 2000, 275, 26370-26375). Fibrillarin and GAR1, components of small nucleolar RNPs (snoRNPs), also interact with SMN. Fibrillarin is a marker for Box C/D snoRNPs, the class that is necessary for cleavage and site-specific methylation of rRNA. Box H/ACA snoRNPs contain GAR1 and guide the pseudouridylation of rRNA (Pellizzoni et al., *Curr. Biol.*, 2001, 11, 1079-1088). Thus, the SMN complex also appears to be involved in snoRNP biogenesis (Jones et al., *J. Biol. Chem.*, 2001, 276, 38645-38651; Pellizzoni et al., *Curr. Biol.*, 2001, 11, 1079-1088). Additional SMN complex substrates are hnRNP U and Q, RNA helicase A, and Epstein-Barr virus nuclear antigen 2 (EBNA2), coilin, and nucleolin (Barth et al., *J. Virol.*, 2003, 77, 5008-5013; Gubitz et al., *Exp. Cell. Res.*, 2004, 296, 51-56; Liu and Dreyfuss, *Embo J.*, 1996, 15, 3555-3565; Mourelatos et al.,

Genes & Development, 2002, 16, 720-728; Yong et al., Trends Cell Biol., 2004, 14, 226-232). Because most SMN complex substrates are components of various RNP complexes involved in RNA processing, the SMN complex may take part in many aspects of cellular RNA metabolism (Gubitz et al., Exp. Cell. Res., 2004, 296, 51-56).

[0019] Disclosed in U.S. Pat. No. 6,646,113 is an antisense isolated nucleic acid complementary to the nucleic acid encoding a human Survival of Motor Neuron-Interacting Protein 1, wherein said nucleic acid encodes a protein that differs from the amino acid sequence disclosed by a mutation that inhibits binding of the Survival of Motor Neuron protein, and further wherein said mutation is selected from the group consisting of a deletion of the carboxyl terminal 89 amino acids relative to the amino acid sequence disclosed therein and a deletion of the carboxyl terminal 162 amino acids relative to the amino acid sequence disclosed therein. Also disclosed are antisense oligomers of between about 10 to about 30, and more preferably about 15 nucleotides (Dreyfuss et al., 2003).

[0020] U.S. pregrant publication 20030228617 discloses a kit comprising a plurality of oligonucleotide primers and instructions for employing the plurality of oligonucleotide primers to determine the expression level of at least one of the genes represented in a group of sequences, said group including a nucleic acid sequence of a partial cDNA and a full-length cDNA corresponding to the human survival of motor neuron protein interacting protein 1 (SIP1) gene (Aune and Olsen, 2003).

[0021] The role of Gemin2, Gemin4, Gemin5, Gemin6, and Gemin7 in RNA metabolism makes these attractive targets for therapeutic and investigative strategies aimed at antisense technology. Consequently, there remains a need for agents capable of effectively modulating Gemin2, Gemin4, Gemin5, Gemin6, and Gemin7 function.

[0022] Antisense technology is an effective means for reducing the expression of one or more specific gene products and can therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications.

[0023] Consequently, there remains a long-felt need for agents that specifically regulate gene expression via antisense mechanisms. Disclosed herein are antisense compounds useful for modulating gene expression pathways, including those relying on mechanisms of action such as RNaseH, RNAi and dsRNA enzymes, as well as other antisense mechanisms based on target degradation or target occupancy. One having skill in the art, once armed with this disclosure will be able, without undue experimentation, to identify, prepare and exploit antisense compounds for these uses.

SUMMARY OF THE INVENTION

[0024] Provided herein are oligomeric compounds, especially antisense nucleic acid and nucleic acid-like oligomers, e.g., antisense oligonucleotides, which are targeted to a nucleic acid encoding a Gemin Gene, and which modulate the expression of a Gemin Gene. Gemin Genes disclosed herein include Gemin2, Gemin4, Gemin5, Gemin6, Gemin7. Also disclosed are pharmaceutical compositions including said oligomeric compounds, and methods of using said oligomeric compounds to modulate expression of a Gemin Gene.

[0025] In one embodiment, the invention provides oligomeric compounds of from, e.g., 13 to 30 nucleobases in length targeted to a nucleic acid molecule encoding a Gemin Gene, e.g., Gemin2 (SEQ ID NO: 7), wherein said oligomeric com-

pound specifically hybridizes with said nucleic acid molecule encoding the Gemin Gene and inhibits the expression of the Gemin Gene. In some embodiments, the oligomeric compound is 20 nucleobases in length. In further embodiments, the oligomeric compound is an antisense oligonucleotide.

[0026] The oligomeric compound can be chimeric and include at least one modified internucleoside linkage, e.g., a phosphorothioate internucleoside linkage; and/or at least one modified sugar moiety, e.g., a 2'-O-methoxyethyl sugar moiety, and/or at least one modified nucleobase, e.g., a 5-methylcytosine. In one embodiment, the oligomeric compound is an antisense, chimeric oligonucleotide 20 nucleobases in length and includes at least one phosphorothioate internucleoside linkage and at least one 2'-O-methoxyethyl sugar moiety and at least one 5-methylcytosine.

[0027] Pharmaceutical, therapeutic and other compositions comprising the oligomeric compounds of the present invention are also provided. In one embodiment, the invention provides a composition that includes an oligomeric compound of the invention and a pharmaceutically acceptable carrier, e.g., colloidal dispersion system, or diluent.

[0028] Further provided are methods of modulating the expression of a Gemin Gene, e.g., Gemin2, in cells, tissues or animals comprising contacting said cells, tissues or animals with one or more of the compounds or compositions of the present invention. In some embodiments, the methods are performed *in vitro*.

[0029] Methods of treating an animal, particularly a human, suspected of having or at risk for a disease or condition associated with expression of a Gemin Gene are also set forth herein. Such methods include administering a therapeutically or prophylactically effective amount of one or more of the oligomeric compounds or compositions of the present invention to an animal, particularly a human.

[0030] Further provided are methods of identifying the relationship between a Gemin Gene and a disease state, phenotype, or condition by detecting or modulating said Gemin Gene comprising contacting a sample, tissue, cell, or organism with one or more oligomeric compounds, measuring the nucleic acid or protein level of said Gemin Gene and/or a related phenotypic or chemical endpoint coincident with or at some time after treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound.

[0031] Further provided are methods of screening for modulators of a Gemin Gene expression by contacting a target segment of a nucleic acid molecule encoding said Gemin Gene with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding said Gemin Gene.

[0032] Also provided is the use of the compounds or compositions of the invention in the manufacture of a medicament for the treatment of one or more conditions associated with a target of the invention. Further contemplated are methods where cells or tissues are contacted *in vivo* with an effective amount of one or more of the disclosed compounds or compositions. Also provided are ex vivo methods of treatment that include contacting cells or tissues with an effective amount of one or more of the compounds or compositions of the invention and then introducing said cells or tissues into an animal.

DETAILED DESCRIPTION OF THE INVENTION

[0033] Overview

[0034] Disclosed herein are oligomeric compounds, including antisense oligonucleotides and other antisense compounds for use in modulating the expression of nucleic acid molecules encoding a Gemin Gene, e.g., Gemin2, Gemin4, Gemin5, Gemin6, Gemin7, and the like. This is accomplished by providing oligomeric compounds which hybridize with one or more target nucleic acid molecules encoding a Gemin Gene. As used herein, the terms “target nucleic acid” and “nucleic acid molecule encoding a Gemin Gene” have been used for convenience to encompass DNA encoding a Gemin Gene, RNA (including pre-mRNA and mRNA or portions thereof) transcribed from such DNA, and also cDNA derived from such RNA.

[0035] In one embodiment, the oligomeric compounds of the invention are antisense compounds, e.g., antisense oligonucleotides. The principle behind antisense technology is that an antisense compound, which hybridizes to a target nucleic acid, interferes with gene expression activities such as transcription or translation. This sequence specificity makes antisense compounds extremely attractive as tools for target validation and gene functionalization, as well as therapeutics to selectively modulate the expression of genes involved in disease.

[0036] The term “oligomeric compound” refers to a polymeric structure capable of hybridizing to a region of a nucleic acid molecule. This term includes oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics and chimeric combinations of these. Oligomeric compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular. Moreover, branched structures are known in the art. An “antisense compound” or “antisense oligomeric compound” or “antisense oligonucleotide” refers to an oligomeric compound that is at least partially complementary to the region of a nucleic acid molecule to which it hybridizes and modulates (increases or decreases) its expression. Consequently, while all antisense compounds can be said to be oligomeric compounds, not all oligomeric compounds are antisense compounds. Antisense oligonucleotides may be chemically modified or unmodified. Nonlimiting examples of oligomeric compounds include primers, probes, antisense compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, and siRNAs. As such, these compounds can be introduced in the form of single-stranded, double-stranded, circular, branched or hairpins and can contain structural elements such as internal or terminal bulges, loops or mismatches. Oligomeric double-stranded compounds can be two strands hybridized to form double-stranded compounds or a single strand with sufficient self complementarity to allow for hybridization and formation of a fully or partially double-stranded compound.

[0037] Antisense Mechanisms

[0038] Oligomeric compounds that modulate Gemin Gene expression via antisense mechanisms are one embodiment of the invention. While not wishing to be bound by theory, antisense mechanisms fall into two general non-exclusive categories. These categories are antisense mechanisms that (1) involve target degradation and (2) involve an occupancy-based mechanism wherein the cellular machinery is stalled and may or may not involve target degradation component.

[0039] A target degradation mechanism can include an RNase H mechanism. RNase H is a cellular endonuclease

which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are “DNA-like” elicit RNase H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression.

[0040] A target degradation mechanism can include RNA interference (RNAi). RNAi is a form of posttranscriptional gene silencing that was initially defined in the nematode, *Caenorhabditis elegans*, resulting from exposure to double-stranded RNA (dsRNA). In many species the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals and is believed to have an evolutionary connection to viral defense and transposon silencing (Guo and Kempheus, *Cell*, 1995, 81, 611-620; Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 1998, 95, 15502-15507). The RNAi compounds are often referred to as short interfering RNAs or siRNAs. Recently, it has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the siRNAs which are the potent inducers of RNAi (Tijsterman et al., *Science*, 2002, 295, 694-697). Both RNAi compounds (i.e., single- or double-stranded RNA or RNA-like compounds) and single-stranded RNase H-dependent antisense compounds bind to their RNA target by base pairing (i.e., hybridization) and induce site-specific cleavage of the target RNA by specific RNases; i.e., both work via an antisense mechanism (Vickers et al., 2003, *J. Biol. Chem.*, 278, 7108-7118). Double-stranded ribonucleases (dsRNases) such as those in the RNase III and ribonuclease L family of enzymes have been postulated to play a role in RNA target degradation. Double-stranded ribonucleases and oligomeric compounds that trigger them are further described in U.S. Pat. Nos. 5,898,031 and 6,107,094.

[0041] Nonlimiting examples of an occupancy based mechanism include inhibition of translation, modulation of splicing, modulation of poly(A) site selection and disruption of regulatory RNA structure. A method of controlling the behavior of a cell through modulation of the processing of an mRNA target by contacting the cell with an antisense compound acting via such a mechanism is disclosed in U.S. Pat. No. 6,210,892 and U.S. Pre-Grant Publication 20020049173.

[0042] Certain types of antisense compounds which specifically hybridize to the 5' cap region of their target mRNA interfere with translation of the target mRNA into protein. Such oligomers include peptide-nucleic acid (PNA) oligomers, morpholino oligomers snf oligonucleosides (such as those having an MMI or amide internucleoside linkage) and oligonucleotides having modifications at the 2' position of the sugar. This is believed to occur via interference with ribosome assembly on the target mRNA. Methods for inhibiting the translation of a selected capped target mRNA by contacting target mRNA with an antisense compound are disclosed in U.S. Pat. No. 5,789,573.

[0043] Antisense compounds targeted to specific splice variants of an RNA can be used to modulate the populations of alternatively spliced RNA products (see U.S. Patent Application entitled “Isoform-Specific Targeting of Splice Variants” filed Aug. 29, 2003, Ser. No. 10/651,772).

[0044] Antisense compounds targeted to a specific poly(A) site of mRNA can be used to modulate the populations of alternatively polyadenylated transcripts. In addition, anti-

sense compounds can be used to disrupt RNA regulatory structure thereby affecting, for example, the stability of the targeted RNA and its subsequent expression. Methods directed to such modulation are disclosed in U.S. Pat. No. 6,210,892 and Pre-Grant Publication 20020049173.

[0045] siRNAs

[0046] In another embodiment of the invention, oligomeric compounds of the invention comprise double-stranded antisense compounds encompassing short interfering RNAs (siRNAs). As used herein, the term "siRNA" is defined as a double-stranded compound having a first and second strand and comprises a central complementary portion between said first and second strands and terminal portions that are optionally complementary between said first and second strands or with the target mRNA. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. In one nonlimiting example, the first strand of the siRNA is antisense to the target nucleic acid, while the second strand is complementary to the first strand. Once the antisense strand is designed to target a particular nucleic acid target, the sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and either strand may contain modifications or additions to either terminus. For example, in one embodiment, both strands of the siRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. It is possible for one end of a duplex to be blunt and the other to have overhanging nucleobases. In one embodiment, the number of overhanging nucleobases is from 1 to 6 on the 3' end of each strand of the duplex. In another embodiment, the number of overhanging nucleobases is from 1 to 6 on the 3' end of only one strand of the duplex. In a further embodiment, the number of overhanging nucleobases is from 1 to 6 on one or both 5' ends of the duplexed strands. In another embodiment, the number of overhanging nucleobases is zero.

[0047] In one embodiment of the invention, double-stranded antisense compounds are canonical siRNAs. As used herein, the term "canonical siRNA" is defined as a double-stranded oligomeric compound having a first strand and a second strand each strand being 21 nucleobases in length with the strands being complementary over 19 nucleobases and having on each 3' termini of each strand a deoxy thymidine dimer (dTdT) which in the double-stranded compound acts as a 3' overhang.

[0048] Each strand of the siRNA duplex may be from about 8 to about 80 nucleobases, 10 to 50, 13 to 80, 13 to 50, 13 to 30, 13 to 24, 19 to 23, 20 to 80, 20 to 50, 20 to 30, or 20 to 24 nucleobases. The central complementary portion may be from about 8 to about 80 nucleobases in length, 10 to 50, 13 to 80, 13 to 50, 13 to 30, 13 to 24, 19 to 23, 20 to 80, 20 to 50, 20 to 30, or 20 to 24 nucleobases. The terminal portions can be from 1 to 6 nucleobases. The siRNAs may also have no terminal portions. The two strands of an siRNA can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single-stranded character.

[0049] In another embodiment, the double-stranded antisense compounds are blunt-ended siRNAs. As used herein the term "blunt-ended siRNA" is defined as an siRNA having no terminal overhangs. That is, at least one end of the double-stranded compound is blunt. siRNAs whether canonical or blunt act to elicit dsRNase enzymes and trigger the recruit-

ment or activation of the RNAi antisense mechanism. In a further embodiment, single-stranded RNAi (ssRNAi) compounds that act via the RNAi antisense mechanism are contemplated.

[0050] Further modifications can be made to the double-stranded compounds and may include conjugate groups attached to one of the termini, selected nucleobase positions, sugar positions or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, the compounds can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the compounds can be fully or partially double-stranded. When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary when they base pair in Watson-Crick fashion.

[0051] Compounds

[0052] The oligomeric compounds in accordance with this invention may comprise a complementary oligomeric compound from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). In other words, a single-stranded compound of the invention comprises from 8 to about 80 nucleobases, and a double-stranded antisense compound of the invention (such as a siRNA, for example) comprises two strands, each of which is from about 8 to about 80 nucleobases. In some embodiments, oligomeric compounds of the invention are 10 to 50, 13 to 80, 13 to 50, 13 to 30, 13 to 24, 19 to 23, 20 to 80, 20 to 50, 20 to 30, or 20 to 24 nucleobases in length. In one embodiment, the oligomeric compounds are 20 nucleobases in length.

[0053] Contained within the oligomeric compounds of the invention (whether single or double stranded and on at least one strand) are antisense portions. The "antisense portion" is that part of the oligomeric compound that is designed to confer antisense activity by one of the aforementioned potential antisense mechanisms. One of ordinary skill in the art will appreciate that this comprehends antisense portions of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases.

[0054] In one embodiment, the antisense compounds of the invention have antisense portions of 10 to 50 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases.

[0055] In one embodiment, the antisense compounds of the invention have antisense portions of 13 to 80 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases.

[0056] In one embodiment, the antisense compounds of the invention have antisense portions of 13 to 50 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of

13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases.

[0057] In one embodiment, the antisense compounds of the invention have antisense portions of 13 to 30 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleobases.

[0058] In some embodiments, the antisense compounds of the invention have antisense portions of 13 to 24 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleobases.

[0059] In one embodiment, the antisense compounds of the invention have antisense portions of 19 to 23 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 19, 20, 21, 22 or 23 nucleobases.

[0060] In one embodiment, the antisense compounds of the invention have antisense portions of 20 to 80 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases.

[0061] In one embodiment, the antisense compounds of the invention have antisense portions of 20 to 50 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases.

[0062] In one embodiment, the antisense compounds of the invention have antisense portions of 20 to 30 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases.

[0063] In one embodiment, the antisense compounds of the invention have antisense portions of 20 to 24 nucleobases. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 20, 21, 22, 23, or 24 nucleobases.

[0064] Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

[0065] Exemplary compounds include oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). Other compounds are represented by oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative antisense compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target

nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). It is also understood that compounds may be represented by oligonucleotide sequences that comprise at least 8 consecutive nucleobases from an internal portion of the sequence of an illustrative compound, and may extend in either or both directions until the oligonucleotide contains about 8 to about 80 nucleobases.

[0066] One having skill in the art armed with the antisense compounds illustrated herein will be able, without undue experimentation, to identify further antisense compounds.

[0067] Chemical Modifications

[0068] As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base (sometimes referred to as a "nucleobase" or simply a "base"). The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound. In addition, linear compounds may have internal nucleobase complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

[0069] Modified Internucleoside Linkages

[0070] Specific examples of oligomeric compounds useful of the present invention include oligonucleotides containing modified e.g. non-naturally occurring internucleoside linkages. As defined in this specification, oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom and internucleoside linkages that do not have a phosphorus atom. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0071] Oligomeric compounds can have one or more modified internucleoside linkages. Modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, phosphonoacetate and thiophosphonoacetate (see Sheehan et al., *Nucleic Acids Research*, 2003, 31(14), 4109-4118 and Dellingr et al., *J. Am. Chem. Soc.*, 2003, 125, 940-950), selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be

abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

[0072] N3'-P5'-phosphoramidates have been reported to exhibit both a high affinity towards a complementary RNA strand and nuclease resistance (Gryaznov et al., *J. Am. Chem. Soc.*, 1994, 116, 3143-3144). N3'-P5'-phosphoramidates have been studied with some success *in vivo* to specifically down regulate the expression of the c-myc gene (Skorski et al., *Proc. Natl. Acad. Sci.*, 1997, 94, 3966-3971; and Faira et al., *Nat. Biotechnol.*, 2001, 19, 40-44).

[0073] Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050.

[0074] In some embodiments of the invention, oligomeric compounds may have one or more phosphorothioate and/or heteroatom internucleoside linkages, in particular —CH₂-NH—O—CH₂-, —CH₂-N(CH₃)-O—CH₂- (known as a methylene (methylimino) or MMI backbone), —CH₂-O—N(CH₃)-CH₂-, —CH₂-N(CH₃)-N(CH₃)-CH₂- and —O—N(CH₃)-CH₂-CH₂- (wherein the native phosphodiester internucleotide linkage is represented as —O—P(=O)(OH)—O—CH₂-). The MMI type internucleoside linkages are disclosed in the above referenced U.S. Pat. No. 5,489,677. Amide internucleoside linkages are disclosed in the above referenced U.S. Pat. No. 5,602,240.

[0075] Some oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[0076] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439.

[0077] Modified Sugars

[0078] Oligomeric compounds may also contain one or more substituted sugar moieties. Suitable compounds can comprise one of the following at the T position: OH; F; O—, S—, or N-alkyl; O—S—, or N-alkenyl; O—S— or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Also suitable are O((CH₂)_nO)

,_nCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON((CH₂)_nCH₃)₂, where n and m are from 1 to about 10. Other oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-alkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. One modification includes 2'-methoxyethoxy (2'-O—CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further modification includes 2'-dimethylaminoxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylamino-ethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O—CH₂—O—CH₂—N(CH₃)₂, also described in examples hereinbelow.

[0079] Other modifications include 2'-methoxy (2'-O—CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂—CH=CH₂), 2'-O-allyl (2'-O—CH₂—CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. One 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Antisense compounds may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; 5,700,920; and, 6,147,200.

[0080] In one aspect of the present invention oligomeric compounds include nucleosides synthetically modified to induce a 3'-endo sugar conformation. A nucleoside can incorporate synthetic modifications of the heterocyclic base, the sugar moiety or both to induce a desired 3'-endo sugar conformation. These modified nucleosides are used to mimic RNA like nucleosides so that particular properties of an oligomeric compound can be enhanced while maintaining the desirable 3'-endo conformational geometry. There is an apparent preference for an RNA type duplex (A form helix, predominantly 3'-endo) as a requirement (e.g. trigger) of RNA interference which is supported in part by the fact that duplexes composed of 2'-deoxy-2'-F-nucleosides appears efficient in triggering RNAi response in the *C. elegans* system. Properties that are enhanced by using more stable 3'-endo nucleosides include but are not limited to: modulation of pharmacokinetic properties through modification of protein binding, protein off-rate, absorption and clearance; modulation of nuclease stability as well as chemical stability; modulation of the binding affinity and specificity of the oligomer (affinity and specificity for enzymes as well as for complementary sequences); and increasing efficacy of RNA

cleavage. Also provided herein are oligomeric triggers of RNAi having one or more nucleosides modified in such a way as to favor a C3'-endo type conformation.

[0081] Nucleoside conformation is influenced by various factors including substitution at the 2', 3' or 4'-positions of the pentofuranosyl sugar. Electronegative substituents generally prefer the axial positions, while sterically demanding substituents generally prefer the equatorial positions (Principles of Nucleic Acid Structure, Wolfgang Sanger, 1984, Springer-Verlag.) Modification of the 2' position to favor the 3'-endo conformation can be achieved while maintaining the 2'-OH as a recognition element (Gallo et al., Tetrahedron (2001), 57, 5707-5713. Harry-O'kuru et al., J. Org. Chem., (1997), 62(6), 1754-1759 and Tang et al., J. Org. Chem. (1999), 64, 747-754.) Alternatively, preference for the 3'-endo conformation can be achieved by deletion of the 2'-OH as exemplified by 2'-deoxy-2'F-nucleosides (Kawasaki et al., J. Med. Chem. (1993), 36, 831-841), which adopts the 3'-endo conformation positioning the electronegative fluorine atom in the axial position. Other modifications of the ribose ring, for example substitution at the 4'-position to give 4'-F modified nucleosides (Guillerm et al., Bioorganic and Medicinal Chemistry Letters (1995), 5, 1455-1460 and Owen et al., J. Org. Chem. (1976), 41, 3010-3017), or for example modification to yield methanocarba nucleoside analogs (Jacobson et al., J. Med. Chem. Lett. (2000), 43, 2196-2203 and Lee et al., Bioorganic and Medicinal Chemistry Letters (2001), 11, 1333-1337) also induce preference for the 3'-endo conformation. Along similar lines, triggers of RNAi response might be composed of one or more nucleosides modified in such a way that conformation is locked into a C3'-endo type conformation, i.e. Locked Nucleic Acid (LNA, Singh et al., Chem. Commun. (1998), 4, 455-456), and ethylene bridged Nucleic Acids (ENATTM, Morita et al., Bioorganic & Medicinal Chemistry Letters (2002), 12, 73-76.)

[0082] One conformation of modified nucleosides and their oligomers can be estimated by various methods such as molecular dynamics calculations, nuclear magnetic resonance spectroscopy and CD measurements. Hence, modifications predicted to induce RNA-like conformations, A-form duplex geometry in an oligomeric context, are selected for use in the modified oligonucleotides of the present invention. The synthesis of numerous of the modified nucleosides amenable to the present invention are known in the art (see for example, Chemistry of Nucleosides and Nucleotides Vol 1-3, ed. Leroy B. Townsend, 1988, Plenum press., and the examples section below.)

[0083] Oligonucleotide Mimetics

[0084] Another group of oligomeric compounds includes oligonucleotide mimetics. The term "mimetic" as it is applied to oligonucleotides includes oligomeric compounds wherein the furanose ring or the furanose ring and the internucleotide linkage are replaced with novel groups, replacement of only the furanose ring is also referred to in the art as being a sugar surrogate. The heterocyclic base moiety or a modified heterocyclic base moiety is maintained for hybridization with an appropriate target nucleic acid.

[0085] One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA) (Nielsen et al., *Science*, 1991, 254, 1497-1500). PNAs have favorable hybridization properties, high biological stability and are electrostatically neutral molecules. PNA compounds have been used to correct aberrant splicing in a transgenic

mouse model (Sazani et al., *Nat. Biotechnol.*, 2002, 20, 1228-1233). In PNA oligomeric compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are bound directly or indirectly ($-\text{C}(=\text{O})-\text{CH}_2-$ as shown below) to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA oligomeric compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262. PNA compounds can be obtained commercially from Applied Biosystems (Foster City, Calif., USA). Numerous modifications to the basic PNA backbone are known in the art; particularly useful are PNA compounds with one or more amino acids conjugated to one or both termini. For example, 1-8 lysine or arginine residues are useful when conjugated to the end of a PNA molecule.

[0086] Another class of oligonucleotide mimetic that has been studied is based on linked morpholino units (morpholino nucleic acid) having heterocyclic bases attached to the morpholino ring. A number of linking groups have been reported that link the morpholino monomeric units in a morpholino nucleic acid. One class of linking groups have been selected to give a non-ionic oligomeric compound. The non-ionic morpholino-based oligomeric compounds are less likely to have undesired interactions with cellular proteins. Morpholino-based oligomeric compounds are non-ionic mimetics of oligonucleotides which are less likely to form undesired interactions with cellular proteins (Dwaine A. Brasch and David R. Corey, *Biochemistry*, 2002, 41(14), 4503-4510). Morpholino-based oligomeric compounds have been studied in zebrafish embryos (see: *Genesis*, volume 30, issue 3, 2001 and Heasman, J., *Dev. Biol.*, 2002, 243, 209-214). Further studies of morpholino-based oligomeric compounds have also been reported (Nasevicius et al., *Nat. Genet.*, 2000, 26, 216-220; and Lacerda et al., *Proc. Natl. Acad. Sci.*, 2000, 97, 9591-9596). Morpholino-based oligomeric compounds are disclosed in U.S. Pat. No. 5,034,506. The morpholino class of oligomeric compounds have been prepared having a variety of different linking groups joining the monomeric subunits. Linking groups can be varied from chiral to achiral, and from charged to neutral. U.S. Pat. No. 5,166,315 discloses linkages including $-\text{O}-\text{P}(=\text{O})(\text{N}(\text{CH}_3)_2)-\text{O}-$; U.S. Pat. No. 5,034,506 discloses achiral intermorpholino linkages; and U.S. Pat. No. 5,185,444 discloses phosphorus containing chiral intermorpholino linkages.

[0087] A further class of oligonucleotide mimetic is referred to as cyclohexene nucleic acids (CeNA). The furanose ring normally present in a DNA or RNA molecule is replaced with a cyclohexenyl ring. CeNA DMT protected phosphoramidite monomers have been prepared and used for oligomeric compound synthesis following classical phosphoramidite chemistry. Fully modified CeNA oligomeric compounds and oligonucleotides having specific positions modified with CeNA have been prepared and studied (Wang et al., *J. Am. Chem. Soc.*, 2000, 122, 8595-8602). In general the incorporation of CeNA monomers into a DNA chain increases its stability of a DNA/RNA hybrid. CeNA oligoadenylates formed complexes with RNA and DNA complements with similar stability to the native complexes. The study of incorporating CeNA structures into natural nucleic acid structures was shown by NMR and circular dichroism to proceed with easy conformational adaptation. Furthermore the incorporation of CeNA into a sequence targeting RNA

was stable to serum and able to activate *E. coli* RNase H resulting in cleavage of the target RNA strand.

[0088] A further modification includes bicyclic sugar moieties such as "Locked Nucleic Acids" (LNAs) in which the 2'-hydroxyl group of the ribosyl sugar ring is linked to the 4' carbon atom of the sugar ring thereby forming a 2'-C,4'-C-oxymethylene linkage to form the bicyclic sugar moiety (reviewed in Elayadi et al., *Curr. Opinion Inven. Drugs*, 2001, 2, 558-561; Braasch et al., *Chem. Biol.*, 2001, 8 1-7; and Orum et al., *Curr. Opinion Mol. Ther.*, 2001, 3, 239-243; see also U.S. Pat. Nos. 6,268,490 and 6,670,461). The linkage can be a methylene ($-\text{CH}_2-$) group bridging the 2' oxygen atom and the 4' carbon atom, for which the term LNA is used for the bicyclic moiety; in the case of an ethylene group in this position, the term ENATM is used (Singh et al., *Chem. Commun.*, 1998, 4, 455-456; ENATM: Morita et al., *Bioorganic Medicinal Chemistry*, 2003, 11, 2211-2226). LNA and other bicyclic sugar analogs display very high duplex thermal stabilities with complementary DNA and RNA ($T_m=+3$ to $+10$ C), stability towards 3'-exonuclease degradation and good solubility properties. LNA's are commercially available from ProLigo (Paris, France and Boulder, Colo., USA).

[0089] An isomer of LNA that has also been studied is alpha-L-LNA which has been shown to have superior stability against a 3'-exonuclease (Frieden et al., *Nucleic Acids Research*, 2003, 21, 6365-6372). The alpha-L-LNA's were incorporated into antisense gapmers and chimeras that showed potent antisense activity.

[0090] Another similar bicyclic sugar moiety that has been prepared and studied has the bridge going from the 3'-hydroxyl group via a single methylene group to the 4' carbon atom of the sugar ring thereby forming a 3'-C,4'-C-oxymethylene linkage (see U.S. Pat. No. 6,043,060).

[0091] The conformations of LNAs determined by 2D NMR spectroscopy have shown that the locked orientation of the LNA nucleotides, both in single-stranded LNA and in duplexes, constrains the phosphate backbone in such a way as to introduce a higher population of the N-type conformation (Petersen et al., *J. Mol. Recognit.*, 2000, 13, 44-53). These conformations are associated with improved stacking of the nucleobases (Wengel et al., *Nucleosides Nucleotides*, 1999, 18, 1365-1370).

[0092] LNA has been shown to form exceedingly stable LNA:LNA duplexes (Koshkin et al., *J. Am. Chem. Soc.*, 1998, 120, 13252-13253). LNA:LNA hybridization was shown to be the most thermally stable nucleic acid type duplex system, and the RNA-mimicking character of LNA was established at the duplex level. Introduction of 3 LNA monomers (T or A) significantly increased melting points ($T_m=+15/+11$) toward DNA complements. The universality of LNA-mediated hybridization has been stressed by the formation of exceedingly stable LNA:LNA duplexes. The RNA-mimicking of LNA was reflected with regard to the N-type conformational restriction of the monomers and to the secondary structure of the LNA:RNA duplex.

[0093] LNAs also form duplexes with complementary DNA, RNA or LNA with high thermal affinities. Circular dichroism (CD) spectra show that duplexes involving fully modified LNA (esp. LNA:RNA) structurally resemble an A-form RNA:RNA duplex. Nuclear magnetic resonance (NMR) examination of an LNA:DNA duplex confirmed the 3'-endo conformation of an LNA monomer. Recognition of double-stranded DNA has also been demonstrated suggesting strand invasion by LNA. Studies of mismatched sequences

show that LNAs obey the Watson-Crick base pairing rules with generally improved selectivity compared to the corresponding unmodified reference strands. DNA:LNA chimeras have been shown to efficiently inhibit gene expression when targeted to a variety of regions (5'-untranslated region, region of the start codon or coding region) within the luciferase mRNA (Braasch et al., *Nucleic Acids Research*, 2002, 30, 5160-5167).

[0094] Potent and nontoxic antisense oligonucleotides containing LNAs have been described (Wahlestedt et al., *Proc. Natl. Acad. Sci. U.S.A.*, 2000, 97, 5633-5638). The authors have demonstrated that LNAs confer several desired properties. LNA/DNA copolymers were not degraded readily in blood serum and cell extracts. LNA/DNA copolymers exhibited potent antisense activity in assay systems as disparate as G-protein-coupled receptor signaling in living rat brain and detection of reporter genes in *Escherichia coli*. Lipofectin-mediated efficient delivery of LNA into living human breast cancer cells has also been accomplished. Further successful in vivo studies involving LNA's have shown knock-down of the rat delta opioid receptor without toxicity (Wahlestedt et al., *Proc. Natl. Acad. Sci.*, 2000, 97, 5633-5638) and in another study showed a blockage of the translation of the large subunit of RNA polymerase II (Fluiter et al., *Nucleic Acids Res.*, 2003, 31, 953-962).

[0095] The synthesis and preparation of the LNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their oligomerization, and nucleic acid recognition properties have been described (Koshkin et al., *Tetrahedron*, 1998, 54, 3607-3630). LNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226.

[0096] Analogs of LNA, phosphorothioate-LNA and 2'-thio-LNAs, have also been prepared (Kumar et al., *Bioorg. Med. Chem. Lett.*, 1998, 8, 2219-2222). Preparation of locked nucleoside analogs containing oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described (Wengel et al., WO 99/14226). Furthermore, synthesis of 2'-amino-LNA, a novel conformationally restricted high-affinity oligonucleotide analog has been described in the art (Singh et al., *J. Org. Chem.*, 1998, 63, 10035-10039). In addition, 2'-Amino- and 2'-methylamino-LNA's have been prepared and the thermal stability of their duplexes with complementary RNA and DNA strands has been previously reported.

[0097] Another oligonucleotide mimetic that has been prepared and studied is threose nucleic acid. This oligonucleotide mimetic is based on threose nucleosides instead of ribose nucleosides. Initial interest in (3',2')-alpha-L-threose nucleic acid (TNA) was directed to the question of whether a DNA polymerase existed that would copy the TNA. It was found that certain DNA polymerases are able to copy limited stretches of a TNA template (reported in *Chemical and Engineering News*, 2003, 81, 9). In another study it was determined that TNA is capable of antiparallel Watson-Crick base pairing with complementary DNA, RNA and TNA oligonucleotides (Chaput et al., *J. Am. Chem. Soc.*, 2003, 125, 856-857).

[0098] In one study (3',2')-alpha-L-threose nucleic acid was prepared and compared to the 2' and 3' amide analogs (Wu et al., *Organic Letters*, 2002, 4(8), 1279-1282). The amide analogs were shown to bind to RNA and DNA with comparable strength to that of RNA/DNA.

[0099] Further oligonucleotide mimetics have been prepared to include bicyclic and tricyclic nucleoside analogs (see Steffens et al., *Helv. Chim. Acta*, 1997, 80, 2426-2439; Steffens et al., *J. Am. Chem. Soc.*, 1999, 121, 3249-3255; Renneberg et al., *J. Am. Chem. Soc.*, 2002, 124, 5993-6002; and Renneberg et al., *Nucleic acids res.*, 2002, 30, 2751-2757). These modified nucleoside analogs have been oligomerized using the phosphoramidite approach and the resulting oligomeric compounds containing tricyclic nucleoside analogs have shown increased thermal stabilities (T_m 's) when hybridized to DNA, RNA and itself. Oligomeric compounds containing bicyclic nucleoside analogs have shown thermal stabilities approaching that of DNA duplexes.

[0100] Another class of oligonucleotide mimetic is referred to as phosphonomonoester nucleic acids which incorporate a phosphorus group in the backbone. This class of oligonucleotide mimetic is reported to have useful physical and biological and pharmacological properties in the areas of inhibiting gene expression (antisense oligonucleotides, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids and as auxiliaries for use in molecular biology. Further oligonucleotide mimetics amenable to the present invention have been prepared wherein a cyclobutyl ring replaces the naturally occurring furanosyl ring.

[0101] Modified and Alternate Nucleobases

[0102] Oligomeric compounds may also include nucleobase (often referred to in the art as heterocyclic base or simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), carbazole cytidine(2H-pyrimido(4,5-b)indol-2-one), pyrido-indole cytidine(H-pyrido(3',2':4,5)pyrrolo(2,3-d)pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30,

613, and those disclosed by Sanghvi, Y. S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are known to those skilled in the art as suitable for increasing the binding affinity of the compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. and are presently suitable base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

[0103] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; 5,681,941; and 5,750,692.

[0104] Oligomeric compounds of the present invention can also include polycyclic heterocyclic compounds in place of one or more of the naturally-occurring heterocyclic base moieties. A number of tricyclic heterocyclic compounds have been previously reported. These compounds are routinely used in antisense applications to increase the binding properties of the modified strand to a target strand. The most studied modifications are targeted to guanosines hence they have been termed G-clamps or cytidine analogs. Representative cytosine analogs that make 3 hydrogen bonds with a guanosine in a second strand include 1,3-diazaphenoxazine-2-one ($R_{10}=O$, $R_{11}=R_{14}=H$) (Kurchavov, et al., *Nucleosides and Nucleotides*, 1997, 16, 1837-1846), 1,3-diazaphenothiazine-2-one ($R_{10}=S$, $R_{11}=R_{14}=H$), (Lin, K.-Y.; Jones, R. J.; Matteucci, M. J. Am. Chem. Soc. 1995, 117, 3873-3874) and 6,7,8,9-tetrafluoro-1,3-diazaphenoxazine-2-one ($R_{10}=O$, $R_{11}=R_{14}=F$) (Wang, J.; Lin, K.-Y., Matteucci, M. *Tetrahedron Lett.* 1998, 39, 8385-8388). Incorporated into oligonucleotides these base modifications were shown to hybridize with complementary guanine and the latter was also shown to hybridize with adenine and to enhance helical thermal stability by extended stacking interactions (also see U.S. Patent Application entitled "Modified Peptide Nucleic Acids" filed May 24, 2002, Ser. No. 10/155,920; and U.S. Patent Application entitled "Nuclease Resistant Chimeric Oligonucleotides" filed May 24, 2002, Ser. No. 10/013,295).

[0105] Further helix-stabilizing properties have been observed when a cytosine analog/substitute has an aminoethoxy moiety attached to the rigid 1,3-diazaphenoxazine-2-one scaffold ($R_{10}=O$, $R_{11}=-O-(CH_2)_2-NH_2$, $R_{12-14}=H$) (Lin, K.-Y.; Matteucci, M. J. Am. Chem. Soc. 1998, 120, 8531-8532). Binding studies demonstrated that a single incorporation could enhance the binding affinity of a model oligonucleotide to its complementary target DNA or RNA with a ΔT_m of up to 18° relative to 5-methyl cytosine (dCS^{me}), which is a high affinity enhancement for a single modification. On the other hand, the gain in helical stability does not compromise the specificity of the oligonucleotides.

[0106] Further tricyclic heterocyclic compounds and methods of using them that are amenable to use in the present invention are disclosed in U.S. Pat. Nos. 6,028,183, and 6,007,992.

[0107] The enhanced binding affinity of the phenoxazine derivatives together with their uncompromised sequence specificity makes them valuable nucleobase analogs for the development of more potent antisense-based drugs. In fact, promising data have been derived from in vitro experiments demonstrating that heptanucleotides containing phenoxazine substitutions are capable to activate RNase H, enhance cellular uptake and exhibit an increased antisense activity (Lin, K.-Y; Matteucci, M. J. Am. Chem. Soc. 1998, 120, 8531-8532). The activity enhancement was even more pronounced in case of G-clamp, as a single substitution was shown to significantly improve the in vitro potency of a 20 mer 2'-deoxyphosphorothioate oligonucleotides (Flanagan, W. M.; Wolf, J. J.; Olson, P.; Grant, D.; Lin, K.-Y.; Wagner, R. W.; Matteucci, M. Proc. Natl. Acad. Sci. USA, 1999, 96, 3513-3518).

[0108] Further modified polycyclic heterocyclic compounds useful as heterocyclic bases are disclosed in but not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. No. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,434,257; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,646,269; 5,750,692; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, and United States Pre-Grant Publication 20030158403 filed Nov. 28, 2001.

[0109] Conjugates

[0110] Another modification of the oligomeric compounds of the invention involves chemically linking to the oligomeric compound one or more moieties or conjugates which enhance the properties of the oligomeric compound, such as to enhance the activity, cellular distribution or cellular uptake of the oligomeric compound. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. Nos. 6,287,860 and 6,762,169.

[0111] Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantine acetic acid, a palmitoyl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligomeric compounds of the invention may also be conjugated to drug substances, for example, aspirin, warfarin, phenylbutazone,

ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triodobenzoic acid, flufenamic acid, folic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999).

[0112] Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

[0113] Oligomeric compounds can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of an oligomeric compound to enhance properties such as for example nuclease stability. Included in stabilizing groups are cap structures. By "cap structure or terminal cap moiety" is meant chemical modifications, which have been incorporated at either terminus of oligonucleotides (see for example Wincott et al., WO 97/26270). These terminal modifications protect the oligomeric compounds having terminal nucleic acid molecules from exonuclease degradation, and can improve delivery and/or localization within a cell. The cap can be present at either the 5'-terminus (5'-cap) or at the 3'-terminus (3'-cap) or can be present on both termini of a single strand, or one or more termini of both strands of a double-stranded compound. This cap structure is not to be confused with the inverted methylguanosine "5'cap" present at the 5' end of native mRNA molecules. In non-limiting examples, the 5'-cap includes inverted abasic residue (moiety), 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety (for more details see Wincott et al., International PCT publication No. WO 97/26270). For siRNA constructs, the 5' end (5' cap) is commonly but not limited to 5'-hydroxyl or 5'-phosphate.

[0114] Particularly suitable 3'-cap structures include, for example 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide;

modified base nucleotide; phosphorodithioate; threo-pento-furanosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butane-diol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Tyer, 1993, Tetrahedron 49, 1925).

[0115] Further 3' and 5'-stabilizing groups that can be used to cap one or both ends of an oligomeric compound to impart nuclease stability include those disclosed in WO 03/004602 published on Jan. 16, 2003.

[0116] Chimeric Compounds

[0117] It is not necessary for all positions in a given oligomeric compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even within a single nucleoside within an oligomeric compound.

[0118] The present invention also includes oligomeric compounds which are chimeric compounds. "Chimeric" oligomeric compounds or "chimeras," in the context of this invention, are single-or double-stranded oligomeric compounds, such as oligonucleotides, which contain two or more chemically distinct regions, each comprising at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. Chimeric antisense oligonucleotides are one form of oligomeric compound. These oligonucleotides typically contain at least one region which is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, alteration of charge, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for RNases or other enzymes. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target when bound by a DNA-like oligomeric compound, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNase III or RNaseL which cleaves both cellular and viral RNA. Cleavage products of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0119] Chimeric oligomeric compounds of the invention can be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides, oligonucleotide mimetics, or regions or portions thereof. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922.

[0120] A "gapmer" is defined as an oligomeric compound, generally an oligonucleotide, having a 2'-deoxyoligonucleotide flanked by non-deoxyoligonucleotides. The central region is referred to as the "gap." The flanking regions are referred to as "wings." While not wishing to be bound by theory, the gap of the gapmer presents a substrate recognizable by RNase H when bound to the RNA target whereas the

wings do not provide such a substrate but can confer other properties such as contributing to duplex stability or advantageous pharmacokinetic effects. Each wing can be one or more non-deoxyoligonucleotide monomers (if one of the wings has zero non-deoxyoligonucleotide monomers, a "hemimer" is described). In one embodiment, the gapmer is a ten deoxynucleotide gap flanked by five non-deoxynucleotide wings. This is referred to as a 5-10-5 gapmer. Other configurations are readily recognized by those skilled in the art. In one embodiment the wings comprise 2'-MOE modified nucleotides. In another embodiment the gapmer has a phosphorothioate backbone. In another embodiment the gapmer has 2'-MOE wings and a phosphorothioate backbone. Other suitable modifications are readily recognizable by those skilled in the art.

[0121] Oligomer Synthesis

[0122] Oligomerization of modified and unmodified nucleosides can be routinely performed according to literature procedures for DNA (Protocols for Oligonucleotides and Analogs, Ed. Agrawal (1993), Humana Press) and/or RNA (Scaringe, Methods (2001), 23, 206-217. Gait et al., Applications of Chemically synthesized RNA in RNA: Protein Interactions, Ed. Smith (1998), 1-36. Gallo et al., Tetrahedron (2001), 57, 5707-5713).

[0123] Oligomeric compounds of the present invention can be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0124] Starting Materials and Intermediates

[0125] The following precursor compounds, including amidites and their intermediates can be prepared by methods routine to those skilled in the art; 5'-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite, 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite, 5'-O-Dimethoxytrityl-2'-deoxy-N4-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite, (5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-3'-O-yl)-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite), 2'-Fluorodeoxyadenosine, 2'-Fluorodeoxyguanosine, 2'-Fluorouridine, 2'-Fluorodeoxycytidine, 2'-O-(2-Methoxyethyl) modified amidites, 2'-O-(2-methoxyethyl)-5-methyluridine intermediate, 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate, (5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl)-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite), 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate, 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methyl-cytidine penultimate intermediate, (5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl)-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite), (5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyladenosin-3'-O-yl)-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amidite), (5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosin-3'-O-yl)-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite), 2'-O-

(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminoxyethyl) nucleoside amidites, 2'- (Dimethylaminoxyethoxy) nucleoside amidites, 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine, 5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine, 2'-O-((2-phthalimidoxy)ethyl)-5'-tert-butyldiphenylsilyl-5-methyluridine, 5'-O-tert-butyldiphenylsilyl-2'-O-((2-formadoximinoxy)ethyl)-5-methyluridine, 5'-O-tert-Butyldiphenylsilyl-2'-O-(N,N-dimethylaminoxyethyl)-5-methyluridine, 2'-O-(dimethylaminoxyethyl)-5-methyluridine, 5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine, 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite), 2'- (Aminooxyethoxy) nucleoside amidites, N2-isobutryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite).

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites, 2'-O-(2(2-N,N-dimethylaminoethoxy)ethyl)-5-methyl uridine, 5'-O-dimethoxytrityl-2'-O-(2(2-N,N-dimethylaminoethoxy)-ethyl))-5-methyl uridine and 5'-O-Dimethoxytrityl-2'-O-(2(2-N,N-dimethylaminoethoxy)-ethyl))-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl) phosphoramidite.

[0126] The preparation of such precursor compounds for oligonucleotide synthesis are routine in the art and disclosed in U.S. Pat. No. 6,426,220 and published PCT WO 02/36743.

[0127] 2'-Deoxy and 2'-methoxy beta-cyanoethyl diisopropyl phosphoramidites can be purchased from commercial sources (e.g. Chemgenes, Needham, Mass. or Glen Research, Inc. Sterling, Va.). Other 2'-O-alkoxy substituted nucleoside amidites can be prepared as described in U.S. Pat. No. 5,506,351.

[0128] Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides can be synthesized routinely according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling Va. or ChemGenes, Needham, Mass.).

[0129] 2'-fluoro oligonucleotides can be synthesized routinely as described (Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841) and U.S. Pat. No. 5,670,633.

[0130] 2'-O-Methoxyethyl-substituted nucleoside amidites can be prepared routinely as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

[0131] Aminooxyethyl and dimethylaminoxyethyl amidites can be prepared routinely as per the methods of U.S. Pat. No. 6,127,533.

[0132] Oligonucleotide Synthesis

[0133] Phosphorothioate-containing oligonucleotides (P=S) can be synthesized by methods routine to those skilled in the art (see, for example, Protocols for Oligonucleotides and Analogs, Ed. Agrawal (1993), Humana Press). Phosphinate oligonucleotides can be prepared as described in U.S. Pat. No. 5,508,270.

[0134] Alkyl phosphonate oligonucleotides can be prepared as described in U.S. Pat. No. 4,469,863.

[0135] 3'-Deoxy-3'-methylene phosphonate oligonucleotides can be prepared as described in U.S. Pat. Nos. 5,610,289 or 5,625,050.

[0136] Phosphoramidite oligonucleotides can be prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878.

[0137] Alkylphosphonothioate oligonucleotides can be prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively).

[0138] 3'-Deoxy-3'-amino phosphoramidate oligonucleotides can be prepared as described in U.S. Pat. No. 5,476,925.

[0139] Phosphotriester oligonucleotides can be prepared as described in U.S. Pat. No. 5,023,243.

[0140] Borano phosphate oligonucleotides can be prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198.

[0141] 4'-thio-containing oligonucleotides can be synthesized as described in U.S. Pat. No. 5,639,873.

[0142] Oligonucleoside Synthesis

[0143] Methylenemethylinimo linked oligonucleosides, also identified as MMI linked oligonucleosides, methylene-dimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonyl amino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages can be prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289.

[0144] Formacetal and thioformacetal linked oligonucleosides can be prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564.

[0145] Ethylene oxide linked oligonucleosides can be prepared as described in U.S. Pat. Nos. 5,223,618.

[0146] Peptide Nucleic Acid Synthesis

[0147] Peptide nucleic acids (PNAs) can be prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Pat. Nos. 5,539,082, 5,700,922, 5,719,262, 6,559,279 and 6,762,281.

[0148] Synthesis of 2'-O-Protected Oligomers/RNA Synthesis

[0149] Oligomeric compounds incorporating at least one 2'-O-protected nucleoside by methods routine in the art. After incorporation and appropriate deprotection the 2'-O-protected nucleoside will be converted to a ribonucleoside at the position of incorporation. The number and position of the 2'-ribonucleoside units in the final oligomeric compound can vary from one at any site or the strategy can be used to prepare up to a full 2'-OH modified oligomeric compound.

[0150] A large number of 2'-O-protecting groups have been used for the synthesis of oligoribonucleotides and any can be used. Some of the protecting groups used initially for oligoribonucleotide synthesis included tetrahydropyran-1-yl and 4-methoxytetrahydropyran-4-yl. These two groups are not compatible with all 5'-O-protecting groups so modified versions were used with 5'-DMT groups such as 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp). Reese et al. have identified a number of piperidine derivatives (like Fpmp) that are useful in the synthesis of oligoribonucleotides including 1-[chloro-4-methylphenyl]-4'-methoxypiperidin-4-yl (Reese et al., *Tetrahedron Lett.*, 1986, (27), 2291). Another approach is to replace the standard 5'-DMT (dimethoxytrityl) group with protecting groups that were removed under non-acidic conditions such as levulinyl and 9-fluorenylmethoxy-carbonyl. Such groups enable the use of acid labile 2'-protect-

ing groups for oligoribonucleotide synthesis. Another more widely used protecting group, initially used for the synthesis of oligoribonucleotides, is the t-butylidimethylsilyl group (Ogilvie et al., Tetrahedron Lett., 1974, 2861; Hakimelahi et al., Tetrahedron Lett., 1981, (22), 2543; and Jones et al., J. Chem. Soc. Perkin I., 2762). The 2'-O-protecting groups can require special reagents for their removal. For example, the t-butylidimethylsilyl group is normally removed after all other cleaving/deprotecting steps by treatment of the oligomeric compound with tetrabutylammonium fluoride (TBAF).

[0151] One group of researchers examined a number of 2'-O-protecting groups (Pitsch, S., Chimia, 2001, (55), 320-324.) The group examined fluoride labile and photolabile protecting groups that are removed using moderate conditions. One photolabile group that was examined was the [2-(nitrobenzyl)oxy]methyl (nbm) protecting group (Schwartz et al., Bioorg. Med. Chem. Lett., 1992, (2), 1019.) Other groups examined included a number structurally related formaldehyde acetal-derived, 2'-O-protecting groups. Also prepared were a number of related protecting groups for preparing 2'-O-alkylated nucleoside phosphoramidites including 2'-O-[(triisopropylsilyl)oxy]methyl (2'-O—CH₂—O—Si(iPr)₃, TOM). One 2'-O-protecting group that was prepared to be used orthogonally to the TOM group was 2'-O-[(R)-1-(2-nitrophenyl)ethoxy]methyl]((R)-mnmbm).

[0152] Another strategy using a fluoride labile 5'-O-protecting group (non-acid labile) and an acid labile 2'-O-protecting group has been reported (Scaringe, Stephen A., Methods, 2001, (23) 206-217). A number of possible silyl ethers were examined for 5'-O-protection and a number of acetals and orthoesters were examined for 2'-O-protection. The protection scheme that gave the best results was 5'-O-silyl ether-2'-ACE (5'-O-bis(trimethylsiloxy)cyclododecyloxysilyl ether (DOD)-2'-O-bis(2-acetoxyethoxy)methyl (ACE)). This approach uses a modified phosphoramidite synthesis approach in that some different reagents are required that are not routinely used for RNA/DNA synthesis.

[0153] The main RNA synthesis strategies that are presently being used commercially include 5'-O-DMT-2'-O-t-butylidimethylsilyl (TBDMS), 5'-O-DMT-2'-O-[1(2-fluorophenyl)-4-methoxypiperidin-4-yl] (FPMP), 2'-O-[(triisopropylsilyl)oxy]methyl (2'-O—CH₂—O—Si(iPr)₃ (TOM), and the 5'-O-silyl ether-2'-ACE (5'-O-bis(trimethylsiloxy)cyclododecyloxysilyl ether (DOD)-2'-O-bis(2-acetoxyethoxy)methyl (ACE)). Some companies currently offering RNA products include Pierce Nucleic Acid Technologies (Milwaukee, Wis.), Dharmacon Research Inc. (a subsidiary of Fisher Scientific, Lafayette, Colo.), and Integrated DNA Technologies, Inc. (Coralville, Iowa). One company, Princeton Separations, markets an RNA synthesis activator advertised to reduce coupling times especially with TOM and TBDMS chemistries. Such an activator would also be amenable to the oligomeric compounds of the present invention.

[0154] The primary groups being used for commercial RNA synthesis are:

[0155] TBDMS=5'-O-DMT-2'-O-t-butylidimethylsilyl;

[0156] TOM=2'-O-[(triisopropylsilyl)oxy]methyl;

[0157] DOD/ACE=(5'-O-bis(trimethylsiloxy)cyclododecyloxysilyl ether-2'-O-bis(2-acetoxyethoxy)methyl

[0158] FPMP=5'-O-DMT-2'-O-[1(2-fluorophenyl)-4-methoxypiperidin-4-yl].

[0159] All of the aforementioned RNA synthesis strategies are amenable to the oligomeric compounds of the present invention. Strategies that would be a hybrid of the above e.g. using a 5'-protecting group from one strategy with a 2'-O-protecting from another strategy is also contemplated herein.

[0160] Synthesis of Chimeric Oligomeric Compounds

(2'-O-Me)-(2'-deoxy)-(2'-O-Me) Chimeric Phosphorothioate Oligonucleotides

[0161] Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments can be routinely synthesized by one skilled in the art, using, for example, an Applied Biosystems automated DNA synthesizer Model 394. Oligonucleotides can be synthesized using an automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for the 2'-O-alkyl portion. In one nonlimiting example, the standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at 55° C. The deprotected oligonucleotide is then recovered by an appropriate method (precipitation, column chromatography, volume reduced in vacuo) and analyzed by methods routine in the art.

(2'-O-(2-Methoxyethyl))-(2'-deoxy)-(2'-O-(Methoxyethyl)) Chimeric Phosphorothioate Oligonucleotides

[0162] (2'-O-(2-methoxyethyl))-(2'-deoxy)-(-2'-O-(methoxyethyl)) chimeric phosphorothioate oligonucleotides can be prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

(2'-O-(2-Methoxyethyl)Phosphodiester)-(2'-deoxy Phosphorothioate)-(2'-O-(2-Methoxyethyl)Phosphodiester) Chimeric Oligonucleotides

[0163] (2'-O-(2-methoxyethyl) phosphodiester)-(2'-deoxy phosphorothioate)-(2'-O-(methoxyethyl)phosphodiester) chimeric oligonucleotides can be prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

[0164] Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides can be synthesized according to U.S. Pat. No. 5,623,065.

[0165] Oligomer Purification and Analysis

[0166] Methods of oligomeric compound purification and analysis are well known to those skilled in the art. Analysis methods include capillary electrophoresis (CE) and electrospray-mass spectroscopy. Such synthesis and analysis methods can be performed in multi-well plates.

[0167] Hybridization

[0168] "Hybridization" means the pairing of complementary strands of oligomeric compounds. While not limited to a

particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

[0169] An oligomeric compound is specifically hybridizable when there is a sufficient degree of complementarity to avoid non-specific binding of the oligomeric compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

[0170] "Stringent hybridization conditions" or "stringent conditions" refers to conditions under which an oligomeric compound will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances, and "stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated.

[0171] Complementarity

[0172] "Complementarity," as used herein, refers to the capacity for precise pairing between two nucleobases on one or two oligomeric compound strands. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligomeric compound and the further DNA or RNA are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleobases such that stable and specific binding occurs between the oligomeric compound and a target nucleic acid.

[0173] It is understood in the art that the sequence of an oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure). The oligomeric compounds of the present invention comprise at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an oligomeric compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an oligomeric compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of

complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an oligomeric compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489).

[0174] The oligomeric compounds of the invention also include variants in which a different base is present at one or more of the nucleotide positions in the compound. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine, guanosine or cytidine at this position. This may be done at any of the positions of the oligomeric compound. These compounds are then tested using the methods described herein to determine their ability to inhibit expression of a Gemin Gene mRNA.

[0175] In one embodiment, homology, sequence identity or complementarity, between the oligomeric compound and target nucleic acid is from about 50% to about 60%. In another embodiment, homology, sequence identity or complementarity, is from about 60% to about 70%. In another embodiment, homology, sequence identity or complementarity, is from about 70% to about 80%. In another embodiment, homology, sequence identity or complementarity, is from about 80% to about 90%. In still other embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

[0176] Target Nucleic Acids

[0177] "Targeting" an oligomeric compound to a particular target nucleic acid molecule can be a multistep process. The process usually begins with the identification of a target nucleic acid whose expression is to be modulated. As used herein, the terms "target nucleic acid" and "nucleic acid encoding a Gemin Gene" encompass DNA encoding a Gemin Gene, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. For example, the target nucleic acid can be a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. As disclosed herein, the target nucleic acid encodes a Gemin Gene.

[0178] Target Regions, Segments, and Sites

[0179] The targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. "Region" is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. "Segments" are defined as smaller or sub-portions of regions within a target nucleic acid. "Sites," as used in the present invention, are defined as positions within a target nucleic acid.

[0180] Start Codons

[0181] Since, as is known in the art, the translation initiation codon is typically 5' AUG (in transcribed mRNA molecules; 5' ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon." A minority of genes have a translation initiation codon having the RNA sequence 5' GUG, 5' UUG or 5' CUG, and 5' AUA, 5' ACG and 5' CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. "Start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA transcribed from a gene encoding a protein, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5' UAA, 5' UAG and 5' UGA (the corresponding DNA sequences are 5' TAA, 5' TAG and 5' TGA, respectively).

[0182] The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions which may be targeted effectively with oligomeric compounds of the invention.

[0183] Coding Regions

[0184] The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Within the context of the present invention, one region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

[0185] Untranslated Regions

[0186] Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene), and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. The 5' cap region is also a target.

[0187] Introns and Exons

[0188] Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence, resulting in exon-exon junctions at the site where exons are joined. Targeting exon-exon junctions can be useful in situations where aberrant levels of a normal splice product is implicated in disease, or where aberrant levels of an aberrant splice product is implicated in disease. Targeting splice sites, i.e., intron-exon junctions or exon-intron junctions can also be particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also suitable targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts" and are also suitable targets. It is also known that introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA. Single-stranded antisense compounds such as oligonucleotide compounds that work via an RNase H mechanism are effective for targeting pre-mRNA. Antisense compounds that function via an occupancy-based mechanism are effective for redirecting splicing as they do not, for example, elicit RNase H cleavage of the mRNA, but rather leave the mRNA intact and promote the yield of desired splice product(s).

[0189] Variants

[0190] It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants." More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

[0191] Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants." Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants." If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

[0192] It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Consequently, the types of variants described herein are also suitable target nucleic acids.

[0193] Target Names, Synonyms, Features

[0194] In accordance with the present invention are compositions and methods for modulating the expression of genes

which are presented in Table 1. Table 1 lists the gene target names and their respective synonyms, as well as GenBank accession numbers used to design oligomeric compounds targeted to each gene. Table 1 also describes features contained within the gene target nucleic acid sequences of the invention. Representative features include 5'UTR, start codon, coding sequence (coding), stop codon, 3'UTR, exon,

intron, exon:exon junction, intron:exon junction and exon:intron junction. “Feature start site” and “feature end site” refer to the first (5'-most) and last (3'-most) nucleotide numbers, respectively, of the described feature with respect to the designated sequence. For example, for a sequence containing a start codon comprising the first three nucleotides, “feature start site” is “1” and “feature end site” is “3”.

TABLE 1

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin2	SIP1; SMP-interacting protein 1; survival of motor neuron protein interacting protein 1	Human	AB037701.1	start codon	1	3 1
Gemin2	Same as above	Human	AB037701.1	start codon	1	3 1
Gemin2	Same as above	Human	AB037701.1	CDS	1	798 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	170	171 1
Gemin2	Same as above	Human	AB037701.1	exon	171	255 1
Gemin2	Same as above	Human	AB037701.1	stop codon	213	215 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	255	256 1
Gemin2	Same as above	Human	AB037701.1	exon	256	345 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	345	346 1
Gemin2	Same as above	Human	AB037701.1	exon	346	405 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	405	406 1
Gemin2	Same as above	Human	AB037701.1	exon	406	519 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	519	520 1
Gemin2	Same as above	Human	AB037701.1	exon	520	588 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	588	589 1
Gemin2	Same as above	Human	AB037701.1	exon	589	699 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	699	700 1
Gemin2	Same as above	Human	AB037701.1	exon	700	758 1
Gemin2	Same as above	Human	AB037701.1	exon:exon junction	758	759 1
Gemin2	Same as above	Human	AB037701.1	3'UTR	768	815 1
Gemin2	Same as above	Human	AB037701.1	stop codon	796	798 1
Gemin2	Same as above	Human	AB037701.1	stop codon	796	798 1
Gemin2	Same as above	Human	AB037701.1	3'UTR	799	815 1
Gemin2	Same as above	Human	AB037702.1	start codon	1	3 2
Gemin2	Same as above	Human	AB037702.1	start codon	1	3 2
Gemin2	Same as above	Human	AB037702.1	CDS	1	753 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	170	171 2
Gemin2	Same as above	Human	AB037702.1	exon	171	255 2
Gemin2	Same as above	Human	AB037702.1	stop codon	213	215 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	255	256 2
Gemin2	Same as above	Human	AB037702.1	exon	256	345 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	345	346 2
Gemin2	Same as above	Human	AB037702.1	exon	346	405 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	405	406 2
Gemin2	Same as above	Human	AB037702.1	exon	406	519 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	519	520 2
Gemin2	Same as above	Human	AB037702.1	exon	520	564 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	564	565 2
Gemin2	Same as above	Human	AB037702.1	exon	565	633 2

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	633	634 2
Gemin2	Same as above	Human	AB037702.1	exon	634	744 2
Gemin2	Same as above	Human	AB037702.1	exon:exon junction	744	745 2
Gemin2	Same as above	Human	AB037702.1	stop codon	751	753 2
Gemin2	Same as above	Human	AB037702.1	3'UTR	754	801 2
Gemin2	Same as above	Human	AB037702.1	stop codon	782	784 2
Gemin2	Same as above	Human	AB037703.1	start codon	1	3 3
Gemin2	Same as above	Human	AB037703.1	start codon	1	3 3
Gemin2	Same as above	Human	AB037703.1	CDS	1	135 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	90	91 3
Gemin2	Same as above	Human	AB037703.1	exon	91	175 3
Gemin2	Same as above	Human	AB037703.1	stop codon	133	135 3
Gemin2	Same as above	Human	AB037703.1	3'UTR	136	825 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	175	176 3
Gemin2	Same as above	Human	AB037703.1	exon	176	265 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	265	266 3
Gemin2	Same as above	Human	AB037703.1	exon	266	325 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	325	326 3
Gemin2	Same as above	Human	AB037703.1	exon	326	439 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	439	440 3
Gemin2	Same as above	Human	AB037703.1	exon	440	484 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	484	485 3
Gemin2	Same as above	Human	AB037703.1	exon	485	553 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	553	554 3
Gemin2	Same as above	Human	AB037703.1	exon	554	664 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	664	665 3
Gemin2	Same as above	Human	AB037703.1	exon	665	723 3
Gemin2	Same as above	Human	AB037703.1	exon:exon junction	723	724 3
Gemin2	Same as above	Human	AB037703.1	stop codon	761	763 3
Gemin2	Same as above	Human	BC028095.1	start codon	22	24 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	191	192 4
Gemin2	Same as above	Human	BC028095.1	exon	192	276 4
Gemin2	Same as above	Human	BC028095.1	stop codon	234	236 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	276	277 4
Gemin2	Same as above	Human	BC028095.1	exon	277	366 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	366	367 4
Gemin2	Same as above	Human	BC028095.1	exon	367	426 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	426	427 4
Gemin2	Same as above	Human	BC028095.1	exon	427	544 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	544	545 4
Gemin2	Same as above	Human	BC028095.1	exon	545	658 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	658	659 4
Gemin2	Same as above	Human	BC028095.1	exon	659	703 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	703	704 4
Gemin2	Same as above	Human	BC028095.1	exon	704	772 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	772	773 4
Gemin2	Same as above	Human	BC028095.1	exon	773	883 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	883	884 4

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin2	Same as above	Human	BC028095.1	exon	884	942 4
Gemin2	Same as above	Human	BC028095.1	exon:exon junction	942	943 4
Gemin2	Same as above	Human	BC028095.1	exon	943	1476 4
Gemin2	Same as above	Human	BC028095.1	3'UTR	952	999 4
Gemin2	Same as above	Human	BC028095.1	stop codon	980	982 4
Gemin2	Same as above	Human	BC028095.1	3'UTR	983	1341 4
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	154	155 5
Gemin2	Same as above	Human	BG779734.1	exon	155	239 5
Gemin2	Same as above	Human	BG779734.1	stop codon	197	199 5
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	239	240 5
Gemin2	Same as above	Human	BG779734.1	exon	240	329 5
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	329	330 5
Gemin2	Same as above	Human	BG779734.1	exon	330	389 5
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	389	390 5
Gemin2	Same as above	Human	BG779734.1	exon	390	503 5
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	503	504 5
Gemin2	Same as above	Human	BG779734.1	exon	504	548 5
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	548	549 5
Gemin2	Same as above	Human	BG779734.1	exon	549	659 5
Gemin2	Same as above	Human	BG779734.1	exon:exon junction	659	660 5
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	173	174 6
Gemin2	Same as above	Human	BI602162.1	exon	174	258 6
Gemin2	Same as above	Human	BI602162.1	stop codon	216	218 6
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	258	259 6
Gemin2	Same as above	Human	BI602162.1	exon	259	348 6
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	348	349 6
Gemin2	Same as above	Human	BI602162.1	exon	349	408 6
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	408	409 6
Gemin2	Same as above	Human	BI602162.1	exon	409	453 6
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	453	454 6
Gemin2	Same as above	Human	BI602162.1	exon	454	564 6
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	564	565 6
Gemin2	Same as above	Human	BI602162.1	exon	565	623 6
Gemin2	Same as above	Human	BI602162.1	exon:exon junction	623	624 6
Gemin2	Same as above	Human	BI602162.1	3'UTR	633	680 6
Gemin2	Same as above	Human	BI602162.1	stop codon	661	663 6
Gemin2	Same as above	Human	BI602162.1	3'UTR	664	680 6
Gemin2	Same as above	Human	NM_003616.1	5'UTR	1	83 7
Gemin2	Same as above	Human	NM_003616.1	exon	1	253 7
Gemin2	Same as above	Human	NM_003616.1	start codon	84	86 7
Gemin2	Same as above	Human	NM_003616.1	CDS	84	926 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	253	254 7
Gemin2	Same as above	Human	NM_003616.1	exon	254	338 7
Gemin2	Same as above	Human	NM_003616.1	stop codon	296	298 7
Gemin2	Same as above	Human	NM_003616.1	3'UTR	299	988 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	338	339 7
Gemin2	Same as above	Human	NM_003616.1	exon	339	428 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	428	429 7
Gemin2	Same as above	Human	NM_003616.1	exon	429	488 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	488	489 7
Gemin2	Same as above	Human	NM_003616.1	exon	489	602 7

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	602	603 7
Gemin2	Same as above	Human	NM_003616.1	exon	603	647 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	647	648 7
Gemin2	Same as above	Human	NM_003616.1	exon	648	716 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	716	717 7
Gemin2	Same as above	Human	NM_003616.1	exon	717	827 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	827	828 7
Gemin2	Same as above	Human	NM_003616.1	exon	828	886 7
Gemin2	Same as above	Human	NM_003616.1	exon:exon junction	886	887 7
Gemin2	Same as above	Human	NM_003616.1	3'UTR	896	943 7
Gemin2	Same as above	Human	NM_003616.1	stop codon	924	926 7
Gemin2	Same as above	Human	NM_003616.1	3'UTR	927	1285 7
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	5'UTR	1037	1119 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	1037	1289 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	start codon	1120	1122 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron:exon junction	1289	1290 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	1290	1642 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	1642	1643 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	1643	1727 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	stop codon	1685	1687 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	1727	1728 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	1728	4812 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	4812	4813 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	4813	4902 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	4902	4903 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	4903	5353 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	5353	5354 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	5354	5413 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	5413	5414 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	5414	8720 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	5414	9243 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	8720	8721 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	8721	8838 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	8838	8839 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	8839	9243 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	9243	9244 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	9244	9357 8
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exon junction	9357	9358 8

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site
					SEQ ID NO	SEQ ID NO
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	9358	11805
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron:exon junction	11805	11806
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	11806	11850
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron:exon junction	11850	11851
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	11851	15093
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron:exon junction	15093	15094
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exon	15094	15162
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron:exon junction	15162	15163
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intron	15163	18771
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exон junction	18771	18772
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exон	18772	18882
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exон junction	18882	18883
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон	18883	20474
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exон junction	20474	20475
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exон	20475	20533
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exон junction	20533	20534
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон	20534	23253
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	intrон:exон junction	23253	23254
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	exон	23254	23787
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	3'UTR	23263	23310
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	stop codon	23291	23293
Gemin2	Same as above	Human	nucleotides 19913000 to 19938000 of NT_025892.9	3'UTR	23294	23652
Gemin4	GIP1; gem-associated protein 4	Human	AF177341.2	CDS	1310	4486
Gemin4	Same as above	Human	AF177341.2	intrон:exон junction	1319	1320
Gemin4	Same as above	Human	AF177341.2	CDS	1343	4486
Gemin4	Same as above	Human	AF177341.2	stop codon	4484	4486
Gemin4	Same as above	Human	BG702457.1	exon	5	146
Gemin4	Same as above	Human	BG702457.1	exon:exon junction	146	147
Gemin4	Same as above	Human	BI458671.1	exon:exon junction	44	45
Gemin4	Same as above	Human	BI458671.1	exon	45	140
Gemin4	Same as above	Human	BI458671.1	exon:exon junction	140	141
Gemin4	Same as above	Human	NM_015721.1	5'UTR	1	23
Gemin4	Same as above	Human	NM_015721.1	start codon	24	26
Gemin4	Same as above	Human	NM_015721.1	CDS	24	3200
Gemin4	Same as above	Human	NM_015721.1	exon:exon junction	33	34
Gemin4	Same as above	Human	NM_015721.1	stop codon	3198	3200
Gemin4	Same as above	Human	NM_015721.1	3'UTR	3201	3472
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	exon	1686	1827

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	intron:exon junction	1827	1828 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	intron	1828	4050 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	intron:exon junction	4050	4051 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	exon	4051	4146 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	intron:exon junction	4146	4147 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	intron	4147	5927 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	intron:exon junction	5927	5928 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	exon	5928	9616 13
Gemin4	Same as above	Human	the complement of nucleotides 144000 to 155000 of NT_035414.1	stop codon	9097	9099 13
Gemin5	DKFZP586M1 824 protein; gem-associated protein 5	Human	AL117665.1	CDS	1	3672 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	59	60 14
Gemin5	Same as above	Human	AL117665.1	exon	60	225 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	225	226 14
Gemin5	Same as above	Human	AL117665.1	exon	226	438 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	438	439 14
Gemin5	Same as above	Human	AL117665.1	exon	439	524 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	524	525 14
Gemin5	Same as above	Human	AL117665.1	exon	525	607 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	607	608 14
Gemin5	Same as above	Human	AL117665.1	exon	608	744 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	744	745 14
Gemin5	Same as above	Human	AL117665.1	exon	745	818 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	818	819 14
Gemin5	Same as above	Human	AL117665.1	exon	819	1000 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1000	1001 14
Gemin5	Same as above	Human	AL117665.1	exon	1001	1140 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1140	1141 14
Gemin5	Same as above	Human	AL117665.1	exon	1141	1312 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1312	1313 14
Gemin5	Same as above	Human	AL117665.1	exon	1313	1540 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1540	1541 14
Gemin5	Same as above	Human	AL117665.1	exon	1541	1654 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1654	1655 14
Gemin5	Same as above	Human	AL117665.1	exon	1655	1777 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1777	1778 14
Gemin5	Same as above	Human	AL117665.1	exon	1778	1873 14

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	1873	1874 14
Gemin5	Same as above	Human	AL117665.1	exon	1874	2011 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	2011	2012 14
Gemin5	Same as above	Human	AL117665.1	exon	2012	2159 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	2159	2160 14
Gemin5	Same as above	Human	AL117665.1	exon	2160	2279 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	2279	2280 14
Gemin5	Same as above	Human	AL117665.1	exon	2280	2490 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	2490	2491 14
Gemin5	Same as above	Human	AL117665.1	exon	2491	2742 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	2742	2743 14
Gemin5	Same as above	Human	AL117665.1	exon	2743	2905 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	2905	2906 14
Gemin5	Same as above	Human	AL117665.1	exon	2906	3407 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	3407	3408 14
Gemin5	Same as above	Human	AL117665.1	exon	3408	3504 14
Gemin5	Same as above	Human	AL117665.1	exon:exon junction	3504	3505 14
Gemin5	Same as above	Human	AL117665.1	exon	3505	4569 14
Gemin5	Same as above	Human	AL117665.1	stop codon	3670	3672 14
Gemin5	Same as above	Human	AL117665.1	3'UTR	3673	4586 14
Gemin5	Same as above	Human	BC036894.1	5'UTR	1	63 15
Gemin5	Same as above	Human	BC036894.1	exon	11	229 15
Gemin5	Same as above	Human	BC036894.1	start codon	64	66 15
Gemin5	Same as above	Human	BC036894.1	CDS	64	2301 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	229	230 15
Gemin5	Same as above	Human	BC036894.1	exon	230	390 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	390	391 15
Gemin5	Same as above	Human	BC036894.1	exon	391	572 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	572	573 15
Gemin5	Same as above	Human	BC036894.1	exon	573	724 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	724	725 15
Gemin5	Same as above	Human	BC036894.1	exon	725	844 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	844	845 15
Gemin5	Same as above	Human	BC036894.1	exon	845	977 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	977	978 15
Gemin5	Same as above	Human	BC036894.1	exon	978	1143 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1143	1144 15
Gemin5	Same as above	Human	BC036894.1	exon	1144	1356 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1356	1357 15
Gemin5	Same as above	Human	BC036894.1	exon	1357	1442 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1442	1443 15
Gemin5	Same as above	Human	BC036894.1	exon	1443	1525 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1525	1526 15
Gemin5	Same as above	Human	BC036894.1	exon	1526	1662 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1662	1663 15
Gemin5	Same as above	Human	BC036894.1	exon	1663	1736 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1736	1737 15
Gemin5	Same as above	Human	BC036894.1	exon	1737	1918 15

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	1918	1919 15
Gemin5	Same as above	Human	BC036894.1	exon	1919	2058 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	2058	2059 15
Gemin5	Same as above	Human	BC036894.1	exon	2059	2230 15
Gemin5	Same as above	Human	BC036894.1	exon:exon junction	2230	2231 15
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	839	1057 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	start codon	892	894 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	1057	1058 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	1058	1839 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	1839	1840 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	1840	2000 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	2000	2001 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	2001	3002 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	3002	3003 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	3003	3184 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	3184	3185 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	3185	6774 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	6774	6775 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	6775	6926 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	6926	6927 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	6927	7447 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	7447	7448 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	7448	7567 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intrон:exon junction	7567	7568 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	7568	10365 16

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	10365	10366 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	10366	10498 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	10498	10499 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	10499	11474 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	11474	11475 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	11475	11640 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	11640	11641 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	11641	12950 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	12950	12951 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	12951	13163 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	13163	13164 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	13164	14470 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	14470	14471 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	14471	14556 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	14556	14557 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	14557	17599 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	17599	17600 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	17600	17682 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	17682	17683 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	17683	18921 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	18921	18922 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	18922	19058 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	19058	19059 16

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site
					SEQ ID NO	
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	19059	21020
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	21020	21021
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	21021	21094
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	21094	21095
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	21095	21845
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	21845	21846
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	21846	22027
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	22027	22028
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	22028	25986
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	25986	25987
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	25987	26126
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	26126	26127
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	26127	27126
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	27126	27127
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	27127	27298
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	27298	27299
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	27299	31206
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	31206	31207
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	31207	31434
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	31434	31435
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	31435	33548
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	33548	33549
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	33549	33662

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	33662	33663 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	33663	34395 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	34395	34396 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	34396	34518 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	34518	34519 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	34519	35849 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	35849	35850 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	35850	35945 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	35945	35946 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	35946	36348 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	36348	36349 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	36349	36486 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	36486	36487 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	36487	37540 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	37540	37541 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	37541	37688 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	37688	37689 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron	37689	39722 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	39722	39723 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	exon	39723	39842 16
Gemin5	Same as above	Human	the complement of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	39842	39843 16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron	39843	40382 16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	40382	40383 16

TABLE 1-continued

Gene Targets, Synonyms and Features							
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site	
					SEQ ID NO		
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	exon	40383	40593	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	40593	40594	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron	40594	42690	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	42690	42691	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	exon	42691	42942	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	42942	42943	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron	42943	46480	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	46480	46481	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	exon	46481	46643	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	46643	46644	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron	46644	47287	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	47287	47288	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	exon	47288	47789	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	47789	47790	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron	47790	49614	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	49614	49615	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	exon	49615	49711	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	49711	49712	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron	49712	50659	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	intron:exon junction	50659	50660	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	exon	50660	51724	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	stop codon	50825	50827	16
Gemin5	Same as above	Human	the compleme of nucleotides 2065000 to 2118000 of NT_034779.1	3'UTR	50828	51741	16

TABLE 1-continued

Gene Targets, Synonyms and Features							
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site	SEQ ID NO
Gemin6	FLJ23459; GEM-associated protein 6; gemin 6; hypothetical protein FLJ23459	Human	BG944981.1	exon	2	73	17
Gemin6	Same as above	Human	BG944981.1	5'UTR	7	92	17
Gemin6	Same as above	Human	BG944981.1	exon:exon junction	73	74	17
Gemin6	Same as above	Human	BG944981.1	exon	74	220	17
Gemin6	Same as above	Human	BG944981.1	start codon	93	95	17
Gemin6	Same as above	Human	BG944981.1	exon:exon junction	220	221	17
Gemin6	Same as above	Human	BG944981.1	exon	221	404	17
Gemin6	Same as above	Human	BI600222.1	5'UTR	30	86	18
Gemin6	Same as above	Human	BI600222.1	exon:exon junction	67	68	18
Gemin6	Same as above	Human	BI600222.1	start codon	87	89	18
Gemin6	Same as above	Human	BI600222.1	exon:exon junction	216	217	18
Gemin6	Same as above	Human	BI600222.1	stop codon	596	598	18
Gemin6	Same as above	Human	NM_024775.1	5'UTR	1	86	19
Gemin6	Same as above	Human	NM_024775.1	exon:exon junction	67	68	19
Gemin6	Same as above	Human	NM_024775.1	exon	68	214	19
Gemin6	Same as above	Human	NM_024775.1	start codon	87	89	19
Gemin6	Same as above	Human	NM_024775.1	CDS	87	530	19
Gemin6	Same as above	Human	NM_024775.1	exon:exon junction	214	215	19
Gemin6	Same as above	Human	NM_024775.1	stop codon	528	530	19
Gemin6	Same as above	Human	NM_024775.1	3'UTR	531	703	19
Gemin6	Same as above	Human	NM_024775.1	stop codon	589	591	19
Gemin6	Same as above	Human	NM_024775.8	5'UTR	1	57	20
Gemin6	Same as above	Human	NM_024775.8	exon:exon junction	38	39	20
Gemin6	Same as above	Human	NM_024775.8	exon	39	185	20
Gemin6	Same as above	Human	NM_024775.8	start codon	58	60	20
Gemin6	Same as above	Human	NM_024775.8	start codon	58	60	20
Gemin6	Same as above	Human	NM_024775.8	CDS	58	561	20
Gemin6	Same as above	Human	NM_024775.8	exon:exon junction	185	186	20
Gemin6	Same as above	Human	NM_024775.8	stop codon	498	500	20
Gemin6	Same as above	Human	NM_024775.8	stop codon	559	561	20
Gemin6	Same as above	Human	NM_024775.8	3'UTR	562	646	20
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	exon	1043	1114	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron:exon junction	1114	1115	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron	1115	1804	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron:exon junction	1804	1805	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	exon	1805	1951	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	start codon	1824	1826	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron:exon junction	1951	1952	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron	1952	2090	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron:exon junction	2090	2091	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	exon	2091	2274	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron:exon junction	2274	2275	21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron	2275	4356	21

TABLE 1-continued

Gene Targets, Synonyms and Features						
Target Name	Synonyms	Species	Genbank #	Feature	Feature Start Site	Feature Stop Site SEQ ID NO
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	intron:exon junction	4356	4357 21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	exon	4357	4926 21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	stop codon	4669	4671 21
Gemin6	Same as above	Human	nucleotides 5647000 to 5653000 of NT_005367.10	stop codon	4730	4732 21
Gemin7	Gemin 7; hypothetical protein FLJ13956	Human	AI022330.1	intron:exon junction	117	118 22
Gemin7	Same as above	Human	BM009097.1	exon	2	86 23
Gemin7	Same as above	Human	BM009097.1	exon	2	86 23
Gemin7	Same as above	Human	BM009097.1	exon:exon junction	86	87 23
Gemin7	Same as above	Human	BM009097.1	start codon	95	97 23
Gemin7	Same as above	Human	BM009097.1	stop codon	489	491 23
Gemin7	Same as above	Human	BQ438140.1	start codon	76	78 24
Gemin7	Same as above	Human	BQ438140.1	CDS	76	471 24
Gemin7	Same as above	Human	BQ438140.1	CDS	76	471 24
Gemin7	Same as above	Human	BQ438140.1	stop codon	469	471 24
Gemin7	Same as above	Human	NM_024707.1	5'UTR	1	221 25
Gemin7	Same as above	Human	NM_024707.1	exon	2	90 25
Gemin7	Same as above	Human	NM_024707.1	exon	2	90 25
Gemin7	Same as above	Human	NM_024707.1	exon:exon junction	90	91 25
Gemin7	Same as above	Human	NM_024707.1	exon	91	213 25
Gemin7	Same as above	Human	NM_024707.1	exon	91	213 25
Gemin7	Same as above	Human	NM_024707.1	exon:exon junction	213	214 25
Gemin7	Same as above	Human	NM_024707.1	exon	214	1631 25
Gemin7	Same as above	Human	NM_024707.1	exon	214	1631 25
Gemin7	Same as above	Human	NM_024707.1	start codon	222	224 25
Gemin7	Same as above	Human	NM_024707.1	CDS	222	617 25
Gemin7	Same as above	Human	NM_024707.1	stop codon	615	617 25
Gemin7	Same as above	Human	NM_024707.1	3'UTR	618	1631 25
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	exon	1467	1551 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intron:exon junction	1551	1552 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intron	1552	2178 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	exon	1561	1649 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intrон:exон junction	1649	1650 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intron	1650	2178 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intrон:exон junction	2178	2179 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	exon	2179	2301 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intrон:exон junction	2301	2302 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intron	2302	12378 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	intrон:exон junction	12378	12379 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	exon	12379	13796 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	start codon	12387	12389 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	CDS	12387	12782 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	stop codon	12780	12782 26
Gemin7	Same as above	Human	nucleotides 1708000 to 1723000 of NT_011109.12	3'UTR	12783	13796 26

[0195] Small Non-Coding RNA-Regulated Regions

[0196] Small non-coding RNA molecules play important roles in regulation of gene expression, developmental timing, viral surveillance, and immunity. Not only the classic transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), but also small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), small interfering RNAs (siRNAs), tiny non-coding RNAs (tnoRNAs) and microRNAs (miRNAs) are now known to act in diverse cellular processes such as chromosome maintenance, gene imprinting, pre-mRNA splicing, guiding RNA modifications, transcriptional regulation, and the control of mRNA translation (Eddy, *Nat. Rev. Genet.*, 2001, 2, 919-929; Kawasaki and Taira, *Nature*, 2003, 423, 838-842). RNA-mediated processes are now also believed to direct heterochromatin formation, genome rearrangements, and DNA elimination (Cerutti, *Trends Genet.*, 2003, 19, 39-46; Couzin, *Science*, 2002, 298, 2296-2297). In one embodiment, regions of target genes that are targets of small non-coding RNAs are suitable targets for oligomeric compounds of the invention.

[0197] One class of small non-coding RNAs known as microRNAs (miRNAs) participates in regulation of gene expression. Mature miRNAs originate from long endogenous primary transcripts (pri-miRNAs) that are often hundreds of nucleotides in length (Lee et al., *EMBO J.*, 2002, 21, 4663-70). These pri-miRNAs are processed by a nucleolar enzyme in the RNase III family known as Drosha, into approximately 70 nucleotide-long pre-miRNAs (also known as stem-loop, hairpin or foldback precursors) which are subsequently processed by the Dicer RNase into mature miRNAs (Lee et al., *Nature*, 2003, 425, 415-419). The current model is that the primary miRNA transcript is processed by Drosha in the nucleus, and the pre-miRNA hairpin precursor is exported from the nucleus through the action of the nuclear export protein exportin-5 (Bohnsack et al., *RNA*, 2004, 10, 185-191; Lund et al., *Science*, 2004, 303, 95-98; Yi et al., *Genes Dev.*, 2003, 17, 3011-3016). Once in the cytoplasm, the pre-miRNA is cleaved by Dicer to yield a double-stranded intermediate, but only one strand of this short-lived intermediate accumulates as the mature miRNA (Ambros et al., *RNA*, 2003, 9, 277-279; Bartel and Bartel, *Plant Physiol.*, 2003, 132, 709-717; Shi, *Trends Genet.*, 2003, 19, 9-12). miRNAs are believed to primarily direct translation repression but have recently been shown to trigger cleavage events.

[0198] More than 200 miRNA genes have been detected in the human genome. Naturally occurring miRNAs are characterized by imperfect complementarity to their target sequences. Artificially modified miRNAs with sequences completely complementary to their target RNAs have been designed and found to function as siRNAs that inhibit gene expression by reducing RNA transcript levels. Accordingly, regions of Gemin Genes targeted by naturally occurring or artificially modified miRNAs are contemplated as suitable target sites for the oligomeric compounds of the present invention.

[0199] Modulation of Target Expression

[0200] As used herein, "modulation" means a perturbation of function, for example, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in expression. As another example, modulation of expression can include perturbing splice site selection of pre-mRNA processing. "Expression" includes all the functions by which a gene's coded information is converted into structures present and operating in a cell and "modulation of expression" means the perturbation of such functions. The functions of DNA to

be modulated can include replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a vector, a plasmid construct or otherwise. The functions of RNA to be modulated can include translocation functions, which include, but are not limited to, translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, and translation of protein from the RNA. RNA processing functions that can be modulated include, but are not limited to, splicing of the RNA to yield one or more RNA species, capping of the RNA, 3' maturation of the RNA and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. Modulation of expression can result in the increased level of one or more nucleic acid species or the decreased level of one or more nucleic acid species, either temporally or by net steady state level. One result of such interference with target nucleic acid function is modulation of the expression of a Gemin Gene. Thus, in one embodiment modulation of expression can mean increase or decrease in target RNA or protein levels. In another embodiment modulation of expression can mean an increase or decrease of one or more RNA splice products, or a change in the ratio of two or more splice products.

[0201] The effect of oligomeric compounds of the present invention on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. The effect of oligomeric compounds of the present invention on target nucleic acid expression can be routinely determined using, for example, PCR or Northern blot analysis. Useful cell lines include, e.g., 1321rX3-7; 3T3-L1, differentiated; 3T3-L1, undifferentiated; 70Z; 7D4; 7F2 (osteoblast); A10; A20; A375; A431; A549; AML-12; ARIP; differentiated Adipocytes; B104; B16-F10; B50; BALC; BB88; BC3H1; BCL; BEAS2B; BHK-21 (fibroblast, kidney); BLO-11 (skeletal muscle); BT-474; BW5147.3 (ATCC TIB-47); BaF3; Mouse primary bone marrow-derived osteoclasts; C2C12; C3A; C3H/10T1/2; C58; C6; CHO (Ovary); CMT-93; COS-7; CT26.WT; Caco-2; ConA; D1 TNC1; D1B; DA-3; DDT1-MF2; DU 145 (prostate); Peripheral Blood Monocyte derived Human Primary Dendritic Cells; E14; EL4; EMT-6; F11; FAT 7 (epithelial, nasal squamous cell carcinoma); Human Primary Dermal Fibroblasts; Mouse Embryonic Primary Fibroblasts; G-361; GH1; GH3; H-4-II-E; H2.35; H8; H9 (Human T Lymphocyte); H9c2(2-1); HASMC (Human Aortic Smooth Muscle Cells); HC252 (differentiated rat neuronal progenitor cell line); HC252 (undifferentiated rat neuronal progenitor cell line); HCT116; HEK A-Z (rt-SLC tx); HEK-293; HEK-293 (Rat VR1 Transfected); HEPA1-6; HFN 36.3; HK-2 (human HPV-16 transformed proximal tubule kidney); HL-60; HMEC (Normal Human Mammary Epithelial Cells); HMVEC-L (Lung Endothelial); HMVEC-d Ad (Human Adult Dermal Endothelial); HMVEC-d Neo (Human Neonatal Dermal Endothelial); HPAEC (Human Pulmonary Artery Endothelial Cells); HT-1080; HeLa; Hec-1A; HepB3; HepG2; Human Primary Hepatocytes; Mouse Primary Hepatocytes; Rabbit Primary Hepatocytes; Rat Primary Hepatocytes; Hut 78 (Human cutaneous T lymphocyte); HuVEC; Huh7; Human H-ras transformed rat intestinal epithelial cells; IC21; IEC-6; IW32; JAR; JEG-3; JUG-3; Jurkat; K-562; K204; Mouse Primary Keratinocytes; L2 (lung); L6; LA4; LBRM-33; LC-540; LL/6; LL2; LLC1; LNCAP; M-3 (Mouse melanoma; skin; melanocyte); MCF7 (breast ade-

carcinoma, w/t p53); MDA; MDA MB 468; MDA MB231; MEF; MH-S; MLE12; MLg2908; MMT 060562; MRC-5; Human Primary Macrophages; Mouse Peritoneal Macrophages; Rat Peritoneal Macrophages; Human Primary Melanocytes; Mia Paca; Human Primary Monocytes; N1S1 (liver); NBT-II; NCCIT; NCI-H292; NCTC 3749; ND7/23; NG108-15 (mouse); NG108-15 (rat); NHDC (Dendritic Cells); NHDF; NHEK (Human Primary Keratinocytes); NHEK-Ad (Human Primary Adult Keratinocytes); NHEK-Neo (Human Primary Neonatal Keratinocytes); NIH/3T3 (mouse fibroblast); NIT-1; NOR-10 (Mouse muscle); NR-8383; NRK; NTERA-2 c1.D1; Rat Primary Neurons; Mouse primary Osteoblasts; Rat primary Osteoblasts; P-19; P388D1 (IL-1 adherent); P388D1 suspension; PANC-1; PC-12; PC-3 (prostate); White Preadipocytes; R2C; R6; RAW264.7; RB++; RBL-2H3; RFL-6; RK3E; RMC; ROS 17/2.8; Raji; Rat Tissue—Cerebellum; Rat Tissue—Cerebrum; Rat Tissue—Hippocampus; Rat-2; Human Primary Renal Proximal Tubule Epithelial Cell; Rin-5F; Rin-M; SK-MEL-28; SKBR; SMT/2A LNM; SV40 MES 13; SW480; SW97; Shionogi; Human Primary Smooth Muscle Bronchial Cell; Mouse Primary Splenocytes; Human Synoviocytes; Mouse Synoviocytes; Rat Synoviocytes; T cell hybridoma 2B4; T-24; T-49 D; T3-3A1; T47D (breast adenocarcinoma, mutant p53); T47D+p53 (breast adenocarcinoma, mutant p53, transfected with wild-type p53); TCMK-1 (kidney); TF1.8; THLE-3; THP-1; TM-3; TM4; TRAMP-C1; U-20S; U-87 MG; U373; U937; UMR-106 (osteosarcoma); VERO C1008; WEHI 231; WISH; Y-1; Y13-238 (spleen); Y13-259 (spleen); YB2/0 (spleen); Yac-1; b.END; mMCD-3; and sw872. The culture of such cells is routine to those skilled in the art. Other cell types well known to one of skilled in the art can be routinely used. Many cell lines and instructions for growing them are obtainable from the American Type Culture Collection (ATCC) (Manassas, Va.).

[0202] Assaying Modulation of Expression

[0203] Modulation of Gemin Gene expression can be assayed in a variety of ways known in the art. Gemin Gene mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR. RNA analysis can be performed on total cellular RNA or poly(A)+mRNA by methods known in the art. Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993.

[0204] Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions.

[0205] Levels of a protein encoded by a Gemin Gene can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to a protein encoded by a Gemin Gene can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F. M. et

al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

[0206] Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F. M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

[0207] Suitable Target Regions

[0208] Once one or more target regions, segments or sites have been identified, oligomeric compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0209] The oligomeric compounds of the present invention can be targeted to features of a target nucleobase sequence, such as those described in Table 1. All regions of a nucleobase sequence to which an oligomeric compound can be targeted, wherein the regions are greater than or equal to 8 and less than or equal to 80 nucleobases, are described as follows:

[0210] Let $R(n, n+m-1)$ be a region from a target nucleobase sequence, where "n" is the 5'-most nucleobase position of the region, where "n+m-1" is the 3'-most nucleobase position of the region and where "m" is the length of the region. A set " $S(m)$ ", of regions of length "m" is defined as the regions where n ranges from 1 to $L-m+1$, where L is the length of the target nucleobase sequence and $L>m$. A set, " A ", of all regions can be constructed as a union of the sets of regions for each length from where m is greater than or equal to 8 and is less than or equal to 80.

[0211] This set of regions can be represented using the following mathematical notation:

$$A = \bigcup_m S(m) \text{ where } m \in N \mid 8 \leq m \leq 80$$

and

$$S(m) = \{R_{n,n+m-1} \mid n \in \{1, 2, 3, \dots, L-m+1\}\}$$

[0212] where the mathematical operator \mid indicates "such that",

[0213] where the mathematical operator \in indicates "a member of a set" (e.g. $y \in Z$ indicates that element y is a member of set Z),

[0214] where x is a variable,

[0215] where N indicates all natural numbers, defined as positive integers,

[0216] and where the mathematical operator \AA indicates "the union of sets".

[0217] For example, the set of regions for m equal to 8, 20 and 80 can be constructed in the following manner. The set of regions, each 8 nucleobases in length, $S(m=8)$, in a target nucleobase sequence 100 nucleobases in length ($L=100$),

beginning at position 1 ($n=1$) of the target nucleobase sequence, can be created using the following expression:

$$S(8)=\{R_{1,8}|n \in \{1,2,3,\dots,93\}\}$$

and describes the set of regions comprising nucleobases 1-8, 2-9, 3-10, 4-11, 5-12, 6-13, 7-14, 8-15, 9-16, 10-17, 11-18, 12-19, 13-20, 14-21, 15-22, 16-23, 17-24, 18-25, 19-26, 20-27, 21-28, 22-29, 23-30, 24-31, 25-32, 26-33, 27-34, 28-35, 29-36, 30-37, 31-38, 32-39, 33-40, 34-41, 35-42, 36-43, 37-44, 38-45, 39-46, 40-47, 41-48, 42-49, 43-50, 44-51, 45-52, 46-53, 47-54, 48-55, 49-56, 50-57, 51-58, 52-59, 53-60, 54-61, 55-62, 56-63, 57-64, 58-65, 59-66, 60-67, 61-68, 62-69, 63-70, 64-71, 65-72, 66-73, 67-74, 68-75, 69-76, 70-77, 71-78, 72-79, 73-80, 74-81, 75-82, 76-83, 77-84, 78-85, 79-86, 80-87, 81-88, 82-89, 83-90, 84-91, 85-92, 86-93, 87-94, 88-95, 89-96, 90-97, 91-98, 92-99, 93-100.

[0218] An additional set for regions 20 nucleobases in length, in a target sequence 100 nucleobases in length, beginning at position 1 of the target nucleobase sequence, can be described using the following expression:

$$S(20)=\{R_{1,20}|n \in \{1,2,3,\dots,81\}\}$$

and describes the set of regions comprising nucleobases 1-20, 2-21, 3-22, 4-23, 5-24, 6-25, 7-26, 8-27, 9-28, 10-29, 11-30, 12-31, 13-32, 14-33, 15-34, 16-35, 17-36, 18-37, 19-38, 20-39, 21-40, 22-41, 23-42, 24-43, 25-44, 26-45, 27-46, 28-47, 29-48, 30-49, 31-50, 32-51, 33-52, 34-53, 35-54, 36-55, 37-56, 38-57, 39-58, 40-59, 41-60, 42-61, 43-62, 44-63, 45-64, 46-65, 47-66, 48-67, 49-68, 50-69, 51-70, 52-71, 53-72, 54-73, 55-74, 56-75, 57-76, 58-77, 59-78, 60-79, 61-80, 62-81, 63-82, 64-83, 65-84, 66-85, 67-86, 68-87, 69-88, 70-89, 71-90, 72-91, 73-92, 74-93, 75-94, 76-95, 77-96, 78-97, 79-98, 80-99, 81-100.

[0219] An additional set for regions 80 nucleobases in length, in a target sequence 100 nucleobases in length, beginning at position 1 of the target nucleobase sequence, can be described using the following expression:

$$S(80)=\{R_{1,80}|n \in \{1,2,3,\dots,21\}\}$$

and describes the set of regions comprising nucleobases 1-80, 2-81, 3-82, 4-83, 5-84, 6-85, 7-86, 8-87, 9-88, 10-89, 11-90, 12-91, 13-92, 14-93, 15-94, 16-95, 17-96, 18-97, 19-98, 20-99, 21-100.

[0220] Thus, in this example, A would include regions 1-8, 2-9, 3-10 . . . 93-100, 1-20, 2-21, 3-22 . . . 81-100, 1-80, 2-81, 3-82 . . . 21-100.

[0221] The union of these aforementioned example sets and other sets for lengths from 10 to 19 and 21 to 79 can be described using the mathematical expression

$$A = \bigcup_m S(m)$$

[0222] where A represents the union of the sets obtained by combining all members of all sets.

[0223] The mathematical expressions described herein defines all possible target regions in a target nucleobase sequence of any length L, where the region is of length m, and where m is greater than or equal to 8 and less than or equal to 80 nucleobases and, and where m is less than L, and where n is less than L-m+1.

[0224] Validated Target Segments

[0225] The locations on the target nucleic acid to which the suitable oligomeric compounds hybridize are hereinbelow referred to as “validated target segments.” As used herein the term “validated target segment” is defined as at least an 8-nucleobase portion of a target region to which an active oligomeric compound is targeted. While not wishing to be bound by theory, it is presently believed that these target segments represent portions of the target nucleic acid which are accessible for hybridization.

[0226] Target segments can include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of a validated target segment (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target segment and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly suitable validated target segments are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of a validated target segment (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target segment and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). It is also understood that a validated oligomeric target segment can be represented by DNA or RNA sequences that comprise at least 8 consecutive nucleobases from an internal portion of the sequence of a validated target segment, and can extend in either or both directions until the oligonucleotide contains about 8 to about 80 nucleobases.

[0227] Screening for Modulator Compounds

[0228] In another embodiment, the validated target segments identified herein can be employed in a screen for additional compounds that modulate the expression of a Gemin Gene. “Modulators” are those compounds that modulate the expression of a Gemin Gene and which comprise at least an 8-nucleobase portion which is complementary to a validated target segment. The screening method comprises the steps of contacting a validated target segment of a nucleic acid molecule encoding a Gemin Gene with one or more candidate modulators, and selecting for one or more candidate modulators which perturb the expression of a nucleic acid molecule encoding a Gemin Gene. Once it is shown that the candidate modulator or modulators are capable of modulating the expression of a nucleic acid molecule encoding a Gemin Gene, the modulator can then be employed in further investigative studies of the function of a Gemin Gene, or for use as a research, diagnostic, or therapeutic agent. The validated target segments can also be combined with a second strand as disclosed herein to form stabilized double-stranded (duplexed) oligonucleotides for use as a research, diagnostic, or therapeutic agent.

[0229] Phenotypic Assays

[0230] Once modulator compounds of a Gemin Gene have been identified by the methods disclosed herein, the compounds can be further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition. Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of a Gemin Gene in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene,

Oreg.; PerkinElmer, Boston, Mass.), protein-based assays including enzymatic assays (Panvera, LLC, Madison, Wis.; BD Biosciences, Franklin Lakes, N.J.; Oncogene Research Products, San Diego, Calif.), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, Mich.), triglyceride accumulation (Sigma-Aldrich, St. Louis, Mo.), angiogenesis assays, tube formation assays, cytokine and hormone assays and metabolic assays (Chemicon International Inc., Temecula, Calif.; Amersham Biosciences, Piscataway, N.J.).

[0231] Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

[0232] Analysis of the genotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the Gemin Gene modulators. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

[0233] The following phenotypic assays are useful in the study of the compounds and compositions of the present invention.

[0234] Cell Proliferation and Survival

[0235] Unregulated cell proliferation is a characteristic of cancer cells, thus most current chemotherapy agents target dividing cells, for example, by blocking the synthesis of new DNA required for cell division. However, cells in healthy tissues are also affected by agents that modulate cell proliferation.

[0236] In some cases, a cell cycle inhibitor will cause apoptosis in cancer cells, but allow normal cells to undergo growth arrest and therefore remain unaffected (Blagosklonny, *Bioessays*, 1999, 21, 704-709; Chen et al., *Cancer Res.*, 1997, 57, 2013-2019; Evan and Littlewood, *Science*, 1998, 281, 1317-1322; Lees and Weinberg, *Proc. Natl. Acad. Sci. USA*, 1999, 96, 4221-4223). An example of sensitization to anti-cancer agents is observed in cells that have reduced or absent expression of the tumor suppressor genes p53 (Bunz et al., *Science*, 1998, 282, 1497-1501; Bunz et al., *J. Clin. Invest.*, 1999, 104, 263-269; Stewart et al., *Cancer Res.*, 1999, 59, 3831-3837; Wahl et al., *Nat. Med.*, 1996, 2, 72-79). However, cancer cells often escape apoptosis (Lowe and Lin, *Carcinogenesis*, 2000, 21, 485-495; Reed, *Cancer J. Sci. Am.*, 1998, 4 Suppl 1, S8-14). Further disruption of cell cycle checkpoints in cancer cells can increase sensitivity to chemotherapy while allowing normal cells to take refuge in G1 and remain unaffected. Cell cycle assays can be employed to identify genes, such as p53, whose inhibition will sensitize cells to anti-cancer agents.

[0237] Caspase Activity

[0238] Programmed cell death, or apoptosis, is an important aspect of various biological processes, including normal cell turnover, as well as immune system and embryonic development. Apoptosis involves the activation of caspases, a family of intracellular proteases through which a cascade of events leads to the cleavage of a select set of proteins. The caspase family can be divided into two groups: the initiator caspases, such as caspase-8 and -9, and the executioner caspases, such as caspase-3, -6 and -7, which are activated by

the initiator caspases. The caspase family contains at least 14 members, with differing substrate preferences (Thornberry and Lazebnik, *Science*, 1998, 281, 1312-1316). For example, a caspase assay can be used to identify genes whose inhibition selectively cause apoptosis in breast carcinoma cell lines, without affecting normal cells, and to identify genes whose inhibition results in cell death in p53-deficient T47D cells, and not in MCF7 cells which express p53 (Ross et al., *Nat. Genet.*, 2000, 24, 227-235; Scherf et al., *Nat. Genet.*, 2000, 24, 236-244).

[0239] Angiogenesis

[0240] Angiogenesis is the growth of new blood vessels (veins and arteries) by endothelial cells. This process is important in the development of a number of human diseases, and is believed to be particularly important in regulating the growth of solid tumors. Without new vessel formation it is believed that tumors will not grow beyond a few millimeters in size. In addition to their use as anti-cancer agents, inhibitors of angiogenesis have potential for the treatment of diabetic retinopathy, cardiovascular disease, rheumatoid arthritis and psoriasis (Carmeliet and Jain, *Nature*, 2000, 407, 249-257; Freedman and Isner, *J. Mol. Cell. Cardiol.*, 2001, 33, 379-393; Jackson et al., *Faseb J.*, 1997, 11, 457-465; Saaristo et al., *Oncogene*, 2000, 19, 6122-6129; Weber and De Bandt, *Joint Bone Spine*, 2000, 67, 366-383; Yoshida et al., *Histol. Histopathol.*, 1999, 14, 1287-1294).

[0241] During the process of angiogenesis, endothelial cells perform several distinct functions, including the degradation of the extracellular matrix (ECM), migration, proliferation and the formation of tube-like structures (Liekens et al., *Biochem. Pharmacol.*, 2001, 61, 253-270). Endothelial cells must regulate the expression of many genes in order to perform the functions necessary for angiogenesis. This gene regulation has been the subject of intense scrutiny, and many genes have been identified as being important for the angiogenic phenotype. For example, the expression levels of the following genes, previously identified as being highly expressed in angiogenic endothelial cells, can be measured as indicators: Integrin beta3, endoglin/CD105, TEM5 and MMP-14/MT-MMP1.

[0242] Integrin beta3 is part of a family of heterodimeric transmembrane receptors that consist of alpha and beta subunits (Brooks et al., *J. Clin. Invest.*, 1995, 96, 1815-1822). Each subunit recognizes a unique set of ECM ligands, thereby allowing cells to transmit angiogenic signals from the extracellular matrix. Integrin beta3 is prominently expressed on proliferating vascular endothelial cells, and it plays roles in allowing new blood vessels to form at tumor sites as well as allowing the epithelial cells of breast tumors to spread (Brooks et al., *J. Clin. Invest.*, 1995, 96, 1815-1822; Drake et al., *J. Cell Sci.*, 1995, 108 (Pt 7), 2655-2661). Blockage of integrin beta3 with monoclonal antibodies or low molecular weight antagonists inhibits blood vessel formation in a variety of in-vivo models, including tumor angiogenesis and neovascularization during oxygen-induced retinopathy (Brooks et al., *Science*, 1994, 264, 569-571; Brooks et al., *J. Clin. Invest.*, 1995, 96, 1815-1822; Hammes et al., *Nat. Med.*, 1996, 2, 529-533).

[0243] Endoglin is a transforming growth factor receptor-associated protein highly expressed on endothelial cells, and present on some leukemia cells and minor subsets of bone marrow cells (Burrows et al., *Clin. Cancer Res.*, 1995, 1, 1623-1634; Haruta and Seon, *Proc. Natl. Acad. Sci. USA*, 1986, 83, 7898-7902). Its expression is upregulated in endot-

elial cells of angiogenic tissues and is therefore used as a prognostic indicator in various tumors (Burrows et al., *Clin. Cancer Res.*, 1995, 1, 1623-1634). Endoglin functions as an ancillary receptor influencing binding of the transforming growth factor beta (TGF-beta) family of ligands to signaling receptors, thus mediating cell survival (Massague and Chen, *Genes Dev.*, 2000, 14, 627-644).

[0244] Tumor endothelial marker 5 (TEM5) is a putative 7-pass transmembrane protein (GPCR) (Carson-Walter et al., *Cancer Res.*, 2001, 61, 6649-6655). The mRNA transcript, designated KIAA1531, encodes one of many tumor endothelium markers (TEMs) that display elevated expression (greater than 10-fold) during tumor angiogenesis (St Croix et al., *Science*, 2000, 289, 1197-1202). TEM5 is coordinately expressed with other TEMs on tumor endothelium in humans and mice.

[0245] Matrix metalloproteinase 14 (MMP-14), a membrane-type MMP covalently linked to the cell membrane, is involved in matrix detachment and migration. MMP-14 is thought to promote tumor angiogenesis; antibodies directed against the catalytic domain of MMP-14 block endothelial-cell migration, invasion and capillary tube formation in vitro (Galvez et al., *J. Biol. Chem.*, 2001, 276, 37491-37500). MMP-14 can degrade the fibrin matrix that surrounds newly formed vessels potentially allowing the endothelial cells to invade further into the tumor tissue (Hotary et al., *J. Exp. Med.*, 2002, 195, 295-308). MMP-14 null mice have impaired angiogenesis during development, further demonstrating the role of MMP-14 in angiogenesis (Vu and Werb, *Genes Dev.*, 2000, 14, 2123-2133; Zhou et al., *Proc. Natl. Acad. Sci. USA*, 2000, 97, 4052-4057).

[0246] Angiogenesis is stimulated by numerous factors that promote interaction of endothelial cells with each other and with extracellular matrix molecules, resulting in the formation of capillary tubes. This morphogenic process is necessary for the delivery of oxygen to nearby tissues and plays an essential role in embryonic development, wound healing, and tumor growth (Carmeliet and Jain, *Nature*, 2000, 407, 249-257). Moreover, this process can be reproduced in a tissue culture assay that evaluated the formation of tube-like structures by endothelial cells. There are several different variations of the assay that use different matrices, such as collagen I (Kanayasu et al., *Lipids*, 1991, 26, 271-276), Matrigel (Yamagishi et al., *J. Biol. Chem.*, 1997, 272, 8723-8730) and fibrin (Bach et al., *Exp. Cell Res.*, 1998, 238, 324-334), as growth substrates for the cells. For example, HUVECs can be plated on a matrix derived from the Engelbreth-Holm-Swarm mouse tumor, which is very similar to Matrigel (Kleinman et al., *Biochemistry*, 1986, 25, 312-318; Madri and Pratt, *J. Histochem. Cytochem.*, 1986, 34, 85-91). Untreated HUVECs form tube-like structures when grown on this substrate. Loss of tube formation in vitro has been correlated with the inhibition of angiogenesis in vivo (Carmeliet and Jain, *Nature*, 2000, 407, 249-257; Zhang et al., *Cancer Res.*, 2002, 62, 2034-2042), which supports the use of in vitro tube formation as an endpoint for angiogenesis.

[0247] Adipocyte Differentiation and Insulin Signaling Assays

[0248] Insulin is an essential signaling molecule throughout the body, but its major target organs are the liver, skeletal muscle and adipose tissue. Insulin is the primary modulator of glucose homeostasis and helps maintain a balance of peripheral glucose utilization and hepatic glucose production. The reduced ability of normal circulating concentrations of insulin to maintain glucose homeostasis manifests in insulin resistance which is often associated with diabetes, central obesity, hypertension, polycystic ovarian syndrome, dyslipidemia and atherosclerosis (Saltiel, *Cell*, 2001, 104, 517-529; Saltiel and Kahn, *Nature*, 2001, 414, 799-806).

[0249] Insulin promotes the differentiation of preadipocytes into adipocytes. The condition of obesity, which results in increases in fat cell number, occurs even in insulin-resistant states in which glucose transport is impaired due to the anti-lipolytic effect of insulin. Inhibition of triglyceride breakdown requires much lower insulin concentrations than stimulation of glucose transport, resulting in maintenance or expansion of adipose stores (Kitamura et al., *Mol. Cell. Biol.*, 1999, 19, 6286-6296; Kitamura et al., *Mol. Cell. Biol.*, 1998, 18, 3708-3717).

[0250] One of the hallmarks of cellular differentiation is the upregulation of gene expression. During adipocyte differentiation, the gene expression patterns in adipocytes change considerably. Some genes known to be upregulated during adipocyte differentiation include hormone-sensitive lipase (HSL), adipocyte lipid binding protein (aP2), glucose transporter 4 (Glut4), and peroxisome proliferator-activated receptor gamma (PPAR-gamma). Insulin signaling is improved by compounds that bind and inactivate PPAR-gamma, a key regulator of adipocyte differentiation (Olefsky, *J. Clin. Invest.*, 2000, 106, 467-472). Insulin induces the translocation of GLUT4 to the adipocyte cell surface, where it transports glucose into the cell, an activity necessary for triglyceride synthesis. In all forms of obesity and diabetes, a major factor contributing to the impaired insulin-stimulated glucose transport in adipocytes is the downregulation of GLUT4. Insulin also induces hormone sensitive lipase (HSL), which is the predominant lipase in adipocytes that functions to promote fatty acid synthesis and lipogenesis (Fredrikson et al., *J. Biol. Chem.*, 1981, 256, 6311-6320). Adipocyte fatty acid binding protein (aP2) belongs to a multi-gene family of fatty acid and retinoid transport proteins. aP2 is postulated to serve as a lipid shuttle, solubilizing hydrophobic fatty acids and delivering them to the appropriate metabolic system for utilization (Fu et al., *J. Lipid Res.*, 2000, 41, 2017-2023; Pelton et al., *Biochem. Biophys. Res. Commun.*, 1999, 261, 456-458). Together, these genes play important roles in the uptake of glucose and the metabolism and utilization of fats.

[0251] Leptin secretion and an increase in triglyceride content are also well-established markers of adipocyte differentiation. While it serves as a marker for differentiated adipocytes, leptin also regulates glucose homeostasis through mechanisms (autocrine, paracrine, endocrine and neural) independent of the adipocyte's role in energy storage and release. As adipocytes differentiate, insulin increases triglyceride accumulation by both promoting triglyceride synthesis and inhibiting triglyceride breakdown (Spiegelman and Flier, *Cell*, 2001, 104, 531-543). As triglyceride accumulation correlates tightly with cell size and cell number, it is an excellent indicator of differentiated adipocytes.

[0252] Insulin mediates its effects by suppressing the RNA expression levels of enzymes important for gluconeogenesis and glycogenolysis, and also by controlling the activities of some metabolic enzymes by post-translational mechanisms (Hall and Granner, *J. Basic Clin. Physiol. Pharmacol.*, 1999, 10, 119-133; Moller, *Nature*, 2001, 414, 821-827; Saltiel and Kahn, *Nature*, 2001, 414, 799-806). However, the mechanisms by which insulin regulates these genes are not fully

understood. Genes in liver cells cells that are involved in regulating glucose metabolism are identified by monitoring changes in the expression of selective insulin-responsive genes in a cell culture model. Primary human hepatocytes are difficult to obtain and work with in culture. Therefore, the insulin signaling assay as used in the Examples can be performed in the hepatocellular carcinoma cell line HepG2. Insulin responsive genes that can be evaluated in this assay are phosphoenolpyruvate carboxykinase (PEPCK), insulin-like growth factor binding protein 1 (IGFBP-1) and follistatin.

[0253] IGFBP-1 is one of a family of six secreted proteins that bind insulin-like growth factor (IGF) with high affinity and thereby modulate IGFs action in vivo (Baxter, *Am. J. Physiol. Endocrinol. Metab.*, 2000, 278, E967-976; Lee et al., *Proc. Soc. Exp. Biol. Med.*, 1997, 216, 319-357). IGFBP-1 is characterized by dynamic variability of levels in circulation due to the regulation of its hepatic secretion (Lee et al., *Proc. Soc. Exp. Biol. Med.*, 1997, 216, 319-357). The multi-hormonal regulation of PEPCK and IGFBP-1 are similar. Glucocorticoids and cyclic AMP (cAMP) stimulate transcription of the IGFBP-1 gene expression whereas insulin acts in a dominant manner to suppress both basal and cAMP or glucocorticoid-stimulated IGFBP-1 gene transcription (O'Brien and Granner, *Physiol. Rev.*, 1996, 76, 1109-1161). PEPCK catalyzes the rate-limiting step in gluconeogenesis, and thereby contributes to hepatic glucose output (Hall and Granner, *J. Basic Clin. Physiol. Pharmacol.*, 1999, 10, 119-133; Moller, *Nature*, 2001, 414, 821-827; Saltiel and Kahn, *Nature*, 2001, 414, 799-806). In hepatoma cells, studies have shown that the expression of PEPCK is stimulated by glucocorticoids, glucagon (via cAMP), and retinoic acid. Insulin acts in a dominant manner to suppress these stimulations as well as basal transcription (O'Brien and Granner, *Physiol. Rev.*, 1996, 76, 1109-1161). In HepG2 cells, prolonged serum starvation induces the expression of PEPCK and subsequent insulin stimulation significantly reduces the PEPCK mRNA level.

[0254] Follistatin is significantly stimulated by insulin in HepG2 cells. Interestingly, follistatin levels have been shown to be higher in women with polycystic ovary syndrome (PCOS) (Norman et al., *Hum. Reprod.*, 2001, 16, 668-672). PCOS is a metabolic as well as a reproductive disorder, and an important cause of type 2 diabetes mellitus in women. It is often associated with profound insulin resistance and hyperinsulinemia as well as with a defect in insulin secretion (Dunai, *Endocr. Rev.*, 1997, 18, 774-800; Nestler et al., *Fertil. Steril.*, 2002, 77, 209-215).

[0255] Inflammation Assays

[0256] Inflammation assays are designed to identify genes that regulate the activation and effector phases of the adaptive immune response. During the activation phase, T lymphocytes (also known as T-cells) receiving signals from the appropriate antigens undergo clonal expansion, secrete cytokines, and upregulate their receptors for soluble growth factors, cytokines and co-stimulatory molecules (Cantrell, *Annu. Rev. Immunol.*, 1996, 14, 259-274). These changes drive T-cell differentiation and effector function. In the effector phase, response to cytokines by non-immune effector cells controls the production of inflammatory mediators that can do extensive damage to host tissues. The cells of the adaptive immune systems, their products, as well as their interactions with various enzyme cascades involved in inflammation (e.g., the complement, clotting, fibrinolytic and kinin cascades) all

represent potential points for intervention in inflammatory disease. The inflammation assay measures hallmarks of the activation phase of the immune response.

[0257] Dendritic cells can be used to identify regulators of dendritic cell-mediated T-cell costimulation. The level of interleukin-2 (IL-2) production by T-cells, a critical consequence of T-cell activation (DeSilva et al., *J. Immunol.*, 1991, 147, 3261-3267; Salomon and Bluestone, *Annu. Rev. Immunol.*, 2001, 19, 225-252), is used as an endpoint for T-cell activation. T lymphocytes are important immunoregulatory cells that mediate pathological inflammatory responses. Optimal activation of T lymphocytes requires both primary antigen recognition events as well as secondary or costimulatory signals from antigen presenting cells (APC). Dendritic cells are the most efficient APCs known and are principally responsible for antigen presentation to T-cells, expression of high levels of costimulatory molecules during infection and disease, and the induction and maintenance of immunological memory (Banchereau and Steinman, *Nature*, 1998, 392, 245-252). While a number of costimulatory ligand-receptor pairs have been shown to influence T-cell activation, a principal signal is delivered by engagement of CD28 on T-cells by CD80 (B7-1) and CD86 (B7-2) on APCs (Boussiotis et al., *Curr. Opin. Immunol.*, 1994, 6, 797-807; Lenschow et al., *Annu. Rev. Immunol.*, 1996, 14, 233-258). While not adhering to a specific mechanism, inhibition of T-cell co-stimulation by APCs holds promise for novel and more specific strategies of immune suppression. In addition, blocking costimulatory signals may lead to the development of long-term immunological anergy (unresponsiveness or tolerance) that would offer utility for promoting transplantation or dampening autoimmunity. T-cell anergy is the direct consequence of failure of T-cells to produce the growth factor IL-2 (DeSilva et al., *J. Immunol.*, 1991, 147, 3261-3267; Salomon and Bluestone, *Annu. Rev. Immunol.*, 2001, 19, 225-252).

[0258] The cytokine signaling assay identifies genes that regulate the responses of non-immune effector cells (initially endothelial cells) to cytokines such as interferon-gamma (IFN-gamma). The effects of the oligomeric compounds of the present invention on the regulation of the production of intercellular adhesion molecule-1 (ICAM-1), interferon regulatory factor 1 (IRF1) and small inducible cytokine subfamily B (Cys-X-Cys), member 11 (SCYB 11), which regulate other parameters of the inflammatory response, can be monitored in response to cytokine treatment.

[0259] Kits, Research Reagents, and Diagnostics

[0260] The oligomeric compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. Furthermore, antisense compounds, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

[0261] For use in kits and diagnostics, the oligomeric compounds of the present invention, either alone or in combination with other compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

[0262] As one nonlimiting example, expression patterns within cells or tissues treated with one or more compounds or compositions of the present invention are compared to control cells or tissues not treated with compounds and the patterns

produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

[0263] Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, 2000, 480, 17-24; Celis, et al., *FEBS Lett.*, 2000, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U.S.A.*, 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, 2000, 286, 91-98; Larson, et al., *Cytometry*, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, 1999, 35, 1895-904) and mass spectrometry methods (To, *Comb. Chem. High Throughput Screen*, 2000, 3, 235-41).

[0264] Therapeutics

[0265] The specificity and sensitivity of antisense technology is also harnessed by those of skill in the art for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense drugs have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds are useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

[0266] For therapeutics, an animal, such as a human, suspected of having or at risk of having a disease or disorder which can be treated by modulating the expression of a Gemin Gene is treated by administering compounds in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to said animal, a therapeutically effective amount of an antisense compound that inhibits expression of a Gemin Gene. In one embodiment, the antisense compounds of the present invention effectively inhibit the levels or function of a Gemin Gene RNA. Because reduction in Gemin Gene mRNA levels can lead to alteration in Gemin Gene protein products of expression as well, such resultant alterations can also be measured. In one embodiment, the antisense compounds of the invention inhibit the expression of a Gemin Gene causing a reduction of RNA by at least 10%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100%.

[0267] For example, the reduction of the expression of a Gemin Gene can be measured in a bodily fluid, tissue or organ of the animal. Bodily fluids include, but are not limited to,

blood (serum or plasma), lymphatic fluid, cerebrospinal fluid, semen, urine, synovial fluid and saliva and can be obtained by methods routine to those skilled in the art. Tissues or organs include, but are not limited to, blood (e.g., hematopoietic cells, such as human hematopoietic progenitor cells, human hematopoietic stem cells, CD34+ cells CD4+ cells), lymphocytes and other blood lineage cells, skin, bone marrow, spleen, thymus, lymph node, brain, spinal cord, heart, skeletal muscle, liver, pancreas, prostate, kidney, lung, oral mucosa, esophagus, stomach, ilium, small intestine, colon, bladder, cervix, ovary, testis, mammary gland, adrenal gland, and adipose (white and brown). Samples of tissues or organs can be routinely obtained by biopsy. In some alternative situations, samples of tissues or organs can be recovered from an animal after death.

[0268] The cells contained within said fluids, tissues or organs being analyzed can contain a nucleic acid molecule encoding a Gemin Gene protein and/or the Gemin Gene-encoded protein itself. For example, tissues or fluids procured from patients can be evaluated for expression levels of the target mRNA or protein. Additionally, the mRNA or protein expression levels of other genes known or suspected to be associated with the specific disease state, condition or phenotype can be assessed. mRNA levels can be measured or evaluated by real-time PCR, Northern blot, in situ hybridization or DNA array analysis. Protein levels can be measured or evaluated by ELISA, immunoblotting, quantitative protein assays, protein activity assays (for example, caspase activity assays) immunohistochemistry or immunocytochemistry. Furthermore, the effects of treatment can be assessed by measuring biomarkers associated with the disease or condition in the aforementioned tissues and fluids, collected from a patient or subject receiving treatment, by routine clinical methods known in the art. These biomarkers include but are not limited to: glucose, cholesterol, lipoproteins, triglycerides, free fatty acids and other markers of glucose and lipid metabolism; liver transaminases, bilirubin, albumin, blood urea nitrogen, creatine and other markers of kidney and liver function; interleukins, tumor necrosis factors, intracellular adhesion molecules, C-reactive protein and other markers of inflammation; testosterone, estrogen and other hormones; tumor markers; vitamins, minerals and electrolytes.

[0269] Pharmaceuticals and Methods of Treatment

[0270] The compounds of the present invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. In one aspect, the compounds of the present invention inhibit the expression of a Gemin Gene. Consequently, the compounds are useful in the treatment of disorders and diseases related to Gemin Gene expression. Use of the compounds, compositions and methods of the invention may also be useful prophylactically. The compounds of the invention can also be used in the manufacture of a medicament for the treatment of diseases and disorders related to Gemin Gene expression.

[0271] Methods whereby bodily fluids, cells or tissues are contacted with an effective amount of one or more of the antisense compounds or compositions of the invention are also contemplated. Bodily fluids, cells or tissues can be contacted with one or more of the compounds of the invention resulting in modulation of Gemin Gene expression in the bodily fluids, cells or tissues. An effective amount can be determined by monitoring the modulatory effect of the antisense compound or compounds or compositions on target

nucleic acids or their products by methods routine to the skilled artisan. Further contemplated are ex vivo methods of treatment whereby cells or tissues are isolated from a subject, contacted with an effective amount of the antisense compound or compounds or compositions and reintroduced into the subject by routine methods known to those skilled in the art.

[0272] Further contemplated herein is a method for the treatment of a subject suspected of having or at risk of having a disease or disorder comprising administering to a subject an effective amount of an isolated single stranded RNA or double stranded RNA oligonucleotide directed to a Gemin Gene. The ssRNA or dsRNA oligonucleotide may be modified or unmodified. That is, the present invention provides for the use of an isolated double stranded RNA oligonucleotide targeted to a Gemin Gene, or a pharmaceutical composition thereof, for the treatment of a disease or disorder.

[0273] In one embodiment, provided are uses of a compound of an isolated double stranded RNA oligonucleotide in the manufacture of a medicament for inhibiting Gemin Gene expression or overexpression. Thus, provided herein is the use of an isolated double stranded RNA oligonucleotide targeted to a Gemin Gene in the manufacture of a medicament for the treatment of a disease or disorder by means of the method described above.

[0274] Salts, Prodrugs and Bioequivalents

[0275] The oligomeric compounds of the present invention comprise any pharmaceutically acceptable salts, esters, or salts of such esters, or any other functional chemical equivalent which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the oligomeric compounds of the present invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

[0276] The term "prodrug" indicates a therapeutic agent that is prepared in an inactive or less active form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE ((S-acetyl-2-thioethyl)phosphate) derivatives according to the methods disclosed in WO 93/24510 or WO 94/26764.

[0277] The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

[0278] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms

somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 22 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

[0279] For oligonucleotides, examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine. Sodium salts of antisense oligonucleotides are useful and are well accepted for therapeutic administration to humans. In another embodiment, sodium salts of dsRNA compounds are also provided.

[0280] Formulations

[0281] The oligomeric compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such

uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756.

[0282] The present invention also includes pharmaceutical compositions and formulations which include the oligomeric compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including but not limited to ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer (intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Sites of administration are known to those skilled in the art. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

[0283] Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

[0284] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0285] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0286] Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

[0287] Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the oligomeric compound which may be present as a solution in

the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Pat. No. 6,287,860.

[0288] Formulations of the present invention include liposomal formulations. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes which are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

[0289] Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

[0290] Formulations of the present invention include dendrimers, which are hyperbranched polymers. Dendrimers are built around a central core to which the branch points are attached. Thus the core is encapsulated in a web of branch points. Dendrimers form a monodisperse material of uniform molecular weight providing more predictable pK and biodistribution properties. Hyperbranched dendrimers offer a unique opportunity of polyfunctionalization with desired carrier or targeting molecules for targeted drug delivery. Short dendrimers can also be used to attach multiple carriers to a single oligomeric compound thus increasing chances of uptake by the cluster effect. Dendrimers can be attached to oligomeric compounds of the invention to target solid tumors which have a leaky vasculature while avoiding glomerular filtration by virtue of their large size. Due to dendrimers' cage like structure they protect their core and thus an oligomeric compound can be protected from degradation by encapsulating it within a dendrimer. Dendrimers can be programmed to self-destruct under certain pH, oxidative and enzymatic conditions and thus can be used as osmotic bombs attached to oligomeric compounds to disrupt lysosomal membranes and release attached oligomeric compounds. Dendrimers have also been used to target molecules to specific organs and intracellular compartments; therefore, such uses can be applied to oligomeric compounds of the invention. Dendrimers can also serve as biocompatible carriers for oligomeric compounds of the invention to increase their plasma circulation time.

[0291] The pharmaceutical formulations and compositions of the present invention may also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860.

[0292] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of oligomeric compounds, particularly oligonucleotides. In

addition to aiding the diffusion of non-lipophilic compounds across cell membranes, penetration enhancers also enhance the permeability of lipophilic compounds. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Penetration enhancers and their uses are further described in U.S. Pat. No. 6,287,860.

[0293] In general, a composition's bioavailability is said to be "enhanced" when its relative bioavailability is greater than the bioavailability of a composition substantially consisting of pure oligomeric compound, i.e. oligomeric compound in the absence of a penetration enhancer.

[0294] Organ bioavailability refers to the concentration of compound in an organ. Organ bioavailability may be measured in test subjects by a number of means, such as by whole-body radiography. Organ bioavailability may be modified, e.g. enhanced, by one or more modifications to the oligomeric compound, by use of one or more carrier compounds or excipients, etc. as discussed in more detail herein. In general, an increase in bioavailability will result in an increase in organ bioavailability.

[0295] Suitable embodiments provided herein are compositions comprising one or more pharmaceutically acceptable penetration enhancers, and methods of using such compositions, which result in the improved bioavailability of oligonucleotides administered via non-parenteral modes of administration. Heretofore, certain penetration enhancers have been used to improve the bioavailability of certain drugs. See Muranishi, *Crit. Rev. Ther. Drug Carrier Systems*, 1990, 7, 1 and Lee et al., *Crit. Rev. Ther. Drug Carrier Systems*, 1991, 8, 91. It has been found that the uptake and delivery of oligonucleotides can be greatly improved even when administered by non-parenteral means through the use of a number of different classes of penetration enhancers.

[0296] In some embodiments, compositions for non-parenteral administration include one or more modifications from naturally-occurring oligonucleotides (i.e. full-phosphodiester deoxyribosyl or full-phosphodiester ribosyl oligonucleotides). Such modifications may increase binding affinity, nuclease stability, cell or tissue permeability, tissue distribution, or other biological or pharmacokinetic property. In some embodiments, compositions for administration to a subject, and in particular oral compositions for administration to an animal or human subject, will comprise modified oligomeric compounds having one or more modifications for enhancing affinity, stability, tissue distribution, or other biological property.

[0297] Oral compositions for administration of non-parenteral oligomeric compounds can be formulated in various dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The term "alimentary delivery" encompasses e.g. oral, rectal, endoscopic and sublingual/buccal administration. A common requirement for these modes of administration is absorption over some portion or all of the alimentary tract and a need for efficient mucosal penetration of the nucleic acid(s) so administered. Consequently, such oral oligomeric compound compositions can be referred to as "mucosal penetration enhancers."

[0298] Delivery of a drug via the oral mucosa, as in the case of buccal and sublingual administration, has several desirable features, including, in many instances, a more rapid rise in plasma concentration of the drug than via oral delivery (Har-

vey, Chapter 35 *In: Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, page 711).

[0299] Oligomeric compounds, such as oligonucleotides, may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Pat. No. 6,287,860. Oral formulations for oligonucleotides and their preparation are described in detail in U.S. application Ser. No. 09/108,673 (filed Jul. 1, 1998), Ser. No. 09/315,298 (filed May 20, 1999) and Ser. No. 10/071,822, filed Feb. 8, 2002.

[0300] Endoscopy may be used for drug delivery directly to an interior portion of the alimentary tract. For example, endoscopic retrograde cystopancreatography (ERCP) takes advantage of extended gastroscopy and permits selective access to the biliary tract and the pancreatic duct (Hirahata et al., *Gan To Kagaku Ryoho*, 1992, 19(10 Suppl.), 1591). Pharmaceutical compositions, including liposomal formulations, can be delivered directly into portions of the alimentary canal, such as, e.g., the duodenum (Somogyi et al., *Pharm. Res.*, 1995, 12, 149) or the gastric submucosa (Akamo et al., *Japanese J. Cancer Res.*, 1994, 85, 652) via endoscopic means. Gastric lavage devices (Inoue et al., *Artif. Organs*, 1997, 21, 28) and percutaneous endoscopic feeding devices (Pennington et al., *Ailment Pharmacol. Ther.*, 1995, 9, 471) can also be used for direct alimentary delivery of pharmaceutical compositions.

[0301] In some embodiments, oligomeric compound formulations may be administered through the anus into the rectum or lower intestine. Rectal suppositories, retention enemas or rectal catheters can be used for this purpose and may be preferred when patient compliance might otherwise be difficult to achieve (e.g., in pediatric and geriatric applications, or when the patient is vomiting or unconscious). Rectal administration can result in more prompt and higher blood levels than the oral route (Harvey, Chapter 35 *In: Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, page 711). Because about 50% of the drug that is absorbed from the rectum will bypass the liver, administration by this route significantly reduces the potential for first-pass metabolism (Benet et al., Chapter 1 *In: Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, N.Y., 1996).

[0302] In one embodiment, oral oligomeric compound compositions comprise at least one member of the group consisting of surfactants, fatty acids, bile salts, chelating agents, and non-chelating surfactants. Further embodiments comprise oral oligomeric compound comprising at least one fatty acid, e.g. capric or lauric acid, or combinations or salts thereof. One combination is the sodium salt of lauric acid, capric acid and UDCA. Other embodiments comprise methods of enhancing the oral bioavailability of an oligomeric compound, the method comprising co-administering the oligomeric compound and at least one penetration enhancer.

[0303] Other excipients that may be added to oral oligomeric compound compositions include surfactants (or "surface-active agents"), which are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligomeric compounds through the alimentary mucosa and other epithelial membranes is enhanced. In addition to bile

salts and fatty acids, surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and perfluorchemical emulsions, such as FC-43 (Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

[0304] Fatty acids and their derivatives which act as penetration enhancers and can be used in compositions of the compounds of the present invention include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines and mono- and di-glycerides thereof and/or physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, 8:2, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7:1, 1-33; El-Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654). Examples of some fatty acids are sodium caprate (C10) and sodium laurate (C12), used singly or in combination at concentrations of 0.5 to 5%.

[0305] In one embodiment, oligomeric compound compositions for oral delivery comprise at least two discrete phases, which phases may comprise particles, capsules, gel-capsules, microspheres, etc. Each phase may contain one or more oligomeric compounds, penetration enhancers, surfactants, bio-adhesives, effervescent agents, or other adjuvant, excipient or diluent. In one embodiment, one phase comprises at least one oligomeric compound and at least one penetration enhancer. In one embodiment, a first phase comprises at least one oligomeric compound and at least one penetration enhancer, while a second phase comprises at least one penetration enhancer. In one embodiment, a first phase comprises at least one oligomeric compound and at least one penetration enhancer, while a second phase comprises at least one penetration enhancer and substantially no oligomeric compound. In one embodiment, at least one phase is compounded with at least one degradation retardant, such as a coating or a matrix, which delays release of the contents of that phase. In one embodiment, a first phase comprises at least one oligomeric compound and at least one penetration enhancer, while a second phase comprises at least one penetration enhancer and a release-retardant. In particular embodiments, an oral oligomeric compound comprises a first phase comprising particles containing an oligomeric compound and a penetration enhancer, and a second phase comprising particles coated with a release-retarding agent and containing penetration enhancer.

[0306] A variety of bile salts also function as penetration enhancers to facilitate the uptake and bioavailability of drugs. The physiological roles of bile include the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 *In: Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, N.Y., 1996, pages 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Bile salts contemplated herein include, for example, cholic acid (or its sodium salt, sodium cholate, or other pharmaceutically acceptable salts), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucocholate), glycholic acid (sodium glycocholate), glycdeoxy-

cholic acid (sodium glycdeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (CDCA, sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 *In: Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583). UDCA and CDCA have been used effectively as penetration enhancers for oligonucleotides, and even more effectively when combined.

[0307] In one embodiment, penetration enhancers useful in some embodiments are mixtures of penetration enhancing compounds. One such penetration enhancer is a mixture of UDCA (and/or CDCA) with capric and/or lauric acids or salts thereof e.g. sodium. Such mixtures are useful for enhancing the delivery of biologically active substances across mucosal membranes, in particular intestinal mucosa. Other penetration enhancer mixtures comprise about 5-95% of bile acid or salt(s) UDCA and/or CDCA with 5-95% capric and/or lauric acid. Particular penetration enhancers are mixtures of the sodium salts of UDCA, capric acid and lauric acid in a ratio of about 1:2:2 respectively. Another such penetration enhancer is a mixture of capric and lauric acid (or salts thereof) in a 0.01:1 to 1:0.01 ratio (mole basis). In particular embodiments capric acid and lauric acid are present in molar ratios of e.g. about 0.1:1 to about 1:0.1, in particular about 0.5:1 to about 1:0.5.

[0308] Other excipients include chelating agents, i.e. compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligomeric compound through the alimentary and other mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315). Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of betadiketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1; Buur et al., *J. Control Rel.*, 1990, 14, 43).

[0309] As used herein, non-chelating non-surfactant penetration enhancers may be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary and other mucosal membranes (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1). This class of penetration enhancers includes, but is not limited to, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621).

[0310] Some oral oligonucleotide compositions also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or

analog thereof, which may be inert (i.e., does not possess biological activity per se) or may be necessary for transport, recognition or pathway activation or mediation, or is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177).

[0311] A "pharmaceutical carrier" or "excipient" may be a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, EXPLOTAB); and wetting agents (e.g., sodium lauryl sulphate, etc.).

[0312] Oral oligomeric compositions may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.

[0313] One of skill in the art will recognize that formulations are routinely designed according to their intended use, i.e. route of administration.

[0314] Formulations for topical administration include those in which the oligomeric compounds of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA).

[0315] For topical or other administration, oligomeric compounds of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be

complexed to lipids, in particular to cationic lipids. Fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Pat. No. 6,287,860. Topical formulations are described in detail in U.S. patent application Ser. No. 09/315,298 filed on May 20, 1999.

[0316] Combinations

[0317] In accordance with the present invention certain pharmaceutical compositions contain one or more antisense compounds and one or more other agents which function by a non-antisense mechanism. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one can achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0318] Chemotherapeutic Agents

[0319] For example, in the treatment of cancer, one or more of the agents can be chemotherapeutic agents. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramidate, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUDR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin, pemetrexed and diethylstilbestrol (DES). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention.

NONLIMITING DISCLOSURE AND INCORPORATION BY REFERENCE

[0320] While certain compounds, compositions and methods of the present invention have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds of the invention and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.

EXAMPLE 1

[0321] The effect of oligomeric compounds on target nucleic acid expression was tested in one or more of the following cell types.

[0322] 3T3-L1 cells: The mouse embryonic adipocyte-like cell line 3T3-L1 was obtained from the American Type Culture Collection (Manassas, Va.). 3T3-L1 cells were routinely cultured in DMEM, high glucose (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 80% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 4000 cells/well for use in oligomeric compound transfection experiments.

[0323] A10 cells: The rat aortic smooth muscle cell line A10 was obtained from the American Type Culture Collection (Manassas, Va.). A10 cells were routinely cultured in DMEM, high glucose (American Type Culture Collection, Manassas, Va.) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 80% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 2500 cells/well for use in oligomeric compound transfection experiments.

[0324] A549 cells: The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (Manassas, Va.). A549 cells were routinely cultured in DMEM, high glucose (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum, 100 units per ml penicillin, and 100 micrograms per ml streptomycin (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 5000 cells/well for use in oligomeric compound transfection experiments.

[0325] AML-12 cells: AML12 (alpha mouse liver 12) cell line was established from hepatocytes from a mouse (CD 1 strain, line MT42) transgenic for human TGF alpha. Cells are cultured in a 1:1 mixture of DMEM and Ham's F12 medium (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum, 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 5 ng/ml selenium, and 40 ng/ml dexamethasone (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 5000 cells/well for use in oligomeric compound transfection experiments.

[0326] b.END cells: The mouse brain endothelial cell line b.END was obtained from Dr. Werner Risau at the Max Plank Institute (Bad Nauheim, Germany). b.END cells were routinely cultured in DMEM, high glucose (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 3000 cells/well for use in oligomeric compound transfection experiments.

[0327] B16-F10 cells: The mouse melanoma cell line B16-F10 was obtained from the American Type Culture Collection (Manassas, Va.). B16-F10 cells were routinely cultured in DMEM, high glucose (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of

approximately 7000 cells/well for use in oligomeric compound transfection experiments.

[0328] CHO cells: The Chinese hamster ovary cell line CHO was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). CHO cells were routinely cultured in Ham's F12K media (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum and 2 mM L-glutamine, which was adjusted to contain 1.5 g/L sodium bicarbonate (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 6000 cells/well for use in oligomeric compound transfection experiments.

[0329] HEPA 1-6 cells: The mouse hepatoma cell line HEPA 1-6 is a derivative of the BW7756 mouse hepatoma that arose in a C57/L mouse and is supplied by the American Type Culture Collection (Manassas, Va.). The cells are propagated in DMEM, high glucose, supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin. Cells were routinely passaged by trypsinization and dilution when they reached approximately 80% confluence. Cells were seeded into 96-well plates at a density of approximately 4000 cells/well for use in oligomeric compound transfection experiments.

[0330] Primary mouse hepatocytes: Primary mouse hepatocytes were prepared from CD-1 mice purchased from Charles River Labs. Primary mouse hepatocytes were routinely cultured in Hepatocyte Attachment Media supplemented with 10% fetal bovine serum , 1% penicillin/streptomycin, 1% antibiotic-antimitotic (Invitrogen Life Technologies, Carlsbad, Calif.) and 10 nM bovine insulin (Sigma-Aldrich, St. Louis, Mo.). Cells were seeded into 96-well plates (Falcon-Primaria #3872) coated with 0.1 mg/ml collagen at a density of approximately 10,000 cells/well for use in oligomeric compound transfection experiments.

[0331] HepG2 cells: The human hepatoblastoma cell line HepG2 was obtained from the American Type Culture Collection (Manassas, Va.). HepG2 cells were routinely cultured in Eagle's MEM supplemented with 10% fetal bovine serum, 1 mM non-essential amino acids, and 1 mM sodium pyruvate (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Multiwell culture plates are prepared for cell culture by coating with a 1:100 dilution of type 1 rat tail collagen (BD Biosciences, Bedford, Mass.) in phosphate-buffered saline. The collagen-containing plates were incubated at 37° C. for approximately 1 hour, after which the collagen was removed and the wells were washed twice with phosphate-buffered saline. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 8,000 cells/well for use in oligomeric compound transfection experiments.

[0332] HUVEC cells: The human umbilical vein endothelial cell line HuVEC was obtained from the American Type Culture Collection (Manassas, Va.). HuVEC cells were routinely cultured in EBM (Cambrex Bio Science, Walkersville, Md.) supplemented with SingleQuots supplements (Cambrex Bio Science, Walkersville, Md.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence were maintained for up to 15 passages. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 10000 cells/well for use in oligomeric compound transfection experiments.

[0333] MLg2908 cells: The mouse lung cell line MLg2908 was obtained from the American Type Culture Collection

(ATCC) (Manassas, Va.). MLg2908 cells were routinely cultured in MEM (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 3000 cells/well for use in oligomeric compound transfection experiments.

[0334] P388D1 cells: The murine macrophage cell line P388D1 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). P388D1 cells were routinely cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% sodium pyruvate (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 65-75% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 15,000 cells/well for use in oligomeric compound transfection experiments.

[0335] T-24 cells: The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 4000-6000 cells/well for use in oligomeric compound transfection experiments.

[0336] Treatment with antisense compounds: When cells reached approximately 65-75% confluence, they were treated with oligonucleotide. Oligonucleotide was mixed with LIPO-FECTINT™ (Invitrogen Life Technologies, Carlsbad, Calif.) to achieve a final concentration of 3 µg/mL LIPOFECTINT™ per 100 nM oligonucleotide in 1 mL OPTI-MEM™-1 or Eagle's MEM (Invitrogen Life Technologies, Carlsbad, Calif.). For cells grown in 96-well plates, wells were washed once with 100 µL OPTI-MEM™-1, Eagle's MEM or serum-free culture medium and then treated with 130 µL of the oligonucleotide/OPTI-MEM™-1 or Eagle's MEM/ LIPO-FECTINT™ cocktail. Cells were treated and data were obtained in duplicate or triplicate. After 4-7 hours of treatment at 37° C., the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

[0337] Control oligonucleotides are used to determine the optimal oligomeric compound concentration for a particular cell line. Furthermore, when oligomeric compounds of the invention are tested in oligomeric compound screening experiments or phenotypic assays, control oligonucleotides are tested in parallel with compounds of the invention. In some embodiments, the control oligonucleotides are used as negative control oligonucleotides, i.e., as a means for measuring the absence of an effect on gene expression or phenotype. In alternative embodiments, control oligonucleotides are used as positive control oligonucleotides, i.e., as oligonucleotides known to affect gene expression or phenotype.

[0338] Control oligonucleotides are shown in Table 2. "Target Name" indicates the gene to which the oligonucleotide is targeted. "Species of Target" indicates species in which the oligonucleotide is perfectly complementary to the target mRNA. "Motif" is indicative of chemically distinct regions comprising the oligonucleotide. Certain compounds in Table 2 are composed of 2'-O-(2-methoxyethyl) nucleotides, also known as 2'-MOE nucleotides, and designated as "Uniform MOE". Certain compounds in Table 2 are chimeric oligonucleotides, composed of a central "gap" region consisting of 2'-deoxynucleotides, which is flanked on both sides (5' and 3') by "wings". The wings are composed of 2'-O-(2-methoxyethyl) nucleotides, also known as 2'-MOE nucleotides. The "motif" of each gapmer oligonucleotide is illustrated in Table 2 and indicates the number of nucleotides in each gap region and wing, for example, "5-10-5" indicates a gapmer having a 10-nucleotide gap region flanked by 5-nucleotide wings. Similarly, the motif "5-9-6" indicates a 9-nucleotide gap region flanked by 5-nucleotide wing on the 5' side and a 6-nucleotide wing on the 3' side. ISIS 15839 is a "hemimer" composed of two regions of distinct chemistry, wherein the first 12-nucleotides are 2'-deoxynucleotides and the last 8 nucleotides are 2'-MOE nucleotides. ISIS 15344 is a "hemimer" composed of two regions of distinct chemistry, wherein the first 9 nucleotides are 2'-deoxynucleotides and the last 11 are 2'-MOE nucleotides. ISIS 13513 is a chimeric oligonucleotide composed of multiple regions of distinct chemistry, denoted with a motif of "6-8-5-1" and comprised of a 6-nucleotide wing flanking an 8-nucleotide gap region followed by 5 2'-MOE nucleotides and terminating with a 2'-deoxynucleotide at the 3' end. The internucleoside (backbone) linkages are phosphorothioate throughout the oligonucleotides in Table 2. Unmodified cytosines are indicated by "uC" in the nucleotide sequence; all other cytosines are 5-methylcytosines.

TABLE 2

Control oligonucleotides for cell line testing, oligomeric compound screening and phenotypic assays				
ISIS # Target Name	Species of Target	Sequence (5' to 3')	Motif	SEQ ID NO
117386 C/EBP alpha	Human	CCCTACTCAGTAGGCATTGG	5-10-5	27
15839 CD54	Cynomolgus monkey; Human; Rhesus monkey	G"C"C"CAAG"CTGG"CAT"C"CGT"CA	Hemimer	28
113131 CD86	Human	CGTGTGTCGTGCTAGTCCC	5-10-5	29

TABLE 2-continued

Control oligonucleotides for cell line testing, oligomeric compound screening and phenotypic assays				
ISIS #	Target Name	Species of Target	Sequence (5' to 3')	SEQ ID NO
289865	forkhead box 01A (rhabdomyosarcoma)	Human	GGCAACGTGAAACAGGTCCAA	5-10-5 30
186515	insulin-like growth factor binding protein 1	Human	AGGTAGCTTGATTATGTAA	5-10-5 31
25237	integrin beta 3	Human	GCCCATTGCTGGACATGC	4-10-4 32
196103	integrin beta 3	Human	AGCCCATTGCTGGACATGCA	5-10-5 33
134062	Interleukin 8	Human	GCTTGTGTGCTCTGCTGTCT	5-10-5 34
148715	Jagged 2	Human; Mouse; Rat	TTGTCCCAGTCCCAGGCCTC	5-10-5 35
15346	Jun N-Terminal Kinase-1	Human	CTCTCTGTAGG ^U C ^U CGCTTGG	5-9-6 36
18076	Jun N-Terminal Kinase-1	Human	CTTTC ^U CGTTGGA ^U C ^U CCCTGGG	5-9-6 37
18078	Jun N-Terminal Kinase-2	Human	GTGCG ^U CG ^U CGAG ^U C ^U CGAACATC	5-9-6 38
101759	Jun N-Terminal Kinase-2	Mouse; Rat	GCTCAGTGGACATGGATGAG	5-10-5 39
183881	kinesin-like 1	Human	ATCCAAGTGCTACTGTAGTA	5-10-5 40
342672	Mir-143	Human; Mouse; Rat	ATACCGCGATCAGTGATCTTT	Uniform MOE 41
342673	Mir-143	Human; Mouse; Rat	AGACTAGCGGTATCTTATCCC	Uniform MOE 42
29848	none	none	NNNNNNNNNNNNNNNNNNNNNN	5-10-5 43
129695	none	none	TTCTACCTCGCGCGATTAC	5-10-5 44
129700	none	none	TAGTGCAGGACCTACCCACGA	5-10-5 45
226844	Notch (Drosophila) homolog 1	Human; Mouse	GCCCTCCATGCTGGCACAGG	5-10-5 46
105990	Peroxisome proliferator-activated receptor gamma	Human	AGCAAAAGATCAATCCGTTA	5-10-5 47
13513	Protein kinase C-delta	Human; Mouse	GGA ^U C ^U CCGAAAGAC ^U CA ^U C ^U CAG	6-8-5-1 48
116847	PTEN	Human; Mouse; Rabbit; Rat	CTGCTAGCCTCTGGATTGTA	5-10-5 49
15344	Raf kinase B	Human	CTGCCCTGGATGGGTGTTTT	Hemimer 50
13650	Raf kinase C	Human	TCCCCG ^U CTGTGA ^U CATGCATT	6-9-6 51
336806	Raf kinase C	Human	TACAGAAGGCTGGGCCTTGA	5-10-5 52
15770	Raf kinase C	Mouse; Murine sarcoma virus; Rat	ATGCATT ^U CTG ^U C ^U C ^U C ^U CAAGGA	5-10-5 53

TABLE 2-continued

Control oligonucleotides for cell line testing, oligomeric compound screening and phenotypic assays				
ISIS #	Target Name	Species of Target	Sequence (5' to 3')	SEQ ID NO
30748	Ship-2	Human; Mouse; Rat	CCAAACCTCAAATGTCCCA	4-10-4 54
153704	STAT 1	Human; Rat	AGGCATGGTCTTGTCAATA	5-10-5 55
23722	Survivin	Human	TGTGCTATTCTGTGAATT	4-10-4 56
13920	Ras-Ha	Human	T ^u C ^u CGTCATCGCT ^u C ^u CT ^u CAGGG	3-9-8 475

[0339] The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. Positive controls are shown in Table 2. For human and non-human primate cells, the positive control oligonucleotide is selected from either ISIS 13650 (SEQ ID NO: 51), ISIS 336806 (SEQ ID NO: 52) or ISIS 18078 (SEQ ID NO: 38). For mouse or rat cells the positive control oligonucleotide is ISIS 15770 (SEQ ID NO: 53) or ISIS 15346 (SEQ ID NO: 36). The concentration of positive control oligonucleotide that results in 80% inhibition of the target mRNA, for example, human Raf kinase C for ISIS 13650, is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of the target mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

EXAMPLE 2

Real-Time Quantitative PCR Analysis of Target Gene mRNA Levels

[0340] Quantitation of Gemin Gene mRNA levels was accomplished by real-time quantitative PCR using the ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions.

[0341] Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured were evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. After isolation the RNA is subjected to sequential reverse transcriptase (RT) reaction and real-time PCR, both of which are performed in the same well. RT and

PCR reagents were obtained from Invitrogen Life Technologies (Carlsbad, Calif.). RT, real-time PCR was carried out in the same by adding 20 µL PCR cocktail (2.5x PCR buffer minus MgCl₂, 6.6 mM MgCl₂, 375 µM each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 µL total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

[0342] Gene target quantities obtained by RT, real-time PCR were normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression was quantified by RT, real-time PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA was quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, Oreg.).

[0343] 170 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was pipetted into a 96-well plate containing 30 µL purified cellular RNA. The plate was read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485 nm and emission at 530 nm.

[0344] Presented in Table 3 are primers and probes used to measure GAPDH expression in the cell types described herein. The GAPDH PCR probes have JOE covalently linked to the 5' end and TAMRA covalently linked to the 3' end, where JOE is the fluorescent reporter dye and TAMRA is the quencher dye. In some cell types, primers and probe designed to a GAPDH sequence from a different species are used to measure GAPDH expression. For example, a human GAPDH primer and probe set is used to measure GAPDH expression in monkey-derived cells and cell lines.

TABLE 3

GAPDH primers and probes for use in real-time PCR				
Target Name	Species	Sequence Description	Sequence (5' to 3')	SEQ ID NO
GAPDH	Human	Forward Primer	CAACGGATTGGTCGTATTGG	57
GAPDH	Human	Reverse Primer	GGCAACAATATCCACTTACCAGAGT	58

TABLE 3-continued

GAPDH primers and probes for use in real-time PCR				
Target Name	Species	Sequence Description	Sequence (5' to 3')	SEQ ID NO
GAPDH	Human	Probe	CGCCTGGTCACCAGGGCTGCT	59
GAPDH	Human	Forward Primer	GAAGGTGAAGGTGGAGTC	60
GAPDH	Human	Reverse Primer	GAAGATGGTGATGGGATTTC	61
GAPDH	Human	Probe	CAAGCTTCCGTTCTCAGCC	62
GAPDH	Human	Forward Primer	GAAGGTGAAGGTGGAGTC	60
GAPDH	Human	Reverse Primer	GAAGATGGTGATGGGATTTC	61
GAPDH	Human	Probe	TGGAATCATATTGGAACATG	63
GAPDH	Mouse	Forward Primer	GGCAAATTCAACGGCACAGT	64
GAPDH	Mouse	Reverse Primer	GGGTCTCGCTCCTGGAAAGAT	65
GAPDH	Mouse	Probe	AAGGCCGAGAATGGGAAGCTTGTCA	66
GAPDH	Rat	Forward Primer	TGTTCTAGAGACAGCCGCATCTT	67
GAPDH	Rat	Reverse Primer	CACCGACCTTCACCATCTTGT	68
GAPDH	Rat	Probe	TTGTGCAGTGCCAGCCTCGTCTCA	69

[0345] Probes and primers for use in real-time PCR were designed to hybridize to target-specific sequences. The primers and probes and the target nucleic acid sequences to which they hybridize are presented in Table 4. The target-specific PCR probes have FAM covalently linked to the 5' end and TAMRA covalently linked to the 3' end, where FAM is the fluorescent dye and TAMRA is the quencher dye.

TABLE 4

Gene target-specific primers and probes for use in real-time PCR					
Target Name	Species	Target SEQ ID NO	Sequence Description	Sequence (5' to 3')	SEQ ID NO
Gemin2	Human	7	Forward Primer	CAAATTGACCCAAGAACAGTTGAAA	70
Gemin2	Human	7	Reverse Primer	GTTGCTGTTGCCATTGAAGTGT	71
Gemin2	Human	7	Probe	ACCCGCCCTGAAGGTTATTCCCC	72
Gemin4	Human	12	Forward Primer	GAAGTGCAGGGTCCCAATT	73
Gemin4	Human	12	Reverse Primer	TTCATCCAGACGGTTCTTGA	74
Gemin4	Human	12	Probe	TCTGCCACTTCATGGTGTCA	75
Gemin5	Human	14	Forward Primer	GCaaaAGCTCCTCCTTACCA	76
Gemin5	Human	14	Reverse Primer	GTCACCCCTCTCCACGAAAGG	77
Gemin5	Human	14	Probe	ACTTGGAACACGGGCACCGAAG	78
Gemin6	Human	20	Forward Primer	GAGAAGAACACATCCCCATCA	79
Gemin6	Human	20	Reverse Primer	GACCCCAGCCACACAGAGA	80
Gemin6	Human	20	Probe	TGAACAGGGAGACGCTCCAAGGA	81

TABLE 4-continued

Gene target-specific primers and probes for use in real-time PCR					
Target	Species	SEQ ID NO	Description	Sequence (5' to 3')	SEQ ID NO
Gemin7 Human		25	Forward Primer	CCTTCAAGCCATAAAGATATTGTGTT	82
Gemin7 Human		25	Reverse Primer	TTGGGGAGGCCTGGGATACA	83
Gemin7 Human		25	Probe	CTTTTCTGCTTGAGGCTAAGGCA	84

EXAMPLE 3

Treatment of Cultured Cells with Oligomeric Compounds

[0346] Oligomeric compounds targeted to Gemin Genes presented in Table 1 were tested for their effects on gene target expression in cultured cells. Table 5 shows the experimental conditions, including cell type, transfection method, dose of oligonucleotide and control SEQ ID NO used to evaluate the inhibition of gene expression by the oligomeric compounds of the invention. The control oligonucleotide was chosen from the group presented in Table 2, and in these experiments was used as a negative control. Each cell type was treated with the indicated dose of oligonucleotide as described by other examples herein.

TABLE 5

Treatment conditions of cultured cells with oligomeric compounds					
Target Name	Cell Type	Transfection Method	Dose of Oligonucleotide (nM)	Control SEQ ID NO	
Gemin2	A549	Lipofectin	150	38	
Gemin4	T-24	Lipofectin	150	38	
Gemin5	A549	Lipofectin	150	38	
Gemin6	T-24	Lipofectin	150	38	
Gemin7	T-24	Lipofectin	150	38	

EXAMPLE 4

Antisense Inhibition of Gene Targets by Oligomeric Compounds

[0347] A series of oligomeric compounds was designed to target different regions of the Gemin Genes, using sequences cited in Table 1. The oligomeric compounds and the data describing the degree to which they inhibit gene expression are shown in Table 6.

[0348] All oligomeric compounds in Table 6 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of 10 2'-deoxy-nucleotides, which is flanked on both sides (5' and 3') by five-nucleotide "wings". The wings are composed of 2'-O-(2-methoxyethyl) nucleotides, also known as 2'-MOE nucleotides. The internucleoside (backbone) linkages are phosphorothioate throughout the oligonucleotide. All cytidine residues are 5-methylcytidines.

[0349] The oligomeric compounds were analyzed for their effect on gene target mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from experiments in which cultured cells, as indicated for each target in Table 5, were treated with the disclosed oligo-

meric compounds. A reduction in expression is expressed as percent inhibition in Table 6. If the target expression level of oligomeric compound-treated cell was higher than control, percent inhibition is expressed as zero inhibition. If present, "N.D." indicates "not determined". The target regions to which these oligomeric compounds are inhibitory are herein referred to as "validated target segments."

[0350] As shown in Table 6, SEQID NOs 87, 89, 90, 91, 92, 94, 103, 104, 105, 106, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 121, 122, 123, 125, 127, 128, 129, 130, 131, 132, 135, 136, 137, 138, 139, 140, 141, 142, 145, 146, 147, 148, 149, 150, 151, 152, 153, 156, 157, 158, 161, 163, 166, 177, 178, 180, 188, 193, 195, 210, 225, 228, 229, 232, 238, 241, 242, 243, 244, 245, 246, 249, 250, 251, 252, 253, 254, 255, 256, 257, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 291, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 311, 313, 315, 316, 317, 319, 320, 326, 328, 329, 330, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364, 366, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 380, 381, 382, 383, 384, 385, 387, 388, 393, 394, 395, 396, 397, 398, 399, 401, 402, 403, 410, 411, 412, 414, 415, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 450, 451, 452, 457, 458, 462, 467, 468, 469, 470, 471, 472, 473, 474, demonstrated at least 50% inhibition of a Gemin Gene in this assay. In some embodiments of the invention, oligomeric compounds of the invention comprise at least one of these sequences. In other embodiments, oligomeric compounds of the invention consist of at least one of these sequences.

[0351] The target sites to which these sequences are complementary are examples of "validated target sites" and are therefore sites for designing other oligomeric compounds of the present invention.

TABLE 6

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy gap						
ISIS #	Target SEQ ID NO	Site	Target Sequence (5' to 3')	% Inhib	SEQ ID NO	
297287	1	510	TTACTGTTGCTTGTACATAA	28	85	
297288	2	735	GTCAAAATACCACTAACAGAC	2	86	
297289	3	81	TGCTTCGATCCGGCAATAGC	59	87	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
297292	4	1317	CAATAAAAATTTATATGTAT	5	88	
297293	4	1356	TAGGAGTCAAACAAAATTT	51	89	
297294	4	1381	GCTAAGGCCATCCATTGTCT	54	90	
297295	4	1394	TTTTAATTCTGTGCTAAGG	53	91	
297296	4	1412	GCCATTTAACCCAGATTATT	52	92	
297297	4	1418	CACATTGCCATTAACTCCAG	35	93	
297298	4	1432	TTGCTGACTATGAACACATT	57	94	
297299	4	1439	AATTTTATTGCTGACTATGA	43	95	
297290	5	539	GCCATCTCCCTGATTCAATT	10	96	
297291	6	399	GAAAACCAATCATTGTCACA	8	97	
297230	7	44	CGCAGGGCGCACTAATAGACA	17	98	
297231	7	51	GTCACAGCGCAGCGCAGCA	38	99	
297232	7	57	TTCTAGGTCAACAGCGCAGGC	37	100	
297233	7	71	GGCGCATGCGCCATTCTAG	13	101	
297234	7	95	TTTCAAACCAGCCAGTTCC	48	102	
297235	7	174	GTCAAGTCGCAAGGCTCTAC	81	103	
297236	7	270	GCTACCACAAACATCTGGACA	77	104	
297237	7	287	TCTTGGGTCAATTGAGCT	92	105	
297238	7	294	TTCAACTTCTTGGGTCAT	88	106	
297239	7	308	CACTTGCTCCCTTCAAC	45	107	
297240	7	329	ATCCTGAAAGAGAAAATATTC	19	108	
297241	7	374	GTTGCCATTGAAGTGTGGG	81	109	
297242	7	378	TGCTGTTGCCATTGAAGTGT	90	110	
297243	7	389	GTGCCACTTGTGCTGTTGC	86	111	
297244	7	406	TCGAACAGTTGAAAATGTG	61	112	
297245	7	419	TGTTCACATTCTGTCGAACA	71	113	
297246	7	577	ATAATCTATTCCAGGACTTT	68	114	
297247	7	630	GCCTGATTCTCTGCTAAC	78	115	
297248	7	633	GTTGCCTGATTCTCTGCT	83	116	
297249	7	649	CAAGACACTAGTTACTGTTG	77	117	
297250	7	652	TTCCAAGACACTAGTTACTG	74	118	
297251	7	657	AGATATTCCAAGACACTAGT	74	119	
297252	7	671	CAAACCAATTACTCAGATAT	33	120	
297253	7	682	GTCTCTTCTCCAAACCAAT	52	121	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
297254	7	687	GTAAAGTCTCTTCTCCAAA	53	122	
297255	7	692	CTGGAGTAAAGTCTCTTCT	82	123	
297256	7	697	CAATTCTGGAGTAAAGTCTC	47	124	
297257	7	702	CTTCCAATTCTGGAGTAAA	65	125	
297258	7	706	CCATCTCCCAATTCTGGAG	43	126	
297259	7	735	TTTCAAGACAAGCCAATAA	55	127	
297260	7	738	GGCTTTCAAGACAAGCCA	66	128	
297261	7	742	CAAAGGTTTCAAGACAAG	51	129	
297262	7	746	GTAACAAAGCCTTTCAAGA	57	130	
297263	7	762	AGTGAATGAGCCTCAGGTAA	85	131	
297264	7	873	AAATACCTGCTAACCAAGCA	57	132	
297265	7	876	TCAAAATACCTGCTAACCA	24	133	
297266	7	900	GGCTCATCAGCTAAATCAGC	0	134	
297267	7	903	GATGGCTCATCAGCTAAATC	65	135	
297268	7	908	ATCAAGATGGCTCATCAGCT	79	136	
297269	7	916	TCAGCTACATCAAGATGGCT	71	137	
297270	7	941	AGAAATATCTCTATCCCTG	68	138	
297271	7	970	GTTTCCTCAGAGTTAGGCT	83	139	
297272	7	1004	AAGATGTGTTGAAATCTGTA	77	140	
297273	7	1017	TCACATAGTGTGAAGATGT	79	141	
297274	7	1023	AACCCTTCACATAGTGTGA	80	142	
297275	7	1031	AAGATGTGAACCTTCACAT	0	143	
297276	7	1037	CAGGTTAACATGTGAACCC	18	144	
297277	7	1055	GTATCAATCTGAATTGCACA	81	145	
297278	7	1105	GTGGGATTTCCATTGATAT	69	146	
297279	7	1110	ACTGAGTGGATTTCCATT	83	147	
297280	7	1114	AAAAACTGAGTGGATTTTC	82	148	
297281	7	1121	GTTCATAAAAACTGAGTGG	74	149	
297282	7	1131	TGTTCAAACGTTCATCAA	75	150	
297283	7	1144	GATTACAGAAAAACTGTTCAA	64	151	
297284	7	1150	CTGCTGATTACAGAAAACT	79	152	
297285	7	1164	AATTCTATGCAAGCTGCTT	89	153	
297286	7	1182	TGTAAAATTTCATCATACAA	48	154	
297300	8	1981	TAAGTAACCCATTAAAGAC	36	155	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
297301	8	4803	ATCCTGAAAGCTAGAGATCA	58	156	
297302	8	5344	TGTTCACATTCTAAGGAAG	60	157	
297303	8	7356	GGAATAAGGTTATCTACCTT	71	158	
297304	8	14948	CAAAGAAAGCTAATTGTTT	42	159	
297305	8	18873	TGCAACTTACCACTAACAGGC	36	160	
297306	8	19918	TAATCACTGTACAGTCAGA	64	161	
297307	8	20524	TTAACTATACCTGCTAACCA	28	162	
297452	9	6	TGGGCACAGAGCAATCACAC	75	163	
297450	9	129	CAATCACACGCCACAGGAT	45	164	
297451	9	427	CAATCACACAGCCACAGGAT	41	165	
297453	9	892	CAAGACGGTGAATGAGATCC	53	166	
297446	10	7	CTTAGGCCTGCTCACAAACCT	0	167	
297447	10	12	CCCGCCTTAGGCCGCTCAC	0	168	
297448	10	41	CACGATGGGAGACGCAGGAG	13	169	
297449	10	80	CTCCCCCTCCGAGAACTCGAA	44	170	
297454	11	63	TCCTTCCAGTCAAAACAAG	31	171	
297455	11	90	TTTCAGGGAAACGGTCCACC	49	172	
297386	12	15	CCTAGGTCCATGGCGCGAC	0	173	
297387	12	22	CAAGGGTCCTAGGTCCATGG	0	174	
297388	12	24	TTCAAGGGTCCTAGGTCCAT	0	175	
297389	12	53	CATGCAGAAATAGTCATTCT	40	176	
297390	12	108	GTTAATTCTGCCAGTGCCTT	53	177	
297391	12	203	TCTTCAGGCAAAGGGCTGG	59	178	
297392	12	210	GCTTCTTCTTCAGGCCAAA	27	179	
297393	12	282	TGCCACCAGTGTCTGTGTC	62	180	
297394	12	471	TCTTCGGCAGAAGTGTCAAC	43	181	
297395	12	694	GATCCGACTCTGGATCTGTG	35	182	
297396	12	767	CCTCTGTCAGCGAACACA	25	183	
297397	12	837	GAGTCCACACAGAGATCAC	28	184	
297398	12	843	GTGTCGGAGTTCCACACAGA	19	185	
297399	12	849	TTCTGGGTGTCGAGTTCCA	42	186	
297400	12	980	CCCGCAGCAGGTGGTGCAGG	0	187	
297401	12	1076	TCTGGCTGAAGGAAGTCAGA	52	188	
297402	12	1164	AGGAAGTCCCTGACACACTC	0	189	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
297403	12	1173	GTTTCCTCAGGAAGTCCCT	48	190	
297404	12	1199	AGGCCCTGTTCTTCAGCACC	42	191	
297405	12	1215	GCTGTGATATCCTCCAAGGC	42	192	
297406	12	1269	CACACTCCATATGGCGGTC	62	193	
297407	12	1302	AAGGCCACACTTCTTCAGA	18	194	
297408	12	1337	TGTTACTCCCCAGGCAGGCT	55	195	
297409	12	1374	AGCCTCAACACCAAGTCTGG	31	196	
297410	12	1469	CTGCGTAACATTCCAGGATC	45	197	
297411	12	1559	CATAAGCCAGCAACTTTCA	32	198	
297412	12	1579	GTCTTCCTGAAAACCTCCA	38	199	
297413	12	1584	TTGAGGTCTTCTTGAAAACC	43	200	
297414	12	1655	GGGCCACGGAGGCCACAGCT	18	201	
297415	12	1686	ACCGTGACTTCCGGGTGCAC	0	202	
297416	12	1724	TGCCGAGATTGACCACAGCC	48	203	
297417	12	1762	AGGGAAGGCAGTGAGAATCT	33	204	
297418	12	1781	CTTCCACAAACCTAAGGGCA	46	205	
297419	12	1857	GGTGTAGAGAACTTCATCCA	31	206	
297420	12	1887	AGGAGCTCTAAAAATTGCTT	23	207	
297421	12	1938	AGAGCAGCCACTGGAATCCC	25	208	
297422	12	1982	AGAAAGGCAGGACAAATTCC	20	209	
297423	12	2018	TCAGACTGAGGTCTACCTCT	51	210	
297424	12	2244	AAGGTCTCAGCATTGGCTGA	25	211	
297425	12	2282	GGAGCCAGGACAGGGACTTG	49	212	
297426	12	2289	TTGCGGTGGAGCCAGGACAG	49	213	
297427	12	2323	CCTCAGGCCACAGTCCAGT	45	214	
297428	12	2471	AGCAGCACTCCATCCAGGCC	0	215	
297429	12	2541	ACCTCCTCAGGATTGCCAC	43	216	
297430	12	2550	AACAGTCTGACCTCCTCAGG	26	217	
297431	12	2616	CGCTGCCACTCCTGAGGGCT	38	218	
297432	12	2633	TGGTCAGCTGGTGAAGGCAG	38	219	
297433	12	2719	AAAGGGCTTCAGGTTGAGCA	40	220	
297434	12	2778	TGGCTGCAGAGAAACTGGAA	44	221	
297435	12	2793	CAATTACGACAGCTATGGCT	43	222	
297436	12	3037	GCAGGTGAGGGTTCCAAGG	0	223	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
297437	12	3077	AGGAGCTGACAGAAAGGGTG	12	224	
297438	12	3086	TCTGGAGCAAGGAGCTGACA	53	225	
297439	12	3189	ACGCCAAGTCAGAAAGCTGCT	0	226	
297440	12	3228	GATCTTCTGCAGACCCGCCA	34	227	
297441	12	3263	CAGCTTTTCGCTCCCGCAC	61	228	
297442	12	3291	ACCCCTACAGACCTGCCATG	53	229	
297443	12	3304	CTGCTCGGGCTGACCCCTA	48	230	
297444	12	3326	TCACATAACTGTAAAGTCCA	45	231	
297445	12	3348	CCATGACTTTTGTGGACAG	71	232	
297456	13	1818	CGGCACCCACCTAGTCCAT	25	233	
297457	13	2360	GTGATACCTCAGGAGCGCAG	0	234	
297458	13	2691	ATAAGGACACTGAGGCGCAG	38	235	
297459	13	4041	GGCCCTAGCTCTGTGGGAGA	19	236	
297460	13	4137	ATAAACTTGCCTGGGAACA	46	237	
297461	13	4300	AATCACACAGCCACAGGGTA	54	238	
297462	13	5440	GGCGAGACCCTCAGCAAAG	15	239	
297463	13	5918	TTCAAGGGCCTGCACACAG	43	240	
297551	14	43	CCTCCAAAACAGCTAGATAC	54	241	
297552	14	64	AGATCCCATTGCAACAGTTC	87	242	
297553	14	112	TCTGATGAGGCACTGAAGAG	83	243	
297554	14	203	TCTATCCATTGATGTAGAAA	64	244	
297555	14	275	GTATGCAAACCCACCAAGGG	76	245	
297556	14	531	GATATGTGCTAGAAATCTGT	67	246	
297557	14	612	GGGAAGGTCTGTCCTCT	39	247	
297558	14	650	TAAGACAATCCCTCTCCTC	30	248	
297559	14	677	TCCACTAACGCTCCAGGGAT	84	249	
297560	14	939	TGGAGCCAGAGGCCATCAGA	85	250	
297561	14	960	GCACGTAAATGACTGCATTG	77	251	
297562	14	991	GGGCTGCTCTATGACAGT	52	252	
297563	14	1076	ATGTGGCTCCACGCCACAC	62	253	
297564	14	1230	CCCCCTGAATGATGCAGTCT	81	254	
297565	14	1291	TGAGGAGGCCGGGAATGATC	66	255	
297566	14	1377	TTCTCAAGGTGGCTTTTC	66	256	
297567	14	1843	ATCATTCTATACAGGGTAGC	63	257	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
297568	14	1864	TGACCTTTCCCTCAATATC	33	258	
297569	14	1893	GAAATAACTCAGGGTGGCCA	56	259	
297570	14	1935	GGAGAACACCTTGAGATCC	70	260	
297571	14	1982	CATAGCCACAAAGGTTGTCTG	64	261	
297572	14	2002	TGGTAGCCAGCTGCTGGTGC	75	262	
297573	14	2073	AAGCAGCCTTGACATACTGA	88	263	
297574	14	2117	CAGCTCCACCGCTTCATACA	70	264	
297575	14	2369	ATCCTCTCTACGATGGCAG	83	265	
297576	14	2395	CTGAGAGCCAGGGAAAGCAGA	83	266	
297577	14	2431	ACCCAGTTGTTGCCAGAAG	79	267	
297578	14	2477	CTGACCCCTGTAGACTTTCAT	71	268	
297579	14	2681	GTTCTGCAGCTCTGAAAGG	68	269	
297580	14	2748	AGTCATGGCAAATGTGAAGC	78	270	
297581	14	2782	GAGGCCATCTGTTGGCTCAG	58	271	
297582	14	2865	ACACTTCCTGCATGATGGT	79	272	
297583	14	2896	TGGTCACAGCCATCAGGGAG	25	273	
297584	14	3088	GCAGTGTCTAACTGCTGGCT	74	274	
297585	14	3125	TGGCTGAGAAGTTTCAGGGT	66	275	
297586	14	3390	TACACTGGCTCTGAGAACTG	69	276	
297587	14	3460	ATTCTCTGATTGCTCGCTCG	79	277	
297588	14	3662	TGTGAAAATTACATACAGA	57	278	
297589	14	3739	GAGTGAATGCTGGTGAGGC	78	279	
297590	14	3794	AAACTTAATCCTTGTGTA	54	280	
297591	14	3822	GTTGTCTATGGTAGGCAGG	80	281	
297592	14	3982	TTTGGGTGACGACAGAAAGT	78	282	
297593	14	4024	GAAGTATTACAAAGGTAGC	74	283	
297594	14	4057	TCTCAAACAAAGCATGACACA	51	284	
297595	14	4092	AAAGGTATCAATAGTCCTAA	77	285	
297596	14	4182	GGCCTATTCATATTCAAAC	87	286	
297597	14	4360	TTCTTGAGCTATTGACTGC	42	287	
297598	14	4375	TGAAACAGTAATTATTCCT	37	288	
297599	14	4492	AATAATCCAAAGGTACATCTA	45	289	
297600	14	4527	TTAAATAGTATTAGGTCC	45	290	
297601	15	20	GAAGCTGCCACAGCCGACCG	57	291	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy gap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID NO	
ISIS #						
297602	15	35	CCGTCAGAGACAAGAGAACG	49	292	
297603	15	55	TCCTGCCCATAACTACAAG	31	293	
297604	15	163	CGGACAAAGGAAGACGGAGGT	63	294	
297605	15	233	GTGCCCACCAACTCTCCTA	64	295	
297606	15	249	CAGAGACCCTTCGGTGTGT	86	296	
297607	15	359	ATGTTCTGTCACAACTGT	76	297	
297608	15	421	ACTATTAAAGCCTTACTCG	54	298	
297609	15	477	GGCTGTCATTCGTAAAC	62	299	
297610	15	498	TGGGTTCTATAAGAGGTGC	76	300	
297611	15	580	ATTATCACCACTATGCCATC	63	301	
297612	15	632	ATCATCATGGCCTCGAAGCC	82	302	
297613	15	658	GGACACCAGGCTATGGAGTG	65	303	
297614	15	769	AAGTAGCAACCTTGT	65	304	
297615	15	783	TGCTTCCAGTGGCTAAGTAG	86	305	
297616	15	803	GATTCGAATGGTTGATCTT	60	306	
297617	15	827	CCCTCGGCCTCTAGAACAGC	77	307	
297618	15	890	TTAACAGTTGGCTATAC	67	308	
297619	15	931	GGTTGATTGCTGGCCAATG	62	309	
297620	15	1516	CCTTCTCCTCCAAGTGACAT	39	310	
297621	15	2049	CATCCCACACCTGGCTGTA	54	311	
297622	16	19049	AAGAACTCACTTGATTGAA	0	312	
297623	16	19178	CAGCCTTATAAGAACATT	62	313	
297624	16	22018	CCAAAGTTACCTATGACAGT	4	314	
297625	16	30470	GGTTGCCATGCCCTCTGGT	60	315	
297626	16	34509	ATTTTGTACCTCTGGAGTG	58	316	
297627	16	44650	AGCTGCTGTAACATTTG	52	317	
297628	16	49702	TAACCTTACCTTAATGCT	5	318	
297694	17	28	GGTACTCAGCAACCATGCTT	83	319	
297695	17	33	CTCTGGGTACTCAGCAACCA	80	320	
297696	17	207	AGAACCTTGGCAGAGACTGG	44	321	
297697	18	713	TTTACCGACATCCAAGAA	0	322	
297698	18	770	GCCCTAACGTTACCTAATT	3	323	
297699	18	807	CTGCGCCTAACCTTAAGCCA	7	324	
297700	18	916	ACCTGAAGATTGCCCATGG	7	325	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy gap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID NO	
ISIS #						
297630	20	8	CTCCTCGCAACTCTGGTAC	70	326	
297631	20	29	CTGGCTAAATCAGTTAAAAA	16	327	
297632	20	36	TTGCCACCTGGCTAAATCAG	63	328	
297633	20	40	ATGATTGCCACCTGGCTAAA	63	329	
297634	20	50	CCATTCACTCATGATTGCCA	87	330	
297635	20	55	TTCATCCATTCACTCATGAT	44	331	
297636	20	84	TGTAATCTGCCATTCTAAG	58	332	
297637	20	90	TGTAATGTAACTTGCAT	73	333	
297638	20	93	CTTTGTAAATGTAATCTTGC	65	334	
297639	20	103	ACTCGGACCTCTTGTAAT	51	335	
297640	20	112	CTGGCTGTCACTGGACCTC	78	336	
297641	20	116	CTCACTGGCTGTCACTCGGA	88	337	
297642	20	119	CTTCTCACTGGCTGTCACTC	58	338	
297643	20	125	CTCATTCTCTCACTGGCTG	81	339	
297644	20	148	GTAGTTAAAACCCATCCTT	56	340	
297645	20	152	GTCTGTAGTTAAAACCCATC	57	341	
297646	20	156	CTGGGTCTGTAGTTAAAACC	66	342	
297647	20	159	AGACTGGGTCTGTAGTTAAA	57	343	
297648	20	166	TTGGCAGAGACTGGTCTGT	82	344	
297649	20	176	AAGGACAATATTGGCAGAGA	24	345	
297650	20	190	TCAAGGAAGTTCACAGGAC	59	346	
297651	20	197	GCCATCTCAAGGAAGTTCA	78	347	
297652	20	199	CTGCCATCTCAAGGAAGTT	58	348	
297653	20	211	GTCACAGACATGCTGCCATC	77	349	
297654	20	214	CCGGTCACAGACATGCTGCC	88	350	
297655	20	232	ACAGCATGCCCCATAATTCC	53	351	
297656	20	240	CAGTCTGCACAGCATGCTCC	80	352	
297657	20	244	TCAACAGTCTGCACAGCATG	68	353	
297658	20	256	TCATTCACTAGTTCAACAGT	53	354	
297659	20	262	TCCCCTCATTCATAGTTTC	36	355	
297660	20	267	TATGGTCCCCTTCATTCA	63	356	
297661	20	269	TCTATGGTCCCCTTCATTCA	62	357	
297662	20	297	TGAACAAATGTCATCAGCTC	59	358	
297663	20	303	CAGACGTGAACAAATGCATC	76	359	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
ISIS #						
297664	20	315	CTTTGCAGTCTCCAGACGTG	84	360	
297665	20	327	CTGGGCTGTATGCTTGAG	79	361	
297666	20	333	GATCCTCTGGCTGTATGCT	68	362	
297667	20	336	CCAGATCCTCTGGCTGTAT	74	363	
297668	20	346	TTTCTCTTCCAGATCCTC	54	364	
297669	20	369	CAAGGCCATTCTTAGGCTG	32	365	
297670	20	372	TCTCAAGCCATTCTTTAGG	60	366	
297671	20	374	CTTCTCAAGCCATTCTTTA	48	367	
297672	20	377	GTTCTCTCAAGCCATTCTCT	68	368	
297673	20	379	TGGTCTTCTCAAGCCATT	71	369	
297674	20	381	TGTGGTTCTCTCAAGCCAT	80	370	
297675	20	385	GGGATGTGGTCCTCTCAAG	65	371	
297676	20	404	GTCTCCCTGTTCAAGTGATGG	86	372	
297677	20	424	ACACAGAGAGTCCTGGAGC	65	373	
297678	20	429	CAGCCACACAGAGAGTCCT	66	374	
297679	20	433	ACCCCAGCCACACAGAGT	69	375	
297680	20	447	GGTCTATAGTCAGGACCCC	62	376	
297681	20	454	TATGGTGGGTCTATAGTCAG	54	377	
297682	20	457	TCATATGGTGGGTCTATAGT	59	378	
297683	20	468	AATTTCTGGATCATATGGT	21	379	
297684	20	472	CTGCAATTCTGGATCATA	83	380	
297685	20	481	TTAGAGCTGCTGCAATTTC	84	381	
297686	20	485	CTCATTAGAGCTGCTGCAAT	81	382	
297687	20	499	CGCGACAGAATAATCTCATT	89	383	
297688	20	511	AGATCCTGAACACCGCACAG	63	384	
297689	20	550	CTGGCCTCTCATGGGAAGC	58	385	
297690	20	590	GATAAAATATAGTCCTTTC	27	386	
297691	20	595	TGAGGGATAAAATATAGTCT	76	387	
297692	20	603	ACATTTATGAGGGATAAAA	70	388	
297693	20	610	ATTTAAACATTATGAGG	32	389	
297701	21	1302	TCTCCGCTGGATCCGCCAT	36	390	
297702	21	1452	ACATTCCTAACATCGCTTCAC	21	391	
297703	21	1795	CTGGCTAAATCTGAAACAA	18	392	
297704	21	1942	GCATACTCACTGGCAGAGA	81	393	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
ISIS #						
297705	21	2844	TCTTTTAAGAGATATAGTGA	58	394	
297706	21	4327	AAAGTAAGTTAGAGGCATC	55	395	
297707	21	4347	AAGGACAATACTTGGAGGA	65	396	
297769	22	144	AGAGCCAAACACTTAGGTCA	55	397	
297770	22	152	TAGATTCAAGAGGCCAACAC	61	398	
297771	22	269	TCCCTGGTGACCTGGCCCCA	80	399	
297772	22	325	TTAAGAAAGATCACACAGGG	34	400	
297773	22	349	GGTGTGACCTGATAAGAAC	59	401	
297774	22	383	GTGCCCATGTTAGAAAGGCA	73	402	
297775	22	410	AGAGGGAGCAAACTCAGGTC	66	403	
297776	22	416	GGAGGAAGAGGGAGCAAAC	39	404	
297766	23	58	CGGCTACTGGTGTCCCCACT	23	405	
297767	23	66	GAGGTCCCGGGCTACTGGTG	30	406	
297768	23	77	ATTGTCTTGGCTTTCCGTCA	26	407	
297785	24	56	TGTCTTGGCTTTCCGTCA	29	408	
297708	25	81	GCCGCCAGACCTTTCCGT	19	409	
297709	25	94	TGTCAACAGAGAACCGCCA	82	410	
297710	25	98	GAGTTGTCAACAGAGAACGCC	68	411	
297711	25	106	AACCAGCTGAGTTGTCAACA	77	412	
297712	25	113	GGTGTGGAACCAGCTGAGTT	48	413	
297713	25	167	GAGAGGAGATCAGCTCAGTG	62	414	
297714	25	176	GGTGCTCCAGAGAGGAGATC	72	415	
297715	25	204	ATTGTCTTGGCTCCCTCCTG	36	416	
297716	25	213	GGAGTTGCAATTGTCTTGGC	68	417	
297717	25	224	GAATGTTCACTGGAGTTGC	83	418	
297718	25	231	GGCACGGGAATGTTCACTGG	76	419	
297719	25	328	CTGGATTTCAAGAACCTCTG	74	420	
297720	25	339	ATGGGACACTCCTGGATTTC	65	421	
297721	25	347	CTTGAGCTATGGGACACTCC	86	422	
297722	25	374	CCCGCTGCTCCTGGATTTC	75	423	
297723	25	507	AAGTTGGCCACATCCAGGTC	82	424	
297724	25	513	ACGTAGAAGTTGGCCACATC	83	425	
297725	25	527	TCTGCAGCTGTGACACGTAG	89	426	
297726	25	537	CCTATGGGAGTCTGCAGCTG	83	427	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
ISIS #						
297727	25	540	ACACCTATGGGAGTCTGCAG	90	428	
297728	25	544	TTGCACACCTATGGGAGTCT	86	429	
297729	25	550	CTCTGCTTGACACCTATGG	87	430	
297730	25	572	TGTCACTACATCGGAGCAGC	0	431	
297731	25	594	GGCTTGAAGGTATATGAAAT	76	432	
297732	25	607	ACAATATCTTATGGCTTGA	85	433	
297733	25	680	GCCCAGAGTCCCTGGCTCGG	70	434	
297734	25	701	GGGAGCTCATAACTCCATGG	72	435	
297735	25	725	TTAAAGCTTGGCTCAAAATT	51	436	
297736	25	741	AGGAGTCCAGACTTGCTTAA	74	437	
297737	25	751	AGGAGGTCTCAGGAGTCCAG	84	438	
297738	25	792	CTTAGAATTCTCTAGAGTTGC	78	439	
297739	25	808	TTCCCTCCAATGGGATCTTA	84	440	
297740	25	822	TGTGAGGTAGAGCATTCTT	93	441	
297741	25	831	TCAGAGTTCTGTGAGGTAGA	86	442	
297742	25	858	GGCAGCAGGCCATATTCT	76	443	
297743	25	885	ACCTCGATGCCCGGTCTTC	76	444	
297744	25	907	AGGTTGTATCCTTTATCACC	83	445	
297745	25	941	ACTTTCAGCCTCTTAATA	37	446	
297746	25	1020	AAACAGGAGTCGAATTTC	30	447	
297747	25	1059	AAGATGACTCCATCCCCGTC	28	448	
297748	25	1070	ACCAGCCCCCTAAAGATGACT	38	449	
297749	25	1083	GGATAAACCCCCCTACCAAGCC	61	450	
297750	25	1114	ACTTGGCCCAGCTCCACTGG	50	451	

TABLE 6-continued

Modulation of Gemin Gene mRNA levels by chimeric oligonucleotides having 2'-MOE wings and deoxy cap						
	Target SEQ ID	Target NO	Site Sequence (5' to 3')	% Inhib	SEQ ID	NO
ISIS #						
297751	25	1161	GACTTGCAGGCCGTGCAGCCC	66	452	
297752	25	1171	CTTTCCAGGAGACTTGCAGGC	43	453	
297753	25	1188	ATGCCGGTCACTCCAGCCTT	44	454	
297754	25	1303	TCCACAGCAACCACAGGTGG	19	455	
297755	25	1331	GGGACAGCGAATCTGCTGTC	20	456	
297756	25	1405	CACCTGATCGCGAATCCTC	56	457	
297757	25	1414	GTGAAGTTGCACCCGTATCG	59	458	
297758	25	1442	TGCAAGGCTGGAGAGAAGAG	48	459	
297759	25	1477	AGGCTTAGTGAAGCGCGTGA	40	460	
297760	25	1504	ATCGCCTGGAAGGTTACTAG	38	461	
297761	25	1515	CTTTTTAAACAAATGCGCTGG	54	462	
297762	25	1524	AACTGCTTCTTTAAACA	14	463	
297763	25	1574	GAAGGCTTCGCTTACATCCT	37	464	
297764	25	1592	ACACACCTTACTTAATGGA	0	465	
297765	25	1601	CGAAACGACACACACCTTAA	10	466	
297777	26	1542	TTGTACTCACCGAGGTCCGC	51	467	
297778	26	1640	GCGGTCTTACCTCTTCCGT	51	468	
297779	26	1647	TGCAGGCGCGGTCTACCTC	68	469	
297780	26	2169	GCCGCCAGACCTAATTAA	54	470	
297781	26	4301	AGACACTAGGAACGCAATGA	80	471	
297782	26	8747	ATGCTATGATGTTGAATGTG	63	472	
297783	26	8992	CTATGCTGTATCAGGATT	78	473	
297784	26	12369	ATTGTCTGGCTGTTGAGTG	61	474	

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 475

<210> SEQ ID NO 1

<211> LENGTH: 815

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

atgcgccgag cgaaactggc tggtttggaaa accatggcgt gggtaccacg ggagtcgcga 60

gtgaaagagt tgatgcctcg gctattgccc gtagagcctt gcgacttgac ggaaggtttc 120

-continued

gtccctcggtacccccgag	gacgcctca	gaatacctga	ggcggttcca	gatcgaagca	180
gctcaatgtc	cagatgttg	ggtagctcaa	attgaccCAA	agaagttaaa	240
agtgtgaata	tttcttttcc	aggatgccAA	cccgccccTG	aaggTTATTC	300
caatggcaac	agcaacaAGT	ggcacAGTT	tcaactgttc	gacagaatgt	360
agaagtca	gaaatcaca	acagttggat	agtaatgtga	caatgccAAA	420
gaagaaggct	ggaagaaatt	ttgtctgggt	gaaaagttat	gtgctgacgg	480
ccagccacaa	atgaaagtcc	tggaaatagat	tatgtacaag	caacagtaac	540
gaataatctga	gtaattgggtt	tggagaaaga	gactttactc	cagaatttggg	600
tatgctttat	tggcttgtct	tgaaaagcct	ttgttacctg	aggctcattc	660
cagcttgcaa	gaaggtgctc	tgaagtgggg	ctcttagtgg	atagcaaaga	720
gttccctgctt	tgaatttatt	aatctgttgg	gttagcaggt	attttgacca	780
gctgtatggcc	catcttgatgt	taqctgatct	ctca		815

<210> SEQ ID NO 2
<211> LENGTH: 801
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

atgcgccgag	cggaactggc	tggtttgaaaa	accatggcgt	gggtaccagc	ggagtccgca	60
gtgaaagagt	tgtgcctcg	gctattgcgg	gttagagcctt	gcfgacttgac	ggaaggtttc	120
gatccctcg	tacccccgag	gacgcctcag	gaatacctga	ggcggttcca	gatcgaagca	180
gctcaatgtc	cagatgttgt	ggtagotcaa	attgacccaa	agaagttgaa	aaggaagcaa	240
agtgtgaata	tttctctttc	aggatgccaa	ccgcggcttg	aaggttattc	cccaacactt	300
caatggcaac	agcaacaagt	ggcacagttt	tcaactgttc	gacagaatgt	gaacaaacat	360
agaagtcact	ggaaatcaca	acagttggat	agtaatgtga	caatgccaaa	atctgaagat	420
gaagaaggct	ggaagaaaatt	ttgtctgggt	gaaaagttat	gtgctgacgg	ggctgttgg	480
ccagccacaa	atgaaagtcc	tggaatagat	tatgtacaaa	ttggtttcc	tcccttgctt	540
agtattgtta	gcagaatgaa	tcaggcaaca	gttaacttagtg	tcttggaaata	tctgagtaat	600
tggtttggag	aaagagactt	tactccagaa	ttgggaagat	ggctttatgc	tttattggct	660
tgtcttggaa	agcccttgg	acctgaggct	cattcaactga	ttcggcagct	tgcaagaagg	720
tgctctgaag	tgaggctt	agtggtattt	tgaccaacgt	gatttagctg	atgagccatc	780
ttgatgttagc	tgatctctca	g				801

<210> SEQ ID NO 3
<211> LENGTH: 825
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```
<400> SEQUENCE: 3  
  
atgcgccgag cggaactggc tggtttggaa accatggcggt gggtaaccagg ggagtcggca 60  
gttggaaaggat tgatgcctcg gctattgcgg gatcgaagca gctcaatgtc cagatgttgt 120  
ggtagctcaa attgacccaa agaagttgaa aaggaagcaa agtgtgaata tttcttttc 180  
aggatccccaa ccccccctgg aaggtttattc cccaaacactt caatggcaac agcaacaact 240
```

-continued

ggcacagttt tcaactgttc gacagaatgt gaacaaacat agaagtact ggaaatcaca	300
acagttggat agtaatgtga caatgc当地 atctgaatgt gaagaaggct ggaagaaatt	360
ttgtctgggt gaaaagttat gtgctgacgg ggctgttgg ccagccacaa atgaaagtcc	420
tggaatagat tatgtacaaa ttggtttcc tcccttgctt agtattgtta gcagaatgaa	480
tcaggcaaca gtaactagtg tcttggataa tctgagataa tggtttggag aaagagactt	540
tactccagaa ttgggaagat ggcttatgc ttatggct tgccttgaaa agccttgc	600
acctggggct cattcaactga ttccggcagct tgcaagaagg tgctctgaag tgaggctt	660
agtggatagc aaagatgtg agagggttcc tgcttgcata ttatgtatct gcttggtag	720
caggtatccc gaccaacgtg atttagctga tgagccatct tgatgttagt gatctctag	780
ggatagaaga tatttctcat gaaggcagcc taactctgag gaaaa	825

<210> SEQ ID NO 4
 <211> LENGTH: 1553
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4	
gctgtgaccc agaatggcg catgcgccga gcggaactgg ctgggttggaa aaccatggcg	60
tgggtaccag cggagtccgc agtggaaagag ttgatgcctc ggctattgc ggtagagect	120
tgcgacttga cggaaaggctt cgatccctcg gtacccccga ggacgcctca ggaatacctg	180
aggcgggtcc agatcgaagc agctcaatgt ccagatgttggtagetca aattgaccca	240
aagaagttga aaaggaagca aagtgtgaat atttctctt caggatgcca acccgcccc	300
gaagggttatt ccccaacact tcaatggcaa cagcaacaag tggcacagtt ttcaactgtt	360
cgacagaatg tgaacaaaca tagaagtcac tggaaatcac aacagttgaa tagtaatgt	420
acaatgaggt ggggtttgc catgttggcc aggctgtct tgaactcctg acttcatgt	480
atcgectgcc tcggcctccc aaagtgtgg gattacaggg gtgaaccacc gcacccggcc	540
taagccaaaa tctgaatgt aagaaggctg gaagaaattt tgcgtgggtt aaaaatgt	600
tgctgacggg gctgttggac cagccacaaa tggaaatgc tggatagatt atgtacaat	660
tggtttcct cccttgcata gtattgttag cagaatgaat caggcaacag taactagt	720
cttggaaatat ctgagtaatt ggtttggaga aagagacttt actccagaat tggaaatgt	780
gctttatgt ttatggctt gtcttggaaa gcctttgtt cctgaggctc attcactgt	840
tccggcagctt gcaagaaggct gctctgaatgtt gggatagca aagatgt	900
gagggttccct gctttgaatt tattatctg ctgggttagt aggtatccc accaacgt	960
tttagctgtat gagccatctt gatgttagtgc atctctcagg gatagaatgtt atttctcat	1020
aaggcgcctt aactctgagg aaaacaatgc caattcaagt acagattca acacatctt	1080
aacactatgt gaagggttca catcttaacc tgtgcaattc agattgatac tcagaatatg	1140
ggttgatttt aatatctgaa atatcaatgg aaaatcccac tcaatgtt atgaacatgt	1200
tgaacagttt tctgtatca agcagttgc atagaatgtt tatgtgaaa ttttacat	1260
gttcttgggt ctgttttgtt ctttttgtt tttttgtt tttgttattt acttata	1320
atataaaaatt ttatgtggaaa tatgttttgtt ttactaaaat tttgtttgac tcctaaca	1380
agacaatggaa tggccttagc atcagaatgtt aaataatctg gattaaatgg caatgtgtt	1440

-continued

atagtcagca ataaaattaa acattttcc cttaaaaaa aaaaaaaaaa aaaaaaaaaa 1500
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1553

<210> SEQ ID NO 5
<211> LENGTH: 681
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 681
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 5

gggctggttt gaaaaccatg gcgtgggtac cagcggagtc cgcaagtggaa gagtttatgc 60
ctcggttattt gcccggtagag ccttgcact tgacggagg ttccatccc tcggtacccc 120
cgaggacgccc tcaggaatac ctgaggcggg tccagatcga agcagctcaa tgtccagatg 180
tttgtggtagc tcaaatttgc ccaaagaagt tgaaaaggaa gcaaaagtgt aatatttctc 240
tttcaggatg ccaaccggcc cctgaagggtt attcccaac acttcaatgg caacagcaac 300
aagtggcaca gtttcaact gttcgacaga atgtgaacaa acatagaagt cactggaaat 360
cacaacagtt ggatagtaat gtgacaatgc caaaatctga agatgaagaa ggctggaaaga 420
aattttgtct gggtgaaaag ttatgtgtc acggggctgt tggaccagcc acaaatgaaa 480
gtccttggaaat agtattatgtca caaatggtt ttccctccctt gcttagtattt gtttagcagaa 540
tgaatcaggg aagatggctt tatgtttat tggcttgatc tgaaaagcct ttgttacctg 600
aggctcatc actgattcgg cagttgcaa gaagggtgtc tgaagtgggg ctcttagtgg 660
atagcaaaga tgatgagagg n 681

<210> SEQ ID NO 6
<211> LENGTH: 822
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

agcgccgcgc gacggaaact ggctggttt gaaaaccatgg cgtgggtacc agcggagtc 60
gcagtggaag agttgtatgcc tcggcttattt ccggtagagc cttgcactt gacggagggt 120
ttcgatccctt cggttcccccc gaggacgccc caggaatacc tgaggcggtt ccagatcga 180
gcagctcaat gtccagatgt tgggttagt caaatttgc caaaatggacc gaaaaggaaag 240
caaagtgtca atatttctctt ttcaggatgc caaccggccc ctgaagggtt ttcccaaca 300
cttcaatggc aacagcaaca attggcacag tttcaactg ttgcacagaa tggtaacaaa 360
catagaagtc actggaaatc acaacagttt gatagtaatg tgacaatgt tggtttctt 420
cccttgctta gtattttttt cagaatgaat cagggaaatg ggctttatgc ttatgggt 480
tgtcttggaaa agcctttttt acctggggctt catttactga ttccggcact tgcaagaagg 540
tgctctgtcaag tgagggttctt agtggatgc aaagatgttggggatc tgctttgtatc 600
ttattatctt gcttggttag caggtatccc gaccaacgtt attagtgc tgagccatct 660
tgatgttagt gatctcttcc ggtatggaaatg atatttctca tgaaggccatc cctaactctg 720
aggaaaacaa tgccaattca agtacagatt tcaacacatc ttcaacacta tggtaacggg 780
tcacatctttt acctgtgcaa tcagattgtt actcagaata tg 822

-continued

```
<210> SEQ ID NO 7
<211> LENGTH: 1285
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 25
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 7

taacgcgtccc taaactgccca cttgntcagc tccgcgccta aggtgtctat tagtgcgcct 60
gcgctgtgac ctagaatggg cgcatgcgcgc gagcggaaact ggctgggttg aaaaccatgg 120
cgtgggtacc agcggagtc gcagtggaaag agttgatgcc tcggctattt ccggtagagc 180
cttgcgactt gacggaaaggt ttgcgtccct cggtacccccc gaggacgcct caggaataacc 240
tgaggcgggtt ccagatcgaa gcagctaat gtccagatgt tgtggtagct caaattgacc 300
caaagaagtt gaaaaggaag caaagtgtga atatttctct ttcaaggatgc caaccgcgg 360
ctgaagggtt ttccccaaaca cttcaatggc aacagcaaca agtggcacag tttcaactg 420
ttcgacagaa tgtgaacaaa catagaagtc actggaaatc acaacagttt gatagtaatg 480
tgacaatgccca aaaatctgaa gatgaagaag gctggaaagaa attttgtctg ggtgaaaagt 540
tatgtgctga cggggctgtt ggaccagcca caaatgaaag tcctgaaata gattatgtac 600
aaattgggtt tcctccctt ctttagtattt ttagcagaat gaatcaggcca acagtaacta 660
gtgtcttggaa atatctgagt aattgggtt gagaagaga ctttactcca gaattggaa 720
gatggcttta tgctttattt gcttgtctt gaaagccctt gttacctgag gctcattcac 780
tgattcggca gcttgcaaga aggtgctctg aagtgaggct cttagtgatg agcaaagatg 840
atgagagggtt tcctgctttt aatttattaa tctgcttggt tagcaggtat tttgaccaac 900
gtgatttagt tgatgagcca tcctgatgtt gctgatctt cagggataga agatattct 960
catgaaggca gcctaactct gaggaaaaca atgccaattt aagtacagat ttcaacacat 1020
cttcaacact atgtgaagggtt tcacatctt aacctgtgca attcagattt atactcagaa 1080
tatgggttga tttgaatatc taaaaatca atggaaaatc ccactcagtt tttgtgaaac 1140
agtttgaaca gttttctgtt atcaaggcgc ttgcataaaaa attgtatgtt gaaattttac 1200
ataggttctt ggtgctgtt tttttttttt ttgtttttt ttgtttttt atttactttat 1260
atacatataaa aattttattt gaaaat 1285

<210> SEQ ID NO 8
<211> LENGTH: 25001
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

ttatcaccaa aatgttggac gacaggagta ttctccctt ttcttaagtct gttttccca 60
aaaccagtga aatattgtt accaataac ttttttttgc agccagggtga tatctttcca 120
agtgtcccaa ttgttttagtt acagttccctt agcattaagt acttaataaa gcttggact 180
atcctcaactt tatcttcaat ttagacttac atcctgggtt gaaatcaatt ctttgcac 240
taaaggcagt gccataaataaaa accttctaaa ataaacatca gtgttagaaa 300
ataagtcaat tgtatttactt caattgtattt tttttttttt ttatactttt 360
```

-continued

ttcttcacaca ttcttgcctt gttccctcac ctatgaaatg gagataataa tactatctac	420
ctaacaagat tgacctaaca tttttgttaa tttctgggtg ttagcattag tttcatttt	480
ttcactatTT gtatTTaaac gaagagattt ttctttaaaa caaaaattaa aaagtgcTgg	540
ctattctagg agtaatattc attccaaata aacatacagt gatcttgaa gtggtaagc	600
actagaatttctgttagaa attatTTTT cattcatttg gcattcgata aatcttaggtt	660
ggaatttggTT ctccctttt ggaaggcag tccctgcctt aagagacgg tatattacca	720
cccacttcac aagactgttc taagaatcaa atgagaaaat gtgttatga agagtttaag	780
aatttagagc tccatgaatg ataattacag taatattgtt cattaattca aaaaacattt	840
ttaaggatcc ctcaactacta gggatgcata aaagtgcata accctcgcc tttaccacg	900
gttagaagac aaaacagagg gtaaaagtcc cagaaacgcg ttcgaacca ttcaagcttgg	960
aattaaatttcc tcaGatcTTT tattacacca ccggagcTTT aaccttgagg caagcagcaa	1020
tttGTTcatg cgcaGTTaac GCTCCCTAA ctGCCACTTG ctcaGCTCGC CGCCTAAGGT	1080
gtctattagt acgcctgcgc tgtgacctag aatgggcgcg tgccgcggc ggaactggct	1140
ggTTTgaaaaa ccatggcgTG ggtaccagcg gagtcgcag TGGAAGAGTT gatGCTCGG	1200
ctattgcgg tagagcTTG cgacttgacg gaaggTTG atccctcggt acccccggagg	1260
acgcctcagg aataacctgag gcccgtccag tgagtgattc ggccctggc gggggggctg	1320
gtcttcgtcc ctggccctgg gtacagccct cggcgtctaa ttcccgtcc agtctgtgc	1380
gagttcaggt ctattcagga ttctggatta catcctaacg tggcgcagtt tctgttgaac	1440
gtgattgcac gtatcaagat gtgtgcTTT agatttttt tcaatccaga taatttcaga	1500
aatacattgt ttagtacctc aatttggaaat ctgaattttt ttctgatttc acaatgaact	1560
gtggaaagtgg atcgcttgg ttactacacc tgagcaaaac acaacagaaa tttaatttt	1620
cgcgtttatt acttattttgt aggatcgaag cagctcaatg tccagatgtt gtggtagctc	1680
aaattgaccc aaagaagttg aaaaggaagc aaagtgtgaa tatttctgtg agttttatta	1740
accgtctggaa gattaccccc aaccccccTTT taaaagact aacgctttc ctatagtatc	1800
tgacagcatc aattatgacg taagattga ctactccgtg caaagtttgc cattcgcttgc	1860
tacttttcc ttcaGAAAGA caatttggcat ttactgcctc taaagaggct ttctgttaact	1920
ctagccTTTg tggagtgttT cccatTTTAC ttcaGGACAT tatccagtcc ttcaaaaggaa	1980
gtctttaaat gggTTactta tgTTatTTT tatttttgc ttgtttgtt gtttataagag	2040
aggggagtctc tgTTgcgcgc tggtctggaa ctccctggct caagtgtatcc tccctccct	2100
gccacccaaa gcgTTgggat cacaggcgtg agccacctca cctggccct ttattttta	2160
aggaactttt tccagttattt ggattttgtt ttaatcttag tggcTTTgc atgttctgaa	2220
tttGACCAAG ttcaGTTTTT tttaagaata gaaacccaga tggcttacac ttTTTTTTT	2280
tttttttttT agacagtTTTc actcttggTTT cccaggctgc agtgcagtgg tgcaGatctca	2340
gctcaCTgcA acctctgcCT tccggTTca agcgattacc gtcgcTcAgc ctcccgagta	2400
gctgggatttta caggcgcCTT ccaccacacc cggctaattt ttgttattttt agtagagacg	2460
gggtttcacc atgttgcCA gtctggTTTt gaactcctga cctcgtatgc cgcccacctc	2520
tgcctcccaa actgctggaa ttacaggtgt gagccaccat acccggcTTT acacttttat	2580
agctacttgc acactctggaa cattttcatt tattttatTA tccagcacat cttaattaa	2640

-continued

gcaactaggt	tgtgcgggc	attgggaatt	caacagaggg	taagacaaaa	aaggttctta	2700
ccctttaga	gtttacatac	cctcctgagg	aagacagaga	gtaaacaagc	aaacaataa	2760
ttacatattg	tgattattgc	tatgaagaaa	ataagcatgt	ataataatca	ataaatgaca	2820
gaactactgt	agaggaatca	tagaagggct	ctcttttc	ccctttttt	tttgcgtctc	2880
aattttcgc	ccaggctgga	gtgcagtggc	acaatctcg	ctcatcaca	cctctgcctc	2940
tcaggttcaa	gagcttctct	tgcctcagcc	ccctgagtag	ctaggattac	aggegtgtgc	3000
caccacacct	gactaattt	tgtattttta	gtagagacgt	ggttttacca	tgttggccag	3060
gctggctctca	aactcctgac	ctgaagtgtat	ctgcctgcct	ctgcctccta	aagtgcgtgg	3120
attacagatg	tgagccacca	cgcctggcca	gcaaaggct	ctctaaggag	gtgttattha	3180
acctaagctc	aaaggagggt	ggcattttat	tttatttctt	tttctttttt	tttttttttt	3240
gagatggagt	ctcagagtct	cgctctgtcg	cccaggctgg	agtgcagtgg	cgcgatctcg	3300
gctcactgca	acctctgcct	cccggttca	caccattctc	ctgcctcagc	ctcccgagta	3360
gctgggacta	caggcgcctg	ggagagtgcc	atttaaata	gttgatagta	atttcctttt	3420
catgctcaaa	gtagtttctc	tgatacttgt	aatcaggaaa	tttaattca	gacactgtaa	3480
ttttccttat	aattcctctt	cagggttttt	tagttgatgg	acatttaatg	gaacagaatg	3540
tcttaatata	cctaatttga	tggattgatt	gattgattga	ttgagacagg	gtctcgctt	3600
gttgcacagg	ccagagtaca	gtgcacacgt	catagotcac	tgcagcctcg	agttcttggg	3660
ctcaagccat	cctccccacct	cagtctcccc	agtagctgag	atgacaagca	tgtgccaccg	3720
tgcccagcta	attgtatttt	tttgcgcac	ggggcttta	tatgttgctc	aggctgtatg	3780
tgctttttta	gaaaacagaa	gtatggctgg	gcttagtggc	tcacacctgt	aatcccagca	3840
ctttgggagg	ccaagtcagg	cggatcacct	gaggtggggg	gttcaagacc	agcccgacca	3900
acatggagaa	accccatctc	tactaaaaat	acaaaattag	ccgggtgtgg	tggcacatgc	3960
ctgtatccc	agctactcg	gaggctgagg	caggagaatt	gcttgaaccc	gggagacgga	4020
gattgcagt	agctgagatg	gccattgcac	tccagcctga	gcaacaggag	cgaaactccg	4080
tctcaaaaaaa	aaaaaaaaag	aaaacagaag	tagacaattt	aaagttaagc	gtcttaagt	4140
acatttgcc	cataccaaag	ttcttatttt	taattttatt	gatacataat	aatcataatt	4200
tcatgcttta	tcacgcaggc	acaataataa	ttgtacatat	ttatggatgat	tatgtgatat	4260
tttgatacat	gcatacaatg	tataataatc	agtaatttagg	atagccatca	cctcatttat	4320
catttttttc	tttgggaac	attcaaatct	tctagatgtt	ttgaaatata	caataaaatta	4380
ttgttaactg	tagtcactct	actgtgctat	tgaatgctag	aactcattcc	ttctaactgt	4440
attcataacc	agaattctt	atttgtggta	tatctctttt	tttgcctctg	ttttgttatt	4500
ctagaaggc	aggtagggct	agatcatatt	ctccaggctc	atgtcattta	gatttcata	4560
aaactccaaac	tataaacctt	tccagatttc	tctgattaag	gtgactaagg	ctctttccct	4620
aatattttta	actgagatata	aaataataaa	gtgaaatgcc	tactttttta	catctgcaaa	4680
aatattttat	tttcttgtat	aatctttatt	ttattataca	ctttatcttg	gttttacttt	4740
tgctttgcag	aggcatgaga	ttcttagttt	gacactaatg	ttgatcctaa	tattttgtgaa	4800
cttgatctct	agctttcagg	atgcacaccc	gcccctgaag	gttattcccc	aacacttcaa	4860
tggcaacagc	aacaagggtgc	acagtttca	actgttcgac	aggttaagtgt	catatttaat	4920

-continued

ctaattaagc ccctgttga tttatccatg ttcttagact gtagctggaa aaataaaaatt	4980
tatgatccta aagtatacag aatattcatg aattaattac caaatttattt ttataatcat	5040
tagacatgat acagtttggaa atatccatg agttttgtt atttttattt gtttgggttat	5100
ttatccatg agttttgggg aacagggttgtt ttttgggtac atggataagt tcttttagtgg	5160
tgatccatg gattttgggtg cacttgcac ccaagtagtg tactctgtac ccaatacatg	5220
gtctttaca tctcaccccccc tcccacccctt cccatccatc aagttttaga tggttacaat	5280
tttgcaga aactgatttc agttatccat ttttgaaga gtaccatcta atgtctaagt	5340
tttccctt tagaatgtga acaaacatag aagtcaactgg aaatcacaac agttggatag	5400
taatgtgaca atggatgtta agtttcttag ttttaagatg tacaatgtat acctgattga	5460
aagagtctat atttacttcc agtcgttaaa gattcaacttg cctagtcagt gttactttca	5520
ttctcttcaa tataccatata atagtaacaa ttcattacat tagtagctg gaaagtata	5580
atttcatga caaattttttt tttttttttt tttttagaca gggcttgcct ctgtctccc	5640
ggctagatg cagtcatggc tcactgcagc cttgacccctt tgggctcaag tgatccccc	5700
accaccgcct tccaagtagc tcgaaacttaa ggcataatacc accatgccc gctaattgtt	5760
aaaattttttt gttagagacaa ggtctccctg tggttacccag gctggctct tactcctggg	5820
ctcaagtgtat cctcctgccc tagectcccc gagtgctgaa ttacaggcat gagctactgt	5880
accaggcctt tcatgtcaat tttaattcac aatatctgg gggactttgg ataggtgact	5940
gtgaaacttc cacaagtttt taaggattct tctagacatt tactttctag gaaataaata	6000
cattttcaat atttacaaaa aaaattgaat aaagccttaa tggatccctc tgatgagggt	6060
atgggccat gcagtaaact cacatgttaa cagaacttgtt gaatggattc tgcttctgt	6120
taatgtgatg agtctgtgtc acaattccag tgacatataa gtgaaacctg tcatgtat	6180
tgtcatgcat atgcctata ttatccatgt ttagatataa cttaagccc ttttagat	6240
atatcaggac taccaaatga aaaaaggagt tgaaagatg atacattgtc tcaggacagt	6300
agtttttaac cttttagggg acttcattt ctttcgtaga atctaatgaa agctatttat	6360
cttcagaggg aaaaaaaaaatg cacatgtca caacattta gttcaggta gttcatagat	6420
tttagatttt agaagcttcc tttaggcagt gtttcctgtat atctttaca tggtgacaca	6480
tttagataaaa tgactgcttg catatttttc ctgaaaccag ccgaaagctg agagattcag	6540
tatatggcat ctctgtatgc ttctgcatac catttggaaag ctctgctcca ggaaaagcgt	6600
gaaggaaatg aacttatac ttgcataatgg tcatttaact tgtaaaaggt atagtagtgc	6660
cttctatcaa agaagcatgc gcacataaac acacaaaagg tatgcttaag gttcaaacc	6720
aagttggctt gtttctaaag cttgtgtgcc tttgactatg caatggtgcc ttcttagtac	6780
caaggatgtt tgtagatgtt agggcaggg cttaggttgtt aaatataattt ttttcttac	6840
tttagcgaaag gcctttggg tgcataccca ctaactaaaa aagaagccac atcagtaaca	6900
ttatgacttg ataaaaattttt gtcaaaaatg gaaatgacct aacataatttgg attcaataaa	6960
ctatggtcca tcagaacagt ggaatattat gtagcaattt taatgttttgc tcatggcaaa	7020
tgcaaaatc atataagtaa taaaatgaaa atgtttaaa gtacactctg agccaggcac	7080
agtggctcat gcctataatc ccagcactttt gggaggctga ggtggcaga tcacccgt	7140
tcaggagttc gagaccagcc tgggcaacat ggcaaaaccc ttttcttattt taaattttt	7200

-continued

aaaaaaaataaa	gtacactgtg	atggcaactg	tgtgaaaaca	taaacattt	tttattaatt	7260
gatccaataa	tttaagcatg	tgctatattt	aataatcagg	atattcagta	ctaactgaaa	7320
cagaaacagc	ttctgaccta	atagagtgtt	aggaaaaggt	agataacctt	attccaagac	7380
aatagggtt	aacttgttag	tggctctatg	ttcatcgtga	ggtttattt	tatTTattt	7440
tatTTattt	atTTTTga	gatggagtt	tgcttgcgtt	gcccagtctg	gagtgcagtg	7500
gcacaatctt	ggctcaactgc	aacctctgtc	tcttggattc	aagcaattct	cctgcctcag	7560
cctcccaagt	agctgggatt	acaggctgcct	gccaccacac	ccagctaatt	tttgcatttt	7620
tagtagagac	ggggTTTcac	catatttcca	ggctagtc	gaactcctga	cctcagggtga	7680
ttcatcctaa	ggatTTaatg	aaagctactt	atcccttaggg	ggaaaatgca	cctatgcaaa	7740
gtaatataca	aggtgatatg	tacaaacaaa	ggTTatTTtg	ttaaggaggt	tatattgagc	7800
tgaatgcctc	tcccaaatacg	tcctgcgtcc	tgcttttct	gtctggcagc	atgagtagat	7860
ctgtttcttc	tttgactgga	caacccttca	aatatgtgaa	atatgtatc	atgtctctt	7920
acatgggata	aatatccttc	attctattaa	gtgttcttgg	tgcatTTTT	ccccatact	7980
tatTTctgtc	tttatcatcc	tctttggac	acaccattgt	ctgtcagtgt	ccactaaagt	8040
cttgccaaa	ctaaacacat	cttggctggg	cacagtggct	cacacttgta	atcccagcac	8100
tttggaaagc	caaaggagaa	gaattgctt	aggccaggag	tttgagacca	gcctggcaa	8160
catagtgaga	caactatctc	tacaaaaaaa	atTTaaaat	tatcaggcat	ggtggcacat	8220
gcctgttagtc	ccagctactc	aagaggctga	ggtggcagaa	ttatTTgagc	ccgagattca	8280
ggctgcaatg	aactgtatc	acacctctgc	actccaaactt	gggcacaga	gcaagaccc	8340
gtctcaaaaa	atgtatataat	aaggaaaaac	aacatgtccc	acatattgt	tagccactta	8400
ggcactatgt	ttgtcagggc	tgccataaca	gactagggtgg	attaaacaac	agaaatgtat	8460
ttatTTctc	agtcttgaag	gctgaaagtc	aaagaacaag	gtggcagca	ggttggctc	8520
ttttgtttg	tttgTTTgtt	tttgaggca	gagtttcgt	tttgcgtccc	aggctagagt	8580
gcaatgacgc	aatctctgtc	cactgcagcc	tccgcctccc	aggctcgagt	gattctcctg	8640
cctcagccctc	tggtagctg	ggattacagg	tgtgcaccac	cacatccggc	taatTTTT	8700
ttttttgtat	tttttagtag	aggtggggtt	ttgccatgtt	ggccaggctg	gtcttgaact	8760
cctgacttca	tgtgatcgcc	tgccctggcc	tcccaaagt	ctgggattac	aggcgtgaac	8820
cacccgcaccc	ggcctaaggt	tggctcttcc	tgaggcttt	ctccttggct	tgcatagggc	8880
caccttctcc	ctgttttctc	acgtggcttt	tcctctgtgt	gtgggagtcc	ctgggtgtctc	8940
tttgcataatc	caaatttcct	cttataagga	cactagtaag	attggattac	ggctcaccc	9000
aatggcctca	atTTaaat	atcacttctt	taaaggccct	gtctccaaat	acagtcacat	9060
tctgaggta	tggagttaa	ggTTtaaca	tacaaattt	ggggcagaga	ttctccccat	9120
aactggctcc	gtatcttgg	gttgcgtta	tggaaatatg	gaaggactta	acttctttt	9180
ttttactgtt	cagtgtaaaa	atataacac	aggaataat	cagTTTTT	tttttctt	9240
tagccaaat	ctgaagatga	agaaggctgg	aagaaattt	gtctgggtga	aaagttatgt	9300
gctgacgggg	ctgttggacc	agccacaaat	gaaagtcc	gaatagatta	tgtacaagta	9360
agggctgtgt	ggataaacag	aacaaaaagc	atTTaaattt	tggtgcacca	cttaatataa	9420
ggggcagca	aactctaccc	tggccaaagt	ccagttcatg	gccttttta	tatccatgag	9480

-continued

ctaaggattg	tttttaggtt	ttgaaagagt	aaaaaaagaaa	caaataatat	gtggctgaga	9540
ctttatgtgg	cctgcaaagc	ctaaaatatt	tgctgtctga	ctcttgatag	aaaatgtttg	9600
ccaaccaga	cttagtttat	tagcttca	acctaacaaa	acagcttagt	ttctgaaaca	9660
atttactgtg	actttttta	gttggcttc	atatccctta	tgttggtt	ggtaatcatt	9720
ttatgagttg	gataagattc	atagttttt	taaatgatga	ggcatcaggc	aaacagtgtt	9780
atgagtagcc	agggaaaaaa	tggaaatcga	cacaattaga	tgctttaaa	tgcataatca	9840
catctatcac	ttcatgggcc	tgtaaaaat	aaatcacata	ttctaaagat	gaaatgttg	9900
ggatatctt	aaaattcatg	tggctgtaat	cataagttat	gtagacaact	ccttgcctt	9960
caggatttac	ctgcccccaa	gtttgcaggt	gttcctttag	aatccagtgc	atgcctctgc	10020
attagcgctt	actccctata	gcatgttagt	cttttcagtt	caacaggtat	ttattttttg	10080
ctatatggtg	ccacattgtg	tttttcacat	ttaaaactaa	ttttcctaa	aaatgtaaaa	10140
agccccaaaga	atcaataaaaa	agaccaagaa	tcacccctcc	cctgcccag	aaaaaatagc	10200
caaaggatat	agataacctca	cagaaggaa	ataaaattat	tcttatatga	caagatgcca	10260
aaaatcaatt	gtaatagaag	tataacataa	ctatgccaag	gtgctatttt	tcaggtaaca	10320
tattggccaa	gaaagtttga	tacaccatat	tgacaagagc	tggggaaaca	agcactctta	10380
gacgtggta	aggagtataa	atagactcaa	atcttaggaa	agttaatttg	gtactcttc	10440
tatataacca	attgatctt	tggatgatat	ccttaacata	tgctacattt	caaaaatagc	10500
tatataatata	tatataatata	tatTTTTT	ttttttttt	ttttttttt	ttgagacagg	10560
gtcttcttcc	gtcatccagg	ctggagtgc	gtagtgcact	catagctcat	tcagcttca	10620
acctcctggg	ctcaagcaat	cctccacgt	cagcctcaa	cataccaggg	gcagcaggca	10680
cccaccacca	cacccagcta	atTTTTaaat	tttttgcagc	gataagttt	ttaattttt	10740
aaaaaaaaattt	ttttgttagag	agaagtttcc	accatgtgc	aagggtggcc	tgaaactcct	10800
gggctcaggo	aatcctcctg	ctgggattat	aggcatgago	tatcatggct	agccaaaaat	10860
ggTTTTTaaat	ttataaaagaa	ttaaaactta	cttatttgc	ttatTTTcag	agaatacata	10920
caagtaaaat	acaccatgtt	aaaaaaacc	cttaaggaag	taagcgttt	atgtatatcc	10980
tcttaagttt	ctcacaaatc	agtggatttt	tcataattag	caatcacagc	ctcagactcc	11040
aaagtagact	ttaaaaattt	gaatcaaatt	aggTTTaaa	aatgtcattc	taattcaagt	11100
gtccttaatt	cttggaaaata	ttagctttag	ctgaagattt	tggaaatggtg	tatacaacat	11160
attaatgtca	tcttatcaat	gttacagttt	tattggatat	acttaataag	ttatTTTTT	11220
caagtactat	catgtaaaaa	atTTTTtagc	ttaacattt	tacttactaa	aatcataactt	11280
tatTTTTaaa	tttacaaattt	cagaccaggt	gagggtggct	atgcctgtaa	tcacagcact	11340
ttggggaggct	ctggcaggta	gatcacttgc	gctcaggagt	tccagaccaa	cctgggcaac	11400
atggcaaaac	ctcatctcta	ccaaaaatac	aaaaaaatta	gctgggcgtg	ttgacatgca	11460
cctgtggtcc	tagctactcg	tgaggctgag	gtgggagcat	cacctgagcc	caggaagcag	11520
aggTTGcagt	gagccaagat	cgcGCCacta	cactccagcc	tgggtgacag	agtgagaccc	11580
catctaaaaa	aaaaattaca	tattcaaat	ttaaggcgtt	atTTTCTCC	gcattacaaa	11640
catagtagtt	tccggaatgt	ctcattgtt	tggacaatga	aagaatttcc	ttttatTTT	11700
tctttgtttc	taaacaacag	tgtggcaaga	aattcaccag	tttgaaaaaa	aaaaatgaag	11760

-continued

cttataatac cattagtaa aattcagtct catttttct ttcagattgg ttttcctcc 11820
ttgcttagta ttgttagcag aatgaatcag gtaaaattaa taatagagat atatgcattc 11880
tttggttgc attgtgtgtg aaagtattt aattgttaat acatatactg aattcttaca 11940
gtatgcaaga ctgtgtctta agctcttaa tggttcttta ttaatcctta ctacaaccct 12000
ctatggagag ttattattga taactacttt ttatagatga gggaaacagca ttggaggta 12060
agtaacttgc aggtgggttt tcagcaagta aatggcagta ctgagattca gtgccaggt 12120
gatctaactc cagagctcat gctctgttt aatcatggt ctagagtatt catttctgt 12180
gcttcagtt ataagtctta gattctgggg tttgaattaa atacaaggtc cctgacttac 12240
aatggttcag tttaggattc ctttttccc accatgcctg gctaattttt gtattttcag 12300
tagagagagg atttgtcat gttggccacg ttgggtctcgactcctggcc tcaactgatc 12360
cacccacacctt ggoctcccaa agtgctggaa ttacaggcat gagccaccat gcccagccat 12420
tttaggaatt ttcaacttta caatgtgttt atcagcacat aacccattt caagttcagg 12480
ggcatctgtttaa ctaaggtagt attgtctattt ctagttctag atgtcctata cattctatta 12540
agattgaaat atggggccgg cgccggggct tatgcctgtat atccggcac tttgggaggt 12600
caaggcaggt ggatcacaag gtcaggagtt cgagaccagc ctggccaaca tggtaaaaacc 12660
ccatctctac taaaaataca aaaattagct ggatgtggag gtgtgcactt gtaatcccag 12720
ctatgggaa ggcgtggca ggagaatcg ttgaacctgg gaggcagagg ttgcagttag 12780
ccgagatcgt gccattgcac tccagcctgg gcgcacaggc gagactctgt ctcaaaaaaa 12840
aaaaaaaaaaaaa agattgaaat atatgatttc ttggatcaaa agggaaagat tatggagttt 12900
ggtttttcag ttttttagga gtaaggactc ttattcattt aaaaagcaaa taaaaattta 12960
attttatctt cacatagcat tgggtacett tggaaaggctt tttttttttt tttggcaggg 13020
tctcattctc ttgccccatgc tggagttacag tgatgtgatc ttggctact gcagtcttg 13080
actttggggc tcaggcaatc ctcccacctc agcctctgg tagctggac cacaggcatg 13140
tgctaccatg cctggctaat tttgtttatt tttggtagag acaaggcttc actgtgttg 13200
ccaggctggc ctggaaactcc tgagctcaag cgatccctcc acctcagcct cccaaagtgc 13260
tggyaataca ggtgtgaacc actggggccca gccaacaatt tttttgtgg gtgatattct 13320
cttggaaata atacacaagc tgacagtgtt acttaatcat ttgcattaaag atattgtac 13380
agtcatacta aattccatca gtgtcatttt tggtaacc atcaactgtat tttgaataaa 13440
ccagagatta tttcaagag tttgataaaat ccatctgtat agtttaagaa cagattttc 13500
tccacctaataa tttttattca gatttgtact ttgatataat ttgaatttag aaataaactg 13560
atggttttt tgggtttttt tgggtttttt tgggttttga gagggagtct cgctctgtcg 13620
ccaggctggc gtgcagtggc acaatcttgg ctcactgca cctccacctc ccaggttcaa 13680
gcaattcccc tgcctcagcc tccctagtag ctaggactac aggccacac catcacacc 13740
agctaattttt ttgtatTTTA gcaggatgg ggtttaccgt gttggccagg atggtctttg 13800
tctcccgacc ttgtgatcca cccgcctcag cctccaaag tgctggattt ataggcatg 13860
gcccacccgcg cctggccaaac tgcgtgttatttttata catctttttt tttttttttt 13920
tttgagacag agtttgcct tttggccagg ctgtactgaa gggccaggat ctgcgtcac 13980
tgcaacctct gcctcctggg ttcaagcagt tctcctgtct cagcctcccg agtagctagg 14040

-continued

attacagacc ccgccaccat gcctggctaa ttttgtatt ttttagtagag acggggttt 14100
gcccgttgttgg ccaggctggc ctcaaactcc tgacctcagg tgtgcatttgc tttttttttt 14160
ttttttttt ttttgagaca gagtctcaact ctgttgcggc ggctggatg cagtggcaaa 14220
atcctggctc actgcaacct ctgcctccca ggttcaaggg attccccggc ctcagcctcc 14280
ctagtagctg ggactgcatt cactcacccat catgcggcggc taattttgtt attttttagta 14340
gagatgggggt ttcaccatgt tggectggct ggtctcaaac tgacatcaag tgatccacct 14400
gcctcgccct cccaaagtgc tgagattact ggcaagagcc actgagccct gccacaaaata 14460
cattttctttaa acccttgcgtt aagtctttca agtagttaca aactaaatta ttaatagttt 14520
caaactaaat cctaggattt aaaccaaggt gttagttgtt atttgaaagt gtgaaaatata 14580
ttgttttaaa agcctactg gggctaggcg cggtgcctca cacctgtgtt cgcgcactt 14640
tggggaggccg aggagggccgg atcacctgag gtcgagagtt cgaccagccct gaccaacatg 14700
cagaaaccct gtctctacta aaaataaaaaa aattagccgg acgtgggttgc acgcgcatt 14760
aatctcagct actcaggggg ctgaggcagg agaattgtt gaacccggga ggcggaggtt 14820
gcagtgagcc aagatcgcac cagtgcgcctc cagcctggc aacagagtga gactctatct 14880
caaaaaaaaaa aaaaaaaaaa aaaaaaaaaa tcattggata agccgcctaa tcaaactaat 14940
tagagtcaaa caaatttagct ttctttgaaa gtttaagaa tgaggccatt tttaacatca 15000
gagttgcctt ctaataaaac ttaatgaaac tcatgttgc ttcatgtttt attattaata 15060
caactcttct ccacccctc tttttttttt taggcaacag taactgtgtt cttggaaata 15120
ctgagtaatt ggtttggaga aagagacttt actccagaat tggtagtttgc tcatgttttt 15180
cttttcataa tggtaggcataa aattagacgt tttgggtcaaa ctgtggccca catatacaat 15240
ggtgctccta taggattata atactgttattttactgcac attttctttt tttttttct 15300
ttttttttt tttttttttt ttgagacaag gtctcgctct gttacccagg ctgggggtca 15360
gtattacaat catagctcac tgcaaccttg atctcccccag ctcaagcaat cctctgcct 15420
caatctcctg agtagctggg actacaggcg catgcagcca cgcgcagg tttttttttt 15480
ttgtttttt ttttttttat tagagacaag gtctcaactgt gttgtccagg ctggcttgc 15540
actgagtcca aatgatcctg cctcctcacc ctcccaaaat gctggaaatt acaggcatga 15600
gccaccatgt gtgcggccctt ttgtttttt taaatagaga cgaggctca ccatgttccc 15660
caggctgate tcagactcct aggcctcaact gttctccca cttggccctc ccaaaactgtt 15720
tggattacaa gcatgagcca ctgagccggc ctcccttcca gtatttaaat atgttttagat 15780
ctggccaggc acagtggtctc atgcctgtaa tcccaactac tagggaggc tgaggcagg 15840
ggatcaccta aggccaggga ggttgaggct gcagtgcgc atgattgtgc cactgcactg 15900
cactctagcc ttagtgacag agttagaccc tatcttaaga aataaaatata tggttttttt 15960
ggatgcacaa atgtttacca ttatgttaca gttgcctaca gtatttagta tagtaatgtt 16020
ctatataatgtt tggtagccca ggagcaattt gctatgcaat atagtctagg tataatgtac 16080
tataccatct aggtttgtgt aagtataactc tatgtatgttc atccagggtc aaaaatcacc 16140
taacaatgca tttctcagaa tataatctccc ttcatcaactt gatgcacatc tggactttgtt 16200
gtgatgctac ggttttttattt tttttttttt gttttgacat ggaatctccc 16260
tctgttgccc aggctggagt gcagtagcgc gatctcgccct cactgcagcc tccacccct 16320

-continued

ggtttcaagt gattctcctg cctcagccctc ccaagtagct gggattacag gcacctgcctc 16380
ccacacccag ctaatttttg tatttttgta gagacaggct ttctccatgt tggccagact 16440
ggtcttgaac tcatgacccctc aggtgatctg cccgcctcca cctctcaaag tggtaattt 16500
acaggcgtga gccactgcac ccagccagta tttatattta tatttatattt tgatatatgt 16560
tgtgtgtgtg tatatacata tgtataatct gaactatact tggtgttagt caaaataaga 16620
acactagaat gtaaatcaac atactacttc cttcatttagaa aaagtcttgg agaaaaaaag 16680
tcaatgaaag agttgtatgtt tattctggta caaggtacaa actccttatac tcattgcaga 16740
caagtttggtt tttttttttt tttttttttt ttgagatggta gtctcactct gtccacccagg 16800
ctgcagtgcac gtgggtccat ctgggctcac tgcaacctct gcctcccaag ttcaagcaat 16860
cctccctgcct cagccctctg agtagctggg acaagtgttag agaaatattta atttaaatta 16920
aatatttaat ttaaatgcta gctttacata gtaaatgtat cccttaaaaat ttgagtcaag 16980
ttgaaacata taatttttttt ttatagaaaaa agaattccac aatttgtaaa agaaacctgg 17040
atttgaatct ttttctgtaa gaaaaagtct taactattgtt tttgagtttgc cctgaggAAC 17100
ccatattgtg ttttctgtataa attgttatttta aatatttgc ctaatattttt ttaggtttcc 17160
ccgaagtgtat atgttgccta gaataaacaa agttgtatatactactggtg gaaataacaaa 17220
tttggtataa cttttccagg atacaatctg gtgatcatat ctgaaaaacc ttgatgaata 17280
tacataccct ttgtcaccat tttacttgca atacttaata aactttcccc atgttggtaa 17340
atgagattaa acaagggaaat gttattaaat actctaaaca agacacttaa cattcccttg 17400
ttaatcccat ttaactacaa gggatggctg agtgggggtgg ctcactctgt taatcccagc 17460
acttagggag gcccgggtgg gcggtacttgc tggatggctgg agttcgacac cagcctggcc 17520
aacatggtga aaccccccattc tctactaaaa atacaaaaat tagctgagca tggtggcggg 17580
cgccctgtgt cccagacttgc caggaggctg aggccaggagg attgttgc cctggggaggc 17640
agaggttgca gtgagccgag atggcaccac tgcactccag cctggatgac agaacggagac 17700
tccatctcga aaaaaaaaaaag aaaaaggaca aaaacaacat ggttaacattt ttattatgt 17760
ttataaataa aaaagatggc tacaagatga tattacaact gatgaaattt tattgaaaaa 17820
agggtgtaca gcccggcatg gtggctcagc cctgtatct caccactttt ggaggctaa 17880
gcaggcagat cacttggatgtt caggagttcg agaccaggctt gtaacacatg gtggaaaccc 17940
gtctcttataa aaaatacaaa attagccggg tgggtggta catgcctgtat attccaggt 18000
ctcaggatgc tgagacagga gaatttgcgg aacccggggag gcagggatgg cagtgagccg 18060
agatcgccgc attgcactcc agcctggca acaagagtga aactctgtct caaaaaaaaaa 18120
gaaagttgtataa catacgaata gaaaaacaa gaacattttt aaagtgaatc aaagtttgc 18180
ctggaaatgtt gggactgcag gttttttttt gtggctgtgg tattcttcac agttttctg 18240
catcaaataat gtattcatat tttttttttt tttttttttt taaaagggag tggggataca 18300
ttgagccctgtt caaaatgtt ataaaaatgtt caaaatgtt ttttcatctgtt agtataatgtt 18360
ctttgtatgtt ccccaaggatggaa caaaattataa caattataaa atgatttcta tatctgtcc 18420
tacagaacaa agaaaaaaat gtatcttaat tttttccatgtt attttatattt atcttaatgt 18480
agtgttctgc ttacaaatgtt gaaacttccta tcataagaat atctgaaaca aactctttgg 18540
agatcaggaa atattttgag gtatccatgtt tttttttttt tttttttttt gataattatgtt gataacaagag 18600

-continued

ataaacacctg gctctccaaa tgaggcttc ttgtctatac ccaaacataa tatagttaaa 18660
tgttctatga atttattcat agcagataat caggcataac atggacatt taaaaataa 18720
acttctggtt cagtatttgt ctaaatatta atttttgaa tttttttta gggaaagatgg 18780
ctttatgctt tattggcttg tcttggaaag ctttggtaa ctgaggetca ttcaactgatt 18840
ggcgagcttg caagaagtg ctctgaagtg aggctttag tggttaagttg caacttactg 18900
tttaaaatataa aaagcaccca ccaatttataa tggtggtaaa gaaggagttc agtgaard 18960
gaaaacacat ggaatattttt attgggtggca attagatttg taaagccaa aataatagta 19020
gcttaaataa tatggaaatg ttttctgaga taaagaagtc tgagccggc gtgggtggc 19080
acacctataa tcccagact ttgggaggct gaggcggtg gtcacactga ggtcaggagt 19140
ttgagaccaa cctggccac atggtaaac cccgtctcta ctaaaaatac aaaatttgc 19200
tgggtgtgggt ggtgggtgct tgtcatccca gtcactcagg aggctgaggc aggagaatcg 19260
ttcgaaccca ggaggcgagg gttgcagtga gctgagattt caccactgca ctccctgc 19320
ggcaacagag caagactctg tctcaaaaaa gaagtaggta aaaaaatttag attttacta 19380
agatggcagt aacccaccca cacctttagt ttttgcata tgggttttc atccctatgc 19440
tcatcttatg atccaagatg gtcgtgttag ctccagcctt tttttttttt tttttttttt 19500
cttttattgt gagatggagt ctcgcctgt caccgaggct ggagtgcata ggtgcggct 19560
ggctcaactg caacccccc ttcccaagggtt caagcaattt ccctgcctt gcctccagag 19620
tagctgagat tacaggtgcc cgccaccatg cctggctaat ttttgcattttt ttagtagaga 19680
cagggtttca ccatgtggc cagactggc tcaaaactgt gacttcaagt gatccacactg 19740
cctcagccctt ccaaagtgtt gggattacag gcatgagcta ctgcacctgg tgggtgtgt 19800
tgtgtgtgtg tgtgtatataa tatgtgtgtg tgtgtgtgtg tatatatataa tatctttata 19860
tatatatctt tatataattc agtaatgaat atataataa acagtaagaa tcctgtgtct 19920
tgactgtaca gtgattaataa tatattatataa atattctata atattctata tatatccctca 19980
catatattgt atgcattataa tagaggaaca ataagaatcc tgggtcttgc ctacagtgtat 20040
aaatatattt attcatatataa gtatattataa atatattttat tatatatgaa tacatattca 20100
ctacagttaa gacacatataa taatataatataa gaatataatataa atatataattc atcactgtac 20160
agttaagaca caggattctt attgttcctt tagtaggaac caggggaaaaa tttcccccaa 20220
gttatcccccc ttagatccctt ctttatTTTT tttccctat tcagaatctt tattttaaag 20280
atagtcttag atgtttctca aggaatcattt aactctacag ttctctgtt ttttttttag 20340
ggctcttattt tccacatgtat gattactgtc atataataaa gttttcatgt ttcgtgtttt 20400
acatcttaat agaaaattta tttcaaaaatgt aataggaaca gacaatattt aaattttct 20460
ttttttttttt ttaggatagc aaagatgtg agagggttcc tgctttgaat ttattatct 20520
gcttgggttag caggtatagt taatccttgg ctctttattt atttatcagt gaggtcagtg 20580
aggtagatc gtatattataa catttggttt ttgtttgggtt ggttttttt tgagtctcac 20640
tctgttgctta tagtttaggt gcagtggegc aatcacagct cactagagct ttaacttct 20700
gggctccagc aatcccccacca cctcagccctc ctgagtagct aggaccacaa ccaagcacca 20760
ccacacctgg ctaattaaaaaaa aaaaattgttc gtagagacag ggtctacta tggtggccag 20820
gctggtctca aaactccctgg gctcaagcga tcctccacc taaggcctccgaaagtcagg 20880

-continued

gattacaggt gtaaaaggccac tgcattcagc ctgcattttt gtttaattgc ctgtgtctcg 20940
cgttcatttt cagttgtggc atattttat tttagtatctg ttttatttca ttttttacat 21000
agaaattctt cttggaattt atttgaaaac tttttttgtt gttttgtttt gagacagagt 21060
ctcgatctgt tgcccaggct ggagtgcata ggcaccatct cggctacta caaccttac 21120
ctccctgggtt caagcaattc tccccctca gctcccaag tagctggct tacaggcacc 21180
tgccatcatg cccggctaattt tttttaattt ttgtggagac ggagttcac cattattggc 21240
caggcagtaa aacacacata tttattttag gtctctctt ggacatattt ttgttccata 21300
gatcagtgtt ttatattcat tgccagttacc tttttaaagc ttataaatat acttaaatat 21360
tgggaaggca agtaatctt tttccatattt ttcacatattt caatatctt ttttttgatc 21420
tacaataattt atgctgtga tgataattaa catttactgg gcaattttgtt ccaagcattt 21480
ttcttagtga ggaacccatt taatccttctt aagggtggta ctgttaacag tttacagatg 21540
aggaaaccat ggcagagaga ggttaataaa tattactacc atcacaaagc tagtaagtgt 21600
tagagtaatg atccaaaccc aggcaactt gactccggag ctaaactttt aactatgtt 21660
atcaaaaattt aagctaatac ctacccatc tttttttttt tttttttttt tttttttttt 21720
tagcattgcc ctacttactt tatgtatagt atctctactc tttacaatag atcagagttt 21780
tgggggggtt tttttttttt ttttaataaa tttttttttt tttttttttt tttttttttt 21840
ttttttttttt ttacagataa tgacacagat tttttttttt tttttttttt tttttttttt 21900
aaaccagtaa ttaatgaaac ctcagacaag tttttttttt tttttttttt tttttttttt 21960
tacagtattt tgcaattttt aaagcaaaaaa cattcaatgtt tttttttttt tttttttttt 22020
tttagataaaa atggaaaaaaat ttcttagacta caaaaggttt tttttttttt tttttttttt 22080
tagaagacac aaagatttga aagtttagga aaaaaaggac cgggcattttt tttttttttt 22140
tgtaatccca ccacttttttggg aggccaaaggc ggggtggatca cttttttttt tttttttttt 22200
actaggctgg ccaacatggt gaaacccatc tttttttttt tttttttttt tttttttttt 22260
acgggtgggtt acggccatgtt tttttttttt tttttttttt tttttttttt tttttttttt 22320
acctggggagg tggagggttgc agttagtgc gatcgatcc tttttttttt tttttttttt 22380
caagaacggaa actccatctc aaaaaaaaaa gaaaaaaagaa aaaaaaaaggaa aagctggggc 22440
acagtactc acacccatgtt tttttttttt tttttttttt tttttttttt tttttttttt 22500
gtccagggggtt tcaagaatgc agttagtgc gatcgatcc tttttttttt tttttttttt 22560
atttatctt ataatttacat aaaatgtt tttttttttt tttttttttt tttttttttt 22620
tacatttggat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 22680
tcttagttaac cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 22740
aaagtataag tagggccat tttttttttt tttttttttt tttttttttt tttttttttt 22800
gaggctggag aattgtttga gcccaggat tttttttttt tttttttttt tttttttttt 22860
catggccatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 22920
aaatataaac aaacacgtt tttttttttt tttttttttt tttttttttt tttttttttt 22980
aacaatctgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 23040
cagttataat acgtttctca tttttttttt tttttttttt tttttttttt tttttttttt 23100
tggcttcata atttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 23160

-continued

atggacgttt ggggtgtta tggctttgg ctattaaaaa tagtgctaca gttaatatct 23220
ttatacataa atttttgtt tttttttac taggtatTTT gaccaacgtg attttagctga 23280
tgagccatct tgatgttagt gatctctcag ggatagaaga tatttctcat gaaggcagcc 23340
taactctgag gaaaacaatg ccaattcaag tacagattt aacacatctt caacactatg 23400
tgaagggttc acatcttaac ctgtgcaatt cagattgata ctcagaataat gggttgattt 23460
gaatatctga aatatcaatg gaaaatccc ctcagttttt gatgaacagt ttgaacagtt 23520
ttctgtatac aaggcagttt catagaaattt gtatgtgaa attttacata ggttcttgg 23580
gtgttttgt tctttttttt tttttgtt ttttgttatt tacttatata catataaaat 23640
tttattgaaa atatgtttt gttactaaaaa ttttgttga ctcctaacaa aagacaatgg 23700
atggcccttag catcagaattt aaaataatct ggattaaatg gcaatgtgtt catagtcagc 23760
aataaaatata aacattttc cctttaagct cagcactttt tttttttttt ttttttttc 23820
tttgagatgg agtctcgctc tgcacccag gctggagtgc agtggcagga tctcagctca 23880
ctgcaacctc tgcctccag gttcaagtga ttctctgtcc ccaggctccc gagtagctgg 23940
atctacaggt gtcggccacc aagcctggct aattttgtt ttttttagtag aaacagggtt 24000
tcacccatgttgc gcgcaggctg ctcttgaact cctgtatctca ggtgatccgc ccgcctcagc 24060
ctccccaaatg gctgggatta caggcatgag ccactgtgcc tggcctcaat attttttattt 24120
ttaaatgtt tattgcacaa atagaactttt atctaacaaa tcactttcaa aaataacagg 24180
tcaactgttt taattttgtt atgtcactta taacttacctt atttctgtat caggttagaa 24240
tggtttctgc ttaaagttaac acaaaagatc caagtggcaa tggttcttca aatagggtt 24300
tttctcagat aacaagaagt ctaaaggagc tggccactgg cattgggttta gtgactcagt 24360
gatatcaggg gctcagattt ctttagcattt tctgtatgg aaacaagatg gccattgcag 24420
ttcaagccaa tgcgtgttca ttcaagacaa aaagaagggg aagcaggccc ttccacatct 24480
gatcccttttcc tcataaatgtt aaaaatctttt ctagaaatttt agatcagact tgcgttcatc 24540
tgcttagccat aatgtacaa catgtacc ccttgccttcc aggaaagtgg gaaaatgaag 24600
ctgtacgcct ttccagtcactt actaatggaa ggtggaaag gaaaatgggg attggaaattt 24660
accatggatc agacaaccaa cagtttgcc accagttata attagagcag aggtcattttt 24720
atatttgaat cttttgttca atgtcttcat aaagctactt ttattttat tttttttttt 24780
ttttgagacg agtctcgctt ggttgccttccag gctggagtgc agtgacgcaa tctcggttca 24840
cgcaacccctcc acctcccccagg ttcaagtgtat tctccacctt cagccttctg agcagctggg 24900
actacagaca tgcaccacccg cacccageta atttttttgtt gtttttagta gagaccgggt 24960
ttcaccatgt tggtcaggctt ggttcaaac tccctgacttc a 25001

<210> SEQ ID NO 9
<211> LENGTH: 4752
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

tggccgtgtt attgtctgtt gcccattacc ctgtggccgt gtgactgttgc ctgtggccat 60
taccctgtgg ccgtgtgattt gctgtgtgc ccattaccctt gtggccgtgtt gattgtctgg 120
tgcccttattt cctgtggccgt tgcgtattgtt ctgtggccat taccctgtgg ccgtgtgattt 180

-continued

gctctgtgcc cattaccctg tggccgtgtg attgtctgt gcccattatac ctgtggccgt	240
gtgattgctc tgtgcccatt atccctgtggc cgtgtgattt ctctgtgccc attatccctgt	300
ggccgtgtga ttgctctgtg cccattatcc tggccgtgtg tgattgtgc tggcccaatt	360
accctgtggc cgtgtgattt ctctgtgccc attatccctgt ggcgtgtga ttgctctgtg	420
ccattatcc tggccgtgtg tgattgtct gtgcccatta tcctgttagcc gtgtgattgc	480
ttctgtgccc attaccctgt ggctgtgtga ttgctgtgt gcccattatac ctgtggctgt	540
gtgattgtcg ctgtgcccatt taccctgtgg ctgtgtgattt gctctgtgcc cattaccctg	600
tggctgtgtg attgctctgt gcccattatac ctgtggccgt gtgattgtcg ctgtgcctgt	660
taccctgtgg ctgtgtgattt gctctgtgcc cattaccctg tggctatgt cccttcatct	720
gtcatgagaa gtcagactgt catgtcctgt ggtacatgt cagtggcccc ttagtttg	780
actgtcctcc tatttctaaa cccctctccc cacatctct gctggccccag cctttgtgg	840
agggtctcgc ctcagcagcc cagtttttc tttcacaca cttttctgtt aggtatctat	900
tcaccegtctt ggttccgggtg atccccctgt ggcagatacc ttcagaatcc acatttccca	960
gcttacttcc ctccctgaaact tccacctggc atttccgttg ctggaggaca tctgtacatt	1020
gatggccaaa gctgaactca tcttcctca cacctgtctt gatttccttc cattttctgt	1080
atgtgatgtc acctgggtggc ctcccagttt ccaggctgga gagctggaa gccattctgg	1140
attccctggc caagtccttc tgactccagc tggcagtgg ctcttgcattt catccattct	1200
ccccgtccgc ttagtgcattt taaaaccctt gtcattctaa accatgacag cctactaaca	1260
gcagtggcca tctggaaaca ttttactat actgtcttat ttggcttgc tggcggcagg	1320
acccttgaac atctgtgaag aaatgactat tctgcatgga ggcttcttc tggccgagca	1380
gctgttccac cctaaggcac tggcagaatt aacaaagtct gactggaaac gtgttggacg	1440
gccccatcgta gaggccttaa gggagatctc ctccgtgc gcacactccc agccctttgc	1500
ctggaaagaag aaagccctga tcatcatctg ggccaagggtt ctgcageccgc accccgtgac	1560
cccgccgac acagagacac ggtggcagga agacctgttc ttctcggtgg gcaacatgt	1620
ccccaccatc aaccacacca tcctcttgc gctgtcaaa tccctggaaag cttctggact	1680
ctttatccag ctccctgatgg ccctgcccac caccatctgc catgcagaac tagagcgctt	1740
tctggAACAT gtgaccgttg acacttctgc cgaagacgtg gccttcttc tggacgtctg	1800
gtggggagggtg atgaaggcaca agggtcaccc gcaggacccc ctgtctccc agtttagtgc	1860
aatggcccat aagtacactgc ctgccttaga tgagttcccc catccctcaa agaggcttag	1920
gtcagaccca gacgcgtgcc ccaccatgcc cctgttggcc atgctgetcc gccccgtgac	1980
acagatccag agtcggatcc tggcccccggg gaggaagtgc tggcgtgttccca accacccgt	2040
tgacatgctg actgtgtttt cgctgacaga ggacgacccc caggaggtgt ctgcacccgt	2100
gtatctggac aaactggcca cgggtgatctc tggcgtggaaac tggacacccc agaattccca	2160
ccaccagcag ggcgtggcag agaagggtaa ggaggccgaa cgggatgtca gcctgaccc	2220
gctggccaaa ctccccactg agaccatccc cgtgggtgtt gagttccgttcc accacccgt	2280
gccccggagggtg gggggagggtg tgcaggccgt gctccgcagc agccaggggaa caagttacga	2340
cagctaccgg ctgtgcgaca gtctgacttc cttcagccag aacgcgcacgc tctacctgaa	2400
ccgcaccagc ctgtccaagg aggacaggca ggtggctctt gagctggcgg agtgtgtcag	2460

-continued

ggacttcctg	aggaaaacga	gcacgggtct	gaagaacagg	gccttggagg	atatacacagc	2520
ttccattgcc	atggccgtca	tccagcagaa	gatggaccgc	catatggaag	tgtgctacat	2580
ttttgcctct	gagaagaagt	gggccttctc	ggacgagtgg	gtacgcctgcc	tggggagtaa	2640
cagggccctc	ttcccgagac	cagacttggt	gttggaggctg	ctggaaacag	tgatagacgt	2700
cagcacagct	gacagagcca	tccctgagtc	tcaagatccgg	caggtgtatcc	acctgatcc	2760
ggaatgttac	gcagacac	ccctgccagg	taaaaataaa	gtccttgcag	gtatcctgcg	2820
ttcctggggg	cgaaaggccc	tctctgaaaa	gttgcgtggct	tatgtggagg	gtttcagga	2880
agaccta	acaacttta	accagctcac	tcaagatgc	tccgaacagg	gcttggcaaa	2940
agctgtggcc	tccgtggccc	gcctggatcat	agtgcacccg	gaagtacgg	tgaagaaaat	3000
gtgcagcc	gctgtggatca	atctcggcac	ccacaagttc	ctggcccaga	ttctca	3060
cttccctgcc	cttaggttt	tggaaagtgc	gggtcccaat	tcatctgcca	ctttcatgg	3120
gtcatgc	aaagaaaaccg	tctggatgaa	gttctctaca	cccaaggaa	aaaagcaatt	3180
tttagagctc	ctgaactg	tgatgagtc	cgtgaaaccc	caagggattc	cagtggctc	3240
tcttcttgc	ccagacgagg	tgctgaagga	atttgcctg	ccttcttgc	ggttagatgt	3300
tgaagaggta	gacctcagtc	tgaggatctt	catccagact	ctagaggcaa	acgcgtgtc	3360
agaggaatac	tggctccaga	cctgctcccc	gttccactc	ctcttcagct	tgtgccagct	3420
cttggaccgc	ttcagcaat	actggcagct	tcccaaggag	aagcggtgcc	tctctttgga	3480
taggaaggat	ctagcgatcc	atatcctg	gtccctgtgt	gagattgtat	cagccatgc	3540
tgagac	tcccccggat	tctggatcaa	gtccctgtcc	tggctccacc	gcaagttaga	3600
acagctagac	tggactgtgg	gcctgaggct	gaagagcttc	ttcgaggggc	acttcaagtg	3660
tgaagtgc	gccacactt	ttgagatctg	taagcttca	gaagacgagt	ggacccc	3720
ggcccaccca	gggtacgggg	ctggcacggg	gtccctggcc	tggatggagt	gtgtgcgt	3780
ctccagcggc	atctcggaga	ggatgctgtc	tctcttgg	gtggacgtgg	gcaatcc	3840
ggaggtcaga	ctgttcagca	aaggcttct	ggtggccctg	gtgcaagtca	tgccttgg	3900
cagccctcag	gagtggcagc	gccttcacca	gtgaccagg	agactgctgg	agaagcagct	3960
cctccatgtc	ccttatagcc	tggaaatat	tcaagttgtt	cccctgtca	acctgaagcc	4020
cttgc	gagttgcaac	tctccgtct	cttcgttgg	actttccagt	ttctctgcag	4080
ccatagctgt	cgtaattggc	ttcctctg	aggctgaa	cacgtggtca	aactcc	4140
tggc	acccgcctcc	tggactc	caggcgata	caggcagctg	gccc	4200
tcaaggacca	gacgaggacc	tgacccagga	agccctgtt	gttacaccc	aggtgttctg	4260
ccatgctctg	cacatcatgg	ccatgctca	cccgagg	tgtgagccac	tctacgttt	4320
agccttggaa	accctcac	gtatgagac	tttgc	accaccc	ctgtcagctc	4380
cttgctccag	agggcacacg	agcagcg	ctt	aaagtcc	attgctgagg	4440
tgaagaacgg	cggccaaaccc	tgttgc	gagaa	gtgac	ttctgacttg	4500
ctggggccca	acatggcggg	tctgc	agaag	atcagc	acttac	4560
aaaagctggg	cttcaacatg	gcagg	tctgt	agggtc	aga ccc	4620
cagttatgt	aaactgtcca	caaaa	aggta	gtgtaa	aga aaat	4680
ttgggtat	gtaacgtaca	aactatcata	aaaattctcc	tcttccaa	aaaaaaa	4740

-continued

aaaaaaaaaa aa	4752
<210> SEQ ID NO 10	
<211> LENGTH: 720	
<212> TYPE: DNA	
<213> ORGANISM: Homo sapiens	
<220> FEATURE:	
<221> NAME/KEY: misc_feature	
<222> LOCATION: 458	
<223> OTHER INFORMATION: n is a, c, g, or t	
<400> SEQUENCE: 10	
agcgggagggt tgtgagcagg cctaagcgcg gcccgcgtgg ctccctgcgtc tccccatcgta	60
ccgtgcgtcc cgccgcgcgt tcgagttctc ggagggggagg gggcgtagc cccgcgcagc	120
cgccggcgtc gcccgcgtgg accttagaccc ttgaacatct gtgaagaataact gactattctg	180
catggaggct tcttgctggc cgagcagctg ttccacccta aggcactggc agaattaaca	240
aagtctgact gggaaacgtgt tggacggccc atcgtggagg ccttaaggga gatctcctcg	300
gctgcagcac actccccagcc ctttgcctgg aagaagaaag ccctgatcat catctggcc	360
aaggttctgc agccgcaccc cgtgaccccg tccgacacag agacacgggt gcaggaagac	420
ctgttttctt cggtgggcaa catgatcccc accatcanac acaccatctt cttcgagctg	480
ctcaaatccc tggaaagcttc tggactcttt atccagctcc tggatggccct gcccaccacc	540
atctgcacatg cagaactaga gcggtttctg gaacatgtga ccgttgacac ttctgcccga	600
gacgtgagct tcttcctggc cgtctgggtgg gaggtgtatga agcacaagggt tcacccgcag	660
gaccctgtct ctcaccatgtt agtggaaatgg cccataagta cctgactgcc tttagatgaga	720
<210> SEQ ID NO 11	
<211> LENGTH: 671	
<212> TYPE: DNA	
<213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 11	
agcgggagtcc cgccgcaccc cgccgcgtgc cgccatggac cttagatgtgg ggccatgagt	60
accttggttt tgactggaag gagctgtggg gtggaccgtt tccctgaaat ctggatggat	120
gtttgaagcc tggatccaaat gacccttgaa catctgtgaa gaaatgacta ttctgcatgg	180
aggcttcttg ctggccgagc agctgttcca ccctaaaggca ctggcagaat taacaaatgc	240
tgactggaa cgtgttggac ggcccatgt ggaggccctt aaggagatct cctcggtgc	300
agcacactcc cagccctttg cctggaaagaa gaaagccctg atcatcatct gggccaagggt	360
tctgcagccg caccctgtca cccctgtca cacagagaca cggtgtggcagg aagacctgtt	420
cttctcggtg ggcaacatgtca tccccagcat caagcacacc atccctttcg agctgctcaa	480
atccctggaa gcttctggac tctttatcca gtcctgtatg gcccgtccca caacatctgc	540
catgcagaac tagagcgctt tctggaaatgt gtcggccgtt acaacttctgc cgaagacgtg	600
ggcttcttcc tggacgtctg gtggggagggtg atgaaacaca agggtcaccc gcaggacccc	660
ctgctctccc a	671
<210> SEQ ID NO 12	
<211> LENGTH: 3472	
<212> TYPE: DNA	
<213> ORGANISM: Homo sapiens	

-continued

<400> SEQUENCE: 12

tggcggccgc	cggcgctgcc	gccccatggacc	taggaccctt	gaacatctgt	gaagaaatga	60
ctattctgca	tggaggcttc	ttgctggccg	agcagctgtt	ccaccctaag	gcactggcag	120
aattaacaaa	gtctgactgg	gaacgtgtt	gacggccat	cgtggaggcc	ttaagggaga	180
tctcctcgcc	tgcagcacac	tcccagccct	ttgcctggaa	gaagaaaagcc	ctgatcatca	240
tctggggccaa	ggttctgcag	ccgcaccccg	tgaccccgtc	cgacacagag	acaecggtgc	300
aggaagacct	gttcttctcg	gtgggcaaca	tgateccccac	catcaaccac	accatccctc	360
tcgagctgct	caaataccctg	gaagcttctg	gactctttat	ccagctcctg	atggccctgc	420
ccaccacca	ctggccatgca	gaactagagc	gctttctgga	acatgtgacc	gttgacactt	480
ctgccaaga	cgtggcccttc	ttcctggaca	tctgggtggaa	ggtgtatggaa	cacaagggtc	540
acccgcagga	ccccctgctc	tcccagttt	gtgcaatggc	ccataagtac	ctgcctgcct	600
tagatgagtt	cccccatcct	ccaaagaggc	ttaggtcaga	cccagacgcg	tgccccacca	660
tgccccctgtt	ggccatgctg	ctccgcgggc	tgacacagat	ccagagtcgg	atccctggcc	720
cggggaggaa	gtgctgtcg	ctggccaacc	tggctgacat	gctgactgtg	tttgcgtgaa	780
cagaggacga	cccccaggag	gtgtctgaa	ccgtgttatct	ggacaaaactg	gccacgggtg	840
tctctgtgt	gaactcggac	acccagaatc	cctaccacca	gcaggcgctg	gcagagaagg	900
tgaaggaggg	agaacgggat	gtcagcctga	cctcgctggc	caaactcccc	agtgagacca	960
tttctgtgg	ctgcgagttc	ctgcaccacc	tgctgcggga	gtggggggag	gagttgcagg	1020
ccgtgctccg	cagcagccag	gggacaagtt	acgacagcta	ccggctgtgc	gacagtcgt	1080
cttccttcag	ccagaacgcg	acgctctacc	tgaaccgcac	cagcctgtcc	aaggaggaca	1140
ggcaggttgt	ctctgagctg	gccccggatgt	tcaggggactt	cctgaggaaa	acgacacgg	1200
tgctgaagaa	cagggccttg	gaggatatca	cagctccat	tgccatggcc	gtcatccagc	1260
agaagatgg	ccgccccat	gaagtgtgt	acattttgc	ctctgagaag	aagtggccct	1320
tctcggacga	gtgggttagcc	tgccctggga	gtaacagggc	cctctccga	gagccagact	1380
tgggttttag	gctgctggaa	acagtgtat	acgtcagcac	agctgacaga	gccatccctg	1440
agtctcagat	ccggcagggt	atccacactga	tcctggat	ttacgcagac	ctctccctgc	1500
caggtaaaaa	taaagtccctt	gcaggatattcc	tgcgttcctg	ggggcgaag	ggccctctcg	1560
aaaagttgt	ggcttatgtg	gagggttttc	aggaagacct	caataacaact	tttaaccagc	1620
tcactcagag	tgcctccgaa	cagggtttgg	aaaaagctgt	ggcctccgtg	gcccgcctgg	1680
tcatactgca	cccgaaagtc	acggtaaga	aatgtgcag	cctggctgtg	gtcaatctcg	1740
gcacccacaa	gttcctggcc	cagattctca	ctgccttccc	tgcctttagg	tttggaaag	1800
tgcagggtcc	caattcatct	gccactttca	tgggtgtcat	cctcaaagaa	accgtctgg	1860
tgaagttctc	tacaccaag	gaagaaaagc	aatttttaga	gctcctgaac	tgcctgtat	1920
gtccccgtgaa	accccaaggg	atccctgtt	ctgctttct	tgcctgtat	gaggtgtat	1980
aggaatttgt	cctgcctttc	ttgaggat	atgttgaaga	ggtagacctc	agtctgagga	2040
tcttcatcca	gactcttagag	gcaaaacgcgt	gcccggaggg	atactggctc	cagacactgt	2100
ccccgttcc	actccctttc	agcttgcgc	agctcttgg	ccgccttgc	aaatactggc	2160
cgcttcccaa	ggagaagcgg	tgcctcttt	tggataggaa	ggatcttagcg	atccatatcc	2220

-continued

tggagctctt	gtgtgagatt	gtatcagcca	atgctgagac	cttctcccg	gatgtctgga	2280
tcaagtccct	gtcctggctc	caccgcaagt	tagaacagct	agactggact	gtgggcctga	2340
ggctgaagag	cttcttcgag	gggcacttca	agtgtgaagt	gccagccaca	cttttgaga	2400
tctgttaagct	ttcagaagac	gagtggacct	cccaggcccc	cccagggtac	ggggctggca	2460
cgggggctct	ggcctggatg	gagtgtctgt	gctgtccag	cggcatctcg	gagaggatgc	2520
tgtctctctt	ggtgggtggac	gtgggcaatc	ctgaggaggt	cagactgttc	agcaaaggct	2580
ttctgggtggc	cctggtgcaa	gtcatgcctt	ggtgtcagccc	tcaggagtgg	cagegccttc	2640
accagctgac	caggagactg	ctggagaagc	agctcctcca	tgtcccttat	agcctgaaat	2700
atattcagtt	tgttcccttg	ctcaacctga	agcccttgc	ccaggagttg	caactctccg	2760
tcctcttcct	gaggactttc	cagttctct	gcagccatag	ctgtcgtaat	tgggttcctc	2820
tggaaggctg	gaaccacgtg	gtcaaactcc	tctgtggcag	tctgaccgc	ctcctggact	2880
cagtcaggcgc	gatacaggca	gctggccctt	gggttcaagg	accagagcag	gacctgaccc	2940
aggaagccct	gtttgtttac	accagggtgt	tctgccatgc	tctgcacatc	atggccatgc	3000
tccaccggga	ggtctgtgag	ccactctacg	ttttagcctt	ggaaaccctc	acctgctatg	3060
agactttgag	caagaccaac	ccttctgtca	gtcccttgct	ccagaggcga	cacgagcagc	3120
gcttcttaaa	gtccattgtct	gagggcatttgc	gccctgaaga	acggcgccaa	accctgttgc	3180
agaagatgag	cagttcttgc	cttggcgtgg	ggagctgggc	cccaacatgg	cgggtctgca	3240
gaagatcagc	agtttcttac	ctgtgcggga	gcgaaaaagc	tgggcttcaa	catggcaggt	3300
ctgttaggggt	cagaccggag	cagectggac	tttacagtttgc	tgtgaaactg	tccacaaaaaa	3360
gtcatggcaa	taatgggtgt	aagaaaatag	tttcttgggt	atttgttaac	tacaaactat	3420
cataaaaaatt	ctccttttc	gcatctcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaa	3472

<210> SEQ ID NO 13

<211> LENGTH: 11001

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1)...(11001)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 13

ggtagggccct	gtgttccagt	gggggctttt	ggacttgact	ttagtgttta	ggaggacaga	60
gtccctctcc	cctctgtgt	gctggggat	tagtaatca	gccttgaaga	gataagggc	120
tggggcctca	acctccaaag	aggetgtcac	tggagaatgg	tctcctgccc	tcagatcttgc	180
ggcatttcca	cagcacactg	tcccccttgt	ccttccaaat	acctacatac	gctttgtaa	240
taggagagct	gggaaactcca	cccaaaacca	tacaaaaagt	tagtctgtgt	atttggacgc	300
ctccccagca	ctcagtcacc	gagtttctcc	tttccaacag	cagtcactct	catgcagtt	360
aagtgttta	ttgatgtctc	ggctaagttt	gcgacagttt	caggacattt	cagccatcaa	420
ggtctaagaa	gcccttcca	ttcccgagga	gccctcagcc	agccctttc	tccctcatct	480
cctcactctg	gcccgcgtgc	ccctcatggc	gtccatcttgc	gacgccccctt	tgttcgcgt	540
ccacgcccccc	cacttccttc	ttcgtcagct	cctccactttt	ggccgcgttag	ccctctatgg	600
cgtccatctt	ggacgccccct	ttgttcgcgc	tccacgcccc	ccacttcctt	ttcgtcagc	660

-continued

tcctccactt	tggcccgcta	gcccctcatg	gcttcacatc	tggacgcgcc	tttgttcgca	720
ctccacgccc	cccacttcct	tcttcgtcag	ctcctccact	ttggcccgct	agccccctcat	780
ggcggtccatc	ttgcacgccc	ctttggttgc	gttccacgca	ccccacttcc	tttttcgtca	840
gttcctccac	tttggccgca	tagccctca	tgggttccat	tttggacgca	ccttttttca	900
cgctccaago	cttccacttg	gcccggctc	tcacgtctga	ggccgggggg	ccggggatgt	960
cgcagtcgca	ctgggtggcc	tgttgtaca	agccgttagac	cagcagttc	tcctgategc	1020
tcacgggacc	cttcagctgc	tttggggccg	cgccagctca	actccacttg	gcacatgggg	1080
tggtgtgggc	ggtccctgggt	gctagaagct	ggagggtggag	agttggagtg	gctgttacta	1140
ctcgatctca	ggggggaggag	acaggcacgc	gatgtttgt	ttttgtcaag	cacagattgc	1200
aagctcgggg	tccagcgtaa	acccaccat	gtttggctc	acacggcgca	ttttctgggg	1260
aggaccagcc	gtcaaaaagc	gtctaggata	cggaacgctg	ctgtctggag	ggggggggcg	1320
ggcaggagcg	cgttggggga	ctgtatgtgg	cgccgagctgg	gggggtggga	gttggaaagcct	1380
cgcggtgtgc	ggccggcgctg	ggtgtggggc	gtccccgggg	aggcgctcg	tgggggtgaa	1440
ctgtgtgcgg	ggcacccccg	gggttaccgg	gtgagggtga	atggggggcc	ggggaaatcat	1500
gagccccacc	cgctgggacc	ccggaagagg	ggccggggcag	ggacgggtgc	ggaggggtct	1560
agtgagcgac	gtccgggtac	tttggggctg	gtggggggc	tctggccgaa	ggcgccgctg	1620
tgcgttggc	gctgtcgta	gtaagaactg	cgccgtcgca	ggggaggctg	tggggggggc	1680
cggggggagg	ttgtgagcag	gcctaagegc	ggccgcccgt	gttcctgcgt	ctcccategt	1740
gcccgtcgca	cccgcccgcg	ttcgagttct	cgagggggg	ggggcggttag	ccccggcgca	1800
ccgcccgggt	cgccgcccatt	gacctaggtg	ggtgccgcgg	ctcccccggcc	ccgggctgcgc	1860
tccagcaatg	cgccaccaga	gccccgtcg	ccccgtcggt	cttcctctgt	cgccacacgt	1920
cgccggggcc	cggaccgaaa	cgtccccccg	gtccggggcg	gtctagggtt	ccccgggtgg	1980
ccttgggggg	gggtgggtccg	ggtccccccg	cgccgttggc	cgccgttgc	cgccctccggc	2040
ccccctcgct	tgtaaaacacg	gagcagacgt	gaagtttagag	cccttggaa	cgccccgggg	2100
tccgtcgacgt	gtttggaa	acgggctccc	tccgagcacc	cctgggggcc	ccgacggcc	2160
catttcctga	acggcagctg	cgtttgcag	caagtgttct	aacgctccaa	gtgtcttacg	2220
ctcatgacgt	ttccctcatcg	acagagcggt	gagaatggaa	gtgtgttcc	ccactgagtt	2280
tttggggact	ttgcatttgc	atcgccgagg	tacagtgtcc	tttgggggtt	tgcgtgggtc	2340
acaccccgcc	tggggggggc	tgcgttccgt	agttatca	tttggaaacct	gggtgcgtcc	2400
ggattcagaa	tcttacaggc	aaggcttggg	agggagccca	taggaactag	atgtccctg	2460
ctaaatcttgc	gcacacgctg	ctaagaccag	gaggctgttc	tgggagagct	gggggtgagg	2520
caccccgaga	tgtgtcagca	gttagtgggt	ggggggaaat	ggtctgggtc	ccggccccca	2580
acagcttttc	aggagcgaa	tggcagagct	ctaagggttt	ggagccccctc	agccgttaatt	2640
gtttcccgac	cccaccacat	tcaggctggg	acaccctcg	caaatcgtt	ctgcgcctca	2700
gtgttccctat	ctcttagagca	ggaataactag	ttctcaaaag	gtgattgtga	atagaagaga	2760
tcttacactgt	gtaccaccta	gcacagtgtc	tggcatggg	taggtgttta	ataaacctaa	2820
gaagcgccgt	gtggcaagca	ctagtttaacc	atccatgata	gagtaaccgg	gtatttcca	2880
gctagtaacc	gcccgggac	tttactacttc	aaactgtgc	tacttaatgc	gcctggaaagg	2940

-continued

caggtgttta	ggccaaaca	tctgctcaac	taagccaata	atgcaataaa	attaaattta	3000
cagcgtcagg	agggactata	ttttggacc	ctggagago	ctcctgagcc	agaaagaagg	3060
gcggtaaccc	ccagggaggt	ccccctcgca	gcgtaaccct	ccctggagt	cggtctcagc	3120
cactgtgaga	tgagatggat	tgccctccaca	agtgggtac	atagtgtga	gccctggcc	3180
tgctgcccct	cccataaaatg	gtgggagggg	taagatggtc	cttagtctcc	tggagtca	3240
gttttctctg	ctgggtctg	gcctgtgaaa	atgggaata	tgagctctt	ggggcatgac	3300
agactgagga	aggagtagca	tctctca	ctggaaagg	ggagatgact	caggaatgag	3360
gaatagggag	cagtgttgc	accctcg	tagttctgg	gccaaggaa	acatacctga	3420
taaagaccta	catccttga	tgtttctgag	ctggggagg	caaagaata	tgacaagatt	3480
ctggtcttgc	caaccatgaa	aagggttggg	gaaaccaaca	ttaactgagc	acctaattag	3540
actctgtaac	tggatttta	ctgtagctc	atctcattt	tccatcatag	cgtcccg	3600
agatgggtc	aggagatagc	agtgc	caactgaa	ggcttgact	gtatata	3660
catgatcccc	aaaggcataa	catgaagtct	gtattatccc	cacatatgca	gaaggaaggc	3720
ttggagaagc	aatctgacca	agatcacatc	cctttttt	tttcggagat	ggagggggag	3780
tctca	tgttccagc	tagtctgaa	ctcctggc	caggatcca	cctgc	3840
cccccaagt	agctggatt	acaagtgc	gccactgaa	ctggccagaa	tcacatcatt	3900
ttaaatggc	tgaacttagga	tttaaacc	tgtctgatta	aacatccaa	gatgttt	3960
atggtaagtc	tgtgtcaatc	gttagtccc	tgaaggaagg	cttaatctag	cacagtatt	4020
tctgtatcta	ctccctgg	tctccacag	agctagg	atgat	actt	4080
tggaaggagc	tgtgggttgg	accgttccc	tgaaagctag	aagaatgtt	gaagc	4140
cccaaggcaa	gtttataaag	agtgaaggca	gggcttgt	gattc	ctgtgtt	4200
ctctgtggct	atgtgattgc	tctgtgccc	ttaccctgt	gctgtgt	tgctgtgt	4260
cccg	taccc	tgtggctgc	tgtgt	gtgt	ccatt	4320
ctctgtgccc	attatcctgt	ggcgtgt	tgc	ctgtgt	ccatt	4380
tgattgtgc	tgtgcccatt	accttgt	tgtgt	ctgtgt	cattatc	4440
tggctgtgt	attgctctgt	gccattatc	ctgtggctgt	gtgattgctc	tgtgcccatt	4500
atccctgtgc	cgtgtgattt	cttctgt	cattacc	tggctgtgt	attgctgt	4560
tgcccattat	cctgtggcc	tgtgattgt	gctgtgccc	ttaccctgt	gcccgtgt	4620
tgc	cattacc	gtggccgtgt	gactgtgt	gtgcccatt	ccctgtgg	4680
gtgtgattgc	tgc	attacc	gtgtgt	ttgctgt	cccattatc	4740
tgtggccgt	tgattgtct	gtgcccatt	ccctgtgg	gtgtgatt	tctgtgccc	4800
ttaccctgt	gcccgtgt	tgctgtgt	ccattatc	gtggccgtgt	attgctgt	4860
tgcccattat	cctgtggcc	tgtgattgt	ctgtgcccatt	tatcctgt	ccgtgtgatt	4920
gctctgtgc	cattacc	tgggccgtgt	attgtgt	tgc	ccctgtggcc	4980
tgtgattgt	ctgtgcccatt	tatcctgt	ccgtgt	gat	ccat	5040
tggctgtgt	attgctctgt	gccattatc	ctgtgt	gtgattgt	ctgtgcccatt	5100
taccctgtgg	ctgtgtgatt	gtgtgt	ccattatc	gtggctgtgt	gattgctgt	5160
gtgcccatt	ccctgtggct	gtgtgattgc	tctgtgccc	ttaccctgt	gctgtgt	5220

-continued

tgctctgtgc ccattatcct gtggccgtgt gattgtgt gtgcctgtta ccctgtggct	5280
gtgtgattgc tctgtgcccc ttaccctgtg gctatgtcc cttcatgtt catgagaagc	5340
tcaagctgtca tgcctgtgg tacatgtca gtggcccctg tagttgtac tgccttccta	5400
tttctaaacc cctctccccca cattctgtc tggcccaagcc tttgtggag ggtctcgct	5460
caggcagccca gctttttttt ttcacacact ttccctgaag gatctcatc accgtcttgg	5520
ttccggtgat ccctctggg cagataccctc tcagaatcac atttcccagc ttacttcct	5580
cctgaacctc cacctggcat ttccgttgc ggaggacatc tgtaccttga tggccaaagc	5640
tgaactcatc ttccctcaca cctgtctga ttctctcca ttccctgtat gtgtatgtcac	5700
ctgggtggct cccagttccc aggctggaga gctcggaaagg cattctggat tcctcggcca	5760
agtccctctg actccagctg tgcaagtggct ctgttagtca tcccttcctcc cggtccgctg	5820
atgtccttta aaacccttgt catctcaaac catgacagcc tactaacagc agtggccatc	5880
tggaaacatt ttcaactatac tgcgttattt ggcttgcgtc tgcgtggac ccttgaacat	5940
ctgtgaagaa atgactattc tgcgtggagg ctcttgcgtc gcccggcgc tggccaccc	6000
taaggcactg gcagaattaa caaaatgtca ctggaaacgt gttggacggc ccattgtgg	6060
ggccttaagg gagatctcct cggctgcagc acactcccag ccctttgcct ggaagaagaa	6120
agccctgate atcatctggg ccaagggttct gcagccgcac cccgtgaccc cgtccgacac	6180
agagacacgg tggcaggaag acctgttctt ctgcgtggc aacatgtacc ccaccatcaa	6240
ccacaccatc ctcttcgagc tgctcaaatc cctggaaagct tctggactct ttatccagct	6300
cctgtatggcc ctgcccccca ccatctgcca tgcagaacta gagcgtttc tggAACATGT	6360
gaccgttgac acttctgccc aagacgtggc ctcttcctg gacgtctgggt gggaggtgat	6420
gaagcacaag ggtcacccgc aggacccct gctctccag ttttagtgcaa tggccataaa	6480
gtacactgcct gccttagatg agttccccc tccctccaaag aggcttaggt cagacccaga	6540
cgcggtcccccc accatgcccc tggccat gctgtccgc gggctgacac agatccagag	6600
tccggatccctg ggccccggga ggaagtgtcg tgcgtggcc aacctggctg acatgtgtac	6660
tgtgtttgcg ctgacagagg acgacccca ggaggtgtct gcaaccgtgt atctggacaa	6720
actggccacg gtgatctcg tgcgttactc ggacacccag aatccctacc accagcaggc	6780
gctggcagag aaggtaagg aggccagaacg ggatgtcagc ctgacactcg tggccaaact	6840
nccccagtga gaccattttc gtgggtcg agttccgtca ccacctgtcg cgggagtgaaa	6900
gggnaggagt tgcaaggccgt gctccgcgc agccaggggaa caagttacga cagttacccgg	6960
ctgtgcgaca gtctgacttc cttagccag aacggcgacgc tctacctgaa ccgcaccac	7020
ctgtccaaagg aggacaggca ggtggctct gagctggcg agtgtgtcag ggacttcctg	7080
aggaaaacga gcacgggtct gaagaacagg gccttggagg atatcacacg ttccattgoc	7140
atggccgtca tccagcagaa gatggaccgc catatggaaat tgcgttacat ttgtccct	7200
gagaagaagt gggcccttc ggacagggtgg gtagcctgccc tggggagtaa cagggccctc	7260
ttccgacago cagacttggt gttgaggtcg ctggaaacag tgatagacgt cagcacagct	7320
gacagagcca tccctgagtc tcagatccgg caggtgtatcc acctgtatcc ggaatgttac	7380
gcagacactct ccctgcccagg taaaaataaa gtccttgcag gtatccgtcg ttccctgggg	7440
cgaaaggggcc tctctgaaaaa gttgtggct tatgtggagg gttttcagga agacactcaat	7500

-continued

acaactttta accagctcac tcagagtgcc tccgaacagg gcttggcaaa agctgtggcc	7560
tccgtggccc gcctggcatc agtgcacccg gaagtacacgg tgaagaaaat gtgcagcctg	7620
gctgtggtca atctcggcac ccacnaagtt cctggccag attctcactg ccttccctgc	7680
ccttaggtt gtggaaagagc agggtccaa ttcatctgcc actttcatgg tgcatgcct	7740
caaagaacc gtctggatga agttctctac acccaaggaa gaaaagcaat ttttagagct	7800
cctgaactgc ctgatgagtc ccgtgaaacc ccaaggatt ccagtggctg ctcttcttga	7860
gccagacgag gtgctgaagg aatttgcct gccttcttg aggttagatg ttgaagaggt	7920
agacctcagt ctgaggatct tcatccagac tctagaggca aacgcgtgcc gagaggaata	7980
ctggctccag acctgtccc cgtttccact cctttcage ttgtgccagc tcttggaccg	8040
cttcagcaaa tactggcagc ttcccaagga gaagcggtgc ctctcttgg ataggaagga	8100
tctagcgatc catatcctgg agctcctgtg tgagattgta tcagccaatg ctgagacatt	8160
ctccccggat gtctggatca agtccctgtc ctggctccac cgcaagttt aacagctaga	8220
ctggactgtg ggctctgaggc tgaagagctt cttecgaggg cacttcaagt gtgaagtgcc	8280
agccnacanc tttttagat ctgtaagctt tcagaagacg agtggacctc ccaggccccac	8340
ccagggtacg gggctggcac ggggctcccg gcctggatgg agtgctgctg cgtctccagc	8400
ggcatctcg agaggatgct gtctcttgc gtggtgacg tggcaatcc tgaggaggtc	8460
agactgttca gcaaaaggctt tctggggcc ctgggtcaag tcatgcctt gtgcagccct	8520
caggagtggc agcgccctca ccagctgacc aggagactgc tggagaagca gctccctcat	8580
gtcccttata gcctggaaaata tattcagttt gttccctgc tcaacctgaa gccccttgc	8640
caggagttgc aactctccgt cctttccctg aggactttcc agtttctctg cagccatagc	8700
tgtcggtatt ggcttcctct ggaaggctgg aaccacgtgg tcaaactcct ctgtggcagt	8760
ctgacccggcc tcctggactc agtcaggcg atacaggcag ctggccctt ggttcaaggaa	8820
ccagagcagg acctgaccca ggaaggccctg tttgttaca cccaggtgtt ctgcctatgt	8880
ctgcacatca tggccatgtt ccacccggag gtctgtgagc cactctacgt tttagcccttgc	8940
gaaaccctca cctgctatga gactttgagc aagaccaacc cttctgtcag ctccctgtc	9000
cagagggcac acgagcagcg cttcttaaag tccattgtcg agggcatcg ccctgaagaa	9060
cgccgcacaaa ccctgttgcga gaagatgagc agcttctgac ttggcgtggag gagctggcc	9120
ccaacatggc gggctctgcag aagatcagca gcttcttacc tgtgcgggag cgaaaaagct	9180
gggcttcaac atggcaggc ttttaggggtc agaccggagc agcctggact ttacagttat	9240
gtgaaactgt ccacaaaaag tcatggcaat aatggtgtaa agaaaatagt ttcttggta	9300
tttgtaacgt acaaactatc ataaaaatttcc tctctttcg catctcactt tgtctcttct	9360
aagtccgcct cagcaatagc ccaggattaa atatgctcg aaattgggtt tagtgtcttc	9420
aagatcaaat ccagccagga ggaacatgtt cataactgga cttttccatc ctagattttg	9480
gcaaaataagc ccaaaggatgtaa aaccatgtga gtggaaaaag cattacatgg tacgtataaac	9540
ccccctcaag agttatttcg tcttttaatg ttttttctt gaggtatctt ggaaaggaca	9600
gcagcttggaa aaaaatcca gtccagccct ggctctgcct ctggccatga gactgctgtg	9660
cccgagaggc ctgcacaatt ctaaaatgag aggattggag gaccaagata aactcagtg	9720
cgaggggctaa ggtagtgac ctcaagaaaa tgggtccct ctgaatttgag gagtggtac	9780

-continued

agtctttgtt gctcagacta gccttgaacc cctggactca agtgatcctc ccacccatcagc	9840
ctcctgagta gctggacaa taagcacacc cacttccat acagtctaa ctccatctat	9900
tcagtcaccc ccaaaggccc tactgtgaag acgagacctg gcaaaccag cagagatgtg	9960
ctgaatggat gggtcacgtt agctttgcc tcaggagggg ttgtcaagat ttggatgaat	10020
gaatggttt gataagggaa tgatgtgtgc aggaacataa aaaatgagtt tggccaggt	10080
gcggtgactc acacctgtaa tctcagcact ttgggaggcc gagggggag gatcactga	10140
gaccagccaa catatgaaag ccctgtctct aaaaaaaaaa aaccacaaaa attagctagg	10200
tgtggtgaca cacagctgta gtcccagcta ctcagggttc taaagcagga ggctcacttg	10260
atcctggag gtagaggctg cagtaagctg agatcagacc actgcactcc agccttggtg	10320
acagagttag accctgtcta aaacaaaaaa aaaaaaaaatt gagagtggc taggcatggt	10380
ggctcacacc tgtaataatc ccagtgcctt gggaggctga ggcaggagga tcacttgagg	10440
ccaggaggttt gagaccagcc tggcaacag agataacctg tctctacaaa aaaaaaaaaa	10500
aatgagttt aaggtgtctga ggtatgagga aactatgaaa attggctgg gacatgttta	10560
atgtgtgaga taaaaggggg aaaaaatatg tccccatact ccctccatat ccacaccctc	10620
cttcacaatg gggcattact caggttctcc tcaggtaaag taggcttgc tccctgacca	10680
ataatcggtc ttccactctc ccaattccta gtaagattca cttatgaaga gaagaaacgg	10740
tctcaagttt cgtgtacca ctacgttgc actctggaa ccttcaatgt attactgaga	10800
ccatgaacca caaaaaatagg tttgagttagt gttgtgacca gaccttctg gaggctgaaa	10860
gcattcacac acacacccct ctgcttagta catggacaca gaccttgagc cacagcacac	10920
ggcagccagt cgagctaggt cacaggatga ttcttacagg acactgatat tggatgttattt	10980
cacaaattagt aataagttgg g	11001

<210> SEQ ID NO 14
<211> LENGTH: 4586
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

acgcgtcgac tccattggcc cagcaatcaa ccaacacago tggtatctag ctgtttggaa	60
ggtgaactgt tgcaatggga tctcactcaa tcttggagac gggaaatacac cctttcagtt	120
gcctcatcag aaggggcaaaa tcattcaaga attgtgttta atttatgtcc tttacaaaca	180
gaggatgaca aacagctgtt actttctaca tcaatggata gagatgtaaa atgttggac	240
atagccacctt tggagtgcag ctggaccctt cttcccttg gtgggtttgc atacagcctg	300
gttttctttt ctgtggacat aggtcttttgc gccatagggtt ttggggatgg catgatccgt	360
gtatggata cactctccat aaagaacaac tatgtgtga aaaattttg gcaaggcggt	420
aagtccaagg ttacagcgct gtgtggcac ccaaccaagg aagggttgc agttttggaa	480
actgtatgtt gaaaagtggg attgtatgtac acctactcca acaagcctcc acagatttt	540
agcacatatac ataagaagac tgttatatacg ttagcctggg ggccaccaggat accccccatg	600
tcacttggag gagaaggaga cagaccccttcc cttgtttat acagctgtgg aggagaagg	660
attgtcttac agcataatcc ctggaaagttt agtggagaag cctttgacat caacaaactc	720
atcagggaca ccaattcaat caaatacaaa ttgcctgtac acacagagat aagttggaaa	780

-continued

gcagatggca aaatcatggc tcttggcaat gaagatggat caatagaat atttcagatt	840
cccaacctga aactgatctg tactatccaa cagcatcaca agcttgtgaa taccattagc	900
tggcatcatg agcatggcag ccagccagaa ttgagctatc tgatggcctc tggctccaac	960
aatgcagtca tttacgtgca caacctgaag actgtcatag agagcagccc tgagtctcaa	1020
gtgaccatta cagaggcccta ccggccctc tcagggcata cggccaagat taccagtgtg	1080
gcgtggagcc cacatcatga tggaggcgt gatatcgctt cctatgtgg tacagccccag	1140
gtgtggatg ctctccggga agagccctg tgcaatttc gaggacatca aggtcgactg	1200
ctttgtgtgg catggctcc tttggatcca gactgcattctt attcaggggc agatgacttt	1260
tgtgtgcaca agtggctcac ttccatgcaa gatcattccc ggccctctca aggcaaaaaa	1320
agtattgaat tggagaaaaa acggctctctt caacctaagg caaagccaa aaagaagaaa	1380
aagcccaccc ttgagaactcc tgtaaagctg gaatcgattt atggaaatga agaagaaaagc	1440
atgaaggaga actcaggacc tggatggaaat ggtgtgtcg accaagaagg ggaggagcaa	1500
gcacgggagc cggaattacc ctgtggcctt gctccagcgg tttcttagaga accagttatc	1560
tgcactccag tttccctcagg ctttgaaaag tcaaaagtca ccattaataa caaagtctt	1620
ttactgaaaa aggagccacc aaaagagaag ccagaaacct taatcaagaa gagaaaaagct	1680
cgttccttgc ttcccctgag tacaaggctg gaccacagat ccaaagagga gcttcattcag	1740
gactgtttgg tactagcaac tgcaaaagcac tccagagago tgaatgaaga tggatgtctgt	1800
gatgttgagg aaagatttca tctggggctt ttcacagaca gggctaccct gtatagaatg	1860
attgtatattt aaggaaaaagg tcacttagaa aatggccacc ctgagttatt tcaccagtt	1920
atgctttgga aaggggatct caaagggtttt ctccagactg cagcagaaag aggggagctg	1980
acagacaacc ttgtggctat ggcaccagca gctggctacc atgtgtggct atggctgtg	2040
gaagcttttgc ccaaaccatgtt gtcgtttcag gatcgtatg tcaaggctgc ttctcaccta	2100
cttccatcc acaaagtgtt tgaaggctgtc gagctgtca agtcaaaaccatgttacagg	2160
gaagctatttgc ctttgcgttgc ttatgtatgc gccaatgtttt tggccaaaaa gggggatgc	2220
tacctcagct ggggaaccgt cctagaaaga gatggccact atgctgttagc tgccaaatgc	2280
tattttagggg ccacttgc ttatgtatgc gccaatgtttt tggccaaaaa gggggatgc	2340
gcatacttta gaacggctgc agatgtggctt gccatcgtag gagaggatga gttgtctgt	2400
tccctggctc tcaatgtgc ccaagagctg cttctggcca acaactgggtt gggagccctt	2460
gaageccctgc agctgcataa aagtctacag ggtcagatgtt tggatgttttgc ttcttggag	2520
ctactgttca ggcattcttgc gggaaagcag ctttcagagg gcaaaagctc ctccctttac	2580
cacacttggaa acacggccac cgaaggccctt tcgtggaga gggtgactgc agtgtggaa	2640
agcatcttca gccttgcacac ccctgagcag tatcaggaaat ctttcagaaat gctgcagaac	2700
atcaagtacc catctgttca aaataacaca cctgccaatc agtcctgttgc tcacatgttgc	2760
catgacttgc ccctggcgtt gctgagccaa cagatggccctt cttggcgttca ggttgcgttgc	2820
gctgccttc gggcggtggt ccggagctat gactcaggaaat gcttcaccat catgcaggaa	2880
gtgtactcag cttttctccc tggatgtgtt gaccacatggaa gagacaatgtt gggggatgtt	2940
caatccccctg ccacaccatgtt tttcaaaaatgtt tggaggccctt ttttttttttgc tggggctgttgc	3000
tatgaatttgc ggtggctctt ctccagacccat tggccaaattt ccagtgtctg ggttgcgttgc	3060

-continued

ggtcacagaa cactcttgt tgagccaagc cagcagttag acactgccag cactgaagaa	3120
acggaccctg aaaccttctca gccagagcca aacaggccct cagaactaga cttgagactc	3180
acagaagaag gtgagcgaat gctgagttact ttaaggago tctttcaga aaagcatgcc	3240
agtctccaaa actcacagag aactgttgct gaagtccaag agacccggc agaaatgatc	3300
cgacaacacc aaaagagtca actctgtaaa tccacagcaa atggcctgta taagaatgaa	3360
ccggaagtag aagcagagca gcccctctgc agttctcaga gccagtgtaa agaagaaaaa	3420
aatgagccac tttctctgcc tgagttAACc aaaaggctta ccgaggcaaa tcagagaatg	3480
gcaaaaatttc ctgagagcat taaggcctgg cccttcccag atgtgctgga gtgtgcctc	3540
gtcctgcttc tcatcaggc ccactttct ggctgtctgg cccaggaaat gcagcagcag	3600
gccccaaagac tccttcagaa atacggcaac acgaaaactt acagaagaca ctgcagacc	3660
ttctgtatgt gaattttcac acacccgtaa gaaactgcca aattgaaaat gtttgacatc	3720
tttcacctct cgatgttatgc ctcaccagac attcaactctg gtccctagat gttttgcag	3780
taatccaaaa gaatacacaac aaggattaag tttgaatcaa ccctgcctac ccatagacaa	3840
cgggtggatct gacttttagac tcaattgtgg tctcctactg gagggagat catgaaaagc	3900
ccacagtagt tattcagaac taacacctgc agagtgttgg tcatctctac agccttaggc	3960
aggttcacc aaaagaggag aaacttctgt cgtcacccaa agtgttacat gcttaaaaca	4020
caagctacct ttgttaatac ttcatctgtat cagaagtgtg tcatgctgtt ttgagatgga	4080
gttgctgcat tttaggacta ttgatacctt ttttaattt ttttataat atttaatttgc	4140
aaagaggaga cccttccttc tctactctt catagactga agtttgaata tgaaataggc	4200
cttaaccatc atgttgactc tcctgtcaga attttaggtt ggaaatttgg ttttatttt	4260
tcatgttaatt gcttatttga acagatcaact tactaaagct tttagaagaag tgattcaaatt	4320
gtgtgttttc ctttcagttt tataacaaat ggattgttgc cagtcacata gtcaggaaat	4380
aaattactgt ttcaatggtt cttaaacttt cttggatcat aggatcctt tgagaatcag	4440
attaaagccaa aagataactct ttggagaaaa atgcataatc ctaatttgc atagatgacc	4500
tttggattat tggactctga ctattggac cctaaatact atttaattat aaatcttct	4560
tttctccctca aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa	4586

<210> SEQ ID NO 15
<211> LENGTH: 2301
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

ccacgcgtcc ggctacgagc ggctggctgt ggccagttctt cttgtctctg acggcttgc	60
gttatggggc aggagccgcg gacgctgcgc ccctccccca actggactcg cgcccgctgc	120
agcgatgccc tgccccgggg cctctttggc ttgcggcgcg ggaccccgat cttccctgtc	180
cgcggtggcc cgggcgcagg cgagagtccaa gggacaccccc cgtttcgagt cataggagag	240
ttgggtggac acacccaaag ggtctctggc ttcacatttt ctcacacccc tggcgttgc	300
aacctctgtg ccaccagctc cgacgatggg actgtaaaa tatggatgt agagacaaaa	360
acagttgtga cagaacatgc actccatcg catacgatata caacattaca ttggcctcct	420
cgagtaaagg acttaatagt atctggggat gaaaaaggag tagtttctg ttactgggtt	480

-continued

aacagaaaatg acagccagca cctttata gaaccaggaa caatttctgttacttg	540
tcacctcatc atgaagattt agtagccatt ggctacaagg atggcatagt ggtgataatt	600
gacatcgta agaaaggaga agtattatcat aggcttcgag gccatgtga taaaaatccac	660
tccatagct ggtgtccct gcctggtaa gattgtttat ctataaacca agaggaaact	720
tcagaagaag ctgaaattac caacggaaat gctgttagcac aagctccagt aacaaaaggt	780
tgctacttag ccactggaag caaagatcaa accattcgaa tctggagctgttcttagagc	840
cgaggggtga tgatttgaa attgcctt ctgaagaa gaggagggg tatagaccca	900
actgttaaag agcgcctttg gttgacactc cattggccca gcaatcaacc aacacagctg	960
gtatctagct gtttggagg tgaactgttg caatggatc tcactcaatc ttggagacgg	1020
aaatacaccc ttttcagtgc ctcatcgaa gggcaaaatc attcaagaat tggatggat	1080
ttatgtcctt tacaaacaga ggtatgacaaa cagctattac tttctacatc aatggataga	1140
gatgtaaaat gttggacat agccacctt gagtgcagct ggacccttcc ttcccttgg	1200
gggttgcac acagcctggc tttctttctt gtggacatag gctcttggc catagggtt	1260
ggggatggca tgatccgtgt atggaataca ctctccataa agaacaacta tgatgtgaaa	1320
aattttggc aaggcgtgaa gtccaaaggtt acagcgctgt gctggccacc aaccaaggaa	1380
ggttgcttag ctttggAAC tgatgtggaa aaagtggat tggatgacac ctactccaa	1440
aaggctccac agatttctag cacatcat aagaagactg tataacttt agcctgggg	1500
ccaccagtagc cccccatgtc acttggagga gaaggagaca gaccccttcc tgcttatac	1560
agctgtggag gagaagggat tggatgttacag cataatccc ggaagcttag tggagaagcc	1620
tttgcacatca acaaactcat cagggacacc aattcaatca aatacaaatt gcctgtacac	1680
acagagataa gttggaaagc agatggcaaa atcatggctc ttggcaatga agatggatca	1740
atagaatataat ttcagattcc caacctgaaa ctgatctgtc ctatccaaca gcatcacaag	1800
cttgtgaata ccattagctg gcatcatgag catggcagcc agccagaatt gagctatctg	1860
atggcctctg gctccaaacaa tgcagtcatt tacgtgcaca acctgaagac tggatcatag	1920
agcagccctg agtctccagt gaccattaca gagccctacc ggaccctctc agggcatacg	1980
gccaagatta ccagtgtggc gtggagccca catcatgtg gaaggctggat tggatgttcc	2040
tatgtggta cagcccgagggt gtggatgtt ctccggaaag agccctgtg caatttccga	2100
ggacatcgag gtgcactgct ttgtgtggca tggatccctt tggatccaga ctgcacatctat	2160
tcagggcag atgactttt gttgcacaag tggctcaattt ccattgtcaaga tcattcccg	2220
cctcctcaag gcaaaaaaaatg tattgaattt gagaaaaaac ggctctctca acctaaggca	2280
aagccaaaaa aaaaaaaaaa a	2301

<210> SEQ ID NO 16
<211> LENGTH: 53001
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

tggagtgcag tggcgcaatc tctgtcaact gcaacttccg cctccagggt tcaagcgatt	60
ctccctgcctc agccctcccta gtatttggat tcttagggatt gttgcattttt actttttttt	120
tttttttggat atggagtcctc gctgtgtggc caggctagag tgcagtgccg tgatctccgc	180

-continued

tcacagcaac ttccgcctcc cgggttcaag cgattctct gcctcagcct cccgagcagc	240
tgggattaca ggccgcgtgcc accacacccg gcttatttttta ttattttatt ttatttttgt	300
tttttaatag agacgagggtt tcactatgtc gaccaggccg gtcttttaac tcctgaccc	360
gtgatccctcc cgccctcgccc tcccaaagtg ctgggattac aggctgtgagc caccgcaccc	420
ggcctcttgt gtatatcttt aaaacacccc cacaactago aaagtgcctt ggcacatagc	480
gctcaaaaaa cgttggacgg gatagtggtt gaacagctcc aaataataaa ctggtagcct	540
gggggggtgg ttccactagt ctaatccctc aattttgtc ctttctgtgg gaagttagaa	600
tgcttaaccc cggggctgtg ctcaggcagc acctgaccct agccagggtt gggggccgacc	660
tcctaccgcg ggcttaggtac tgagggccag tgccagcacgc gtggtccccgc cttcccgac	720
ccggcggtag cgggaacgcgca acgcgcgggtg ctggctgggc ctgcgcgc accgtacgcg	780
ctgcccggaga aggccggggct cggagttcac cccgcggccg tccctaccta aggctgtgagg	840
ctacagcggg tcggctgtgg cagttctct tgcactgcg ggctgttagt tatggggcag	900
gagcccgccgaa cgctgcccgc ctcccccaac tggtaactgcg cccgctgcag cgatgcgtg	960
ccggggggcc tctttggctt cgccgcgcgg acctccgtct tcctgtccg cgtggggcccg	1020
ggcgcaggcg agagtcagg gacaccccg tttcgaggtt actcaccacc cttggggcccg	1080
agacttactg cccttgcac gctccccagg ggcgcggagt ggacgactcc accccgtttt	1140
ctacagctag gggaaactgag gcccaggctg ggaggagagg cagcccacag tcactaagct	1200
gagttgccttc tggctctcta atgagctaca ccatgctgtg gcccgggggtt cccgcctct	1260
ggagcttcca cgtggggccg cttgtttact gaaaaggtag ccttgcatac tctcgccat	1320
ttatatggct cccctggcca gcctgggtcg cgccagcccc ccgggagcct tcctgggggtt	1380
gggggctaacc cacagctgca ggccttaagc aagatcctgc aacgtgtggc attccttact	1440
gtaagatgaa tgggttgaac cagatgtttt caggctccaa actaggctt gattgtgcct	1500
taggatatga catgccaggt gatttattct ggcacatct aaataagagt cactttcaca	1560
ttatattgagc tgcgtttccag tctgtgaact aagcagagca aggtatatac acattcattt	1620
cacagtttag aagctgaggc tcagagactt gttcgaagtc acgtggcaca gccaatatac	1680
gcacttggga attctgagtg taagtccgtc ggtgtttcag ttataccatg ggttaagtaa	1740
ctccaaagca tctgctcaact tgcataccaa caacagtatg attctggccag gAACCTTGGGA	1800
tagcacttcg attaaccttag cgtctgggtt tgcttaaagt cataggagag ttgggtggac	1860
acacccgaaag ggtctctggc ttcacatccc ctcataccccc tggtcagttac aacccctgtg	1920
ccaccagctc cgacgatggg actgtgaaaa tatgggatgt agagacaaaa acagttgtga	1980
cagaacatgc actccatcag gtaccatggc ttactggttt ctcaaaccgt ttttatctat	2040
ctgtgctgag ggttctctg ttgcagacta gttttgtctg ctcatactgtg caaaagtaact	2100
tgttaattgtt ttcattaattt agataagaaa ctatattgtt agatgtctca acttttttg	2160
aaaggagata tataacaacc agagggtggc aaactgtctt gtgcctgttt ttgcaaataag	2220
gttttattag aataacaacca cactaattca ttttaagtatt gtctatgact gctttcatgc	2280
tacaagagtt gagtagttgc aacaggcatg gtatggccca caaggctaa aacaattacc	2340
ctctgggttat tgatacaaat ggactccctga tataactgtt aaatgcgtga atgaaactca	2400
tttctaagct agatagttac ttgtatgtacc tgcctttga gagaacaaag gaaaagacct	2460

-continued

-continued

aacccaggag	gtagaggatg	tggtagccca	ggattgagcc	attgcacccc	agcctggca	4800
acaagagcga	aactctgtct	caaaaaaaca	aacaaacaaa	aattagccag	acttggtggc	4860
gcacacctgt	aagcccaagct	actcaggagg	gtgaggcagg	agaatcgctt	gaacctggc	4920
agtggagggt	gcagttagat	gagattgcac	cactgcactc	cagcctgagc	gacagagcaa	4980
gactctatct	caaaaaaaaaa	agtcaatgtat	agtgtatggat	catgaaatct	gtgtgcatt	5040
gggttaggggg	atgtatggaa	agacaggatgt	gggtgagtga	tagtggaaat	ggaaggggac	5100
tggatccggca	gtctcttcaa	gtgggagcag	tgttgttagta	gggttgatag	agaggatgaa	5160
cagaaagggtg	gtagggcagga	gtcaggggag	gatcttcaga	atagtattat	tcccaagaaag	5220
cttgcattcag	atttctaaat	agcttgcattc	gttggtgatt	aggttgcata	acttggcagt	5280
tttcaagtc	cgggtcttca	aagggtgaca	tactcttagt	tttcttttaa	aaaaaaaaaa	5340
taaataaaago	tgtgctggtg	ttcttccttg	togaatgctg	taatgtgtag	gaagtgtgaa	5400
taggtacagc	cactttgttat	aatgcagttt	tgtactttct	aataaaaatg	cataatatctt	5460
aacatcctgg	cagttccatt	actagtcattc	aaacctgaaa	ttgtcttaga	tgtgtacatg	5520
aacattaata	gcattttttt	gttgtaaaaa	agtggaaagcc	cttcaaaagg	aaaatgaata	5580
aactttgaaa	tattcacaca	gtgcgtact	aatacaatag	tgtaatgact	ggccaggaac	5640
tagagttacg	tgttatcaaca	tggatgatt	acaaacagaa	tgagtggaaa	aaacaagctg	5700
caggaaaata	gatgatagca	tttatgtgca	gttttaaat	atgcaaaatc	tatatcttat	5760
ttaggaatat	atacaaagaa	aggcttagaa	tgtatataaca	caattcacaa	atagagttt	5820
acctctgggt	agggaaagaa	aaggagaaga	gatctggcaa	ggagagaggt	ttgattgtaa	5880
tggatgtac	agaggacttc	agctctattt	gtaatttattt	ttctttaggca	gggttagtga	5940
ttactttttt	tatgtatctg	aagtcattca	ttttttaaaa	gctatttagaa	tttctcagtt	6000
tcttttgaat	tcataaaaatg	acagccttgg	aatatgcagg	tctagagtgt	agaattctgc	6060
aactttgtt	aagttcacag	tttaaaaagt	agtatcactt	ataaagaaag	agatttttt	6120
ccagtcact	aggacaaaat	tatctctagt	tagaagagtt	ggccgggtgt	ggtggctgat	6180
gcctataatc	ccatcacttt	aggaggccaa	cgcaggtaga	ttgcttgagc	ccaggagttt	6240
gagaccagcc	atgagcaaca	tggtaaaacc	tcatctctac	aaaaaaatac	aaaaattagc	6300
tgggcatttgc	atgtacctt	agtcccagct	actcagtccc	aggctgaggt	ggggaggattt	6360
cttgagcttg	ggaagtcaag	gctgcagtaa	gtggtgattt	tgccactgca	ctccagcttg	6420
ggcaacagag	aaggaaaaaa	gaagagttgc	tgcaccccttgc	caaaaaactat	gaaaattcccc	6480
ttagaacaaa	atcatggtcc	actgtgagtt	ttgttaccagg	caacatacat	agtattacct	6540
agtgcacaaga	gtttgtatcat	agagagaagg	gttttaacaa	aaccaggagg	cataaggtag	6600
gcactttaaa	aaaaggaaaa	agcaaaatata	ttttttgtcc	tcttcctcc	tccgccacc	6660
caaatgcacc	taactttaag	gaatgcgcac	atggtaactc	caagccaaa	tgtttactag	6720
agactctgtt	ctgtcttcat	tttttttagta	atatttctaa	ctttttttt	ttagctacaa	6780
ggatggcata	gtggtgataa	ttgacatcag	taagaaagga	gaagttattt	ataggcttcg	6840
aggccatgtat	gatgaaatcc	actccatgc	ctgggttccc	ctgcctggtg	aagattgttt	6900
atctataaac	caagaggaaa	cttcaggtag	agatggttta	agggaaagtt	aagtccactt	6960
gagacctgaa	gaacagaacg	ggtacaatta	tatcattttt	tatttattat	ttatTTTgg	7020

-continued

agacggagtt ttgctttgt tgcctaggct ggagcgtat ctcggctcac cgcaacctcc	7080
gcctccccggg ttcaagcgat tctctgcct cagcccccgg agtagccggg attacaggca	7140
tgcgccacca cgcccagcta attttgtatt ttttagtagag acaggttct ccatgttggg	7200
caggctggtc ttgaactccc gacctcaggt gatccacctg ctcagcctc ccaaataatgt	7260
gggattacag gcgtgagcca ctgcaccagg ccgaattata tcatttaat tatacctaaa	7320
acttcaaatt ttatagttca gacctatgaa agagatagct aagtttgaa aactcttgc	7380
aactaatttt ttatatttag tgctgttta atgtaaatta aaaacaaaat tgccacctat	7440
ctcatagaag aagctgaaat taccaacggg aatgctgtag cacaagctcc agtaacaaaa	7500
ggttgtact tagccactgg aagcaaagat caaaccattc gaatctggag ctgttctaga	7560
ggccgaggta agattgtatct ttctttgtg atgtaaccta tggatctgtg gtggaaatgg	7620
agggtttct gttcttatttgc ttctgagggt gtgtcatcta tttgagagca gttcttact	7680
ttttgtctta gaatttgc ttctcatttgc agcctggctt agactctcttca ttctctca	7740
atctggcattt agagattagt atttccatgtt cattccagga gaagacaagg atctcttgc	7800
ttatagaagg gtcagtgttt ggcatggaga gcagaatatt tgtaataaaa acaggaatata	7860
tagaacatgtatggcctaa gccaggagaa tggaaaatata cttaagatgtt agagctttt	7920
atgcacaaat gcagaataaaa ttacatacac ccagcataga attatgtgtaa aagctcatt	7980
ttatccaaat tataagagccc ctaatcatt tagcttccc aaatgtcttctt tgaaacagaa	8040
cttttatctt taagttaaa aattgagaga aactcttaggc ataatgaata ttatagttat	8100
atcatagaat ataaccttta tagtaaaaat cttgttttc tctttcttagc gggcttcttct	8160
tctttcttca ttttattttta tttttttgg cagttttta agctgtgggt gaaaatataaa	8220
catttgcattt ctttatcttca tttaagatgtt catttaagatgtt gatgtaaatgtt cactctaaag	8280
ttgtgcact gtcacagcca cccatctcca gaatttactt ctccatttcc ccctccccca	8340
ggccctggca accatcattc tgctttcagc tctatgattt tgactactct gagtatttcc	8400
ttttagtggaa gttatacata tgatatgtct ttttggattt ggttattttc acttagcata	8460
tatccccgag gttcattgtatgtt gttggatccg tatgtcagca tattttttttt ttctaaaggct	8520
gaataatattt ccattgtgtg tatgtccac attttacttta cccactcatc cacttggat	8580
aaataaaaattt tcgggtggc aaaagaaata gcaactaaat ataaaaactttt ctttttaattt	8640
ctcagcaagg caatgtactt ctatagaagg gtgcgcctt acagatggag caatggtag	8700
cgcacacatgg gacaacggag gggagggggtt cttatccctg acgcatgtgg ccctgtgc	8760
tgtgtcggttccctatcagc tagggatggc ccgcacagggc taaaacttattt ctgattcgct	8820
gatttaaaga gatgtccggg gtaagttttt tgatggaga aaatgggtt ggcaggaaaa	8880
atggttatgg cagagcagga aatcagaatg agtcagggtt gggcaggtaa tcggaaatgg	8940
tcaggatggc gcaaggtaatc gaaaaagggtt gtttttacga ggaagttaaat tttaaaaaca	9000
gaagccaaat aattgaacat actgacatata tgattttttt aagagaaattt tagaactcat	9060
atctcacaca ctgtatggaca tttgggttgc ttccatgttt tactattctt aataatatgc	9120
tatgagcatg gatgtactttt ctacttttattt tgaaaccatg atagttttat catatggcc	9180
caaatgcattt gaaagcaatgtt agcacaacac ttggaaatgtt atccaggctt catcgtgg	9240
aggtaactaa tagtataattt tggttggaaagaca gaactttttt aaggtttaca ggctacttct	9300

-continued

tggcatactg cagctaaaac tccaaagtggg aacataaggc tgaggatccc tccaggaggg	9360
taacctctag acttagaggt gtctggtaaa atggccttca attgtggttg tgcagcagaa	9420
tcagctggag agtctttgga aaaatgttagg ttcttgtaacc ccacctcaga tctactgagt	9480
ccgaatctct aggagttagg ccctggcgta tgtattttt aaagttccac ctgtggttcc	9540
gatgcacaat acagctaaa aaacgggtat tagaagcatg tcgggtggag gtactcccc	9600
cccacagcac gttcaactgcc aaattttctt ttgttggatt tcttgcgac tagaaatag	9660
aatcccaacc tctgttcttt tcactttgga gttatgtcac tgcaataactt ttgggtacac	9720
aactcagctg tgttactagc tgggttctca gttttacttg ggaactcatt ttcccagacg	9780
aaaaaaatact cttttcttt tgaggcagag tctctctctg tcgcccaggc tggagtgcag	9840
tggcacgate tcagctcaact gcaagctcca cctcctgggt tcatgccatt ctccgcctc	9900
agcctcccgaa gtagctggga ctacagggtc ctgccaccac gcccggctaa ttttttgta	9960
tttttagtag agacagggtt tcaccatgtt agccaggatg gtctcgatct cctgacctcg	10020
tgatcctccc gcctcgccct ctcaaagtgc tgggattaca ggcatgagcc accgcgccc	10080
gc当地aaaaaaa aaaaatactc ttaatacgtt gaggttgtca agatagcctg tcgaagcttg	10140
tttgacctaa atgttagctag actagtattt accagtattt atagtgatta aaattataac	10200
cataataatg gttaaaattt taaccattgg aaaaatgagat ctgaattcta agtagccaaa	10260
ctaacaagct ttacacgcgc agactgtgtt ttatgaacca ccgggtgactt catgcgttta	10320
gtttcaactgt cttagtgcct cactggcattt cttttaatc tgcagggggtt atgattttgt	10380
aattgcccctt tctgaagaga agaggagggg gtatagaccc aactgtttaaa gagcgcctt	10440
ggttgacact ccattggccc agcaatcaac caacacagct ggtatctagc tgttttgggt	10500
aagtcttttt tggtcatgtt ttctcagata tattttgttt ttcttattttg cctcaagtcc	10560
tccttaggatg gagaaagtaa tggcaaggc ttgttattatg atgggcatt tgaaatggaa	10620
aaattatgag actaatgcct gtgttatcta ctaacagago tgtaaaaaga tcacataatg	10680
atagtccggc agtaggaat atggactctg aagtcagaac taaaattttag aatcactttt	10740
tcacttactg ctttgcattt cttagcaaga cccttactt ttctgagctt cagtcacttc	10800
aagtgttagaa agggagatg gttataatat ttctctttt gttggatggc tatgcccatt	10860
cagtaaacaa agttcatgtt ctacactt ctgtggctg gagataaaatc tgttttaaagg	10920
gttagtccaaat atactcacat gttcaagaa gaacgaaatg atataataaa ctgtcttct	10980
gtctccctta gctacttggc tcccccttctt gtgattaaat tttttttttt ttttggaaaca	11040
gggtcttgcctt ctgtcacccca ggctggagtg cagtggtgc aacacagctc actgcagect	11100
caacccctcg ggctcaagca attctccac ctcagctcc caagtaactg ggaccataga	11160
tgtgcaccac catgcccac taattttttt aattgtttgtt agggacggtc tcactttgtt	11220
gcccaggctg gtcttgcgtt cggggcttca agcaatccctc ctgccttgc ctcctagaat	11280
gctgagatgtt cagatgtgaa ctactgcacc cagcctccc agagatattt tgcgttgcatt	11340
ttcagcatat gcaatttttc tctccttaaa cgacaacaaa tcatttgca gctatgagcc	11400
cagactctgtt ctcaacagtc actgttttc agatcggtt taaaagaact aatgcttgcatt	11460
ttttcccttc acagagggtga actgttgca tgggatctca ctcaatctt gggacggaaa	11520
tacaccctct tcagtccttc atcagaaggc caaaatcattt caagaattgt gtttaattt	11580

-continued

tgtccttac aaacagagga tgacaaacag ctattactt ctacatcaat ggatagagat 11640
gtaagaatgc ttatttcac tcagcattgt agagcagcag tttacaactt gggtggatg 11700
agagggcttt tcaaaggcac ctgtcaagtc gtaatactcc acccctgact ccaatttcag 11760
agttactgct acagatcagc actgaatata tcaatagctc acatgttaagg agaatgtgaa 11820
gaccaccaa aatagtttt tggtaaagca gacataataa agaaggtagg ttttgccag 11880
ggaaggatgt attaggtcaa gcttgtccaa cccacagctc aggtggttt taagttcatc 11940
agctgtgtt agtgttagt tttttttt ttctgagaca gagtcttgc ctgtctcca 12000
ggctggagtg cagtgggtg atcttggctc actgcaagct ccacccccc agtttacgc 12060
cattctcctg cctcagcctc tcgagtagct aggactacag gctgttatca cctacgccc 12120
gctaattttt tgggtgtt ttttagtagag atggagttt actgtgttgg ccaggatggc 12180
ctcgatctcc tgacacctgt atctgcctgc ctcagctcc caaagtgtctg ggattacagg 12240
cgtgagccac ggccctggc ctgtgttag tggactttt gtgtggccca agacaattct 12300
gcttcagtg tggccccaga aagccaaaag attggacacc cctgtgttag gtcctcatgc 12360
tatggtttat cctggttgt agtgtatgtt gcagaataga aatcttcag agagaattga 12420
ctttatgtt aagcctatta ccttactgtt ttgcagttt gctaggctt tttggtagac 12480
ttcattttct cccaaaggctg tctcttaaac aagtgtatgt taaaaattta ccactcctcc 12540
ttccctgggt atgataaggt gttttgcctt ttgagagago agttcttgc tttttccact 12600
gtgctgaggc catcttccttc ctttagagttt gccaaatgag ggggttacca gtgtataat 12660
aggacagaaa gaccaccgaa cttggagaca ggaggcgtgg gttctggttt attaattgtg 12720
taaccctgaa ttacacgtgac atctttggga ataaatatat tttaagatcc cttaagcaa 12780
cataatttat tactatttt ttttcttag cagtgcattt ttcatttcct gctggaaagac 12840
atgcatttac ctacccttgt cttagatgtt atcccatgtt acatatcagg tttttttcc 12900
tatttcctgt ttctttttta tggtttagcc cttaccgtt atcttgcag gtaaaatgtt 12960
gggacatagc caccttggag tgcagctgga cccttccttc ccttggggg tttgcataca 13020
gcctggctt ctcttcgtg gacataggct cttagatgtt aggtgttgg gatggcatga 13080
tccgtgtatg gaatacactc tccataaaga acaactatgt tggaaaaat ttttggcaag 13140
gcgtgaagtc caagggtaca gcggtaaagg ttctttttt gagttgtt tgaacttttt 13200
ttttccaaa taattctctt ttatgcctgt tcatttaat gctgtgtt gagaatcaaa 13260
agttttaaag tattttcaat gaagtttggaa actaggaaag cagaatgtt ctgtaaaccaa 13320
acccatttac ctccagagtt taaattttt aaggctctgt tcatctcagc atttttctt 13380
atagtaagaa gttgaaataa gcctgactgt atattcatag aaaatgcgtt aagtataag 13440
ataaccaaat gttgaaatgg catcaaaat tggaaaatgtt taatgtatgt tcccttc 13500
ttgatgttgg aaggtatata aatgatttt gaaaaatgtt aattataaaa catggaaagc 13560
aggttataaa acagtatgtt taattttttt gggttctctt aaaatgttac ctttttttt 13620
gctattgaat ctaaaggtaa taaattttt tggttaaaa agaaaatcaa acaacacaaa 13680
aatagagaaa ggaacacattt tttccctacc ctaccctcca ctccagtc ccaactgtat 13740
aatccagaga accactgtgg acagttttagt atctatcttt tcaaattttt taaacttattt 13800
aatattaataa gaaactgttatt ttctaaattt tccagaatc tcttattccg actcgacagt 13860

-continued

tataatgtca tatcattttac gtatggaaac tcattttgtt ttttcatttg tgtataagtt 13920
tattcacaaa aatatctgga aagagagata caacatctgc agtccgggtt ttgaatgaaa 13980
gattacagat gacatttgcact ttgtttttt tggtgtttt tttttttttt tttttttttt 14040
cagagtctca ctctgtcgcc caggctggag tgccgtggca caatctcgcc tcactgcaag 14100
ctccgectcc cgggttcacg cctttctcct gcctcagcct cccgagtagc tgggactaca 14160
ggcgccccgc accacgcctg gctaattttt ttttttttta gttagggcag gggttactg 14220
tgtagccag gatggtctcg atctctgtac ctctgtatcc gcctgcctt gcctcccaa 14280
gtgtctggat tacaggcgtg agccactgctg cccggccgac ttttttttttta atacccttt 14340
tctcccttaa ataatgaaga aatcagagca agacagttt ccctttggat gcttaaagg 14400
taatgttaagg attcccttaa ctatatgccc cacttcttat attctcactt ggaaactctt 14460
ttttttgttag ctgtgtggc acccaacc 14520
tggaaaagtggatggattgtatg acacacttac 14580
catttggcc cggggagccaa aaggggtggc caccctgtct 14640
ccttttcata acgttgcctt ttcaatttga agaccacaaa tcagttgtt ggttagactct 14700
tccacatttt ggacttgcata gttatctcct ttttttttttta ataccctttt 14760
cctatgtttc gtatgtactt gaagttatgtt cttagaactac 14820
ttaaccacag gtgattactg atcaatttgc 14880
aagtgtaaaa tacacaccag agttccgagt cttaatattt aaagaaaaatt aaaaatctca 14940
ataattattt ttttttgcattt acattttaaa taataacttcc 15000
atacattact aaaattttac ttttttctt ttttttttttta aaatatggct actagaaaaac 15060
tttaggttac atatacattt catctttgtt gtttacatgtt 15120
ctcttagggc ttgattagaa tccagacctg ttttttttttta tacaccgtt 15180
atttatactt aaagtaattha 15240
attttaaatg cacaagggc atccgtgact aatggctacc ttattgaaca acactgttct 15300
agaccaggcg ttggtaacc atggtccatg aattaagaat gtttttgctt ttaagtggc 15360
tggagaaaaaa tcaaaagaat gttttatgac atatgaagat taaaataaaat tcaagttca 15420
gtgtctgtttaa gtgaaattttt attgggacat gggtgcactc ctttttttac attctgtctg 15480
gtgtctttca tactaccaca gcagagtgga qtatgttgg cagggaccac atggctcaca 15540
aaggctgaaa tatttacaga aaaggttggc cagcctctgt ctttagatcat tcatttctga 15600
gtgaaaatca tttatgatac tgcagagctg ttttttttttta ttggagaca gagtttcgt 15660
cttcttgcctt aggctggagttt gcagttggat gatctcagttt caccacaaacc 15720
gggttcaaggc gattctctg cctcagcctc ctgtgttttttta gggattacag gcatgtggca 15780
ccacacctgg ctaattttttgc 15840
ggctggtctttaa cctcaggtga tccaccctca gcctcccaa gtgtctggat 15900
tacagatgtt agctaccgtg cccggccaga gctgtccctt gtatatgcag ttcttgaagt 15960
attcatgttag aacctacatg cagttgacta ttcttgcctt ttaactctca aaaaagaaca 16020
ctattttaag gcctggcactg gtgggtca 16080
qccggggggat gctqaaqgtca qgagattqag accatctgg ctaacacqgt qaaagcccg 16140

-continued

ctctactaaa aatacaaaaa attagctgga tgtggtagtg ggccgcgtta ttctcagcta 16200
ctcgggaggc tgaggttagga gaattgcctg aaccaggag gcccggatgg cggtgagccg 16260
agatcgtgcc actgtgctcc agcctggca acagagcaag actccatctc aaaaaaaaaa 16320
aaaaaaaaactg tttaaagat ttatcaaag tacactgtt ttaatcaaat aaaacttaaa 16380
tagttctata tcaccatgaa attgctaatt ctattaaattt attatatcct ggttattata 16440
agctgaatat tcagactaac agtacaaaag ccatgtaata gccagagagt ggtgggtatt 16500
gccctagagc tattgttagg catttgcca gaactgccta ttctattct tttagatata 16560
ggctaaagta ggccggggcac agtggctgcc agcactttgg gaggccgacg cgggcagatc 16620
acgaggtcag gagatcgaga ccattcctggc taacactgtg aaacccatc tctactaaaa 16680
gtacaaaaaa tttagccgggc ttgggtggcag gtgcctgttag tcccaagtc tccagaggct 16740
gaggcaggag aatggtgtga acccaggagg cgaggttgc agtgagcggg gattgcacca 16800
ctgcactcca gcctgggtga cagagcgaga ctccgtctct aaaacagaaa aaaagaaaaat 16860
aaataggcta aagtataaat tagcctgtt ataaaatata aatttctttt agaaattttg 16920
atttattctc tagattgtatc actataaattt tgcagataa atggaaatgtaa gtcagctgct 16980
aatttattcat aggctctggaa attctacaat catacaaaaga atgtatgata atttatggta 17040
aaagaataaa caatgctgcc tggtttttc tacaaggtaa agcattctt actgacacat 17100
cacatcat taccacaaca accttcaaaa atgccttttag gagtacgcct tctttaaaag 17160
acaatcacaa actgaaaatc tctctaccct gaaatcttgc ctcaatttttag gaaatgtgat 17220
gttaatggca cagagtaatg ctaaaatgac ttctcatctt ttacatgacc gtaaagtgaa 17280
tacatttggg tgggtgataat atatgttctg gctagatggg taagagtaac atttttggg 17340
gggtaaaata tggggggac ttaatcgaaa tggtagtaaa tgcattttt tgatatttaa 17400
atataattta aatgtaaata ttatatgata attaactgct ttacagtcaa ctattttggag 17460
caagatattt ttaattttttt tttctccat tatttagtagt tatgtttata atggggacct 17520
tttagaaaaa gatggctgtt tttcattttt gctttttttt ttaatctcc atttggcttc 17580
tctccctgct cttctaaagg cctccacaga tttctagcac atatcataag aagactgtat 17640
atacttttagc ctggggggca ccagtacccc ccatgtcact tggtaagtat ctgaacaatt 17700
ccataacaaa tatgagagta ttcttccttc agttaatcc taaaatatta aagatggaaa 17760
gagtcataaa tggcttagtg cactgactgc ttatgtggc tacttatgtc cccagggtt 17820
catgaagaca gtatggcag atgataaattc acatgtcctg ggagaaaccat tttaccata 17880
ataagcttcc ccaaactcac taaagcattt ttcttcattt tgatctgaaa ttttcattt 17940
tatgtatagt tatcatgctg ggtcctgata cccagtctaa tatttttcac taaaacttc 18000
tgtctttttt taattttatac agaatttagaa tgataactca gtatattaaat ggaataatata 18060
ctattttcac ccacaggaaa agcaaaactt aagtttctga aatgatctct tgcctttgt 18120
tcagcatttc gtcctttcc ctcttcctgc ccctcagcct tgcctttctt tttcttattc 18180
ctaaagtaat ggtcttttc tattagctt ttacataatgtt gtattcatca aaagtctctg 18240
ataaactttt cttaccatc tatgtgaaa catctgtaaa tttctatagg aattgcatta 18300
catagagagg ataagtagat ttatcagaac tcaagtagca ttggaaatttg tagttcattt 18360
atgcaacaaa tggttactgg gtatttgatt tgcgtatctac cagtggtaaa agtaaaaactt 18420

-continued

gctcttagaa	aacccacca	gaattactgt	ttgcttctta	aaaattaaca	agaagattgc	18480
tgtgatacta	aggaaatcac	tgcttgatg	acatctctt	gttataagac	atagaaaagt	18540
ctactgtgct	atgttatcc	caaagagtac	tcatttctgg	aagaaaaagc	aaattctca	18600
aagctttga	gaacatata	gtttgtttc	tgatcccagc	tttggacc	ctattattat	18660
gaataccaga	agactgttta	aagcaaatat	gttacatca	ataaattaac	ctagaattat	18720
agtagtatag	ttttttact	tctgctcca	acaactgtgt	tcaggtggaa	agaacagtga	18780
ttttattcca	atgttattaga	atgttcaaa	tatatagttc	ttttaaaaca	actatgttagt	18840
atggatgg	catactatag	caacaaatag	ttaagctgt	gaagtcacaa	actgataagt	18900
ttctttctt	atttcataca	ggaggagaag	gagacagacc	ttcccttgct	ttatacagct	18960
gtggaggaga	agggattgtc	ttacagcata	atcccctggaa	gcttagtggaa	gaagccttgc	19020
acatcaacaa	actcatcagg	gacaccaatt	caatcaaagt	gagttcttgt	ggtcctgaag	19080
tatTTCTT	ttacatcaca	gateccctcg	ttgttccat	cttgcaaat	aatgctgtt	19140
attggagatt	accatcatca	tactaagtca	gatttcttaa	atgttcttat	aggctgtgc	19200
atgaatttgt	gagttatata	tcttaggagt	ctttatccctc	gaataaaaaca	aagaggta	19260
tctcagacag	tgagtatgag	gcaaaaaat	aaaaaagcca	aaaagaact	actgaaaaaa	19320
aggctgtct	caattgcaac	aatgatTTT	tataaacttt	caggtgttat	gtataaagca	19380
tcctttcag	gccaaccact	ttcaccaag	tgtatgtgt	gtaaaaataa	caataatata	19440
gtatccaaat	gcaactgcat	ggtgtttac	tcaagacaaa	attgtcattt	tgtttttaat	19500
tttcttagaa	aatgattcta	gatttacacg	aagctacaaa	aataatacac	ataatttgct	19560
tatATCCTT	acccagattc	ccacatttaa	ttacatttg	gttctcatgc	tatcagtatg	19620
tgccagaact	gtcttttaa	agtcataacct	taaatgtga	gatttcctta	tttccttacc	19680
ctttttgtg	tgtgtgacag	agtctcactc	tgtcactcg	gctggagtgc	agtggcgtga	19740
tcttggctta	ctgcaacactc	cggeectctta	ggttcatgag	atttcctgc	ctcagccctcc	19800
caagtatctg	ggactgcagg	catgggccac	catgcccagg	taattttgt	atTTTTAAG	19860
tagagatgg	gttccacca	gttggccagg	ctgggttga	acttctgagc	tcaagtgtac	19920
cacctgctt	ggcctcctta	cccttcaaa	tgagtatTTT	tatTTTTTA	cttattttt	19980
ttttgagaca	gagcctgtt	ctgtcgccca	ggctggagt	cggtggcgc	atctcagctc	20040
actgcagcct	ccacccctcg	gaatcaagt	attctcatgt	ctcagccacc	tgagtagctg	20100
ggattacagg	cacgtccaa	gactggctaa	tttttgc	ttagtagag	acagggtttc	20160
accatgttg	ccaggctgt	atctcgact	cctggcctca	agtgtatccac	cccacttgc	20220
ctccccaa	actgattata	ggcatgagcc	accatgccc	gccccaaatga	gcattttat	20280
attattgctc	attactttta	tggcttagt	aaaagtaaca	ttagttata	aattgggtta	20340
tattgttgc	tatTTCCCT	cattgtctt	aattttatct	aaacattaac	attcagcaat	20400
gaataagaga	caaattcgt	gttccta	cttttcaat	ttattggcac	ttgaatgtgt	20460
ggatcagagg	ttcatgt	gagtctgagc	tggatata	aatttgaat	cccttcacaa	20520
taaagatagt	tgaagaagct	gtggacatgt	atgaggtgg	ttaaagagac	aattaacaag	20580
agaagagggc	ccaggcagcc	ttggggata	ccagcatata	gatatggag	gaaatgatt	20640
cagggaaaga	agctttaag	ggtatgaaaa	caaggagat	gtatata	ttcttaagg	20700

-continued

cctcatggtc cccacattgt ccaagctgat gggcacagat cagtttaatt aagtatata 20760
ttcacaaggtaaagcactgt aaacattttag tacttattgg ccttgggggt tttttgttt 20820
tgtttttttg gcccagtagt gaaatgagaa tttagaatgc tgttcttagt aatccttta 20880
ctaattatgt agattattta caagaatagc tggtgtataa taaaacgtt tttaaactct 20940
agggattttt ttttctatcg ctgtcattgc tgatttgtga gatatgtata tagtcaagat 21000
tggttgttt tgctttctag tacaattgc ctgtacacac agagataagt tggaaagcag 21060
atggcaaaat catggctt ggcaatgaag atgggtatgt atttgcctt ttaagataaa 21120
aaatttgcaa tcgcacatat atttgatcac aagctgacta atgcacatctg taatgttagc 21180
tggggggcc cagttgtatt tggtatttt atttattctt gatatcctc gctgatccag 21240
tagtgccttg tgtcttttag aactacagaa ttattnatgat atttgcggcc cattgagagt 21300
atttggctac actgtatccc ggctgtcttg tccctcacaa aatggtcacc tcctatgtt 21360
aactgcataa atctccatatt ttttaagta agcctagtc gaaatgtttt ttaggtctgt 21420
atcctgacca gtgttaatca tagtaacaca gtcataattc agccattgtatgtt 21480
tttagcttc tccctatcat catttgcata taatgcctga tgaacacaat tttatcaagc 21540
attgttagaa tgcttaggaga ttgttacact gaggtgtgtt gggaaagttt aatttctaaa 21600
aattaatttt tttaagaaaa gaattgttag gatattgcta gaatttttaa aagctaaata 21660
tacttttgg agaataactt tttatacttg attttttatg agagaatgac ctggcagtg 21720
atagaaagggtt atatcctttt ccacccatc tttccttgac tgacggatg agggagctac 21780
tatttgcatt gtaacttgta atttgcatac ccattttctt tggtttgtatg tggttcttat 21840
tccagatcaa tagaaatatt tcagattccc aacctgaaac tgatctgtac tatccaacag 21900
catcacaagc ttgtgaatac cattagctgg catcatgagc atggcagccca gccagaattt 21960
agctatctga tggcctctgg ctccaacaat gcagtcattt acgtgcacaa cctgaagact 22020
gtcataggta actttgggtt ctccataact ggggatgata tgcgttgc agctactttc 22080
cattctatac ttgttactt ttactttat ttgttgcatt ataataaaat aagtattttt 22140
cttactactt ttctgttcc aaaagtgata gattcatttt attttaaaat tcttcaaac 22200
atgacaaaaaa tggtaacaga aatgaagtt ggccaggcac agttgctcac acctgtatc 22260
ctggcactttt aggaggccac aacgagaaga ttattttgtgg ccaggatttt gagaccagcc 22320
tgtaaatag tgaggctccg tctctacaaa aaattgaaaaa taaaaacaaat ttttgcggg 22380
ttagagggtgc atgccttttag tccctgatc ttggggaggct gagctgagag gatcatctg 22440
ttcttaggatg ttgaggctgc agtgcatac atttgcacca ctgcacccca gcctgggtt 22500
cagagcacac cctatctcaa aaaagaaaga aaaaaaaaaatg aagttttccc ctaaaatttc 22560
atcattcaat aaccaggatgtt attggcttgc tatataatttt ctctagattt tataaaatgtca 22620
tagcctacat atgtatacat gttatgtat attaataatgtt ttgcacttct gtgtacttgt 22680
gtgaaagaat aatcttctgt tccctgatc aaataaaatg ctatataaaat tataatgtgc 22740
ttgcagtttt ttctctaaa ttacaatattt ttagatggc catcttttgc tgcgttgc 22800
caaggatctatc tcttgcgtt attaacaat atctgtcagc caggcgcagt ggctcatacc 22860
tgtaatccatc gcactttggg aggccatagt ggaaggatag ctggagacca ggagtttggaa 22920
accaggctgg gcaatgttagg gagacccccac ctatacaaaaa aataaaaattt aaaaaaaaaaa 22980

-continued

cagttacctg ttcattccat tatatggct taccataatg tatccattcc acaattaat 23040
gacattcaaa ttatttatcc tttttacaa ttttaagttagt attacaataa actgcctt 23100
acatagatct tcgtgaacat gaatgaataa tttttgtata gaaaattcta gaagtggaa 23160
tgcttagttaa aaagatgttag tttttatac ttactgctaa gcggctctcc aaaaacatta 23220
tgccatTTaa tacttccgcc agcagtttt gagtgttaca cacaacaga ggacacatac 23280
ctcattcccc tgTTTgattt catctgattc tcacaatctt gtgagggtga taggtaacgt 23340
tatcctcatt ttccaaatga ttacactgag gcccagaaag gttagctaa ttattcaagc 23400
aagtagcatc gctaatacat gataggcct agattcaacc tttagtgctc taattgcagt 23460
gtctgtatgt gttctagcaa gtactattcc atgcttaatg agttaacttt catatggta 23520
taatTTTtac cataagaat cttaaatttc actgaggccc ctTCGGCacc tggaaaacca 23580
tagtaggtgg tcagaagagc cagTTTaaa tatgagtgaa gtgggattac ttttttcc 23640
aatatgaaga aattataatc tgacactaaa ttgtttcag agtgcataa aacatgtgc 23700
ctcagccata gtggaaatag ttacatTTTt catttctcta gaatttactt cagtagttt 23760
ctaagaatcc tatgtgtAAC aagaaaaat atTTTgggtt cttagtgaa ctccctgagg 23820
aaaaggcaata tggaaaaagt attaaaatgt agatgtgtt tccttagtaat aaatagtaga 23880
cagtgtataa ctaatgaaca taagttagaa agctgattct ggtcctttagt attattattg 23940
ggattctaaa ttaatcatcc actttatATC atatctacta aataatagag aaaggaagaa 24000
aactgccaga atccattttt atTTTtaccc tcttattttt aaatatttga gacacagagg 24060
aaagttataa gaattgtaca aagaaatcgc atatacttt tccttataat agattcaaca 24120
atTTTtaatg tggcgttata ttggcTTTt tctgtgtgcg tggatgtatg tagTTTtcc 24180
taccaattat cagTTTgtta gtttaactta atatataata gtttaatctt tcccttaaaa 24240
tatacacaaac tattattgtt caatTTaaac aaatgttta ggctacgtgt ggtggctcat 24300
gcctataatc ccaacacttg aggagaccat ggcaggaaga tcacttgatt agctggacat 24360
gatgggttacc tatggccca gttactcaca ggctgagggt ggaggatccc ttgagccca 24420
gagttggagg ctacagtttag ctatATGact gtcactgtac tccaccctt gccacagggt 24480
aagacctagt ctctttaaaa aaaaaaaaaa aaaaagtaaa atagtgtaat cagccaccca 24540
tattctagtt gtgtcaggat atccaatgtat gttcttaata gtgtttttt ttttctccag 24600
tgcagattcc aatgcaggat cacctatttgc cattttgttgc tcatgtctct ttagtctct 24660
ttcatctata ataatttctc agtctttaa aaattattta tttagggccgg gcggtggcgg 24720
tcacgctat aatccccggca ctttgggagg ccaaggtggg cggatcgctc gaggtccgg 24780
gttcgaaacc agcctggcca acatggtgaa accctgtctc tactaaaaat acaaaaatta 24840
gctgggcttggcgtat cctataatcc cagctactca ggaggctgag gcaggagaat 24900
ggTTTgaaacc tgggaggcag aggttgcatt gagccgagat cgtgccattt cactccagcc 24960
tgggagatga tgaaactcc atctcaaaaa aaaaaaaaaattt atgtgtgtat ttattttttt 25020
tttagaaact ggggtctact gtattgttca ggggtggagtg tagtggtgca gttatagtc 25080
atgacagtct ccaatttctg gactcaagcc gtcctccac ctcagttcc ttagttagtt 25140
ggactacagg cacataaccac catgcccagc taggtgggtt ttgtttttt gtgttttcc 25200
tttttttga gacagggtct cactctgtca cccaggctgt agtacagtgg cacgatctca 25260

-continued

gctcaactaca acctctgcct cccaggctca agcagtcac ccatactcagc ctccatgt 25320
gctggacta taggttgca ccaacacacc cggttaattt ttgtatTTT ttttagagt 25380
cagggtttcc acaggccggt cttgaactcc tgaactcaag caatttgcac accttggct 25440
cccaaagtgc tgggattata ggcgtgagcc gacacgcctg gccaagccag actttttaa 25500
atcttatgtg acactttga ggaagatagg gcactcgTT tgtagatgt ttctcatTTT 25560
gcatttgtct ggtatTTCT catgactata ttcaaaattt acatTTAGC tagaatatCC 25620
tataagttat aatgagacct aacacttctt gtggtaatct atatgctaag cactgtggat 25680
gtgtccacac tcTTaataac taacaatgtt gcctgctaaa aatcacctag acttgggagg 25740
ctgaggcagg agaatcgctt gaaccaggaa ggcggaggTT gcagtggc gagattgcgc 25800
cattgcatttgc cGCCATTGCA ctccagcctg agcaacaaga gCGAAACTCC atctcaaaaa 25860
aaaaataacc tagaaagtgt atggcaaaat cttgattctt gtcATGTGAA tgcCTTCCTG 25920
gatgtactttt gttttttttt ttgttattag tagtagcago agtgtatgtct ttccTTTGC 25980
tttttagagag cagccctgag tctccagtga ccattacaga gcccTACCGG accCTCTAG 26040
ggcatacggc caagattacc agtgtggcgt ggagcccaca tcatgtggaa aggctggat 26100
ctgCTTCCTA tgatggtaac gcccaggta tattgtgtcc ttgtccCTGT gggTCCTCA 26160
ctgtgtactc taacaaattt tttttttttt tccccagtt gtgaacaggt tccccCTCCC 26220
ccattatcat catctactga aggagatTT ctggggotcta ggaggcatt tagttcatt 26280
ccacataggg cctaggctaa gactgggTTT ttttttttGT tacttagatg aaggggaaAG 26340
tattgtatTTT agtagactaa ctctaaccatt ttacagatt tcattctgac tcactatcaG 26400
tatggTggac taatatgata tgcaaagtac tctttCTGT tcagacactg aaatgtggc 26460
taaaaatcac aaaacaattt ttaataata aattggtaag tcagaaatct ccaagttcta 26520
aataaaataaa gatgaaatgc caagccagat ctatgaggGA ggacttggG atatcagaac 26580
tagagctggg gacttaacat ctgtgtatgt tctcgTTT tagttgagtt taattgagat 26640
gtctgcacaa agctggggc cggcaaggc tgcCTCTGT gaaactgagt tcagaataat 26700
tcaagaaata gaaaggaaat tggccaatta ctcaaggagt tggagacaaa agattcacct 26760
atgagaaatt agaagtctaa ttctgtgt agatgtggc tatttttttC gtgataccag 26820
aatctcaagc cccaaagtta acatacagta ttggTTcag acagtggaaat ccatgggaca 26880
ccagtagaaag ctcattcaaa atcatccccG tagaaatgtc tatgcatctc caagcacaga 26940
agtctctcac agggaaatAGC actttCTGT aattgaactt ctaagagaaa actctaaatC 27000
acctgaggaa ataagaggcc gcagattgtt ttgtttttt gtttttGTT tttaatttaga 27060
aaacatactg cccaaacaat agaataacca gaaaatgtct ttccggccat gtgttttgg 27120
gttttaggtgt gggatgctct cggggaaagag cccCTGTGCA atttccggagg acatcgagg 27180
cgactgcttt gtgtggcatg gtctccTTG gatccagact gcatctattc aggggcagat 27240
gactttgtgt tgcaacaagtg gtcacttcc atgcaagatc attccggcc tcctcaagg 27300
cagtcagaac ctagagctta tctaattttt ttctccCTT tcttaataat tgagttgatc 27360
aggattgagc aaggaagaca ttctgtgtt gcatTTGT CAGTAGGGCA ggggtctgag 27420
cctaagcaag aaagcagCCA caagggcttG agaacaacac cacccacaat aggaagagc 27480
ataccttagca ctcagatctt ggtttttttt ttgagacaga gtcctcgctc gttgcccaga 27540

-continued

ctggaatgtatgtggcgtgat cttggctgc tgcagccccc acctcctggg tttaaggcaat 27600
tctcgacacct tgacccctt agtagctggg actacagggtg cgcaactacca tgctggctaa 27660
ttttttgtt ttttttagtag agacgggatc tagccatgtt ggccaggctg gtctcaaact 27720
cctggcctca agtgatctgc ctatcaacct cccaaagtgc taggattaca ggcattgagcc 27780
accgtgcccc gccccagatct tggtttctaa atgacattct ccactaaaaa tgtccatggc 27840
ttcttggaga aatggctgg tccagtctgg gacaggtaga gaacaaactg aacctggAAC 27900
attcttatgc cagaaaggaa ggcagttactc aaagaattca ggagacatgt caaaaggaca 27960
aaagaaacag cttgaagagg ttcccactga ccaaactctgg gacaactgtt aaacataagt 28020
aagaggaggg caggtgcgtat ggctcacacc tctaattccca gcactttggg aggccgagat 28080
gggcggatca caaggctggg agatccgaga ccatcctgac taacagggtg aaccctgtct 28140
ctactaaaaa tacaaaaaat tacccggcg tggttggcg tgcctgttagt cccagctact 28200
cgggaggctg aggcaggaga atggcgtgaa gccaggaggc ggagcttgca gtgagccgag 28260
attgcgccac tggactccag cctgggtgac acagcgagac tccgtctcaa aacaaaaaaa 28320
agagaaagta agaggaaaaat tccattctgt gctaagaaag attaatttgtt atcagacttg 28380
ccataagcaa ctgaaagct agacaaaata tattaagcaa ctgctggca cagtggctca 28440
tgtctgtatt cccagactt tgggaagcca aggcttaggg atcacttgag gccaggagtt 28500
tgagaccago ctggcaacag agcgagatcc catttcctaco aagaactgca aaataaaaagc 28560
aaataggaaa aattggccaa gcatgctggc tcactcttat aatcccaaca ctttggatg 28620
ccgaggcagg agatggcatt gagcccgaga gttcaggact aacctggaca acataggggg 28680
acactgtctc tggaaataa gttttttttt tattttaaat gaaagaatat attaaacaac 28740
tagaaattta cacccaaaga aatgaaatga tgggtccaca taaagacttg taaaagaatg 28800
ctcatatgtat ctttatctgt gatcacccaa aactggtaac aatccaaatg tccatcatca 28860
gataaaatgaa ttaattgtgg tatatcctta cagtaggtttt ctattccaca ataaaaagaa 28920
ggtaacaact gataaagaac aaaatggatg aatcttagaa aacattatgc caagcagaag 28980
cagccaggca caaaagacta catactgtct aattctgttt atgtgaaattt cttttttttt 29040
tttcttggaaa cggagtctta ctctgtcacc caggccagag tgcagtggcgtt cactctggc 29100
tcactacaac ctctggccca caggttccaa caattctccct gcctcagccct tttgagtagc 29160
tgtgactata ggtgcgtgcc tcacacccag ctaattgtttt gtgttttag tagagacagg 29220
gattcaccat gttggctagg ctggatttga actcttgacc tcagatgtc tgcccgccctc 29280
agcctccaa agtgctgggat ttataggcat gagccactgc gcccgggtt tggaaattc 29340
ttcaacaggc aaaactaaac cacagtgaga gcaaaatgtt gattgcctag ggctcaagca 29400
gggggtatata tttactacaa agaggctgg tggaaatattt agattgttac aaaagtaatt 29460
gtgggtgggg taggtactttt gtacccaaatg attttttttt tgggttattt tattatatta 29520
ccccctcagta aagatgattt taaagtaacg aaaggataaa aacctaaaaa tgtaatata 29580
gaaaccttaa aatgttaat gtaacagtaa tggaaatattt catgagtccaa gaccgatata 29640
ataaataat ggggagaagc acaagctttt ctttgcgtt ggtgcacccaa tagatgca 29700
gctcttcctt tgggttagat gtagagtttca atcctggat tagaagttca ctttggggc 29760
caggcacagt agtcacgccc tggatccca gtactttggg aggccagctg atcacttgag 29820

-continued

cccgagggtgtt tgataccaggc ctggccaaca tgacaaaacc ccatctctac aaaaaaaaaaa 29880
aaaaaaaaaaa atacaaaaat tacccaggca tggtgtcgca cacctgtagt cccagctatt 29940
caagaggctg aggcaaggagg attgcttgag cctggaaaggta caagtaaggc tgccgtgaac 30000
ggagattctg ccacccgact ccagccaga caacagagca agaacctgtc tcaaaaaaaga 30060
gaaaaaaaaaga aaaaacaaac tcaccatgg gcagtcata tagtaacaat ttttaatcaa 30120
gaaacatcg tgaatacAAA aacttagtaga tgcaaataact tagtagttaa acaggggaaa 30180
taccctttta gggagtaact tgcaagacac acccctaatac aggtgatcaa agtaaacca 30240
atgggacgaa taaaattag ctgctaccc atagattgcc ctgcataaac acagcagcac 30300
taatgtgcataccatgctaa gatgcataacc ctaaatctag tcatgaaaaa catctggcag 30360
acctaaattg agggaaattg gacaaaataa ctgtcttgta atcttcagaa gtttcagatt 30420
atgaaaagtca aaggaaaacc atgcaactaa ctgttccagg ctgaaggaa ccagaaaaggc 30480
atggcaacca aatgttaccat gtgatcctgg attgattcct tttgctataa aagacatctg 30540
ggtaggccgg gcgtgggtggc tcatgcctgt aatcccagca ctttgggagg ccgaggcagg 30600
cagatcacct gaggtcaggaa gttttagacc accctgcacca acatggtaa accccgtctc 30660
tactgaaaat acaaaaatta gctggcggtg gttgtcggtg cctgtatcc cagctactca 30720
ggaggcgtgaa gcaggagaat cgcttgaacc tggggaggcag aagttgcgtt gagctgagat 30780
ctcgccatttgcactcccgcc gggcaagaa gagcgaacc accctccaaa aaaaaaaaaaa 30840
aaaaaaaaaaa aaggacatct gggtaaaattt ggcagaactt aaatagagag tatggagtag 30900
gtggcgttag tgaatcgtag taatttcctg attccatgg ttgtactatg gtgacgtcg 30960
agcatgtcctt gttcataaga cacacactaa aatatttggg ttttatttggg catcatgttt 31020
atgatttaat gaaatttcaa aagggtttgg ttaatattgt gataatataa ttctaaaagt 31080
tcattgagaa gaaagggaaat gggtaaaat gctattaaag aggaatgaga tattggagtt 31140
taccacccatgtgctttt accaagaatg tatacttttgc tcaatgcctt attgtgattc 31200
ttgtaggcaaa aaaaagtattt gaattggaga aaaaacggct ctctcaacct aaggcaaaaggc 31260
ccaaaaagaa gaaaagcccc accttgagaa ctccctgtaaa gctggaaatcg attgtatggaa 31320
atgaagaaga aagcatgaag gagaactcgac gacctgttga gaatgggttg tcaagaccaag 31380
aagggggagga gcaagcacgg gagccggaaat taccctgtgg ctttgcctca ggggttatgt 31440
ggcagaatcc tgggtatcac taggatttca tgggtcggtc tggggaaacta agcttaggtcc 31500
ttactcagtt tgaaacttcg ctgttcccat ttttccaaact cttggaaaca gcatttagttt 31560
tttttggtaa gctttattca agtctctaaa ataaacatct ttgaagttt aaaggggttc 31620
tagtggatgt ttgtgggtggaa atagtaaaat ttctacagag aaaacttctt attcaacttg 31680
ggcaaggtaa aaccgtggga cgaagcgaag ctgggtcagt tgggtacata ggaacttaca 31740
tggggaaaagt tttAACAGTA tgacatcgat agccacatTTT ggtggaaacta actactgtcc 31800
cttacaaatgt tctgacccatg aagctaccac cactgtggga acttgcaagc tctcaccccc 31860
ttacgtggag tttgtacgac gctttctgtc ttctcacaga aaaaaaaaaatgt gtgaatggtt 31920
attaggtttt tcttagtggatgtaa atagctgttagt tgatggctct cagatgtctc aaaaaacagt 31980
gttctatcac taacaaaaaa actgttaggt aaaaattttca gcaactttt tattttgtac 32040
atattactcgq qaccctgtqa qaatqqtttca gcaacttttca gcaacttttca gcaacttttca 32100

-continued

gtaaaataaa cgattaaata gcaaacagtg taagtagaaag cagtaactca tacttaattc 32160
taaaacagaa tccattgtat tgacagtatt gaaatggcta gaatatagga tacaaggcat 32220
tcctgatgct ctccatccca agggatagct gtttagacaca tagttgggt aaataaagag 32280
caaaaagcct aatggatttta ttatTTggc tcatcagaat gctttctag tcgggtacag 32340
agacacatac ctctagcccc agatcctcag gaggctgagg caggagaacc gcttgaggcc 32400
agcctggca acacagcaag acccccattc tctttatTTt tctttttttt aaaaagtctt 32460
tctttcacaa aatggctata caaaacatgg atcaacaagt tgtttttaaa aagttcctgt 32520
gctcaggatt gtgacaccat attgcataca cctagttttc tctattatttta aagttactcc 32580
tgtagtgta attaaatatg caattagttac ttatgacct agaaatgtaa aaagtgcctt 32640
gtcacctgag caaagtatag gaactccttg gctttagttaaa taaagttgtg gaggcgttgg 32700
agcttttcc ttagtcaaag ttcaaagtaa ggccggcatg gtgggtcatg cctgtaatcc 32760
cagcactatg ggaggccaag gaaagagact tgcttcaacc caggagttt agactagcc 32820
aagcaacata gggaaaccccc atctttgcaa aaaatataaa aattaccaag ataatggctt 32880
gtgcctatag tcctagccac tctgggaggc tgaggagggg aggatcacct gagcccagg 32940
ggtaaggcc tcagtactg tgattgcacc cactgcactc cagcctggc aacagttata 33000
tcttatctt aacccaaaga aaaaaaaaaa agtaagccag gagcgggtggc tcacgcctgt 33060
aatcccagca gtttggagg ctgaggcagg tggatcacct gaggtcaggaa gtttggatc 33120
accctggcca acatggcgaa accctgttc tactaaaaat acaaaaatttta gccaggcatg 33180
gtggcttgtg ccagctactg gcgaggctca ggcaggaaat ttgcttggac ctagggggca 33240
gagggttgcag taagccaaga ttgcgccact gaatttccag cctgggcac agagtggac 33300
ttcgctctaa aaaaaaaaaa aaaaccaaag taatagactt acagattctt gaaaacagct 33360
agtttggag gtggggaaagg gggaaactact cctacttctt ttccagtgc ttttatctca 33420
aaagttttgg taatagatga attgattata ttgcttaagct tggaaatggct cttaattttt 33480
acaaagaact gaaattctgt attattgttta tccttaactt tttttttctt ttttccccca 33540
tgatgttagtt tctagagaac cagttatctg cactccaggc ttctcaggct ttgaaaagtc 33600
aaaagtccacc attaataaca aagtcatTTTt actgaaaaag gagccaccaa aagagaagcc 33660
agggttgtat ctgtatatta aaatacagta ttttgttaaa gcaaggctaa atattacata 33720
tattacacgc aactgtcaaa aaacagtgtg gtttcttgc tttttttata ggttcaaaat 33780
atttgttaggt ttctgtatgg tgggtttttt gtttgggtt tttttttttt gagacagatt 33840
ttcactccag tcacccaggc tggagtgcag tggcacactc ttggctact acaaactcca 33900
cttccgggc tcaagcgatc ctccctgcctc agcccccga gtagctgggat cacatgttg 33960
ccggccaccat gcccagctaa ctttgttat ttttagttaga gacggggatt caccatgttg 34020
gccaggctgg tctcgactg ctggcttcca gtgatccgc cgcctcagcc tcccaaagtg 34080
ctgggattac aggccgtgagc cattgtgccc agacttccac ttccatTTt ggtcatgttt 34140
ttgaattttt tttagcactt gatgaaatgt tttgcagttg ttgacactac atcataaaatg 34200
tttagcaagag cgttttgtg tttttttttt tttttttttt tttttttttt ggttcaaaat 34260
cctctttattt aggaggagga gctttctctg cctgtgggtgt cgtcctgcca gtaggttaca 34320
ttcacacaat aggcatccg ttttatgttt ctgatcaggat ctccttcaga tagtatgtac 34380

-continued

tttattaaat ttcagaaaacc ttaatcaaga agagaaaago tcgttccttg cttcccctga 34440
gtacaaggcct ggaccacaga tccaaagagg agcttcatacg ggactgtttg gtactagcaa 34500
ctgcaaagca ctccagaggt acaaaaatgt acttccttgg cccatccata gtctccggg 34560
actggtatat aagggtatgt tacttattta ttaaatgaat gcccaaagaa atgtctaat 34620
tggtttctgt attttatgt tctccagetc tccctccct ccacatccct ataccctac 34680
accttgctgc caaactcccc attgtgaccc accgtcagca ctgccatggc tttgaaatgt 34740
agcgctctgc ttatttcta aatctaattc ctcccaagcca tctgtgtgcc agaattggta 34800
tggtggccta agtatctcag catgaataaa ctccctcaac tcttttcccc attgaacagt 34860
atcctatgga gaaaaaaaaatc ttttttctt attggaaata tgctcataat atggcatttt 34920
tttagaaaaa aatttcatgg aagctttgc tttgtaaatgg ttgtttgaa gggttgtttt 34980
attttgcattt ttcaaaagtct tcatttaatgc tccactatatt tgatattttt ataactttat 35040
tttttaaatt tgaagtttac atggaaaaa gggatgcaca taataaataa aattgatgct 35100
taaggggctg aagcagaagg atcactttag ctcactttaa ggccagctg ggcaacatacg 35160
tgagaccctc tctctatata aaaaaaaaaa ttttttttta atttttttt caaagtaaat 35220
cttcctccca gtcctctgtt tctccctcccc aggaatggag gaccatcctc cctcccggtt 35280
actgtctccc actaccctaa caagggttagt cactatcctg ggccatccatt tgtttcttc 35340
tttgcatttt ttgtactgtt ttgtctgtat tgctcataatca aactattatc agtttctgt 35400
gtcttgcattgg agatgtttta tgcttttatt atatacatag ctttttggaa gctttgtat 35460
gacttcctat aacttacata gttaaccttag tttcacatta ttttccttac tggaaaattta 35520
ctcagttgac ttttttttg aagcaaagga tgaatattga atcccttgc ggttaagtccc 35580
agtgaatatt aaggactttc ttttgcttat taatattgtt ttgtttgtt tttactgcac 35640
ttaaatatgt tctgatttgg gggttcaacttta taacatttta agtgttttg tgtttgcct 35700
cctttgtaac tgcaggagtc tctgttagag ctctgatttc ctcaatgtct gaagtgggtg 35760
ttccaaacat atattcgaa gttattggag agaaaactgt aatcaatgtat atgacttcat 35820
ctgattttt tgcctttta aattaacaga gctgaatgaa gatgtgtctg ctgatgtga 35880
ggaaagattt catctggggc ttttcacaga cagggctacc ctgtatagaa tgattgatatt 35940
tgaagggttag acaaattccag tcaacataat ctcatccatc tttatacttt cccaaacattt 36000
tgtgtgcacc tctttgtgg ctgtcatctt gtgatattat aatggtttagt tttacgtgtc 36060
agctaacttag gttttgagct ccctgtatata catattgata caacccttgc atcatcatag 36120
gatcctaaac atacagcatt cactctgagt acatgtgaag gtgtggaggt gtacagtgc 36180
caagtggct tcagatctta ctgtaatcac tctggtaggt gacacccatc agagaatgac 36240
tgcataatattt aggagctcac tttctcttctt atcttcgttgc tcttttccata caagtcagta 36300
acagatgtttt ctgaaacacc ttccaaacat tatctctctt tcaaacagga aaaggtcact 36360
tagaaaatgg ccaccctgag ttatttcacc agctttagtgc ttggaaagga gatctcaaag 36420
gtgttctcca gactgcagca gaaagagggg agctgacaga caacccgttg gctatggcac 36480
cagcaggtat gggtttgtt tggtttgtct tttcaacaaa agtctatca tctctaggat 36540
acgtccacta aagatggctc ttagcacaatgt cttaagcttg aaatcactta caaatagata 36600
caaagcaata gacagcaata gacaaactaa taaatccaaac ccaaccctt tgaaaaaaag 36660

-continued

caggtcactg acacttaat tggcaaaggc ataattggtg agaacttctt gaaggacaat 36720
ttggccatgt ctagtaaatt taaaagata taatggcaca agtctgttgt ccccagctgc 36780
tcaggaggct gaggcaggag gattgcttaa ggcttaggcgt tcagacat tgcgtctgt 36840
taattgtgcc tgtgaatagc cagtgtattc tagtctggg aacatcatga gacttgtct 36900
ctttaaaaaa aaaaaaggct ggggtgttgtt atccctgatt catgcctgtat acccaggcat 36960
ttcgggaggc cgaggtggc aggtcaactt atcccaggag tttgagacca gcctaggcaa 37020
catggaaaaa gccatctct aaaaaaaaaat taaaaattt tctggcatg gtgacatgt 37080
cctgttagtcc ccgctactcg ggaggctgtg gtgggaggat cacctgagcc cggggagggt 37140
aaggctgcag tgagccatta ttgtgtact ggcgtccagg ctgagccaca gagtgagacc 37200
ctgtctcaaa aaacaataaa aggaaagggg aaaaaaaaaa aagcacgtatg tcatgttacc 37260
tttggctcat cagttatgtat tataggaatt taactgtgtt cacacattcc tttctgtatc 37320
ttttcaactt tttactgttt tttttgtttt acataatcaa acaattgtatg tttcagaatg 37380
tgttagatgaa gcagatgatc cataatggca gctgaattgg tatctaaatg ttctgctgaa 37440
tgcattgacg aaaacaaggc ttttcaacc caaatgtact gggattgtt tttactttt 37500
cttcaactgt tttttcaacc accatctttt atttttcag ctggctacca tttgtggcta 37560
tgggctgtgg aagctttgc caaacagctg tttttcagg atcagttatg caaggctgt 37620
tctcacctac tttccatcca caaatgttat gaaagggtgg agtgcgtcaa gtcaaccat 37680
ttttacaggt ctgtgtggc ctagagttgg gataatactt ggacataatg tgaaaataac 37740
ctaaacttctt ctattgttaa agtaacataa atagaagaaa cagtcctcct gcttcagccc 37800
cctgagtaac tgggactact caggagggtgc atgccaccac atccaactaa ttttttagtt 37860
ttttgttagag acggagtctt gctgtgttgtt ccaagctgtatg tgccaaactcc tgggctcaag 37920
cgatcctcgt gcctcagcct cccaaaggc tgggattaca ggcgtggacc accatgttt 37980
gccaagattt tttttttgtt ctaccctgtt ttgggtttgtt tatcttctt tagagatgtt 38040
taaacttctt ttggtaagt agtaaagggtt tttttttttt tttttttttt atgggtttttt 38100
tttaaacttc gtttagggcaa gtttatcata ttctagaatt agttggacc tcctacattt 38160
tgatatctt cttgaatgcc ttatgcattt aacaaatcaa aactcagatg tctccaaatgc 38220
ctgagtaagc tctggaaatt gttcagctta cagttaccta gtcattttt gtttagactt 38280
aaggagtttc ctttacatac gtggctttta atttagccaa agactcaatg ggatctccag 38340
gcagagttgtt ggtatgtttt ctctggacag ctccctcctt cctagttatcc tgccccctcag 38400
atttccattt tttccctttt tcaactcaga gactgctgat gttttgttca gttttttttt 38460
aggaaaatgg ctttggcag aaagccagtg ccaagatagg gtccttcatca tttgtttctg 38520
ttctttagg gctgaccatc ctatgtcc ttttacctgg tatctaaaaa cagttgtttt 38580
agccattttgc tccagttttt tagttttatg gcaaaaaagggt aagtctggc ccagttactc 38640
catcatggct ggaagtagaa gtccttccat aacttcaaaa tattgtctctc tctagatcac 38700
ttaatctaa taaaacactt tttcccttcaacttta ttttggctac aactcagcag 38760
ttgtatgtca ttgtaaaaat atttgttttac tgagttgttca agatcttccaa aatgttaaca 38820
tatcttattaa taaaatccccccca aaaaatccatca tttcccttac ttttccatca agtctcatca 38880
gaaaattcttta acttatggca aactcaggca cacaagggtt aggtacaatg tttctaaaaat 38940

-continued

tctaattttt gctagaaaaac tcgcattta tcatttagtaa caaatactgt tggttgttt 39000
taatgaagtg ataggcctac tttgttcatt tttgagaaaa acatctgccaa aatacccaac 39060
actgaataac tggttatttattt gtttagtcatt tttttttttt tttagaagaaa gaaggttctaa 39120
tgaaaaagca gccagtttag cttgttaattt gttcatacag gtgttaccta gagacaacca 39180
ttctacttttgaatgcagca gagaacacaa aatgttcttccatccatcacagaaat 39240
taaagtgttt tggacttgac ggattnagta aaatttgtaa tttttactgc ttcatthaagg 39300
gcattcttcc ttttttcca ctgttaagagc caccgccttc cttcttagat gccaggttc 39360
ccaatcactg ctttggcaca atcagtgcacatgtcaacac atttttttttt ttaataaaaa 39420
aagcacataa ctgactctta gcattgttac gaaaatagtt ttaacctcat gaaccctctg 39480
aaagggtctt gaggaccccc taggaatcca cagaccacaa tttagaact gctgatctaa 39540
gtgaagaaac gaatgcagca tatgttctta atttgtctat ataatgcaag tgcaagtttt 39600
aaaggaagtt ggaacaataa gacaacacaa aaggacagt ttgtcctgtc ttacagcccc 39660
tccttaggacc atacacagag gagectttc agattggcta aaggatctgt tcttgcctt 39720
agggaaagcta ttgcgattgc caaggcccg ctgcgccccgg aggacccagt cctgaaggac 39780
ttgtacctca gctggggAAC cgtccttagaa agagatggcc actatgtgt agctgccaaa 39840
tggttaagcctt gaggagtgga gggatgttca caacatagga gagttctgc caggaagggg 39900
aggacaagaa tacaagtaat aagtttagag gtggaggtaa agcagcaagg aattatttaa 39960
aagatatgtat tattcaactt agtttcataa gactcatcag gaactacttc ctgattttt 40020
tatataatc actataacta ttcaagaaaa acctcagcagc cagattaaga aattatgcat 40080
ttttctaatttgcgtcttata acatcaaata aaggaacctc aacccatgctt ggattgaacc 40140
caacagagga gtcattccct ctcattttcc ttatgtcctt aacctatatg atattgtttc 40200
tcatacactc tgctgagttg tggtggccctc agccttcaca ggaacaaccggggcagtgac 40260
atacctggga ccacaggaag gcacatgeag caaagtagat agaaagaaat gattccatcc 40320
tcttagaatg ggaataaaaaa tctgtttgtc acatTTTCTT cacatTTTAA ttcatattat 40380
agctatttag gggccacttg tgcttatgt gcagccaaag ttttggccaa aaagggggat 40440
ggggcatcac tttagaacggc tgcaagtttgc gctgcccattc taggagagga tgagttgtct 40500
gtttccctgg ctctcagatg tgcccaagag ctgctctgg ccaacaactggggcagtgac 40560
caggaagcccccc tgcagctgca tgaaagtctta caggtcagtc tggttatttca tctccttagta 40620
tacaagaggg aagtgtccca aatccctttc tagtcaaatac caagttata acccagttgc 40680
acaagctgtg ccaatttggc aggeccagca agccctggcc atgctatccc actgaagttac 40740
tatgacttgt tagttgccgtt attcagagta agagataata tggtcattca cagtaattcc 40800
cattgtttat ctgtttgtac aaaacacctg tgagccgggc acagttggctc atgcctgttaa 40860
tcccagcact ttggggaggcc gaggcaggca gatcaattga ggtcaggagt ttgagacaag 40920
cctggacaac atggtaaaac cccgtttcaa ctaaaaatac aaaaatttgc cgagcgtgg 40980
ggcacgcttc tgtaatccta gcttacttgg gaggctgagg caggagaatc acttgaaccc 41040
ggaaggcggaa ggtggcagcg agccaagatc cagcctggcc aacatagtgg gactctgtct 41100
caaaaaaaaaaaaaaaa aaaaaaaaaac aaaaaaaaaaa acaccttagt cagcccaaggc cttgggttgg 41160
cagtcctagggttttttttattca gatgttatca gcaactgttcccttgaagag agaatgggtt 41220

-continued

gcctctaaca gaaatcatgg aactctacct gtaaatgccct ctcttaactgt taagctatgg 41280
aaaaaaaaact gggccagatgc cagcagatca cttgagatta ggagttcaag accagcctgg 41340
ccaacatggc gaaatcttgt ctctactaaa aataaaaaaa ttagccaggc atggtggcac 41400
acatctgtaa ttggctact tgagaggcta aggcaggaga attgcttgaa cccaggaggc 41460
agaggttgca atgaaccaag attgtgtcac tgcaactgcag cctacgtgac agagtgagac 41520
tcttcagaaa aaaaagagaa aagtgtggaa aatggaaat ctctttatct cttaaatttt 41580
tttggccca tctgattaaa aatcgtaac ataccactgc cttttgacatcaaaaaca 41640
gattaaagca ttggcacact tacctagttt ctgaaacatgt taaacatttg attcacttta 41700
gataactttg tgagatacta acaagagggtt ttttaagttt ttcattctt aacagagttac 41760
agggccatca gatgggtttt agtgaatat ttagacccca aggaacgtgg tacatgggg 41820
ggtagcttcc taggaacagc agaataaaaaa tggaggcgaa aataggacac cctaaaagat 41880
aatgccactg ggcattttt ataaaatgac caagtctaga gagattttaa ttatccacc 41940
atcaaaaaaa gtttccagaa tgactgttta gcatttttattt tttctttttaa acagcatcct 42000
taacaaagca aaaaaaccata ataagcatat gctaaatattt ctgataagggtt ctatttgg 42060
tttggcaac agagactctt gcaagcttaa ctgagaagat attgtttagt gaggacacaa 42120
ggaatctcat ggcaactaaa aatctgtga aagtagattt tctaggcctt ctctgtgttt 42180
ctgttttctt ctctccatc cagttccctt tattaaacctt atttggacat ggctcctaat 42240
gcctgtccca gctcttggat ctgcaaagct tgcattttcc agcacctttg gcccattatg 42300
cttttattcc tgagtccaaa gtttggtagtggagaa cctgtatggcc ccagcccttc 42360
ttttccctaa actaggctac aaggcttaag tggctggctt gtgtgtggct taaatcattt 42420
tgggttagtgc tacagttggg attctgtgtttt ataaaaatgg tttcttgagc tctaaggata 42480
gattttcccc aaaaggggacc tgggaagtgt ctgtcagatc gcccatttttgc tccctttca 42540
tgcatgactc atatggggca ggtagctcac taatgtgttttcc tgggtgtgtgc agatacaaaag 42600
ggaaataactt tgaaggacac gggagagctt ttgagatcat ccagtgttttcc tccctgtataa 42660
cagttccctt tccttggat cgtgttccag ggtcagatc tgggttttgc ctttctggag 42720
ctactgtccca ggcacatctggaa ggaaaggcag ctttccatggg gcaaaagctc ctcctttaac 42780
cacacttggaa acacgggcac cgaaggccctt ttcgtggaga ggggtactgc agtgtggaa 42840
agcatcttca gccttgacac ccctgagcag tatcagggaaat ctttccatggg gctgcagaac 42900
atcaagttacc catctgtcac aaataacaca cttgtccaaac aggttaagccat tctgttaccat 42960
catttgacat taatctactca gtggtaagac ttccttaatc catgtctattt gtaacgggg 43020
aacaaggcaga atactggact gtgtttcaga aaaggctaaat gcatggccac gccacccgg 43080
aagatccctt tagactaatac aagccctt aactttaaat ttagtattttt atcgttaccat 43140
cctttttgtt tttttttttt tttagttttt gaaggtggat tgcaatggca tggatcttggc 43200
tcactgtccgc cggcaccccttcc cagattcaag tgattctccgc ctttccatgggacttccatgg 43260
gtgattacag gctgtggccca ccacggccag ccactatttc ctttctaaat aagttaaaat 43320
aaaaaggctta gaaaatatacg aaaaaggcaga taataaccca tcaaccagaa ttaacagatc 43380
ttcacatttt gtcatttttta ctttgggg ttttctggat tcatggat ttttgatgg 43440
aggactttat aaaaataaaaaa cagtagggca aagttgaagt ctttcttggat ctttccatgg 43500

-continued

gcccttcaact ccttccctag ctgcacacag gcacccctcg tgtcagtgc acatgtattg 43560
ttttgtgtt tgcttatttc agaggccatt gtttgtaaaa tctatccatg ttgataaaaa 43620
gagatcgtt gatTTTTT aactgctatg tctgccttgc gaatatacct acttctttt 43680
ttttttttt tcctttctg gagactgggt ctcactgtta cccaggctgg tctcgaattc 43740
ctcaagtgtat cctcccgct cagccccc aagtactggg attacaggca tgagccactg 43800
tgcctggcgt agttcttcc ctcattcaa aatgaggaa cattatgata tttatgagga 43860
acaaggcttc tcaaattggta tatactttga aaaacagttg gacagttct tttttctt 43920
tctttttcc ttttctttc ttttttttg aggccgaatt tcactcttgc tgctcaggct 43980
ggagtagcgt ggcatgatat ctgctactg caacctccgc ctcccagggtt caagcaattc 44040
tcctgcctca gccttccaag tagctggat tacaggcatg tgccaccacg cccagctaat 44100
atttttactt tttttttttt ttttagatgga gtctcactct gtcacccggg ctggagtaca 44160
gtggcatgat ctggcgtcac tgcaatctcc gcctccagg ttcaagcaat tctttgcct 44220
cagcctcccg ggttagctggg attacaggca cctgcccacca tgccggcta atttttgtt 44280
tttttagtag agacaggggt ttaccatgt tggccaggctt ggtctcgaac tcctgacetc 44340
gtgattgcc cacttcggcc tcccaaagtg ctgggattat aggcatgacg cactgcaccc 44400
agcctatTTT tcagatTTT agtagagaca gggtttcacc atgttggcca ggctggctt 44460
gaacttctga cctcatgtga tccacctgccc tggcctccaa aaagtgtgg gattacaagt 44520
gtgagccatc acgcctggcc aggcaagtcc ttataaagtt aaacatgcac atgcacccatg 44580
tctcagcagt tctgctaccc agatattcca ctAAAACAAT gaaatcagat ggccacacaa 44640
agacttgtac acaaattgtt acagcagttt agtgcacagt agccaaaaac tagaaacaac 44700
ccaaatgtcc atcaactgtat gaatggatat gcaaaactgtg ttgtgtctat gcagtgaaat 44760
actatactgt ttaacaataa aaaggccag tcttgggtgc tcacacctgt aatcccagca 44820
ctttgggagg ccaacgcggg tggatcggtt gagctcagga gtttggagacc agcctggca 44880
acatggcgaa aacctgtctc tagtAAAAT acaaaaatta gcccgggtgt gtagcacaag 44940
cctgtatcc caggtactag ggtggctaaag gcaggagaat cattcaaattc tgggagacgg 45000
aggctgcagt gagccaagat ggaaccactg cactacagcc tgggttaagag aatgagaccc 45060
tgtctcaaaa aaagaaagta aaaaggaaca aattactgccc acacaaataa tatcggtgtt 45120
agccggggcgt ggtggcgggc tcctgttagtc ccagccactc tggaggctga ggcaagagaa 45180
tggtgtgaac ccaggaggcc aagtttacag tgagccgaga tctgtccact gcactccacg 45240
ctggggcaca gagcaagact ccatctcaa AAAACAAAGA agaagaagaa gaatatcggt 45300
gaatctcaa agctttaag acacaaaaga ctatatactc tgtggttcca ttttatgaa 45360
ttctagaaaa gaaaaattaa aagtgacaac cagttcgtt gttggccatg gggggggc 45420
aggagatcgc ctgcagagga gccggaggcc atatcttcgtt tgatgaaa ttttctgtct 45480
tgatTTTGTCTT ggttagtggtaactatata tttttctcaaa actacataact taaaatttgg 45540
cacatTTTTC ttagttgtac tccaaagctt gttttgtttt gttttgggtt ggttttgatt 45600
ttttttttt gagacagcgtt ctcactctgt cacccaggctt caggtgttagt ggcttactgc 45660
aacctcccgcc tctcggttcc aagcaattct tccgcctcac cctcccaagt agctgggatt 45720
acaggcgtgc accaccaagc ccggctaaatt tttttttttt tttttttttt ttttagagac 45780

-continued

gggcttcac ctgcgggtat ccgcgcgcct cagcctccca aagtgtatggg gttataggtt 45840
tgagcaactg cacccagcct ttatTTTgtt tttattaca gcttttagtt ccagaaactc 45900
actttttgtt ttgttgtttt gtttgtttgt tttgagaggg agtctcactc tcattgtca 45960
actggagtgc agtggcgcaa ttcagctca ccacaaccc caccctccgg gttcaagcaa 46020
ttcttcgtc tcagcctccc gagtagctgg gactacaggg acgcgcacatc atgcctggct 46080
aattttgtg ttttagtagt aggeggggtt tcaccatgtt ggccaggctg gtcttgaact 46140
cctgaccttg tgatctgccc accttggcct cccaaagtgc tgggattaca ggcattgagcc 46200
accgcgcctg gccccactttt tggttaattt aaatgcaaat gtaaagggtgt ttctcagtg 46260
tgaacagact ttaaacaccgg gacgtgtgtg tgctgtgtg caacttagaca tgagagttc 46320
cgatgtggaa agccaaaatg ggtggcgagg acaagaggaa ctttcaaagt gtgaattgtg 46380
tgtacttgtt tccaaatgcg gttcacagga acagtttggt ggcatcctct gcgcctaccg 46440
tgggaggatg ttaactcag actctggctt ctcttcagg ctcctgttcc acatttgcct 46500
tgacttgacc ctggcagtgc tgagccaaca gatggcctcc tgggacgagg ctgtgcaggc 46560
gctccttcgg gcggtggtcc ggagctatga ctcagggagg ttcaccatca tgcaaggaa 46620
gtactcagcc tttctccctg atggtaagtg acttctgtct gcctgaggca caccctttaa 46680
tggacaacat caccaccatt agtgggtgtgg cactgggagt acctagattc taaaagatg 46740
gagattggcc agctgtgtca ttttagttaga aagtttggat tctcttaccg aagcttttaa 46800
gaacaactat actgtttcct ttacctggcc ctacccttta acagcctcct gtccactttc 46860
cacaaggattt aaggagaga gaaataggaa tgttagttaca tgtagttaag aacagaaaaag 46920
aacagcaaaa aagatagaca ttccctgggc tgcatagtca gtcactgaac taaatcattg 46980
tgatTTTca gagagacagt gtatctgtt gtcgtggccc cagagccttc agtagtacaa 47040
atggaaatact ctatcatgct ttgaatgact cctaggatgt agtaatgaga acactgtcgc 47100
aagccaggaa atgttttagcc tccagttggc ttttgggttga aaggcatgtg gcccgggtgg 47160
tcacactgtt gtccttttc ctggggctgtc ctcttgggtt gataagaaat agaacataag 47220
ggcaggaagc cacattctg gcaacttagag aatgtcatga cccagtatct ttttctt 47280
ttccctaggct gtgaccaccc aagagacaag ttgggggacc atcaatcccc tgccacacca 47340
gctttcaaaa gttggaggc cttttttctt tatggcgtc tttatgttattt ctgggtggct 47400
ctctccagac ttgcggccaa ttccagttgtc tgggtttaggg ctggtcacag aacactctct 47460
gtttagccaa gccagcgtt agacactgcc agcactgaag aaacggacc tgaaacttct 47520
cagccagagc caaacaggcc ttcaagaacta gacttgagac tcacagaaga aggtgagcga 47580
atgctgatgtt cttttaagga gctctttca gaaaagcatg ccagtctcca aaactcacag 47640
agaactgtt ctgaatgtca agagaccttgc gcaagaaatgt tccgacaaca cccaaagatg 47700
caactctgtt aatccacagc aatggtctt gataagaatg aaccggaaatg agaagcagag 47760
cagccctct gcaatgttca gatccatgttgg taatgttactgtt gggcaatgttca agacggatgt 47820
aaaaatgacc ctgctggcta ggaacagtgg ttcatgccta taatcccaggc actttggag 47880
gctgaagcag gaggatctt tggccatgg gttcaccacc agccggggca aaaaagcgg 47940
accctgtctc tacaaaaaaa aaaaaaaaaa aaaaaagccc gggcacatgtt gatcacgtt 48000
gtaatcccag cactttggga ggccgaggtt ggcagatcac ttgaatgttca gagtttggaa 48060

-continued

ccagectggc caacatggtg aaacccgtc tctaccaaaa attagctggg tatggtggca 48120
catgcctgta attccagcta cttggggggc tgaggccaga gaatcgttt aacctggca 48180
gcagagggtt cagttagtca aaatcgacc agtgcactcc agcctggca acagagggag 48240
acttcatctc aaaaaataca aataaagtaa ccagggtgtgg tggcatgtac cctgttagcta 48300
cttaggaggc tgaggcagga ggatcacttg aggccaggag ctcaagttca gcctgggcta 48360
catattgaga ccctgtctc agaaaaatta attttttaa attagccagt agtggtggca 48420
tgcacttgta gtccccagcta ctcaggaggc tgaggtggga ggatcactta agcccaggag 48480
ttcgaggctg tagtgagata cgatcatgcc actcatacca gcctgggtga cagaccctgt 48540
ctctacaaaa aaaaaaaaaaa aaaattaaat tttaagaagc caggtgacaa aggaatttta 48600
tttataaaat gagataaaag taacccaggc aggggcataat gctctcaggc cctcctgagg 48660
gctgtgtcat aggcaaaagt ttaaattttt aaaaatatt aaaaataaaa ggtaaaagct 48720
acccaggcat aacaaaagat aatccaaatc aaggatggc aaaggacttg aatagacatt 48780
tctctaaaaa gccagtaagc acaggaaatg atgctcaaca tctcatcatt gggaaatgc 48840
aaatcaaaac tacagtgaag cagcacttca tagccattag gctactatca gagaacaga 48900
acaagtgttg aggaggatgc agagacattg gaacccttgc gcctgttggt gggatgtaa 48960
aatgatgcag ccactgtgga aaacagtaca gcagcacttc ctccagaaat gtaaaataga 49020
atgaccatag gatccagcac ttccacatct gggtatacac cccaaagaat tgaaagcagg 49080
gtctgaaata tgtgcacacc tgtgttcatg gcagcattat tcataatacc caaaacacgg 49140
gagcaaccta agtatccact gacagatgaa tggataagca aaatgtgcca tatccataca 49200
atggaatgtc attcagccctt acgaaggag gacatcatgc tgagtgaaat aagccagtca 49260
caaaaagaca tatactatata gactccactt atatgaacta ctcaaaatag ttaaatttt 49320
agagacagaa agtagaataa tggacagg ggctaaaggga agcagaatga gaagttatg 49380
ttaatgggt ataagatttc agtttacaa aatgacaaga gttttggaa atgggtggtg 49440
gggatgttt tcaccacatt atgaatttat ttaaatac tgaactatgt attttaat 49500
ggctaaatg gtaagctta tggatatac attttaccac agtaaaataa caatgggaga 49560
aaaatgttac ccaggcaag acatacaatt tacaccttt atttttca ctagtaaaga 49620
aaaaaaaat gagccactt ctctgcctga gttacccaaa aggcttaccg aggcaaatca 49680
gagaatggca aaatttcctg agagcattaa ggtaagagtt aaagcagttc atttggtaaa 49740
gcatacttt ttgtgttac acttgactat accacattct tataaagggtc agtacatct 49800
ctgttcagtt tctaaatct ctacccattc atatgtgctt aagaatttag aatccaggct 49860
gggcgtggc gtcacgcct gtaatcccag cgctttggga ggctgaggct ggccgatcat 49920
gaggtcagga gatcaagacc atcctggcta acatggtgaa accccgtct tactaaaaat 49980
aaaaaatatt agccggcgt gggggcaggt gcctgttagtc ccagttactc gggaggctga 50040
ggcaggagaa tagcatggag gcaggagaat ggcgtgaact caggaggcgg agcttgcagt 50100
gagccaagat cacgccactg cactccagcc tggcaacag agcgagactc tgcctcaaaa 50160
aaaaaacaaa aaaaaacaaa aaaaagaat ttagaatcca attactttgg ttagctagaa 50220
tgtttgtga gactagaatt atcgatcaca caagtaattt tatacctcaa tcttcagaga 50280
aaccaaataag attaatagg taagaagtaa aatttaaatt ggtgcctatg attagatagc 50340

-continued

ttacagatgg acaggcttt ttggctgtgg gccaaatat taatagaagc accattttt 50400
agggtggatt tgcataaggc ttagaaaaaga gattgtgcc ttagagaaggc catcgagta 50460
gcccccttag ttttgagtgt catttcctt tggagtaact gttgaagaga aagacaggac 50520
atggccttag gagacagctg gctcagctgt gtccaaagaag tgcataataga tgaacctgag 50580
tgactggcgc ctctgtgc ggtgttgtg gcttcctgc aaatgctcc ttattcatcc 50640
tcatgtcatac gtcttcagg cctggccctt cccagatgtg ctggagtgct gcctcgct 50700
gcttcctatc aggtcccact ttccctggctg tctggccag gaaatgcagc agcaggccca 50760
agagtcctt cagaaataacg gcaacacgaa aacttacaga agacactgcc agaccttgc 50820
tatgtgaatt ttcacacacc ttgaagaaac tgccaaattt gaaatgtttt acatcttca 50880
cctctgcagt tatgcctcac cagacattca ctctggccc tagatgtttt tgcagtaatc 50940
caaaaagaata caaacaagga ttaagtttga atcaaccctg cctaccata gacaacggtg 51000
gatctgactt tagactcaat tgcgtctcc tactggggg aagatcatga aaagccaca 51060
gtagttattc agaactaaca cctgcagagt gttggcatac tctacagcct taggcaggtt 51120
tcacccaaag aggagaaaact tctgtcgta cccaaagtgt tacatgttta aaacacaagc 51180
tacctttgtt aataacttcat ctgatcagaa gtgtgtcatg cttgttttag atggagttgc 51240
tgcatttttag gactattgtt acctttttt aattgtttt ataatattta atttgaaga 51300
ggagaccctt ctctctctac tctttcatag actgaagttt gaatatgaaa taggcctta 51360
ccatcatgtt gactctctgt tcagaattt aggttggaaa tttgggtttt ttcttcatg 51420
taattgctta tttgaacaga tcacttacta aagctttaga agaagtgtt caaatgtgt 51480
ttttcccttc agttttataa caaatggatt gatggcagtc aaatagctca ggaataaatt 51540
actgtttcaa tggttcttaa actttcttgg atcataggat cctttgaga atcagattaa 51600
agccaaagat actctttggaa gaaaaatgc tattcctaatttttgcata tgcacccctt 51660
attattggac tctgactattt gggaccctaa atactattta attataatc tttttttct 51720
cctccttggt tatttaaaca gttgaacagt gtcaggaaca gatgtttctg taatgtcaca 51780
gttgctagca tggaaaatc agagtctggc atgggtgttag gaaggaacac tccttcaga 51840
taattgaact gttttctcta ggattcattt tgaaggcttt tctgctcacg tttgttagtt 51900
attttcaat taattccttag gattggagtt gttggacag tgagaatgaa attcatttac 51960
aggaagtccc aggaaggaga aagtttgagg cagtttcaa agacgtgtat gtgcctagca 52020
ttagagttta ataaactcac aaaggaaat actgttagaat tttagatcctc acagttcttc 52080
atacagtgaa gtgaacttta ggaagacgat gctttgttac cagggatgga gaatcttct 52140
tgattgcaaa gacataaata ggcattggcata ggttagaaaaac ctgccttagt tggtaggaca 52200
ccagttctac caactgctaa aatgaacttt acttacagag gtggaaaaaa tatataactcc 52260
cttccacttg agtaaagagt gatattgtta aactagaatt ctaaattcct ttgtgatctg 52320
tcagaagcat cacctgtggg tggaggagtc ctgcacactc ctcagttact gctttggtaa 52380
gaacaagatt atctatttga gtccaggcat ggttagctcat gcttgcataatc ccaacacttt 52440
gggaaaccaa ggcaagtgaa tcacttgagg acaggagttt gagaccagct gggcagttata 52500
tatggaggca gtatataattt gagaccaaca tttggcagta tataatggagg ggctgaattt 52560
cactcagtttgc tctggcata tggtgacacgc ctgtactctg gatactgtgg aggttgagg 52620

-continued

gggaggattg cttgaggcca ggagttcagg gccagctgt gcaacatgc aagctccat 52680
ctctataagt aatgaataaa cttttaaaa tgaattatgg ccaggcacag tggctcacac 52740
ctgtaatcct agcaacttgg gaggccaagg caggcgatc acctgaggtc aggagttcga 52800
aaccagcctg gcacaatatgg agaaaaccca tctctactaa aaatacaaaa attagctggg 52860
catggtggca catgtctgta atcccagtgt tggaaataag agctcagagt cacaagaaa 52920
atgagcactc aaacaaaaga cttctcagca aggcaaattt acgtccgcag aagggtgctg 52980
ctgcctgcac cagtcacaat c 53001

<210> SEQ ID NO 17

<211> LENGTH: 492

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

gggtctccgc tcaacgatcc ttcccaaag catggttgtc gagtacccag agttgcgagg 60
agtttttaa ctgatttagc caggtggcaa tcatgagtga atggatgaag aaaggcccc 120
tagaatggca agattacatt tacaaggagg tccgagtgc agccagttag aagaatgagt 180
ataaaaggatg gtttttaact acagacccag tctctgccaa ggttctactg tcacccaggc 240
tggaatgcag tggcgagatc tggctcttt gtaacctcca cctcgaggc tcaagcgtt 300
ctccctgcctt agoctcccgaa gtactgggc ctacaggcat ttgcaccac gtctggctaa 360
ttttgttatt ttttgtggag acggggcttc gccatgtgc ccagtattgt ctttgtaac 420
ttcccttgaag atggcagcat gtctgtgacc ggaattatgg gacatgtgt gcagactgtt 480
gaaactatga at 492

<210> SEQ ID NO 18

<211> LENGTH: 972

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

agcggaaagcg atcccttcctc aaagcatggt tgctgagtac ccagagttgc gaggagttt 60
ttaactgatt tagccaggtg gcaatcatga gtgaactgga tgaagaaagg ccccttagaa 120
tggcaagatt acatttacaa agagggtccga cgtgacagcc agtgagaaga atgagtataa 180
aggatgggtt ttaactacag acccagtctc tgccaatatt gtccctgtga acttccttga 240
agatggcagc atgtctgtga ccggaaattat gggacatgtc gtgcagactg ttgaaactat 300
gaatgaaggg gaccagtaga gtgagggaga agctgatgc ctttgttac gtctggagac 360
tgcaacagca tacagccag aggtctgga agagagaaag aacagcctaa agaaatggct 420
tgagaagaag ccacatcccc atcactgaac agggagacgc tccaggact ctctgtgtgg 480
ctggggtcct gactatagac ccaccatatg gtccagaaaa ttgctgcagc tctaattgcag 540
attattctgt cgctgtttca ggatcttatt gaaggacatc ttacagttc cccaatgaga 600
ggccaggaag tgtgaacata ctgatagaaa caagactata tggatccct cataaaatgt 660
ttaaatgtaa atgtacatga ctgtgggtg tggatgtgt tggatgtact aattttgg 720
tgtgtcggtaa aaactcagag gagtgggtta taagtgcata ttccctgggg aaattaatga 780
acttagggca agtataagca tccccatggc ttaagattag gcgcagggac atcgaaactc 840

-continued

gggttgggtc ttacttaac ttttaactt ttttttagatggaaagtc tcgtctgtt	900
gccagggttg aagtgcattt gggcaatttt caggtcgatcc accttccggc ccccagggttc	960
aaccgaatcc cg	972

<210> SEQ ID NO 19
<211> LENGTH: 703
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

gggctcaacg atccttcctc aaagcatggt tgctgagttt ccagagttgc gaggagttt	60
ttaactgatt tagccagggtg gcaatcatga gtgaatggat gaagaaaggc cccttagaat	120
ggcaagatta catttacaaa gaggtccgag tgacagccag tgagaagaat gaggataaaag	180
gatgggtttt aactacagac ccagtctctg ccaatattgt cttgtgaac ttcttgaag	240
atggcagcat gtctgtgacc ggaattatgg gacatgctgt gcagactgtt gaaactatga	300
atgaaggggc ccatagagtg agggagaagc tggatgtt gttcacgtct ggagactgca	360
aagcatacag cccagaggat ctggaaagaga gaaagaacag cctaaagaaa tggcttggaa	420
agaaccacat cccatcaact gaacaggag acgctccaag gactctgtt gtggctgggg	480
tcctgactat agacccacca tatggtccag caaaatttgcgcagctctaa tgagattatt	540
ctgtcgctg ttcaggatct tattgaagga catcttacag ctccatgtt agaggccagg	600
aagtgtgaac atactgtatgg aaaaagacta tattttatcc ctcataaaat gttttaatgg	660
taaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa	703

<210> SEQ ID NO 20
<211> LENGTH: 646
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20

ttgctgagta cccagagttt cgaggagttt ttaactgat ttagccagggtt ggcaatcatg	60
agtgaatggta tgaagaaagg ccccttagaa tggcaagattt acatttacaa agaggtccgaa	120
gtgacagccat gtgagaagaa tgagtataaa ggatgggttt taactacaga cccagtcctt	180
gcctaatattt tccttgcataat cttccatgtt gatggcagca tgcgtgtac cgaaattatgt	240
ggacatgctg tgcagactgt tgaaactatgg aatgaagggg accatagagt gaggggagaag	300
ctgatgcatt tggatgttgc tggagactgc aaacataca gcccagggat tctggaaag	360
agaaaagaaca gcctaaagaa atggcttggaa aagaaccaca tccccatcac tgaacaggaa	420
gacgctccaa ggactctctg tggatgttgc tgcctgacta tagacccacc atatgttccaa	480
gaaaatttgcgcataa tgagattttt ctgtcgctgt ttcaggatct tattgaagga	540
catcttacag ctccatgtt agaggccagg aagtgtgaac atactgtatgg aaaaagacta	600
tattttatcc ctcataaaat gttttaatgg taaaaaaaaaaa aaaaaaaa	646

<210> SEQ ID NO 21
<211> LENGTH: 6001
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

-continued

atcgcaatac	ctggagaaca	aaggcattcc	taatttgt	ttaaagataa	tagtattgtat	60
gcttgaaaaa	tatagtaatt	aagaaaatta	atccttatac	ataaaccctt	gtacagagc	120
gcatctcctc	atacatagga	ctattgtatc	tagggtagac	actttctct	tacttcggg	180
aacatcctac	tctgtctatg	gagcagctgt	tctttcacca	ctttacttcc	ttactaaact	240
tgcttttgt	ttgcactgcg	gactcgctct	gaatttttc	ttgcgcgaga	tccaacaact	300
ctctcctggg	gtctggatca	ggacccttt	cctgttagcaa	ccctatcgct	cttctccacg	360
gcacgttac	ctcacattcc	tagagctta	ggatttactc	tgagggttca	tgtgcttgc	420
ttctaaggcg	aaagtgcatt	tccaagtcta	ctatcattga	ggacctggca	cgagctttt	480
cctcttatt	tatTTTATT	tttaatTTTT	ttgagacgga	gtttcgctct	tgtgccttag	540
gctggagtgc	aatgggtgcga	tctcagcaca	ctgcaacctc	cgcctcccg	gttcaagcga	600
ttctcctgtc	tcagcctct	gagtagctgg	gattacaggo	ccccggccact	aggcccggct	660
aatTTTtgt	atTTTtagta	gagacgggg	ttcaccaatgt	tggccaggct	ggtctcgac	720
tcctgaccgg	tttcgaactc	ctgatccacc	cgcctcggt	tcccaaagt	ctgggattac	780
aggcgtgagc	caccgcgccc	ggccgcttt	tcctctttaa	agaaaaaaag	attatttga	840
ctgtccgtcg	tggcaatgg	gagggatagc	cttagaggac	atggcggttc	attatttatta	900
ttattattac	agaacaatct	tagactctgt	ccgcaccctg	cactctaggt	cccgcgactc	960
tcagacctcc	aagtaggact	acaaaacaga	ggtttctggg	ggaaggaagt	gacgatcg	1020
gcaaagcatg	ctgggtctcg	gccccctccg	ctcaacgatc	cttcctcaaa	gcatgggtc	1080
tgagtaccca	gagtttgcag	gagttttta	actggatatt	ttctcggtt	tcagggtta	1140
acgttaagta	ccatTTgggt	tttagtacag	tgttaggtat	cgtgtggct	caggacagga	1200
ccagaaatct	aagctctaga	gctgttagccg	ctggcccttc	gttgtgcat	cttcaaaca	1260
aatTTtaagg	ggcagttgtc	ataatcggg	ggagcctctc	gatggcggg	tccagcggag	1320
acacagagcc	agagagcg	tgggtggata	tcaggagat	tttctgggtt	agttgaggag	1380
tggggtaac	tcctttgatc	gatggaaagga	aaagcagat	tgaagggttt	gagcatcatc	1440
tgcaggccag	agtgaaagcg	atTTGAATG	tgggtgtgg	tcggaataga	cctgtgccag	1500
atgaatttcc	tcagactgca	cccgccgca	atcggtgacc	cctctgtctt	aggccgaaatt	1560
gtacatattta	actatTTCC	ttttcctgtat	aaaaattctc	aacgacgtt	tacacgtgt	1620
cttttccccca	actatagtat	cagttcttat	cagtagatgc	attaatactt	aattgtatta	1680
agttacttat	tacgaacttg	aggcaaatca	cagatgtct	ctgtctctag	gataggatgg	1740
agattaggg	taagacattt	gcttacgtgg	aacatatatt	aaccagact	ggtgggtt	1800
tcagatTTAG	ccaggtggca	atcatgatgt	aatggatgaa	gaaaggcccc	tttagatgg	1860
aagattacat	ttacaaagag	gtccgagtga	cagccagtga	gaagaatgag	tataaaggat	1920
gggttttaac	tacagaccca	gtctctgc	agttagtatg	catcctactt	gcctgaaatc	1980
ttgacacccc	tttgcgtgc	ctgtatgtt	tagacaaact	aagaaagcag	ataaatgaaa	2040
agctaattat	taatatttc	atataagaat	ttttgtttt	tttgagacag	ggttctactg	2100
tcacccaggc	ttgaaatgcag	tggcgagatc	tcggctttt	gtaacctcca	cctcgagg	2160
tcaagcgatt	ctccgcctt	agcctccga	gtagctggg	ctacaggcat	ttgcaccac	2220
gtctggctaa	ttttgttatt	ttttgtggag	acggggctt	gcatgtgc	ccaggttgg	2280

-continued

ctcaaactcc	ttagtccaa	ggatctgcc	accttagcgt	cacagagtgc	tggcattaca	2340	
ggctgagtc	ctgtacccgg	cctacatgt	agaacttaac	tgcctttgaa	tctaaatgt	2400	
gttctgacta	tggattacct	tatcagacca	ggcaacttca	tagaaattgg	gcatagaaat	2460	
tatttttact	atatatata	atatatata	atatatata	atatatattt	ttttttttt	2520	
ttttttttt	cgggggtgg	atgaatctc	actctgttg	ccaggctgaa	gtgggtcagt	2580	
tacaatctt	gctcaactgca	acttctgect	cccaggttca	agtgattctc	atgectcagc	2640	
ctccccagta	gctggggtta	cacacatgt	ccaacatgcc	ccactaattt	tttgttat	2700	
tagtagagac	ggggtttcgc	tatgttgcc	aggctggct	caaactcctg	acctcagg	2760	
atctgcccac	cttggcctcc	caaagtgt	ggatcatagg	cttgagccac	tgtccccagc	2820	
ctataat	ttttataaaat	acttcaactat	atctttaaa	agaaaaggac	tttaaggccg	2880	
ggcatggtg	ctcacgcctg	taatcccagc	actttggag	gccgaggcg	gtggatcag	2940	
aggtcaggag	atcgagacca	tcctggctaa	catggtaaa	ccccgtctc	actgaaaata	3000	
aaaaaaaaat	tagccggcg	tggtagcagg	cacctgttagt	cccagctact	caggagctg	3060	
ggcaggaga	atggcgtgaa	gctggggaggc	agagcttgcc	gtgagctgag	atcgcgccac	3120	
tgcactctag	cctggacgac	agagcaagac	tccgtctca	aaaaaaaaaa	agaaaaagat	3180	
aaggacttta	aataatgt	accacaaaaa	ctttttttt	tgagatggag	tctcgctgt	3240	
ttgcccaggc	tggagtgcag	tggcggtgatc	tcagttca	gcaacctcca	ccttcccag	3300	
tcaagtgatt	ctcctgcctc	aggctctaa	gtagctgg	ttacaggcgt	gtat	3360	
tagagatgg	gtttcaccat	gttagccagg	acggctctca	tttcctgacc	ttgcaatcca	3420	
cccacctgac	ctccccaaagt	gttggggtta	taggcgtgag	ccacctcacc	tgaccat	3480	
tttttgaga	tggagcctt	ctctgttgcc	caggctggag	ttcaatggct	cgatctcgg	3540	
tcactgcaac	ctctgcctcc	cggattcaag	tgattctct	gcctcagcct	cctaagttag	3600	
tgggatcata	gacatgtgct	accacacccg	gctaattttt	gtat	tttag tagagatgg	3660	
gtttcaccat	gttggccagg	ctggccttga	actccttacc	tcaagtgatt	tgc	3720	
gtcctccaa	agtgcgtgg	ttacaggegt	gagccaccat	gcccggct	gttattgtt	3780	
tttaactct	aaaagttaag	tctaccctgc	cttctcttt	ttttttttt	ttccacgaca	3840	
gagtcttgct	caggctggag	tgcagtggca	tgatctcgg	tcactgcaac	ctctgcctc	3900	
cagggtcaag	caattctctg	cctctgcctc	ccaagtagct	gggattacag	gtgactgcca	3960	
ccacacccag	ctaataattt	tat	tttagt	agggattgg	tttcaccatc	4020	
gttggtctt	aactcctgac	ctcgtgatcc	acccgcctcg	gcctccaaa	gtgcgtgg	4080	
tacaggcgt	agccaccccg	cctggctacc	ctgccttctt	ttctaata	cattaaggc	4140	
attcataact	tgtttaatcc	tttaactgt	tcccacaatg	attggctgt	ggctgggca	4200	
aaagtttacc	tat	tttaggt	ccttagt	gaa	tgttgg	4260	
gtgacaggat	taat	ttcaaa	cagagtagag	tgtcatctat	tat	tttagt	4320
gttgcgtat	cctctaaact	tactttct	ccaaagtatt	gtccttgt	acttcctt	4380	
agatggcagc	atgtctgt	ccgaaattat	gggacatgt	gtgcagact	ttgaaactat	4440	
gaatgaaggg	gaccatagag	tgagggagaa	gctgatgcat	ttgttacgt	ctggagact	4500	
caaagcatac	agcccagagg	atctggaaga	gagaaagaac	agcctaaaga	aatggctt	4560	

-continued

gaagaaccac	atccccatca	ctgaacaggg	agacgctcca	aggactctt	gtgtggctgg	4620
ggtcctgact	atagacccac	cataatggcc	agaaaattgc	agcagctcta	atgagattat	4680
tctgtcgctgt	gttcaggatc	ttatttgaagg	acatcttaca	gcttccaaat	gagaggccag	4740
gaagtgtgaa	catactgata	aaaaaagact	atattttata	cctcataaaa	tgttttaat	4800
gttaatgtac	atgactgtgt	gtgtgttatgt	gtgtgtgtgt	ataattttttt	gttgttttg	4860
taaaatcaga	ggagtggtt	ataagtgcata	atttccttgg	gaaattaatg	aactaggcata	4920
agtatagcat	cccatgcata	aaatttagcac	agggacatca	gaattgtatg	ggtcttctt	4980
tttctttttt	tctttttttt	tttagatgga	gtctcgctct	gttgccaggt	tttagtgcag	5040
tggcgcaatc	tcagctcagt	gcaacctccg	cctccaggt	tcaaccgatt	cccctgcctc	5100
agcctctcga	gtagctggga	ctacaggtgc	acgccaccac	tcccagctaa	ttttttgtat	5160
tttagtagag	atggggtttc	acctgtatgg	gtctttctt	gtgtatgggt	tacacccca	5220
ttttttag	gcaagaaaag	catttggaaa	aaaatgtaac	atgttagatt	caatataaaa	5280
tattatggta	agatcatggt	cttggtaagt	ctcttcacta	actgtatgt	tctgttttta	5340
aaagatgtgt	cttgggtgggg	cgcgggtggct	cacgcctgt	atcccagcac	tttgggaggc	5400
cgagggcaggt	ggatcatgag	gtcaggagat	cgagaccatc	ctggctaaaca	cggtgaaacc	5460
ccttctctac	taaaaataca	aaaaaaatata	gccgggcgt	gtggcaggt	cctgttagtcc	5520
cagctactca	ggaggctgag	gcaggagaat	ggcatgaaco	cgggaggcag	agcttgcagt	5580
gagccgagat	cgcgcactg	cactctagcc	tgggtgacag	agcgagactc	cgtctcaaaa	5640
aaaaaaaaaa	aaattattgg	aacacagcat	tacctattga	attacagttt	tctgggtttt	5700
ttgtggagtt	tttgggggg	ttttttagat	ggagtttca	tcttggcc	caggctggag	5760
tgtaatagt	caatctcggc	ttaccacaac	ctctgcctcc	caggtcaag	caattctcct	5820
gcctcagcct	cctgagtagc	tggattaca	ggcatgcacc	atcacgcccc	actaattttt	5880
tatTTTTTta	gtagagacgg	ggTTTTTca	tgtgggtcag	gctggctca	aactccgac	5940
ctcaggtgat	ccggccgcct	cgccctccca	aagttctggg	attacaggt	tgagccaccc	6000
t						6001

<210> SEQ ID NO 22
<211> LENGTH: 493
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22

cggtttctct	gttgacaact	cagctggttc	cacaccctgg	caattgtgaa	gagttggcca	60
aatgtttgtc	cactgagctg	atctcccttc	tggagcacgg	gggccaccag	gagggaggtc	120
tgtgaaaccc	ctggccctgc	cattgaccta	agtgtgggc	tcttgaatct	aacagactag	180
tttttcaagt	cgtggggat	gggcttgggc	atttttccct	gaaaccttcg	gaaatccttg	240
ccttggagac	tgaaaggata	aaggcctctg	gggccaggtc	accagggaca	atggataacg	300
cctgectcta	ccctccctgg	cacaccctgt	gtgatcttc	ttaaaccagt	ttcttatcag	360
gtcacacctt	ggctccacag	tctgccttc	tacatgggc	acgggtgagg	acctgagtt	420
gctccctctt	cctccaccct	ccagcttgca	ccaaggaaat	gatTTTTT	tttgaaaca	480
gagtctcact	ctg					493

-continued

<210> SEQ ID NO 23
<211> LENGTH: 852
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

gcccaggctc cgccggcttgc ggcctgcccc ggcctctgca gcggggggcgcc cgccggaaagt 60
ggggacacca gtagccgcgg acctcgccaa gacaatgcaa actccagtga acattcccg 120
gcctgtgtctc cgtgctgccc cggggccctg atggcttcag ccgtggcttt gcccctgtatg 180
gacgcagagc ccccttgagg ccagagggttc ctgaaatcca ggagtgtccc atagctcaag 240
aatcccttggaa atcccaggag cagcgggcac gagccgcct tcgggagcgt tacctccgca 300
gcctgtgtgc catgggtgggt catcagggtga gttcacgtt gcacgagggt gtgcgtgtgg 360
ccggccactt tggagccacc gacctggatg tggccaactt ctacgtgtca cagctgcaga 420
ctccccatagg tgtgcaagca gaggcgctgc tccgatgttag tgacattatt tcatataacct 480
tcaagccata aagatattgt gttcactttt ctgcttgagg ctaaggcact gtatcccagg 540
cctcccaatg ttcccagggc aggaactctg ggcccccattgg agttatgagc tcccttggaa 600
ttttgagcca agcttaagc aagtctggac tcctgagacc tcctgggtct agtcagtaaa 660
attctgcaac tcttaggaatt ctaagatccc atttggaaagg atgctctacc tcacagaact 720
ctgaacccta cagaacatat ggccctgtat gccatttcct gaaagaccgg gcatcgggg 780
gaggctgata aaggatacaa ctgcaacagg ggaagggttat acagaggttt aaaaagtccag 840
caccctgtaaag aa 852

<210> SEQ ID NO 24
<211> LENGTH: 851
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

ggttccctct ccccgcccccc agctctggac gtcacccca gtgcaacgcc ctgagtgacg 60
gaaagagcca agacaatgca aactccagtg aacattcccg tgcctgtct ccggctgccc 120
cggggccctg atggcttcag ccgtggcttt gcccctgtatg gacgcagagc ccccttgagg 180
ccagagggttc ctgaaatcca ggagtgtccc atagctcaag aatcccttggaa atcccaggag 240
cagcgggcac gagccgcct tcgggagcgt tacctccgca gcctgtggc catgggtgg 300
catcagggtga gttcacgtt gcacgagggt gtgcgtgtgg ccggccactt tggagccacc 360
gacctggatg tggccaactt ctacgtgtca cagctgcaga ctcccatagg tgtgcaagca 420
gaggcgctgc tccgatgttag tgacattatt tcatataacct tcaagccata aagatattgt 480
gttcactttt ctgcttgagg ctaaggcact gtatcccagg cctcccaatg ttcccagggc 540
aggaactctg ggcccccattgg agttatgagc tcccttggaa ttttggcca agcttaagc 600
aagtctggac tcctgagacc tcctgggtct agtcagtaaa attctgcaac tcttaggaatt 660
ctaagatccc atttggaaagg aatgctctac ctcacagaac tctgaaccct acagaaatat 720
ggccctgtat gccatttcct gaagaccggg ggcacatgggg tgggggtat aaaggataca 780
accctgcaca gggggaaagt tattaaaaga agctgcaaaag tccagccacc cctgaaagat 840
actcccccccg t 851

-continued

<210> SEQ ID NO 25
<211> LENGTH: 1631
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

taggtggtgg	ggggtcgcca	gcaggttccc	tctcccggo	cccagctctg	gacgctcacc	60
ccagtgcAAC	gcctcgAGTg	acggAAAGAG	gtctggCGGc	ttctctgttg	acaactcAGC	120
tggTCCACA	ccctggcaAT	tgtgaAGAGC	tggccaaATG	tttgcact	gagctgatCT	180
cctctctGGA	gcACCGGGGC	caccaggAGG	gagCCAAGAC	aatgCAAACt	ccagtGAACA	240
ttcccgTGcc	tgtgctccGG	ctgccccGGG	gccctgatGG	cttcagCCGT	ggcttGCCc	300
ctgatggACG	cAGAGCCCC	ttgaggCCAG	aggttccTGA	aatccaggAG	tgtcccATAg	360
ctcaagaATC	cctggAAATCC	caggAGCAGC	gggcACGAGC	cgccttcGG	gagcgttAcc	420
tccgcAGCCT	gctggccATG	gtgggtcAtC	aggtgAGCTT	cacgttgcAC	gagggtgtGC	480
gtgtggCCGc	ccactttGGA	gccaccGACC	tggatgtGGC	caacttctAC	gtgtcacAGC	540
tgcagactCC	cataggTGTG	caAGCAGAGG	cgctgctCCG	atgtAGTgAC	attatttCAT	600
ataccttCAA	gccataAAAGA	tattgtgtTC	acttttctGC	ttgaggctAA	ggcactgtAT	660
cccaggCCtC	ccaatgttCC	cgagCCAGGA	actctggGCC	ccatggAGTT	atgagctCCC	720
ttggaaTTT	gagccaAGCT	ttaagcaAGT	ctggactCCT	gagacCtCCT	gggtctAGTC	780
agtaaaACTC	tgcaactCTA	ggaattCTAA	gatcccATTG	gaaggAAATG	tctacCTCAC	840
agaactCTGA	accctACAGA	aatatGGGC	tgctGCCATT	tcctGAAGAC	cggggCATCG	900
aggtggggTG	ataaaggATA	caacCTGCAC	agggggAAgT	tattaaAGAG	gctgcaaAGT	960
ccagccACCC	tgaagataCT	ccccAGTgCT	cccctcTGC	taaAGAACCA	gttacCCCGG	1020
gaaaattcGA	ctcctgtTTT	tcttaattA	actataACCgA	cggggatGGa	gtcatCTTA	1080
ggggctggTA	gggtggTTAT	ccaaggGCTG	aatccAGTGG	agctggGCCA	agtacgACAG	1140
gagtccAGAT	aaaggTGTAG	gggctgcACG	gccgcaAGTC	tcctggAAAG	gctggAGTgA	1200
ccggcatGCC	gggattGGGA	gattaggATT	tgatttcATT	ttggggCGGG	cggtggCTCG	1260
tgctgggtCA	cgtggTcGTG	cccaAGCgCT	cctcctgttG	ccccACCTGT	ggttgctgtG	1320
gactgcACAC	gacAGCAGAT	tcgctgtccc	ctcgTGGAG	gcgaatggTC	ggacCCGAG	1380
tggcggCGCC	cctgataAAA	ggccgAGGAT	tcgcgatCAG	ggtgcaACTT	cactCCtCC	1440
tctcttCTCT	ccagcCTTGC	agcgtggCCG	ttcacatCAC	gcgcTTACT	aaGCTCCTA	1500
tcactagTAA	ccttccAGCG	cattgttAA	aaAGAAAGCA	gtttctgtCC	ctttctgtAG	1560
ttcctttaAG	ttcaggATGT	aAGCgAAgCC	ttccattaAG	taaaggTGTG	tgtcgTTcG	1620
tctcagtCgC	g					1631

<210> SEQ ID NO 26
<211> LENGTH: 15001
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

cactccatGA	cctccatCTG	tccccAGTc	cctcttggat	ctcactttCT	ccatctgtCA	60
aaggaggTAG	ggcaggTTGG	aactAGAGGG	ttatctgAGG	tggTTTCTC	ttcactGCCG	120

-continued

cctccctctga tcaccctttt ttttttgta attttaatt tttcaaaaaa aattatttt	180
aaatagagac agggactcgc tttgtgccc tggttggct gaaaactttg gcttgaagcg	240
ctcctcctgc ttcagcatcc caaagtgcg agattacagg tgtgagacac tgcaactcagc	300
ctcagaccac ccaattttaa gttccatggc aacccagcca cccactatcc cattgccctt	360
attttactct tttttttttt tttttttttt gagatggagt ttcaacttttgg tttttttttt	420
tggagtgcag tggcaegacc tcagctcaact gcaacctccg cttcccggt tcaagtgatt	480
ctcctgcctg acoctccgga gtactggga ttacagatgc ccggctaatt tttctatttt	540
tagtagagac agggtttac acatgttggcc aggctggct cgaactcctg acctcaggttgc	600
atccacccgc ctcagctcc caaagtgcg gaattacagg cgtgagccac cgtgccccggc	660
ctattttatt ctttatacat cactttgtatc aaaccctgaa ggatcttgg tacatattttt	720
ctcattttac cctattctgt cccttctacc cccactagaa cgttaggttcttggaggcagg	780
atggggatcttgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	840
atttatttgcg cacctactat gtgtctgtatc atattttttt aacagatatt tgcagagcac	900
caaatttgttgc acctggacttggt gatctgtgg aaagcaaaagg cccacaggat	960
ccctgcgtaa agaggcccc gcaaggagaa agtgaattctt gactgggcctt ggaataggaa	1020
ggttcatatt cccatttcaaa ggcctcgtt tcccccttttgg taaaatgggg ctgcaggggag	1080
agctggagga caaaatgacc gcctctgtatc cagcccgactt accttttttttgcggcat	1140
ctgaaaccat gatctccagg tttctctgtatc agggcggggg gttcccactg gaagcaagg	1200
gttaggatgttgc ggtatgttgc gggggatggg gatgcaaaaga ccgagctctg cccttaacc	1260
agcaggggagg aagtcttccc ctctctgtatc ctcagtttctt ccctgcctaa aatgggcattc	1320
ccagacgcccc ccaactcgca ggcaggaaaga tcggtcccaa gtgccccggca aagccgcgg	1380
ccagggtggcg acccgggctg tgctggcttc caaggctgcg agccagcccg cgaccacgttgc	1440
gggcagtggc gggggggggc gggaaaccca ggctccggcg cttgcggcctt gccegggcctt	1500
ctgcagcggg ggcggccggcg gaagtggggc caccagtgcg cggggacccctt ggtgagtaca	1560
aggtggatggg gggtcggccat caggtttccctt ccctccggcc ccagctctgg acgctcacc	1620
cagtgcacgc ccctgtatgtatc cggaaagagg taggaccgcg cctgcagcgcc cggctggagg	1680
gacgttctgg tccccacgc ctcctatcatc ggactgttttgcg atcccgatcg ccggcagcg	1740
gaatgccccca cgggggtggg gtgaggagaa gggagaagga gaaaaacttc ccctccggaa	1800
aataataaat ggccacgata acagaagcat cgggtggactt catcccgctt tacctggagc	1860
ggaatcgctc gctcgttgc agcctggagg tggaaagaag gtccagtcg aacgcccagg	1920
gccccggggc gagggtggggc ctggggggccgg ggaggaccta cttgtataaa gaaaaggaga	1980
gcaatgggtg gtcaggccgg aattgaaagg aaactgaccg gccccagggg agaaggggg	2040
ggggagagatt ctgtgtttgg ggttctgtatc ctctcggttgc gccccatttgc gtaatttgc	2100
atcaagatcc acgagccat gatgtctgtatc tggatgtgttgc gatgttgc acgtcaaca	2160
ccttggatataa ttaatttagt ctggcggtt ctctgttgc aactcagctg gttccacacc	2220
ctggcaatttgc tgaagatgtt gccaaatgtt tggatgtgtatc gctgtatcc tctctggagc	2280
accggggccca ccaggaggaa ggtctgtgaa accccctggcc ctggcatttgc cctaagtgttgc	2340
gggcttttgc atctaacaatgtt tttttttttt aagtcgtggg ggtatggggctt gggcattttt	2400

-continued

ccctgaaacc ttccggaaatc cttgccttgg agactgaaag gataaaggcc tctggggcca	2460
ggtcaccagg gacaatggat aacgcctgcc tctaccctcc tgggcacacc ctgtgtgatc	2520
tttcttaaac cagtttctta tcaggtcaca ccttggctcc acagtctgcc tttctacatg	2580
gggcacgggt gaggaccaga gtttgctccc ttttctcca ccctccagct tgacccaagg	2640
aatgatttt tttttttttt ttttggaaac agagtctca tctgtggccc aggctgggt	2700
gcagaggcgt gatctccgct cactgcaacc tccgtctccc tggttcaagg gattctctg	2760
cctcagccctc ctgcgttagct gggattacag atgcgtgcca ccacatccag ctaattttt	2820
ttgtatTTTT agtagagata gggtttccacc atgttagcca ggctggtctt aaactcctga	2880
catcaggtga tctgcctccc tcagtctccc aaagtgcgtt gattacaggt gtgaaccact	2940
gcacccagcc cgaggaaaga tttgacactgc cagttcaact ggccacttta caaaaatggg	3000
gattgcatca atatgaccaa atctcccttg tttttgttt tttttttttt ttttctgtat	3060
ggagaaaaca aggccctata ctggccctcc cttaaattca ttttatccag ggatttaaca	3120
gaattctttg gccactctaa tcctatctaa gtcatttagt aagtactcac cctagagact	3180
agggggTTTC tcttgaaaact caagtgtttaa tctaggctca ggaaagaccc tgggggctgg	3240
tgaggcctga ctaaatttggaa gtgacagtgg tcagagaaaa taaaaatgc aagttagggcg	3300
tgttggcgtg ggctgtat cccagcttct cggaggctg aggtgggagg atatctttag	3360
tccaggagtt caagatttgc gtgggcaata cagcgagacc tcacccctaa gtaaataat	3420
aagtaaatgt gcttttaaa aaatttagaa atgcaaggcc gggcacgggt gctcatgcct	3480
gtaatcccag cactttggga ggctgaagca ggcagatcg gagtttggaa ccagcctggc	3540
caacgtggcc aaaccgcgtc tctactaaaa atacaaaatt agccatgtgc agtggtgcgc	3600
gcctgtatgc ctagttactt gggaggctga ggcaggagaa ttgcttgaac ccggaggcg	3660
gagggttgcag tgagttgaga tcatgccact gtactccago ctggcgacca agagtggagac	3720
tccgtcttaa aaaaaaaaaa aaaatttagaa aatgcaacta tcccttaatt ccattcacgt	3780
ggcttccct gtcaggaaaa aaaaaaaaaa cttggagtc tcccttggct gcttttccc	3840
tcaaattata tatcccttat cctgtccatc accgagggt ctgacccctt cttttttgt	3900
ttgttttgt tgtttgaga tggagtctca ctctgtcatc catgctggaa tgcaatggca	3960
cgtatccgc tcaacttcaac ctccgcttcc cgggttcaag cgattctct gcctcagcct	4020
cccgagtagc tgggattaca ggcacgcacc accacaccca gctaactttt gtatTTTTAG	4080
tagagagagg ttccaccatg ttgaccaggc tggctctatc ctgacccatcg gcatctacc	4140
cacccatcgcc ttcaaaatgt ctgggattac aggcgtgacc tactgcgcc agcctcgacc	4200
tttcaacat agcataatct gaccactct cccattccc attgtccccca gcccatacta	4260
gacgcacatct tcttccacatc ggaccactac agtgcctcc tcattgcgtt cctagtgct	4320
cccttcaatc tcgtttatttgc tccatgcaggc aggcagagga tcctgaggac cttaagccag	4380
attctgcccacca tccttactc agaactgtcc agtggctca gtctcagagt agagacccaa	4440
attgtcatca cagccccacaa ggcactctct ctgtccctgc cccacactcc tccacactgg	4500
ccttgcatac ccccaaaagcc acccttccaa tggatTTTGC attttgcctt tccttctgac	4560
tggaaatctcc acatggctcc attcctaatt tcattcaggat ctatgctcaa acgtaatctt	4620
atcatagggaa tctttccctgg gctcccttga aactaccctc tatcccccaag gctgggtcag	4680

-continued

gtgtctccctc	tggactcattt	cattccagcc	ctactcaactt	tgggtcatca	ctgcctaaagg	4740
acaggcttgt	gtcccattt	ggactgtgag	cccacaagg	cggaactggg	ctctcagtcc	4800
tagacgtgtt	tccaagaccg	cccaatgtgg	gtcatgcaca	gagcaggcac	tcagatgtat	4860
tgctaacaat	gctagataat	gtggatgagt	gaatttttt	tttttgaga	cagggtctca	4920
tactctgtca	cccaggctgg	agtagtgg	cacagttatg	gctcaactgca	gcctccacct	4980
accaggctca	agegatcccc	tcacctcggt	ctccttagta	gctgggactc	tagtcgcaca	5040
ctacccatgc	ccagctaattt	ttttttttt	ttttagaga	tgggttttg	ctatattgt	5100
caggctggtc	ttgaactcct	acgctaaagc	aattctccag	cctcagtctc	ccaagggtgt	5160
gggattatag	tttgagcca	ccgcacctgg	ctagaaaact	tttctttgg	gcataaaaat	5220
gatataaaat	tcaaatttca	gtgtcccagt	aagtaagggtt	ttgttgaga	acagccatgt	5280
tcatttgttt	ccatattgtc	tatggctgt	gttgtgctac	tgtggcagag	ttgagcagtg	5340
acagtaaaat	acttacagag	aaggttcgca	gacctctgt	acgtatttt	ccaagaagaa	5400
aaataaaata	aagttaaaat	tgaaaatatg	ttgcccgtg	ggcgccgtag	ctcacgcctg	5460
taatcccgcc	actttggaa	gctgaactgg	gggtgggtca	cctgagacca	ggagatgtag	5520
accagcctgg	ccaacatgg	gaaaccctgt	ctctactaa	ataaaaaat	tagccaggca	5580
tggtggcgcg	cacctgtat	cccagctact	caggaggctg	aggcaggaga	attgcttcaa	5640
cccaggaggg	agagggttgc	atgagccaag	attgcaccac	tgcaactccag	cctgggggat	5700
agagtgagac	tccatcccc	aaacaatttt	gccaaggagg	attctatttt	ggccacctat	5760
gggcgtgtga	gatcagtaag	atttggcagc	taattatgca	gagtgggtga	tgaggtttag	5820
atgcctccca	gggagagctc	ttttcacat	tttctttcc	aattcttctt	ctttttttt	5880
ttttttgt	ttgagacagg	gtctcaactct	tcccaggctg	gagtgcagtg	gtgcaatcac	5940
atctcaactgc	agcctcagcc	tcctccggct	cactagatct	tcccacctca	gcctccttag	6000
tagctggac	tacaggagcg	caccccttgc	ccagctaattt	tttctatttt	tctggagacg	6060
agatttgtct	atgttgcaca	agctggcttc	aaattcctgg	gctcaagtga	tccacctgcc	6120
tcagectccc	aaagttctgg	aattacaggt	gtgagccacc	tcgtgcccag	ctgcttcttg	6180
ctttctgaaa	ttaaaaattt	ggccgggcac	ggtggctcac	gcctgtataa	ctagcacttt	6240
gggaggccaa	ggcggttgg	tcacctgagg	taaggagttc	aagaccagcc	tggcaacat	6300
ggggaaaccc	cgtctctact	gaaaataaaa	atatcagctg	ggcgtggctcg	cggcacctg	6360
taatcccgcc	tacttggag	gctgagtgac	gagaatcgct	tgaacccggg	aggeggacgt	6420
tgttagtgac	caagatcgcg	ccactgcact	cctgcttggg	cgacaagagc	gagactccat	6480
ctcacaaaaaa	aaaaaaaaaa	aaaagaaat	taaaatttag	tggctggca	tggtgccat	6540
gacctgtat	cccagcaccc	tggggaggctg	aggcaagagg	atcacttgag	cccagggtgg	6600
agaccagcct	ggcaatata	gtgcgacttc	atctctataa	aataaaaataa	aattaattaa	6660
ttaaaaattt	tatttatata	tttattttt	ttgagacaga	gtctcgctgt	gttgtccagg	6720
ctggaggtgca	gtggcatgac	ctcagctcac	tgcagctct	ggctcacggg	ttcaagcgat	6780
tcttatgcct	cacccctctg	agtagttggg	attacaggtg	tgtgccacca	tgcctggcta	6840
atttttgggg	cgtttgtttt	ttttgagat	ggagtcccag	tctgtcaccc	agactggagt	6900
gcagtggcac	aatatctcag	ctcactgcaaa	cctctgcctc	ccgggttcaa	gagagtctcc	6960

-continued

tgcctcagcc	tcctgagtag	gccccgattac	aggagcctgc	caccatgcc	agcccagcta	7020	
attttattta	tttattttt	ttttgagaca	gagtttact	cttggcct	aggctggagc	7080	
gcaatggcgc	agtctcggt	caccacaacc	tctgcctc	gagttcaagt	gatttcctg	7140	
cttcagcctt	ccaagtagct	gggattacag	gcatgcacca	ccactaatta	cagaatgc	7200	
ccatcaggct	aattttgtat	tttttagtga	ggcagggtct	ctccatgttg	gtcaggctgg	7260	
tctcgaactc	ctgacctcag	gtgatccgc	cacctcgcc	tctcaaagt	ctgaaattac	7320	
aggcgtgagc	cacagtgc	ggccaacacc	cggctaattt	tttgtatttct	tagtacagac	7380	
agggtttcac	cgtgttgacc	agggttgtct	caaactcctg	acctcagg	atccgcctgc	7440	
ctcggcctcc	caaagtctg	ggtttacagg	cgggagcc	tgtgccc	ctatgttcat	7500	
gtcttctata	gcatcttta	ttccttc	cctcttgc	acctgttgc	ctgcatcgt	7560	
gtttcatttgc	gggcatcag	gagacgttgc	gcaattc	gagactttaa	aaaaaaactg	7620	
tatttagatgc	caattcacat	tcaccaattc	actgttcc	agtgg	gaca	7680	
tcacaacttgc	aagatggat	gctactggca	tctattaata	ggaggcag	gctaggatgc	7740	
tgctcaaacc	ctacacccat	gcttggaca	gccccca	catagcagat	aattatccag	7800	
ccccaaatgt	caatagtgtc	cagactgagt	agccctgg	catatc	gtctatctgc	7860	
agggtcctgt	cttgcaagg	gctcacagtt	cagg	tcaga	gacaggaaga	7920	
aaaaaggaca	agtttagtca	ggcacagtgg	ctcacgc	taatcccacc	acttggag	7980	
gctgagatgg	gggggatcac	ttgegg	gagttcg	ccagc	ctgac	8040	
aaaccccg	tctactaaaa	ataca	aaaag	tagctgg	tggtgg	8100	
cgcagttct	cgggagactg	aggcaca	aga	atctttttt	ttttttt	ttttttgag	8160
acggagtctc	gctctgtc	ccagg	ctgg	gtc	gtc	ctca	8220
gctccgc	cggggttac	gccattt	tgc	tcc	gag	ctggactac	8280
aggcga	caccacgccc	ggctaa	ttt	ttgtat	ttt	aatagagatg	8340
ttgttagcca	ggatgg	tc	atctc	cctcg	gtc	gcttccaa	8400
agtgtggta	ttacagg	gt	gac	ccac	aca	agaatct	8460
ggaggcggag	gttgc	actg	g	ccg	agg	ttgg	8520
tgagactctg	tctcc	aaaa	agg	aaaa	aaa	agaaacagg	8580
ctgtgcctgg	ccccagg	gttgg	ta	aac	actt	gtc	8640
actagg	tttta	gagagg	gac	aa	agg	ccat	8700
tcctc	tctc	tc	agg	cc	cac	atc	8760
tagcat	atgt	ccc	ag	cc	ca	atc	8820
tagtccc	at	gccc	gc	cc	cc	atc	8880
cagatt	atgc	tttta	ccc	agg	gt	ttt	8940
ctt	atgg	aa	gg	cc	at	aa	9000
taac	aggcata	ggc	agc	aa	ttt	ttt	9060
tact	gtgtc	ac	ca	cc	ttt	ttt	9120
gtt	tttgc	at	gat	tttgc	tttgc	tttgc	9180
agat	ctccgc	tt	act	tgca	ac	cc	9240

-continued

catgagtagc	tgggattaca	ggcacgtgcc	accatgccc	gctaattttt	gtattcttag	9300
tagagacggg	gttccaccat	gttgatcagg	ctggtcttga	actcttgc	tcgtgatecca	9360
cctgctttgg	cctcccaaag	tgctgggatt	acaggcgtga	gccaccgcgc	ccagccaatg	9420
tttgttgtt	ttttagatag	agtattgtc	tgttgcggag	gctggagtac	agtggcaca	9480
tctctgtca	ctgcaaccc	tgcctcccag	gttcaagtga	ttctcatgcc	tcaggctccc	9540
caagtagctg	ggattacagg	cacgcaccac	cacgtccggc	tgattttgt	attttagtac	9600
agacggggtt	ttactatgtt	ggccaggctg	ctctcgaact	cctgacccct	agtgtatcctc	9660
cagcctcagc	ccctaaagtg	ctaggattat	aggcatgcgc	cgccatgcc	agctcattca	9720
tgaattctca	ttggctctca	tggcaggcag	tttctggggg	ctggagatcc	agcagtggga	9780
aaagcaaggt	ggccaccc	aaactcacgg	agggaaagga	gatacaggca	gatacaggga	9840
accgaaaatg	caagagccca	agaagggatt	gccaggcato	gcgcctgagg	atcagcgagg	9900
aggcctgtgt	ggctggggtg	gggagagcaa	gcgttgtaca	ccacgagggt	gccggcagga	9960
tccagagcta	agacagaagc	cacaagaggg	ctccgagcag	aggaggata	tgtatctgact	10020
caggcattaa	cagggtgttg	gggtgcagac	ggcgggggggt	gaaggtggaa	gccagggacc	10080
cagtgaggag	ttgactacag	tactccaggc	aggaagtgtc	tgtggctgca	gcaggatgt	10140
ggcagtggag	gaggtgagaa	gtgttagtt	gtgaataat	aaatatgtt	gtgtgttat	10200
atataagatat	ataatttttt	ttttttttt	tttttagac	agagtcttgc	tctgtcgccc	10260
aggctggagt	actgtggcac	aatctcggt	cactgcaacc	tctgcttccc	aagttaagt	10320
gactctcctg	cctcgccctc	ctgagtagct	gggattacag	gtgcccgc	cgatgcttgg	10380
ctaatttttg	tattttcgt	agagacgggg	tttcaccatg	tggccaggc	tggctcga	10440
ctcctgacct	caagtgtatct	gcccacctcg	gcctccaaa	gtgctggat	tacaggtgt	10500
agccactgct	cccagccta	tacaatttt	ttctcagct	ttttttgtct	tttatgtact	10560
taatattttt	gaagagccca	ggttagttt	gtgtttttt	ttttgtttt	ttctaagaca	10620
aagtctca	cttggccagg	cgtggagtgc	agtggcgcga	tcatagtc	ctgcagcttc	10680
aacctccag	ggctccagtg	attcttttac	ctcagtc	ttagtagctg	ggacttccac	10740
gagtagatt	tcaagcctgg	ctaatgtttt	ttattttag	tagagacgag	gtcttaccat	10800
gttggccagg	ctgcttgc	actcttgcac	gcaagcaatc	ctctcacctt	ggccctcgt	10860
ggtgctggga	ttataggcat	gagccaccat	gcctatccct	gttgccttgc	tttggccagg	10920
aggctggaaag	atcaacttgc	gccagaagtt	caagaccgc	ctcggcaaca	tagtgagacc	10980
ctgtctctt	aaaatttaaa	aaaaaaagaa	aaggaatgc	acagaagtgg	tgccctgc	11040
tcttagtgc	ccattcctgg	agatgttgc	tttgcact	aagttaagg	ggtgcatacc	11100
aggttccctcc	agtataaatt	tgtgtttgc	ctttacagtg	aatgaatatc	ttataagtct	11160
gttaagacta	tgttagatacc	ttataactca	tcaaactccc	atccatgtt	ttttttttt	11220
ttctttttt	tgacacagag	tctcaactcg	tcggccaggc	tagagtgt	tggtgccatc	11280
tctgtca	gcagcctccg	cctttgggt	tcaaattgatt	ctctgcctt	aacctcccg	11340
gtagctggga	ctacaggcgc	atgacaccac	accggctaa	ttttgtatt	tttggtagag	11400
gccccggtttc	gccccatgttgc	ccaggctgtt	ctcgaattcc	tgacactcaag	tgattcgccc	11460
accttggccct	ccccaaatgtt	tgggattaca	ggtgtgagcc	accgcacccg	gccctatcca	11520

-continued

cacatttttg catctattcc ttttatattt atttacttgc cagtctacag taaggattat 11580
attttccttc tcttccttat ttattcattt atttattattt ggtatggatt ctggattct 11640
gttttatcca gtgggtata atctgttaact atcattatgt tattgttcaa ataattccag 11700
atttggcac tgggagccct ttcaagctag ctcatgttg agtggaaatc tatctagaag 11760
atagaatttc ctgatggatt gggtgggtt tggtgtgagag aaagctgggg tttattctt 11820
tttttagaga cagtgtctca ctctgtcacc caagctggag tgcagttca caattacagc 11880
tcactgcaggc ctccatctcc tgggctcaac taatccttct ccctcagccct cctgagtgc 11940
ccagctaatg taaaatatatt atatataattt ttagaaatgg ggtctcgta tattgcccag 12000
gctggctca aactcccaggc ttcaaaatgtga tcctcctgcc ttggcctccaa aaaggctgg 12060
gattacaggc atgagccacc atgcctggcc aggttcatct tttggcaaat atttattgcc 12120
tataagttga gataaaaaca ttataaaagc agacaaaggt ccttccttc acggggctca 12180
tggttttgcg catgtgacac ttttgcattt gatccaagcc attgggggac gatggcacag 12240
attttaggag ggtggatcag tctggggcag gtgcagtggc gtcgccttgt agaccagcc 12300
ctgcttccac tcctccctcc tccattagcc ccatgttac catgtaatga cttccctgtc 12360
tttttcttca ctcaacagcc aagacaatgc aaactccagc gaacattccc gtgcctgtc 12420
tccggcgtcc cccggggccct gatggcttca gcccgtggct tgccccgtat ggacgcagag 12480
cccccttgcg gccagagggtt cctgaaatcc aggagtgtcc catagtctaa gaatccctgg 12540
aatcccaggc gcagcgggca cgagccgccc ttggggagcgtt acatctccgc agcctgtgg 12600
ccatggtggg tcatcagggt agcttcacgt tgacacgggg tgcgtgtgc gcccact 12660
ttggagccac cgacctggat gtggccaaact tctacgtgtc acagctgcag actcccatag 12720
gtgtgcagaagc agaggcgcgtt ctccgtatgtatgttgcattt ttcataacc ttcaaggccat 12780
aaagatattt tgtttacttt tctgttttagt gctaaggcac tgcgttccatg gctcccaat 12840
gttcccggc caggaactctt gggccccatg gagttatgtatgttgcattt ggttgcgttgc 12900
aagctttaag caagtctggc ctccctggat tagtgcgttgc tgcgttgcattt ggttgcgttgc 12960
ctcttaggaat tctaagatcc cattggaaagg aatgcgttac ctcacagaac tctgaaccct 13020
acagaaaat gggctgttgc ccatttcctt aagaccgggg cattgggggtt ggggtataaa 13080
ggatataacc tgcacagggg gaagtttata aagaggctgc aaagtccagc caccctgaag 13140
atactccccca gtgtcccccctt cctgttgcattt aaccgttac cccaggaaaa ttgcacttgc 13200
gtttttctttt aattaactat accgacgggg atggagttcat ctttaggggc tggtaggggt 13260
gttatccaaag ggctgaatcc agtggagctg ggccaaagttac gacaggagtc cagataaagg 13320
tgttagggctt gcacggccgc aagtcttcctt gaaaggctgg agtgcacggc atgcggggat 13380
tgggagatta ggatggattt tcattttggg ggggggggtt gctgtgttgc ggtcaegttgc 13440
tcgtgccttccat gggcttccat tggggccat cctgtgggtt cttgtggacttgc cacacgcac 13500
cagattcgctt gttccctgtt tggaggccaa tggtcggacc ccgagttggcg gggccccctgaa 13560
taaaaggccg aggattcgccg atcagggtgc aacttcactc cttccctttt tctctccagc 13620
cttgcacgttgc ggccgttccat atcacgcgttgc tcaactaagcc tcctatcact agtaaccctt 13680
cagcgcattt gttaaaaaga aagcagtttgc tgcgttgc tttgttttgc ttaagttcag 13740
gtatqtaaqcg aagccttccat ttaaqtaaaat qtgatgttgc tttgttttgc tgcgttgc 13800

-continued

```

tgccggcgcc gatgatgaac cgccgcagga gcagcctcg cggccatcg tccatcgca 13860
gcccggctc cgccgaggcc cggacttagc tctcgagttg ccttggcgac gacgcagetc 13920
gtccggcccc agttcccttt tatggtttca gccccgcctc ctctagttag ccgggtgcgc 13980
ttcggcaagc gtggcggaaag tgccggcgcc aatgtcaagg gttgggtctg agcctagggg 14040
tgtggcttga gctcacgctg gtttttttgcctcgatgta tccaccaggcc ttgtcacccca 14100
ggatttaggt tggcagattc gtctctcgcc tttggaaattt ctacatttcctc ctaggtttt 14160
ttttttaaaa tcaggcctat gataccgctc atgggctcat atttatttttgcattgtat 14220
ttaagttgtat ttttatgcaa ctctaccccg atacagagag ctgttgcgtat aactgcagcg 14280
agcaaatgga ggacttagaga cttagcgaagg ggccgagact tcgtctccag agtatccctg 14340
tcagcatcca tcaactgcac tcataatttgc aatgcagctc ctatccgcct ttctttcg 14400
cttcttcatg ccgttaccac tcttcatcgat ttagtgcgtat ctaatgtttt tcattttttt 14460
cctttttttt ttttggggggggggggaaacgg agtcttgcgtat tgccggccag gctggagtg 14520
agtggcacga tctcggtca ctaaaagctc cgcctcccggttccacca ttctcggtcc 14580
tcaggctccc gagtagctgg gactacaggc gcccggccacc acggccggct aattttttt 14640
attttttagta gagacgggggttccaccgtgt tagccaggat ggtctcgatc tcctaaccctc 14700
gtgatccgcc cgtgtcgcc ttccaaatgt ctgggattac aggcgtgagc caccgcgccc 14760
ggcccattttcc ttcccttcgttgcgtat gtcgttgcgtat gtctaccagg tcggagtgc 14820
ggggcgcgat catagctcgtat tgcacccgtca acctaccggg ctcaagegat ctccccacct 14880
cccaagtagc tgaaactaca ggctccgtat accagaccct gctaattttt aaattttttt 14940
taaagacggg gccttgctat gttggccagg ctggtctcgactcctggac tcaagcgatc 15000
t 15001

```

```

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

```

```
<400> SEQUENCE: 27
```

```
ccctactcag taggcattgg 20
```

```

<210> SEQ ID NO 28
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

```

```
<400> SEQUENCE: 28
```

```
gccaagctg gcatccgtca 20
```

```

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

```

```
<400> SEQUENCE: 29
```

-continued

cgtgtgtctg tgcttagtccc	20
 <pre><210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 30</pre>	
ggcaacgtga acaggtccaa	20
 <pre><210> SEQ ID NO 31 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 31</pre>	
aggtagctt gattatgtaa	20
 <pre><210> SEQ ID NO 32 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 32</pre>	
gcccatgtc ggacatgc	18
 <pre><210> SEQ ID NO 33 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 33</pre>	
agcccatgtc tggacatgca	20
 <pre><210> SEQ ID NO 34 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 34</pre>	
gcttgtgtgc tctgctgtct	20
 <pre><210> SEQ ID NO 35 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 35</pre>	
ttgtccccagt cccaggcctc	20

-continued

```
<210> SEQ ID NO 36
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 36
ctctctgttag gccccgttgg                                20

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 37
ctttccgttg gaccctggg                                20

<210> SEQ ID NO 38
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 38
gtgcgcgcga gccccgaaatc                                20

<210> SEQ ID NO 39
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 39
gctcagtgga catggatgag                                20

<210> SEQ ID NO 40
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 40
atccaagtgc tactgttaga                                20

<210> SEQ ID NO 41
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 41
ataccgcgat cagtgcatct tt                                22

<210> SEQ ID NO 42
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 42

agactagcggtatctttatcc

22

<210> SEQ ID NO 43
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: 1-20
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 43

nnnnnnnnnnnnnnnnnn

20

<210> SEQ ID NO 44
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 44

ttctacacctcgcgcgatttac

20

<210> SEQ ID NO 45
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 45

tagtgccggacctacccacga

20

<210> SEQ ID NO 46
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 46

gccctccatgctggcacagg

20

<210> SEQ ID NO 47
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 47

agcaaaagatcaatccgtta

20

<210> SEQ ID NO 48
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 48

ggaccccgaa agaccaccag

20

<210> SEQ ID NO 49
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 49

ctgcttagctt ctggatttga

20

<210> SEQ ID NO 50
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 50

ctgcctggat ggggtttttt

20

<210> SEQ ID NO 51
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 51

tccccctgt gacatgcatt

20

<210> SEQ ID NO 52
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 52

tacagaaggc tgggccttga

20

<210> SEQ ID NO 53
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 53

atgcattctg ccccaagga

20

<210> SEQ ID NO 54
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 54

-continued

ccaacctcaa atgtccca 18

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 55

aggcatggtc tttgtcaata 20

<210> SEQ ID NO 56
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 56

tgtgctattc tgtgaatt 18

<210> SEQ ID NO 57
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 57

caacggattt ggtcgatttg g 21

<210> SEQ ID NO 58
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 58

ggcaacaata tccactttac cagagt 26

<210> SEQ ID NO 59
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 59

cgccctggta ccagggctgc t 21

<210> SEQ ID NO 60
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 60

gaagggtgaag gtcggagtc 19

-continued

```
<210> SEQ ID NO 61
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 61
gaagatggtg atgggatttc                                20

<210> SEQ ID NO 62
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 62
caagcttccc gttctcagcc                                20

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 63
tggaatcata ttggAACATG                                20

<210> SEQ ID NO 64
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 64
ggcaaattca acggcacagt                                20

<210> SEQ ID NO 65
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 65
gggtctcgct cctggaaAGAT                                20

<210> SEQ ID NO 66
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 66
aaggccgaga atgggaAGCT tgtcatc                                27

<210> SEQ ID NO 67
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 67

tgttctagag acagccgcat ctt

23

<210> SEQ ID NO 68
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 68

caccgacctt caccatcttg t

21

<210> SEQ ID NO 69
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 69

tttgtcagtgc ccagcctcggt ctca

24

<210> SEQ ID NO 70
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 70

caaattgacc caaaagaagtt gaaa

24

<210> SEQ ID NO 71
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 71

gttgctgttg ccattgaagt gt

22

<210> SEQ ID NO 72
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 72

acccggccctt gaagggttatt cccc

24

<210> SEQ ID NO 73
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 73

-continued

gaagtgcagg gtcccaattc 20

<210> SEQ ID NO 74
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 74

ttcatccaga cggtttcttt ga 22

<210> SEQ ID NO 75
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 75

tctgccactt tcatgggtgc at 22

<210> SEQ ID NO 76
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 76

gcaaaagctc ctccctttac ca 22

<210> SEQ ID NO 77
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 77

gtcacccctct ccacgaaagg 20

<210> SEQ ID NO 78
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 78

acttggaaca cgggcaccga ag 22

<210> SEQ ID NO 79
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 79

gagaagaacc acatccccat ca 22

-continued

```
<210> SEQ ID NO 80
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 80
gaccggcagcc acacagaga                                19

<210> SEQ ID NO 81
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 81
tgaacaggaa gacgctccaa gga                            23

<210> SEQ ID NO 82
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward Primer

<400> SEQUENCE: 82
ccttcaagcc ataaagatata tttgttcc                                27

<210> SEQ ID NO 83
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse Primer

<400> SEQUENCE: 83
ttggggaggcc tgggataca                                19

<210> SEQ ID NO 84
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 84
cttttctgtt tgaggcttaag gca                            23

<210> SEQ ID NO 85
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 85
ttactgttgc ttgtacataaa                                20

<210> SEQ ID NO 86
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 86

gtcaaaatac cactaagagc 20

<210> SEQ ID NO 87
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 87

tgcttcgatc cgccaatagc 20

<210> SEQ ID NO 88
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 88

caataaaaattt ttatatgtat 20

<210> SEQ ID NO 89
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 89

taggagtcaa acaaaaatttt 20

<210> SEQ ID NO 90
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 90

gctaaggcca tccattgtct 20

<210> SEQ ID NO 91
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 91

tttaattct gatgctaagg 20

<210> SEQ ID NO 92
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 92

-continued

gccatattaat ccagattatt	20
 <pre><210> SEQ ID NO 93 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 93</pre>	
cacattgcca ttaaatccag	20
 <pre><210> SEQ ID NO 94 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 94</pre>	
ttgctgacta tgaacacatt	20
 <pre><210> SEQ ID NO 95 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 95</pre>	
aattttattt ctgactatga	20
 <pre><210> SEQ ID NO 96 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 96</pre>	
gccatcttcc ctgattcatt	20
 <pre><210> SEQ ID NO 97 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 97</pre>	
aaaaaccaat cattgtcaca	20
 <pre><210> SEQ ID NO 98 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 98</pre>	
cgcaggcgca ctaatagaca	20

-continued

```
<210> SEQ ID NO 99
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 99
gtcacagcgc aggcgcacta                                20

<210> SEQ ID NO 100
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 100
ttctaggta cagcgcaggc                                20

<210> SEQ ID NO 101
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 101
ggcgcatgcg cccattctag                                20

<210> SEQ ID NO 102
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 102
tttcaaaacc agccagttcc                                20

<210> SEQ ID NO 103
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 103
gtcaagtgcg aaggctctac                                20

<210> SEQ ID NO 104
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 104
gctaccacaa catctggaca                                20

<210> SEQ ID NO 105
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 105

tctttgggtc aattttagct

20

<210> SEQ ID NO 106
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 106

ttcaacttct ttgggtcaat

20

<210> SEQ ID NO 107
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 107

cacttgctt cctttcaac

20

<210> SEQ ID NO 108
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 108

atccctgaaag agaaatattc

20

<210> SEQ ID NO 109
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 109

gttgccattt aagtgttggg

20

<210> SEQ ID NO 110
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 110

tgctgttgcc attgaagtgt

20

<210> SEQ ID NO 111
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 111

-continued

gtgccacttg ttgctttgc 20

<210> SEQ ID NO 112
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 112

tcgaacagtt gaaaaacttgt 20

<210> SEQ ID NO 113
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 113

tgttacatt ctgtcgaaca 20

<210> SEQ ID NO 114
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 114

ataatctatt ccaggacttt 20

<210> SEQ ID NO 115
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 115

gcctgattca ttctgtaac 20

<210> SEQ ID NO 116
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 116

gttgccctgat tcattctgct 20

<210> SEQ ID NO 117
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 117

caagacacta gttactgtt 20

-continued

<210> SEQ ID NO 118
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 118

ttccaagaca ctagttactg

20

<210> SEQ ID NO 119
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 119

agatattcca agacactagt

20

<210> SEQ ID NO 120
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 120

caaaccattt actcagatat

20

<210> SEQ ID NO 121
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 121

gtcttttctt ccaaaccat

20

<210> SEQ ID NO 122
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 122

gtaaaagtctc tttctccaaa

20

<210> SEQ ID NO 123
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 123

ctggagtaaa gtctttctt

20

<210> SEQ ID NO 124
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 124

caattctgga gtaaaagtctc 20

<210> SEQ ID NO 125
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 125

cttcccaatt ctggagtaaa 20

<210> SEQ ID NO 126
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 126

ccatcttccc aattctggag 20

<210> SEQ ID NO 127
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 127

ttttcaagac aagccaataa 20

<210> SEQ ID NO 128
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 128

ggctttcaa gacaagccaa 20

<210> SEQ ID NO 129
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 129

caaaggctt tcaagacaag 20

<210> SEQ ID NO 130
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 130

-continued

gtaacaaagg ctttcaaga	20
 <pre><210> SEQ ID NO 131 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 131</pre>	
agtgaatgag ctcaggtaa	20
 <pre><210> SEQ ID NO 132 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 132</pre>	
aaatacctgc taaccaagca	20
 <pre><210> SEQ ID NO 133 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 133</pre>	
tcaaaaatacc tgctaaccaa	20
 <pre><210> SEQ ID NO 134 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 134</pre>	
ggctcatcag ctaaatcacr	20
 <pre><210> SEQ ID NO 135 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 135</pre>	
gatggctcat cagctaaatc	20
 <pre><210> SEQ ID NO 136 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 136</pre>	
atcaagatgg ctcatcagct	20

-continued

<210> SEQ ID NO 137
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 137

tcagctacat caagatggct 20

<210> SEQ ID NO 138
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 138

agaaaatatct tctatccctg 20

<210> SEQ ID NO 139
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 139

gttttcctca gagtttaggct 20

<210> SEQ ID NO 140
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 140

aagatgtgtt gaaatctgt 20

<210> SEQ ID NO 141
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 141

tcacatagtg ttgaagatgt 20

<210> SEQ ID NO 142
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 142

aacccttcac atagtgttga 20

<210> SEQ ID NO 143
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 143

aagatgtgaa cccttcacat

20

<210> SEQ ID NO 144
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 144

caggtaaga tgtgaaccct

20

<210> SEQ ID NO 145
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 145

gtatcaatct gaattgcaca

20

<210> SEQ ID NO 146
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 146

tggggatttt ccattgatat

20

<210> SEQ ID NO 147
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 147

actgagtggg atttccatt

20

<210> SEQ ID NO 148
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 148

aaaaactgag tgggatttc

20

<210> SEQ ID NO 149
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 149

-continued

gttcatcaa aactgagtg	20
 <pre><210> SEQ ID NO 150 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 150</pre>	
tgttcaact gttcatcaa	20
 <pre><210> SEQ ID NO 151 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 151</pre>	
gattacagaa aactgttcaa	20
 <pre><210> SEQ ID NO 152 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 152</pre>	
ctgcttgatt acagaaaaact	20
 <pre><210> SEQ ID NO 153 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 153</pre>	
aatttctatg caagctgctt	20
 <pre><210> SEQ ID NO 154 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 154</pre>	
tgtaaaat tt catcatacaa	20
 <pre><210> SEQ ID NO 155 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 155</pre>	
taagtaaccc atttaaagac	20

-continued

<210> SEQ ID NO 156
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 156

atcctgaaag ctagagatca

20

<210> SEQ ID NO 157
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 157

tgttcacatt ctaaaggaag

20

<210> SEQ ID NO 158
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 158

ggaataaggt tatctacctt

20

<210> SEQ ID NO 159
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 159

caaagaaaagc taattttgttt

20

<210> SEQ ID NO 160
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 160

tgcacttac cactaagagc

20

<210> SEQ ID NO 161
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 161

taatcactgt acagtcaaga

20

<210> SEQ ID NO 162
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 162

ttaactatac ctgctaaacca 20

<210> SEQ ID NO 163
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 163

tgggcacaga gcaatcacac 20

<210> SEQ ID NO 164
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 164

caatcacacg gccacaggat 20

<210> SEQ ID NO 165
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 165

caatcacaca gccacaggat 20

<210> SEQ ID NO 166
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 166

caagacggtg aatgagatcc 20

<210> SEQ ID NO 167
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 167

cttaggcctg ctcacaaacct 20

<210> SEQ ID NO 168
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 168

-continued

ccgcgttag gcctgctcac	20
 <pre><210> SEQ ID NO 169 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 169</pre>	
cacgatggga gacgcaggag	20
 <pre><210> SEQ ID NO 170 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 170</pre>	
ctccccctccg agaactcgaa	20
 <pre><210> SEQ ID NO 171 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 171</pre>	
tccttccagt caaaaacaag	20
 <pre><210> SEQ ID NO 172 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 172</pre>	
tttcagggaa acggtccacc	20
 <pre><210> SEQ ID NO 173 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 173</pre>	
ccttaggtcca tggcggcgac	20
 <pre><210> SEQ ID NO 174 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 174</pre>	
caagggtcct aggtccatgg	20

-continued

<210> SEQ ID NO 175
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 175

ttcaagggtc ctaggtccat 20

<210> SEQ ID NO 176
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 176

catgcagaat agtcatttct 20

<210> SEQ ID NO 177
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 177

gttaattctg ccagtgcctt 20

<210> SEQ ID NO 178
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 178

tcttccaggc aaaggggctgg 20

<210> SEQ ID NO 179
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 179

gctttcttct tccaggcaaa 20

<210> SEQ ID NO 180
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 180

tgccaccgtg tctctgtgtc 20

<210> SEQ ID NO 181
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 181

tcttcggcag aagtgtcaac

20

<210> SEQ ID NO 182
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 182

gatccgactc tggatctgtg

20

<210> SEQ ID NO 183
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 183

cctctgtcag cgcaaacaca

20

<210> SEQ ID NO 184
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 184

gagttccaca cagagatcac

20

<210> SEQ ID NO 185
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 185

gtgtccgagt tccacacaga

20

<210> SEQ ID NO 186
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 186

ttctgggtgt ccgagttcca

20

<210> SEQ ID NO 187
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 187

-continued

cccgcagcag gtgggtcagg	20
 <pre><210> SEQ ID NO 188 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <400> SEQUENCE: 188	
tctggctgaa ggaagtcaaa	20
 <pre><210> SEQ ID NO 189 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <400> SEQUENCE: 189	
aggaagtccc tgacacacactc	20
 <pre><210> SEQ ID NO 190 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <400> SEQUENCE: 190	
gttttcctca ggaagtccct	20
 <pre><210> SEQ ID NO 191 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <400> SEQUENCE: 191	
aggccctgtt cttagcacc	20
 <pre><210> SEQ ID NO 192 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <400> SEQUENCE: 192	
gctgtatata cctccaaggc	20
 <pre><210> SEQ ID NO 193 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <400> SEQUENCE: 193	
cacacttcca tatggcggtc	20

-continued

```
<210> SEQ ID NO 194
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 194
aaggcccaact tcttctcaga                                20

<210> SEQ ID NO 195
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 195
tgttactccc caggcaggct                                20

<210> SEQ ID NO 196
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 196
agcctcaaca ccaagtctgg                                20

<210> SEQ ID NO 197
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 197
ctgcgttaaca ttccaggatc                                20

<210> SEQ ID NO 198
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 198
cataagccag caactttca                                20

<210> SEQ ID NO 199
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 199
gtcttcctga aaaccctcca                                20

<210> SEQ ID NO 200
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 200

ttgaggtctt cctgaaaaacc 20

<210> SEQ ID NO 201
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 201

gggccacgga ggccacagct 20

<210> SEQ ID NO 202
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 202

accgtgactt cggggtgcac 20

<210> SEQ ID NO 203
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 203

tgccgagatt gaccacagcc 20

<210> SEQ ID NO 204
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 204

aggaaaggca gtgagaatct 20

<210> SEQ ID NO 205
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 205

cttccacaaa cctaaggca 20

<210> SEQ ID NO 206
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 206

-continued

ggtgttagaga acttcatcca	20
 <pre><210> SEQ ID NO 207 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 207</pre>	
aggagctcta aaaattgctt	20
 <pre><210> SEQ ID NO 208 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 208</pre>	
agagcagccca ctggaatccc	20
 <pre><210> SEQ ID NO 209 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 209</pre>	
agaaaaggcag gacaaattcc	20
 <pre><210> SEQ ID NO 210 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 210</pre>	
tcagactgag gtctaacctct	20
 <pre><210> SEQ ID NO 211 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 211</pre>	
aagggtctcag cattggctga	20
 <pre><210> SEQ ID NO 212 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 212</pre>	
ggagccagga cagggacttg	20

-continued

```
<210> SEQ ID NO 213
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 213
ttgcgttga gccaggacag 20

<210> SEQ ID NO 214
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 214
cctcaggccc acagtccagt 20

<210> SEQ ID NO 215
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 215
agcagcac tc catccaggcc 20

<210> SEQ ID NO 216
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 216
acctcctcag gattgccac 20

<210> SEQ ID NO 217
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 217
aacagtctga cctcctcagg 20

<210> SEQ ID NO 218
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 218
cgctgccact cctgagggt 20

<210> SEQ ID NO 219
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 219

tggtcagctg gtgaaggcgc

20

<210> SEQ ID NO 220
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 220

aaggggcttc aggttgagca

20

<210> SEQ ID NO 221
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 221

tggctgcaga gaaaactggaa

20

<210> SEQ ID NO 222
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 222

caattacgac agctatggct

20

<210> SEQ ID NO 223
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 223

gcaggtgagg gtttccaagg

20

<210> SEQ ID NO 224
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 224

aggagctgac agaagggttg

20

<210> SEQ ID NO 225
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 225

-continued

tctggagcaa ggagctgaca	20
 <pre><210> SEQ ID NO 226 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 226</pre>	
acgccaagtc agaagctgct	20
 <pre><210> SEQ ID NO 227 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 227</pre>	
gattttctgc agacccgcca	20
 <pre><210> SEQ ID NO 228 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 228</pre>	
cagtttttc gctcccgcac	20
 <pre><210> SEQ ID NO 229 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 229</pre>	
acccttacag acctgccatg	20
 <pre><210> SEQ ID NO 230 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 230</pre>	
ctgctcggtt ctgaccctta	20
 <pre><210> SEQ ID NO 231 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 231</pre>	
tcacataact gtaaagtcca	20

-continued

```
<210> SEQ ID NO 232
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 232
ccatgacttt ttgtggacag                                20

<210> SEQ ID NO 233
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 233
cggcacccac ctaggtccat                                20

<210> SEQ ID NO 234
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 234
gtgatacctc aggagcgcag                                20

<210> SEQ ID NO 235
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 235
ataaggacac tgaggcgcag                                20

<210> SEQ ID NO 236
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 236
ggccctagct ctgtgggaga                                20

<210> SEQ ID NO 237
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 237
ataaaacttgc cttgggaaca                                20

<210> SEQ ID NO 238
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 238

aatcacacag ccacagggtta

20

<210> SEQ ID NO 239
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 239

ggcgagaccc tccagcaaag

20

<210> SEQ ID NO 240
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 240

ttcaagggtc ctgcacacag

20

<210> SEQ ID NO 241
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 241

cctccaaaaac agcttagatac

20

<210> SEQ ID NO 242
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 242

agatcccatt gcaacagttc

20

<210> SEQ ID NO 243
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 243

tctgatgagg cactgaagag

20

<210> SEQ ID NO 244
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 244

-continued

tctatccatt gatgtagaaa	20
 <pre><210> SEQ ID NO 245 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 245</pre>	
gtatgcaaac ccaccaaggg	20
 <pre><210> SEQ ID NO 246 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 246</pre>	
gatatgtgct agaaatctgt	20
 <pre><210> SEQ ID NO 247 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 247</pre>	
gggaaggct gtctccttct	20
 <pre><210> SEQ ID NO 248 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 248</pre>	
taagacaatc ctttcctc	20
 <pre><210> SEQ ID NO 249 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 249</pre>	
tccactaagc ttccaggat	20
 <pre><210> SEQ ID NO 250 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 250</pre>	
tggagccaga ggccatcaga	20

-continued

```
<210> SEQ ID NO 251
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 251
gcacgtaaat gactgcattg                                20

<210> SEQ ID NO 252
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 252
gggctgctct ctagacagt                                20

<210> SEQ ID NO 253
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 253
atgtgggctc cacgccacac                                20

<210> SEQ ID NO 254
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 254
ccctgaata gatgcagtct                                20

<210> SEQ ID NO 255
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 255
tgaggaggcc gggaatgatc                                20

<210> SEQ ID NO 256
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 256
ttctaagggt gggcttttc                                20

<210> SEQ ID NO 257
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 257

atcattctat acagggttagc

20

<210> SEQ ID NO 258
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 258

tgaccttttc cttcaatatac

20

<210> SEQ ID NO 259
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 259

gaaataactc agggtggcca

20

<210> SEQ ID NO 260
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 260

ggagaacacc tttgagatcc

20

<210> SEQ ID NO 261
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 261

catagccaca aggttgtctg

20

<210> SEQ ID NO 262
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 262

tggtagccag ctgctggtgc

20

<210> SEQ ID NO 263
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 263

-continued

aagcagccctt gacatactga	20
 <pre><210> SEQ ID NO 264 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 264</pre>	
cagctccacc gcttcataca	20
 <pre><210> SEQ ID NO 265 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 265</pre>	
atcctctcct acgatggcag	20
 <pre><210> SEQ ID NO 266 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 266</pre>	
ctgagagcca gggaaaggaga	20
 <pre><210> SEQ ID NO 267 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 267</pre>	
acccagttgt tggccagaag	20
 <pre><210> SEQ ID NO 268 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 268</pre>	
ctgaccctgt agactttcat	20
 <pre><210> SEQ ID NO 269 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 269</pre>	
gttctgcagc ttctgaaagg	20

-continued

<210> SEQ ID NO 270
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 270

agtcatggca aatgtgaagc

20

<210> SEQ ID NO 271
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 271

gaggccatct gttggctcag

20

<210> SEQ ID NO 272
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 272

acacttcctg catgatggtg

20

<210> SEQ ID NO 273
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 273

tggcacacgc catcagggag

20

<210> SEQ ID NO 274
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 274

gcagtgtcta actgctggct

20

<210> SEQ ID NO 275
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 275

tggctgagaa gtttcagggt

20

<210> SEQ ID NO 276
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 276

tacactggct ctgagaactg

20

<210> SEQ ID NO 277
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 277

attctctgtt ttgcctcggt

20

<210> SEQ ID NO 278
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 278

tgtgaaaatt cacatacaga

20

<210> SEQ ID NO 279
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 279

gagtgaatgt ctgggtggc

20

<210> SEQ ID NO 280
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 280

aaacttaatc cttgttgta

20

<210> SEQ ID NO 281
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 281

gttgtctatg ggttaggcagg

20

<210> SEQ ID NO 282
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 282

-continued

tttgggtgac gacagaagtt 20

<210> SEQ ID NO 283
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 283

gaagtattta caaaggtagc 20

<210> SEQ ID NO 284
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 284

tctcaaacaa gcatgacaca 20

<210> SEQ ID NO 285
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 285

aaaggatata atatgcctaa 20

<210> SEQ ID NO 286
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 286

ggcctatttc atattcaaac 20

<210> SEQ ID NO 287
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 287

ttcctgagct atttgactgc 20

<210> SEQ ID NO 288
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 288

tgaaaacagta atttattccct 20

-continued

```
<210> SEQ ID NO 289
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 289
aataatccaa aggtcatctta                                20

<210> SEQ ID NO 290
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 290
ttaaatagta ttttagggtcc                                20

<210> SEQ ID NO 291
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 291
gaagctgcca cagccgaccg                                20

<210> SEQ ID NO 292
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 292
ccgtcagaga caagagaagg                                20

<210> SEQ ID NO 293
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 293
tcctgccccca taactacaag                                20

<210> SEQ ID NO 294
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 294
cgacaaaggaa agacggagggt                                20

<210> SEQ ID NO 295
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 295

gtgtccacc aactctccta

20

<210> SEQ ID NO 296
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 296

cagagacctt ttccgttgt

20

<210> SEQ ID NO 297
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 297

atgttctgtc acaactgttt

20

<210> SEQ ID NO 298
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 298

actattaagt cctttactcg

20

<210> SEQ ID NO 299
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 299

ggctgtcatt tctgttaaac

20

<210> SEQ ID NO 300
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 300

tgggttctat aaagagggtgc

20

<210> SEQ ID NO 301
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 301

-continued

attatcacca ctatgccatc	20
 <pre><210> SEQ ID NO 302 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 302</pre>	
atcatcatgg cctcgaagcc	20
 <pre><210> SEQ ID NO 303 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 303</pre>	
ggacaccagg ctatggagtg	20
 <pre><210> SEQ ID NO 304 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 304</pre>	
aagtagcaac ctttgttac	20
 <pre><210> SEQ ID NO 305 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 305</pre>	
tgcttccagt ggctaagtag	20
 <pre><210> SEQ ID NO 306 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 306</pre>	
gattcgaatg gtttgatctt	20
 <pre><210> SEQ ID NO 307 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 307</pre>	
ccctcggcct ctagaacagc	20

-continued

```
<210> SEQ ID NO 308
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 308
tttaacagtt gggtctatac                                20

<210> SEQ ID NO 309
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 309
ggttgattgc tgggccaatg                                20

<210> SEQ ID NO 310
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 310
ccttctccctc caagtgacat                                20

<210> SEQ ID NO 311
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 311
catccccacac ctgggctgtt                                20

<210> SEQ ID NO 312
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 312
aagaactcac tttgattgaa                                20

<210> SEQ ID NO 313
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 313
cagccttata agaacattta                                20

<210> SEQ ID NO 314
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 314

ccaaagttac ctatgacagt

20

<210> SEQ ID NO 315
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 315

ggttgccatg ctttctgg

20

<210> SEQ ID NO 316
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 316

attttgtac ctctggagtg

20

<210> SEQ ID NO 317
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 317

agctgctgtta aacatttgt

20

<210> SEQ ID NO 318
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 318

taactttac cttaatgctc

20

<210> SEQ ID NO 319
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 319

ggtactcagc aaccatgctt

20

<210> SEQ ID NO 320
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 320

-continued

ctctgggtac tcagcaacca	20
 <pre><210> SEQ ID NO 321 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 321</pre>	
agaaccttgg cagagactgg	20
 <pre><210> SEQ ID NO 322 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 322</pre>	
tttaccgaca catccaagaa	20
 <pre><210> SEQ ID NO 323 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 323</pre>	
gccctaagtt cattaatttc	20
 <pre><210> SEQ ID NO 324 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 324</pre>	
ctgcgcctaa tcttaagccaa	20
 <pre><210> SEQ ID NO 325 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 325</pre>	
acctgaagat tgccccatgg	20
 <pre><210> SEQ ID NO 326 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 326</pre>	
ctcctcgcaa ctctgggtac	20

-continued

```
<210> SEQ ID NO 327
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 327
ctggctaaat cagttaaaaa                                         20

<210> SEQ ID NO 328
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 328
ttgccacactg gctaaatcag                                         20

<210> SEQ ID NO 329
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 329
atgattgcca cctggctaaa                                         20

<210> SEQ ID NO 330
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 330
ccattcactc atgattgcca                                         20

<210> SEQ ID NO 331
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 331
ttcatccatt cactcatgt                                         20

<210> SEQ ID NO 332
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 332
tgtaatcttg ccattctaag                                         20

<210> SEQ ID NO 333
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 333

tgtaaatgta atcttgccat

20

<210> SEQ ID NO 334
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 334

ctttgtaaat gtaatcttgc

20

<210> SEQ ID NO 335
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 335

actcggacct ctttgtaaat

20

<210> SEQ ID NO 336
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 336

ctggctgtca ctggacctc

20

<210> SEQ ID NO 337
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 337

ctcaactggct gtcactcgga

20

<210> SEQ ID NO 338
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 338

cttctcaactg gctgtcaactc

20

<210> SEQ ID NO 339
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 339

-continued

ctcattcttc tcactggctg	20
 <pre><210> SEQ ID NO 340 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 340</pre>	
gtagttaaaa cccatcctt	20
 <pre><210> SEQ ID NO 341 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 341</pre>	
gtctgttagtt aaaacccatc	20
 <pre><210> SEQ ID NO 342 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 342</pre>	
ctgggtctgt agttaaaaacc	20
 <pre><210> SEQ ID NO 343 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 343</pre>	
agactgggtc tgttagttaaa	20
 <pre><210> SEQ ID NO 344 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 344</pre>	
ttggcagaga ctgggtctgt	20
 <pre><210> SEQ ID NO 345 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 345</pre>	
aaggacaata ttggcagaga	20

-continued

<210> SEQ ID NO 346
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 346

tcaaggaaagt tcacaaggac

20

<210> SEQ ID NO 347
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 347

gccatcttca aggaagttca

20

<210> SEQ ID NO 348
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 348

ctgccccatctt caagggaaagt

20

<210> SEQ ID NO 349
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 349

gtcacagaca tgctgccc

20

<210> SEQ ID NO 350
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 350

ccgggtcacag acatgctgcc

20

<210> SEQ ID NO 351
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 351

acagcatgtc ccataattcc

20

<210> SEQ ID NO 352
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 352

cagtctgcac agcatgtccc 20

<210> SEQ ID NO 353
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 353

tcaacagtc gcacagcatg 20

<210> SEQ ID NO 354
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 354

tcattcatag tttcaacagt 20

<210> SEQ ID NO 355
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 355

tccccttcat tcatagtttc 20

<210> SEQ ID NO 356
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 356

tatggcccc ttcatccata 20

<210> SEQ ID NO 357
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 357

tctatggtcc ctttcattca 20

<210> SEQ ID NO 358
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 358

-continued

tgaacaaatg catcagcttc	20
 <pre><210> SEQ ID NO 359 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 359</pre>	
cagacgtgaa caaatgcata	20
 <pre><210> SEQ ID NO 360 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 360</pre>	
ctttgcagtc tccagacgtg	20
 <pre><210> SEQ ID NO 361 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 361</pre>	
ctgggctgtt tgctttgcag	20
 <pre><210> SEQ ID NO 362 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 362</pre>	
gatcctctgg gctgtatgt	20
 <pre><210> SEQ ID NO 363 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 363</pre>	
ccagatcctc tgggctgtat	20
 <pre><210> SEQ ID NO 364 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 364</pre>	
tttctctctt ccagatcctc	20

-continued

```
<210> SEQ ID NO 365
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 365
caagccattt ctttaggctg                                20

<210> SEQ ID NO 366
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 366
tctcaagcca tttcttttagg                                20

<210> SEQ ID NO 367
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 367
cttctcaago catttcttta                                20

<210> SEQ ID NO 368
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 368
gttcttctca agccatttct                                20

<210> SEQ ID NO 369
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 369
tggttcttct caagccattt                                20

<210> SEQ ID NO 370
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 370
tgtggttctt ctcaagccat                                20

<210> SEQ ID NO 371
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 371

gggatgtggt tcttctcaag

20

<210> SEQ ID NO 372
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 372

gtctccctgt tcagtgtatgg

20

<210> SEQ ID NO 373
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 373

acacagagag tccttggagc

20

<210> SEQ ID NO 374
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 374

cagccacaca gagagtccctt

20

<210> SEQ ID NO 375
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 375

accccagcca cacagagagt

20

<210> SEQ ID NO 376
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 376

ggtctatagt caggacccca

20

<210> SEQ ID NO 377
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 377

-continued

tatggtgggt ctatagtcag	20
 <pre><210> SEQ ID NO 378 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 378</pre>	
tcatatggtg ggtctatagt	20
 <pre><210> SEQ ID NO 379 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 379</pre>	
aattttctgg atcatatggt	20
 <pre><210> SEQ ID NO 380 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 380</pre>	
ctgcaatttt ctggatcata	20
 <pre><210> SEQ ID NO 381 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 381</pre>	
ttagagctgc tgcaatttc	20
 <pre><210> SEQ ID NO 382 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 382</pre>	
ctcattagag ctgctgcaat	20
 <pre><210> SEQ ID NO 383 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 383</pre>	
cgcgacagaa taatctcatt	20

-continued

<210> SEQ ID NO 384
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 384

agatcctgaa cacgcgcacag

20

<210> SEQ ID NO 385
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 385

ctggcctctc attgggaagc

20

<210> SEQ ID NO 386
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 386

gataaaatat agtcttttc

20

<210> SEQ ID NO 387
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 387

tgagggataa aatatagtct

20

<210> SEQ ID NO 388
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 388

acatttatg agggataaaa

20

<210> SEQ ID NO 389
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 389

attnaaaaaca ttttatgagg

20

<210> SEQ ID NO 390
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 390

tctccgctgg atccccgccat

20

<210> SEQ ID NO 391
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 391

acattccaaa tcgcgttac

20

<210> SEQ ID NO 392
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 392

ctggctaaat ctgaaacaac

20

<210> SEQ ID NO 393
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 393

gcataactcac ttggcagaga

20

<210> SEQ ID NO 394
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 394

tcttttaaga gatatagtga

20

<210> SEQ ID NO 395
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 395

aaagtaagtt tagaggcatc

20

<210> SEQ ID NO 396
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 396

-continued

aaggacaata ctttggagga	20
 <pre><210> SEQ ID NO 397 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 397</pre>	
agagcccaac acttaggtca	20
 <pre><210> SEQ ID NO 398 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 398</pre>	
tagattcaag agcccaacac	20
 <pre><210> SEQ ID NO 399 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 399</pre>	
tccctggtaa cctggccca	20
 <pre><210> SEQ ID NO 400 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 400</pre>	
ttaagaaaga tcacacaggg	20
 <pre><210> SEQ ID NO 401 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 401</pre>	
ggtgtgacct gataagaaac	20
 <pre><210> SEQ ID NO 402 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 402</pre>	
tgccccatg tagaaaggca	20

-continued

<210> SEQ ID NO 403
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 403

agagggagca aactcaggta

20

<210> SEQ ID NO 404
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 404

ggaggaagag ggagcaaact

20

<210> SEQ ID NO 405
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 405

cggctactgg tgtccccact

20

<210> SEQ ID NO 406
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 406

gaggtccgcg gctactggtg

20

<210> SEQ ID NO 407
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 407

attgtcttgg cgagggtccgc

20

<210> SEQ ID NO 408
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 408

tgtcttggct ctttccgtca

20

<210> SEQ ID NO 409
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 409

gcccggcagac ctctttccgt

20

<210> SEQ ID NO 410
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 410

tgtcaacaga gaagccgcga

20

<210> SEQ ID NO 411
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 411

gagtttgtcaa cagagaagcc

20

<210> SEQ ID NO 412
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 412

aaccagctga gtttgtcaaca

20

<210> SEQ ID NO 413
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 413

ggtgttggAAC cAGCTGAGTT

20

<210> SEQ ID NO 414
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 414

gagaggagat cAGCTCAGTG

20

<210> SEQ ID NO 415
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 415

-continued

ggtgctccag agaggagatc 20

<210> SEQ ID NO 416
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 416

attgtcttgg ctcccttcgt 20

<210> SEQ ID NO 417
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 417

ggagtttgca ttgtcttggc 20

<210> SEQ ID NO 418
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 418

gaatgttcac tggagttgc 20

<210> SEQ ID NO 419
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 419

ggcacgggaa tgttcactgg 20

<210> SEQ ID NO 420
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 420

ctggatttca ggaacctctg 20

<210> SEQ ID NO 421
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 421

atgggacact cctggatttc 20

-continued

<210> SEQ ID NO 422
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 422

cttgagctat gggacactcc 20

<210> SEQ ID NO 423
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 423

cccgctgctc ctgggattcc 20

<210> SEQ ID NO 424
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 424

aagttggcca catccaggtc 20

<210> SEQ ID NO 425
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 425

acgtagaagt tggccacatc 20

<210> SEQ ID NO 426
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 426

tctgcagctg tgacacgttag 20

<210> SEQ ID NO 427
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 427

cctatgggag tctgcagctg 20

<210> SEQ ID NO 428
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 428

acacctatgg gagtctgcag

20

<210> SEQ ID NO 429
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 429

ttgcacacct atgggagtct

20

<210> SEQ ID NO 430
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 430

ctctgcttgc acacctatgg

20

<210> SEQ ID NO 431
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 431

tgtcaactaca tcggagcagc

20

<210> SEQ ID NO 432
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 432

ggcttgaagg tatatgaard

20

<210> SEQ ID NO 433
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 433

acaatatctt tatggcttga

20

<210> SEQ ID NO 434
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 434

-continued

```
<210> SEQ ID NO 435
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound
```

<210> SEQ ID NO 436
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 436

```
<210> SEQ ID NO 437
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
```

<400> SEQUENCE: 437

```
<210> SEQ ID NO 438
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
```

<400> SEQUENCE: 438

```
<210> SEQ_ID NO 439
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
      -220- FEATURE
```

<223> OTHER INFORMATION: Antisense Compound

```
<210> SEQ ID NO 440
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
```

<400> SEQUENCE: 440

-continued

<210> SEQ ID NO 441
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 441

tgtgaggttag agcatttcctt

20

<210> SEQ ID NO 442
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 442

tcagagttct gtgaggtaga

20

<210> SEQ ID NO 443
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 443

ggcagcaggc ccatatttct

20

<210> SEQ ID NO 444
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 444

acctcgatgc cccgggtttc

20

<210> SEQ ID NO 445
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 445

agggttgtatc cttttatcacc

20

<210> SEQ ID NO 446
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 446

actttgcaga ctctttaata

20

<210> SEQ ID NO 447
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 447

aaacaggagt cgaatttcc 20

<210> SEQ ID NO 448
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 448

aagatgactc catccccgtc 20

<210> SEQ ID NO 449
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 449

accagccctt aaagatgact 20

<210> SEQ ID NO 450
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 450

ggataaccac cctaccagcc 20

<210> SEQ ID NO 451
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 451

acttggccca gtcactgg 20

<210> SEQ ID NO 452
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 452

gacttgcggc cgtgcagccc 20

<210> SEQ ID NO 453
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 453

-continued

ctttccagga gacttgcggc	20
 <pre><210> SEQ ID NO 454 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 454</pre>	
atgccccgtca ctccagccctt	20
 <pre><210> SEQ ID NO 455 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 455</pre>	
tccacagcaa ccacagggtgg	20
 <pre><210> SEQ ID NO 456 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 456</pre>	
gggacacgcga atctgctgtc	20
 <pre><210> SEQ ID NO 457 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 457</pre>	
caccctgatc gcgaatcctc	20
 <pre><210> SEQ ID NO 458 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 458</pre>	
gtgaagttgc accctgatcg	20
 <pre><210> SEQ ID NO 459 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Antisense Compound</pre>	
 <pre><400> SEQUENCE: 459</pre>	
tgcaaggctg gagagaagag	20

-continued

```
<210> SEQ ID NO 460
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 460
aggcttagtg aagcgcgtga                                20

<210> SEQ ID NO 461
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 461
atgcgctgga aggttactag                                20

<210> SEQ ID NO 462
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 462
cttttaaac aatgcgctgg                                20

<210> SEQ ID NO 463
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 463
aactgtttc tttttaaca                                20

<210> SEQ ID NO 464
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 464
gaaggcttcg cttacatcct                                20

<210> SEQ ID NO 465
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 465
acacacctt acttaatgga                                20

<210> SEQ ID NO 466
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
```

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 466

cgaaacgaca cacaccttta

20

<210> SEQ ID NO 467
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 467

ttgtactcac cgaggtccgc

20

<210> SEQ ID NO 468
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 468

gcggtcctac ctctttccgt

20

<210> SEQ ID NO 469
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 469

tgcaggcgcg gtcctacactc

20

<210> SEQ ID NO 470
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 470

gccgccagac ctaattaatt

20

<210> SEQ ID NO 471
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 471

agacactagg aacgcaatga

20

<210> SEQ ID NO 472
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 472

-continued

atgctatgat gttgaatgtg	20
-----------------------	----

```

<210> SEQ ID NO 473
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 473

```

ctatgctgtt atcaggattc	20
-----------------------	----

```

<210> SEQ ID NO 474
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 474

```

attgtcttgg ctgttgagtg	20
-----------------------	----

```

<210> SEQ ID NO 475
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense Compound

<400> SEQUENCE: 475

```

tccgtcatecg ctccctcaggg	20
-------------------------	----

1. A method of modulating expression of a Gemin gene in a cell comprising contacting the cell with an oligomeric compound of from 13 to 30 nucleobases in length and complementary to a nucleic acid molecule encoding the Gemin gene, and thereby modulating expression of the Gemin gene.

2. The method of claim 1, wherein said oligomeric compound is 20 nucleobases in length.

3. (canceled)

4. The method of claim 1, wherein said oligomeric compound is chimeric.

5. The method of claim 1, wherein said oligomeric compound comprises at least one modified internucleoside linkage.

6. The method of claim 5, wherein the modified internucleoside linkage comprises a phosphorothioate internucleoside linkage.

7. The method of claim 1, wherein said oligomeric compound comprises at least one modified sugar moiety.

8. The method of claim 7, wherein said modified sugar moiety comprises a 2'-O-methoxyethyl sugar moiety.

9. The method of claim 1, wherein said oligomeric compound comprises at least one modified nucleobase.

10. The method of claim 9, wherein said modified nucleobase comprises a 5-methylcytosine.

11. The method of claim 1, wherein said oligomeric compound is an antisense, chimeric oligonucleotide 20 nucleobases in length and comprises at least one phosphorothioate internucleoside linkage and at least one 2'-O-methoxyethyl sugar moiety and at least one 5-methylcytosine.

12. (canceled)

13. (canceled)

14. (canceled)

15. The method of claim 1, wherein the expression of the Gemin gene is reduced by at least 50%.

16. The method of claim 1, wherein the cell is in an animal.

17. The method of claim 16, wherein the animal is a human.

* * * * *